<SEC-DOCUMENT>0001193125-12-460700.txt : 20121108
<SEC-HEADER>0001193125-12-460700.hdr.sgml : 20121108
<ACCEPTANCE-DATETIME>20121108170112
ACCESSION NUMBER:		0001193125-12-460700
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20121108
DATE AS OF CHANGE:		20121108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		121190749

	BUSINESS ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d398930d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-Q
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Mark One) </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the quarterly period ended September&nbsp;30, 2012 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number 001-32335
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>HALOZYME THERAPEUTICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>88-0488686</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11388 Sorrento Valley Road, San Diego, CA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>92121</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(858) 794-8889 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether
the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company<B>&#148;</B> in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of outstanding shares of the registrant&#146;s common stock, par value $0.001 per share, was 112,705,092 as of October&nbsp;31,&nbsp;2012. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HALOZYME THERAPEUTICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#tx398930_1">PART&nbsp;I &#151; FINANCIAL INFORMATION </A></B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#tx398930_1"></A>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_2">Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_3">Condensed Consolidated Balance Sheets &#150; September 30, 2012 (Unaudited) and December 31,
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_4">Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) &#150; Three and Nine Months Ended
 September 30, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_5">Condensed Consolidated Statements of Cash Flows (Unaudited) &#150; Nine Months Ended September 30, 2012 and
 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_6">Notes to Condensed Consolidated Financial Statements (Unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_8">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_9">Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#tx398930_10">PART&nbsp;II &#151; OTHER INFORMATION </A></B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#tx398930_10"></A>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_11">Legal Proceedings</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_12">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_13">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_14">Defaults Upon Senior Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_15">Mine Safety Disclosures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_16">Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_17">Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx398930_18">SIGNATURES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_1"></A>PART I &#151; FINANCIAL INFORMATION </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_2"></A>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_3">
</A>HALOZYME THERAPEUTICS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Note)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,614,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,825,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,464,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,262,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,186,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">567,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,353,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,332,242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,618,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,987,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,363,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,771,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,982,219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,758,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,526,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,556,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,041,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,615,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,470,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,129,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,038,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,301,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,883,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,754,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">870,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">802,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies (Note 10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock - $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock - $0.001 par value; 150,000,000 shares authorized; 112,692,527 and 103,989,272 shares issued and outstanding at
September&nbsp;30, 2012 and December&nbsp;31, 2011, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">345,244,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">255,817,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(294,167,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(245,021,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,189,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,900,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Liabilities and Stockholders&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,982,219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,758,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The condensed consolidated balance sheet at December&nbsp;31, 2011 has been derived from audited financial statements at that date. It does not include, however, all of the
information and notes required by U.S. generally accepted accounting principles for complete financial statements.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_4"></A>HALOZYME THERAPEUTICS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">715,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,156,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,487,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues under collaborative agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,618,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,785,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,103,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,187,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,334,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,942,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,531,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,675,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">440,516</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">201,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,503,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,514,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,476,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,647,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,634,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,263,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,833,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,237,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,364,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,789,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,750,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,086,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,029,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,152,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,218,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,410,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and other income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,005,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,165,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,146,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,354,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net income (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares used in computing net income (loss) per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,305,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,223,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,658,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,282,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,305,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,009,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,658,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,282,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,005,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,165,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,146,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,354,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_5"></A>HALOZYME THERAPEUTICS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,146,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,354,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activies:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,362,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,916,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">796,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">851,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain on disposal of equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,201,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,909,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,618,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(576,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,106,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,183,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,469,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,718,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47,410,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,796,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(873,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(271,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(873,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(271,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,476,845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock under equity incentive plans, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,596,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,141,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,073,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,141,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,789,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,926,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,825,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,255,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,614,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,329,358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental disclosure of non-cash investing and financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable for purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">508,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_6"></A>HALOZYME THERAPEUTICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. Organization and Business </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Halozyme Therapeutics, Inc. (referred to as &#147;we,&#148; &#147;us,&#148; &#147;Halozyme&#148; or the
&#147;Company&#148;) is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. Our research targets the extracellular matrix, an area outside the cell that provides structural support
in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique scientific expertise that allows us to pursue this target-rich environment for the
development of future therapies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research focuses primarily on human enzymes that alter the
extracellular matrix. Our lead enzyme, recombinant human hyaluronidase (&#147;rHuPH20&#148;), temporarily degrades hyaluronan, a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. We are also developing
novel enzymes that may target other matrix structures for therapeutic benefit. Our Enhanze</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> technology is the platform for the delivery of proprietary small and large molecules. We apply our research products in collaboration with other companies as well as for our own proprietary pipeline in
therapeutic areas with significant unmet medical need, such as diabetes, oncology and dermatology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
operations to date have involved: (i)&nbsp;organizing and staffing our operating subsidiary, Halozyme, Inc.; (ii)&nbsp;acquiring, developing and securing our technology; (iii)&nbsp;undertaking product development for our existing product and a
limited number of product candidates; (iv)&nbsp;supporting the development of collaboration product candidates and (v)&nbsp;selling <I>Hylenex</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> recombinant (hyaluronidase human injection). We continue to increase our focus on our proprietary product pipeline and have expanded investments in our proprietary
product candidates. We currently have multiple proprietary programs in various stages of research and development. In addition, we currently have license and collaborative agreements with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.
(&#147;Roche&#148;), Baxter Healthcare Corporation (&#147;Baxter&#148;), ViroPharma Incorporated (&#147;ViroPharma&#148;), and Intrexon Corporation (&#147;Intrexon&#148;), to apply Enhanze technology to these collaborators&#146; biological
therapeutic compounds. Currently, we have received only limited revenue from the sales of <I>Hylenex </I>recombinant, in addition to other revenues from our collaborations. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Summary of Significant Accounting Policies </B></FONT></P>

 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States
generally accepted accounting principles (&#147;U.S. GAAP&#148;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#147;SEC&#148;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of
the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated
financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, filed with the SEC on March&nbsp;12, 2012. The unaudited financial information for the interim periods presented herein
reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring
adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc. All intercompany accounts and transactions have been
eliminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
estimates and assumptions that affect the amounts reported in our consolidated financial statements and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management
believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#146;s estimates. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adoption of Recent Accounting Pronouncements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2012, we adopted Financial Accounting Standards Board&#146;s (&#147;FASB&#148;) Accounting Standards Update
(&#147;ASU&#148;) No.&nbsp;2011-05, Comprehensive Income (Topic 220): <I>Presentation of Comprehensive Income</I> and ASU No.&nbsp;2011-12, <I>Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of
Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU No.&nbsp;2011-5</I>. In these updates, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other
comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each
component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No.&nbsp;2011-05 eliminates the option to present the components of other comprehensive income as part of the
statement of changes in stockholders&#146; equity. The amendments in ASU No.&nbsp;2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.
The amendments in these updates are effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2011. The adoption of ASU Nos. 2011-05 and 2011-12 did not have a material impact on our consolidated financial
position or results of operations. We have presented comprehensive income (loss) in our condensed consolidated statements of comprehensive income (loss). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2012, we prospectively adopted FASB&#146;s ASU No.&nbsp;2011-04, <I>&#147;Fair Value Measurement (Topic 820) &#151; Amendments to Achieve Common Fair Value Measurement and
Disclosure Requirements in U.S. GAAP and IFRS&#148;. </I>The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards (&#147;IFRS&#148;). Consequently, the
amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This pronouncement is effective for fiscal years, and interim periods within
those years, beginning after December&nbsp;15, 2011. The adoption of ASU No.&nbsp;2011-04 did not have a material effect on our consolidated financial position or results of operations. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inventories </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
compared with historical cost and the remaining shelf life of goods on hand. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials inventories consist of raw
materials used in the manufacture of our bulk drug material for <I>Hylenex</I> recombinant product. Work-in-process inventories consist of in-process <I>Hylenex</I> recombinant. Finished goods inventories consist of finished <I>Hylenex</I>
recombinant product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expense costs relating to the purchase and production of pre-approval inventories for which the sole
use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
by regulatory bodies such as the U.S. Food and Drug Administration (&#147;FDA&#148;), inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or
comparable regulatory agencies in foreign countries, costs related to purchases of the active pharmaceutical ingredients (&#147;API&#148;) and the manufacturing of the product candidate are recorded as research and development expense. All direct
manufacturing costs incurred after approval are capitalized as inventory. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
resulting from collaborative arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue in accordance with the authoritative guidance on revenue
recognition. Revenue is recognized when all of the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the seller&#146;s price to the buyer is
fixed or determinable; and (4)&nbsp;collectibility is reasonably assured. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Product Sales </I></B><I>&#150; Hylenex</I> recombinant was approved for marketing by the FDA in
December 2005. From 2005 through January&nbsp;7, 2011, Baxter had the worldwide market rights for <I>Hylenex</I> recombinant under the terms of the amended and restated development and supply agreement with Baxter (&#147;Hylenex
Collaboration&#148;). Baxter commercially launched <I>Hylenex</I> recombinant in October 2009. However, <I>Hylenex</I> recombinant was voluntarily recalled in May 2010 because a portion of the product manufactured by Baxter was not in compliance
with the requirements of the underlying collaboration. Effective January&nbsp;7, 2011, we and Baxter mutually agreed to terminate the Hylenex Collaboration. During the second quarter of 2011, we submitted the data that the FDA had requested to
support the reintroduction of <I>Hylenex</I> recombinant to the market. The FDA approved the submitted data and granted the reintroduction of <I>Hylenex</I> recombinant. <I> </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we reintroduced <I>Hylenex</I> recombinant to the market, shipped initial orders to our wholesaler customers and began
promoting <I>Hylenex</I> recombinant through our sales force. We sell <I>Hylenex</I> recombinant in the United States to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. The wholesale
distributors take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales; however, we do allow the
wholesale distributors to return product that is damaged or received in error. In addition, we allow for product to be returned beginning six months prior to and ending twelve months following product expiration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given our limited history of selling <I>Hylenex</I> recombinant and the lengthy return period, we currently cannot reliably estimate
expected returns and chargebacks of <I>Hylenex</I> recombinant at the time the product is received by the wholesale distributors. Therefore, we do not recognize revenue upon delivery of <I>Hylenex</I> recombinant to the wholesale distributor until
the point at which we can reliably estimate expected product returns and chargebacks from the wholesale distributors. Shipments of <I>Hylenex</I> recombinant are recorded as deferred revenue until evidence exists to confirm that pull-through sales
to the hospitals or other end-user customers have occurred. We recognize revenue when the product is sold through from the distributors to the distributors&#146; customers. In addition, the costs of manufacturing <I>Hylenex</I> recombinant
associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized. We estimate sell-through revenue and certain gross to net sales adjustments based on
analysis of third-party information including information obtained from certain distributors with respect to their inventory levels and sell-through to the distributors&#146; customers. At the time we can reliably estimate product returns and
chargebacks from the wholesale distributors, we will record a one-time increase in net product sales revenue related to the recognition of product sales revenue previously deferred. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales
allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with wholesale distributors and hospitals and the levels of inventory within the distribution channels
that may result in future discounts taken. We must make significant judgments in determining these allowances. If actual results differ from our estimates, we will be required to make an adjustment to these allowances in the future, which could have
an effect on product sales revenue in the period of adjustment. Our product sales allowances include: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Distribution
Fees</I>. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesale distributors for distribution services they provide with respect to <I>Hylenex</I> recombinant. At the time
the sale is made to the respective wholesale distributors, we record an allowance for distribution fees by reducing our accounts receivable and deferred revenue associated with such product sales. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prompt Payment Discounts</I>. We offer cash discounts to certain wholesale distributors
as an incentive to meet certain payment terms. We expect our customers will take advantage of this discount; therefore, at the time the sale is made to the respective wholesale distributors, we accrue the entire prompt payment discount, based on the
gross amount of each invoice, by reducing our accounts receivable and deferred revenue associated with such product sales. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Chargebacks</I>. We provide discounts to end-user members of certain group purchasing organizations (&#147;GPO&#148;) under collective
purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals who are members of the GPOs with which we do not have contracts. The end-user members purchase products from the wholesale distributors at a contracted
discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the end users paid for the product. Given our lack of historical sales data, we recognize chargebacks in the same
period the related product sales revenue is recognized and reduce our accounts receivable accordingly. A GPO fee we incur for these transactions is also recorded in the same period the related product sales revenue is recognized and is included in
accrued expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product Returns</I>. The product returns reserve is based on management&#146;s best estimate of the
product sales recognized as revenue during the period that are anticipated to be returned. The product returns reserve is recorded as a reduction of product sales revenue in the same period the related product sales revenue is recognized and is
included in accrued expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues under Collaborative Agreements </I></B><I>&#150; </I>We have entered into
license and collaboration agreements under which the collaborators obtained worldwide exclusive rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of the collaborators&#146; biologic compounds. The
collaborative agreements contain multiple elements, including nonrefundable payments at the inception of the arrangements, license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative
agreements, reimbursements of research and development services, payments for supply of rHuPH20 API for the collaborator and/or royalties on sales of products resulting from collaborative agreements. We analyze each element of the collaborative
agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the adoption of ASU No.&nbsp;2009-13, <I>Multiple-Deliverable Revenue Arrangements</I>, on January&nbsp;1, 2011, in order for a
delivered item to be accounted for separately from other deliverables in a multiple-element arrangement, the following three criteria had to be met: (i)&nbsp;the delivered item had standalone value to the customer, (ii)&nbsp;there was objective and
reliable evidence of fair value of the undelivered items, and (iii)&nbsp;if the arrangement included a general right of return relative to the delivered item, delivery or performance of the undelivered items was considered probable and substantially
in the control of the vendor. For the collaborative agreements entered into prior to January&nbsp;1, 2011, there was no objective and reliable evidence of fair value of the undelivered items. Thus, the delivered licenses did not meet all of the
required criteria to be accounted for separately from undelivered items. Therefore, we recognized revenue on nonrefundable upfront payments and license fees from these collaborative agreements over the period of significant involvement under the
related agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For new collaborative agreements or material modifications of existing collaborative agreements entered
into after December&nbsp;31, 2010, we follow the provisions of ASU No.&nbsp;2009-13. In order to account for the multiple-element arrangements, we identify the deliverables included within the agreement and evaluate which deliverables represent
units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The
deliverables under our collaborative agreements include (i)&nbsp;the license to rHuPH20 technology, (ii)&nbsp;at the collaborator&#146;s request, research and development services which are reimbursed at contractually determined rates, and
(iii)&nbsp;at the collaborator&#146;s request, supply of rHuPH20 API which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone
basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the collaborator and the availability of research expertise in this field in
the general marketplace. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrangement consideration is allocated at the inception of the agreement to all identified
units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&#147;VSOE&#148;) of selling price or third-party evidence of selling price if VSOE
does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or
determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered
and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonrefundable upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the
license has standalone value from the undelivered items, which generally include research and development services and the manufacture of rHuPH20 API, the relative selling price allocation of the license is equal to or exceeds the upfront license
fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does
not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms of our collaborative agreements provide for milestone payments upon achievement of certain development and regulatory events
and/or specified sales volumes of commercialized products by the collaborator. Effective January&nbsp;1, 2011, we adopted on a prospective basis the Milestone Method. Under the Milestone Method, we recognize consideration that is contingent upon the
achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration is commensurate with either the entity&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a
result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration relates solely to past performance, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A milestone is defined as an event (i)&nbsp;that can only be achieved based in whole or in part on either the entity&#146;s performance
or on the occurrence of a specific outcome resulting from the vendor&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&nbsp;that would
result in additional payments being due to the vendor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursements of research and development services are recognized as
revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is probable. Revenue from the manufacture of rHuPH20
API is recognized when the API has met all specifications required for the collaborator&#146;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and
development services or supply of rHuPH20 API; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of rHuPH20 API. Royalties to be received based on sales of licensed products
by our collaborators incorporating rHuPH20 will be recognized as earned. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The collaborative agreements typically provide the
collaborators the right to terminate such agreements in whole or on a product-by-product or target-by-target basis at any time upon 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any
of our collaborative agreements that contain material financial consequences to us. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cost of Product Sales </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal
costs and manufacturing overhead associated with the production of <I>Hylenex </I>recombinant. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses,
research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no
alternative future uses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advance payments, including nonrefundable amounts, for goods or services that will be used or
rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the
goods to be delivered or services to be performed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone payments that we make in connection with in-licensed technology
or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product
candidates to be uncertain until such licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all
of our licensed technology or product candidates to be uncertain and has expensed these amounts as incurred. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Trial Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work
performed, including actual level of patient enrollment, completion of patient studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts
are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period
in which the facts that give rise to the revision become reasonably certain. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total share-based compensation expense related to all of our share-based awards was allocated as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">913,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">890,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,279,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,944,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,008,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">867,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,082,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,971,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,922,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,757,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,362,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,916,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation expense per basic and diluted share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation expense from:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,164,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">806,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,491,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,318,728</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock awards and restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">757,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">951,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,871,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,597,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,922,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,757,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,362,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,916,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since we have a net operating loss carryforward as of September&nbsp;30, 2012, no excess tax benefits for the tax
deductions related to share-based awards were recognized in the interim unaudited condensed consolidated </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
statements of comprehensive loss for the three and nine months ended September&nbsp;30, 2012. For the three months ended September&nbsp;30, 2012 and 2011, employees exercised stock options to
purchase 7,055 and 38,511 shares of common stock, respectively, for aggregate proceeds of approximately $39,000 and $79,000, respectively. For the nine months ended September&nbsp;30, 2012 and 2011, employees exercised stock options to purchase
426,277 and 2,713,573 shares of common stock, respectively, for aggregate proceeds of approximately $1.9 million and $4.1 million, respectively. In addition, for the nine months ended September&nbsp;30, 2012, upon vesting of 128,000 restricted stock
units (&#147;RSUs&#148;), the RSU holders received net settlement of 81,070 shares of common stock and surrendered 46,930 RSUs to pay for the minimum withholding taxes totaling approximately $347,000. There were no RSUs vested for the three months
ended September&nbsp;30, 2012 or the three and nine months ended September&nbsp;30, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2012,
total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock awards and restricted stock units granted prior to that date was approximately $9.6 million and $7.0 million, respectively, which is
expected to be recognized over a weighted-average period of approximately 2.7 years and 3.6 years, respectively. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fair Value of Financial Instruments </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We follow the authoritative guidance for fair value measurements and disclosures which, among other things, defines fair value,
establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
pricing an asset or liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The framework for measuring fair value provides a hierarchy that prioritizes the inputs to
valuation techniques used in measuring fair value as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quoted prices (unadjusted) in active markets for identical assets or liabilities,</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, and</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants
would use in pricing.</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our financial instruments include cash and cash equivalents, accounts receivable, prepaid expenses,
accounts payable and accrued expenses. The carrying amounts of financial instruments approximate their fair values due to their short maturities. Cash equivalents of approximately $85.0 million and $51.8 million at September&nbsp;30, 2012 and
December&nbsp;31, 2011, respectively, are carried at fair value and are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices for identical securities. We have no instruments that are classified
within Level 2 and Level 3. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Segment Information </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We operate our business in one segment, which includes all activities related to the research, development and commercialization of human
enzymes that either transiently modify tissue to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. This segment also includes revenues and expenses related to (i)&nbsp;research and development
activities conducted under our collaborative agreements with third parties and (ii)&nbsp;product sales of <I>Hylenex</I> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations
as a single operating segment. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Collaborative Agreements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Roche Collaboration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2006, we and Roche entered into a license and collaborative agreement under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and
up to thirteen Roche target compounds (the &#147;Roche Collaboration&#148;). As of September&nbsp;30, 2012, Roche has elected a total of five exclusive targets and retains the option to develop and commercialize rHuPH20 with three additional
targets, provided that Roche continues to pay annual maintenance fees to us. As of September&nbsp;30, 2012, we have received $57 million from Roche, including the $20 million upfront license fee payment for the application of rHuPH20 to the initial
three Roche exclusive targets, $20 million in connection with Roche&#146;s election of two additional exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets, $13 million in
clinical development milestone payments and a $4 million regulatory milestone payment. If Roche successfully develops all five exclusive targets and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $178
million, including up to $17 million for the achievement of clinical development milestones, up to $16 million for the achievement of regulatory milestones and up to $145 million for the achievement of sales-based milestones. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Roche Collaboration, Roche will also pay us a royalty on each product commercialized under the agreement
consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&#146;s obligation to pay royalties. Roche
has the obligation to pay royalties with respect to each product in each country, during the period equal to the longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the
collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the first commercial sale of such product in such country. For products developed for each of the additional targets, Roche may pay us
upfront and milestone payments of up to $47 million per target, as well as royalties on product sales for each of the additional targets consisting of a mid-single digit percent of the net sales of such products. Additionally, Roche will obtain
access to our expertise in developing and applying rHuPH20 to Roche targets. Under the terms of the Roche Collaboration, we were obligated to scale up the production of rHuPH20 and to identify a second source manufacturer that would help meet
anticipated production obligations arising from the Roche Collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to our continuing involvement obligations (for
example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We have
determined that the clinical and regulatory milestones are substantive; therefore, we expect to recognize such clinical and regulatory milestone payments as revenue upon achievement of the milestones. In addition, we have determined that the
sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, we will recognize such sales-based milestone payments as revenue upon achievement
of the milestones. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no milestone payments recognized as revenues under collaborative agreements under the Roche
Collaboration for the three months ended September&nbsp;30, 2012 and 2011. For the nine months ended September&nbsp;30, 2012 and 2011, we recognized $4 million and $5 million, respectively, as revenues under collaborative agreements in accordance
with the Milestone Method related to the achievement of certain regulatory and clinical milestones pursuant to the terms of the Roche Collaboration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Gammagard Collaboration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2007, we entered
into a license and collaborative agreement with Baxter, under which Baxter obtained a worldwide, exclusive license to develop and commercialize a product candidate (currently named HyQ) consisting of rHuPH20 combined with a current Baxter product,
GAMMAGARD LIQUID<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (the &#147;Gammagard Collaboration&#148;). As of September&nbsp;30, 2012, we have received $13
million under the Gammagard Collaboration, including the $10 million upfront license fee payment and a $3 million regulatory milestone payment. If Baxter successfully receives marketing approval for the licensed product candidate and achieves
pre-agreed sales targets, we could receive additional milestone payments of up to $34 million for the achievement of sales-based milestones. In addition, Baxter will pay us a royalty on each product commercialized under the agreement consisting of a
mid-single </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
digit percent of the net sales of such product. The Gammagard Collaboration is applicable to both kit and formulation combinations. Baxter assumes all development, manufacturing, clinical,
regulatory, sales and marketing costs under the Gammagard Collaboration, while we are responsible for the supply of rHuPH20 enzyme. We perform research and development activities at the request of Baxter, which are reimbursed by Baxter under the
terms of the Gammagard Collaboration. In addition, Baxter has certain product development and commercialization obligations in major markets identified in the Gammagard Collaboration. Unless terminated earlier in accordance with its terms, the
Gammagard Collaboration continues in effect until the expiration of Baxter&#146;s obligation to pay royalties. Baxter has the obligation to pay royalties, with respect to each product in each country, during the period equal to the longer of:
(a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the first
commercial sale of such product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to our continuing involvement obligations (for example, support
activities associated with rHuPH20 enzyme), the upfront payment was deferred and is being recognized over the term of the Gammagard Collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have determined that sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, such payments
will be recognized as revenue upon achievement of the milestones. There were no milestone payments recognized as revenues under collaborative agreements under the Gammagard Collaboration for the three and nine months ended September&nbsp;30, 2012.
For the three and nine months ended September&nbsp;30, 2011, we recognized zero and $3 million, respectively, as revenues under collaborative agreements under the Gammagard Collaboration in accordance with the Milestone Method. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ViroPharma and Intrexon Collaborations </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective May&nbsp;10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which
ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma&#146;s commercialized product, Cinryze<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (C1 esterase inhibitor [human]) (the &#147;ViroPharma Collaboration&#148;). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and
to the hereditary angioedema indication, along with three additional orphan indications. As of September&nbsp;30, 2012, we have received $13 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment, a $3 million
clinical development milestone payment and a $1 million annual exclusivity fee. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of
development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million which commenced on May&nbsp;10, 2012 and on each anniversary of the effective
date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for
research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory
milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive a royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such
product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless terminated earlier in accordance with its terms, the ViroPharma Collaboration continues in effect until the
later of (i)&nbsp;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and
(ii)&nbsp;expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Collaboration, with respect to each country, consists of the period equal to the
longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the
first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us.&nbsp;Upon any such termination, the license
granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective June&nbsp;6, 2011, we and Intrexon entered into a collaboration and license
agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon&#146;s recombinant human alpha 1-antitrypsin (rHuA1AT) (the &#147;Intrexon
Collaboration&#148;). In addition, the license provides Intrexon with exclusivity for a defined indication (&#147;Exclusive Field&#148;). As of September&nbsp;30, 2012, we have received $10 million from Intrexon, including a nonrefundable upfront
license fee payment of $9 million and a $1 million annual exclusivity fee. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales target, we could receive additional milestone payments of up to $54
million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive a
nonrefundable annual exclusivity fee of $1 million which commenced on June&nbsp;6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. Intrexon is solely responsible for the
development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to
receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive a royalty on each product
commercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless terminated earlier in accordance with its terms, the Intrexon Collaboration continues in effect until the later of (i)&nbsp;expiration of the last to expire of the valid claims of our patents
covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii)&nbsp;expiration of the last to expire royalty term for a product developed under the
collaboration. The royalty term of a product developed under the Intrexon Collaboration, with respect to each country, consists of the period equal to the longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other
specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the first commercial sale of such product in such country. Intrexon may terminate the agreement
prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with respect to the terminated product, as applicable) will terminate.
Intrexon&#146;s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development services and API supply. We have determined that the license,
research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these units of accounting were determined based on market
conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and
pricing objectives and the nature of the research and development services to be performed for the collaborators. The arrangement consideration was allocated to the deliverables based on the relative selling price method. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of
additional items or meeting other specified performance conditions (the noncontingent amount). As such, we excluded from the allocable arrangement consideration the milestone payments, annual exclusivity fees and royalties regardless of the
probability of receipt. Based on the results of our analysis, we allocated the $9 million upfront license fee received from ViroPharma to the license fee deliverable under the ViroPharma arrangement and the $9 million upfront fee received from
Intrexon to the license fee deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in both the ViroPharma Collaboration
and Intrexon Collaboration. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Collaboration and the $9 million upfront license fee received under the Intrexon Collaboration as revenues under collaborative
agreements upon receipt of the upfront license fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize the annual exclusivity fees as revenues under collaborative
agreements when they are due and payable on each anniversary of the effective date and such amounts are included in the allocable arrangement </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
consideration and recognized based on the relative selling price allocation. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the
related services are performed. We recognize amounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the collaborators and the related title and risk of loss and damages
have passed to the collaborators. We cannot predict the timing of delivery of research and development services and API as they are at the collaborators&#146; requests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are eligible to receive additional cash payments upon the achievement by the collaborators of specified development, regulatory and sales-based milestones. We have determined that each of the
development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In
addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone Method of revenue recognition; therefore, we will recognize the sales-based milestone
payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the three and nine months ended September&nbsp;30, 2011, we recognized a $3 million milestone payment as revenues under collaborative agreements in accordance with the Milestone Method related to the
achievement of a development milestone pursuant to the terms of the ViroPharma Collaboration. There were no milestone payments recognized as revenues under collaborative agreements associated with the ViroPharma Collaboration for the three and nine
months ended September&nbsp;30, 2012. There were no milestone payments recognized as revenues under collaborative agreements associated with the Intrexon Collaboration for the three and nine months ended September&nbsp;30, 2012 and 2011. We
recognized the annual exclusivity fee of zero and $1 million as revenues under collaborative agreements associated with each the ViroPharma and Intrexon Collaborations for the three and nine months ended September&nbsp;30, 2012, respectively.
</FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Inventories </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories consist of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">962,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">201,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work-in-process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">715,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">290,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">508,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,186,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">567,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Property and Equipment, Net </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,207,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,231,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer and office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,524,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,266,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,137,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,019,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,868,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,516,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,505,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,745,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,363,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,771,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization expense totaled approximately $286,000 and $239,000 for the three months ended
September&nbsp;30, 2012 and 2011, respectively, and approximately $796,000 and $852,000 for the nine months ended September&nbsp;30, 2012 and 2011, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Accrued Expenses </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued outsourced research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,735,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,910,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation and payroll taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,339,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,223,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">966,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">481,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,041,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,615,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Deferred Revenue </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue consists of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborative agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,034,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,716,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">319,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,353,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,883,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,470,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,129,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,883,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,754,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Roche Collaboration. </I></B>Under the terms of the Roche Collaboration, Roche paid $20 million to us in December
2006 as an initial upfront payment for the application of rHuPH20 to three pre-defined Roche biologic targets. As of September&nbsp;30, 2012, Roche has paid an aggregate of $20 million in connection with Roche&#146;s election of two additional
exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets. Roche currently retains the option to develop and commercialize rHuPH20 with three additional targets, provided that Roche
continues to pay annual license maintenance fees to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to our continuing involvement obligations (for example, support
activities associated with rHuPH20 enzyme), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We recognized revenue from
the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration in the amounts of approximately $503,000 and $491,000 for the three months ended September&nbsp;30, 2012 and 2011, respectively, and
approximately $1.5 million for the nine months ended September&nbsp;30, 2012 and 2011. Deferred revenue relating to the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration was $30.1 million
and $31.7 million as of September&nbsp;30, 2012 and December&nbsp;31, 2011, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended
September&nbsp;30, 2012, we received approximately $7.0 million in deferred revenue relating to the manufacture of rHuPH20 API for Roche. We recognized approximately $334,000 as revenues under collaborative agreements from deferred revenue relating
to the manufacture of rHuPH20 API for the three and nine months ended September&nbsp;30, 2012. Deferred revenue relating to the manufacture of rHuPH20 API under the Roche Collaboration was $6.7 million and zero as of September&nbsp;30, 2012 and
December&nbsp;31, 2011, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gammagard Collaboration. </I></B>Under the terms of the Gammagard Collaboration,
Baxter paid us a nonrefundable upfront payment of $10 million. Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the $10&nbsp;million upfront payment was deferred and is being recognized
over the term of the Gammagard Collaboration. We recognized revenue from the upfront payment under the Gammagard Collaboration in the amounts of approximately $121,000 for each of the three months ended September&nbsp;30, 2012 and 2011 and
approximately $362,000 for the nine months ended September&nbsp;30, 2012 and 2011. Deferred revenue relating to the upfront payment under the Gammagard Collaboration was $7.2 million and $7.6 million as of September&nbsp;30, 2012 and
December&nbsp;31, 2011, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Hylenex Collaboration</I></B>. In February 2007, we and Baxter amended certain
existing agreements for <I>Hylenex </I>recombinant and entered into the Hylenex Collaboration for kits and formulations with rHuPH20. Effective January&nbsp;7, 2011, we and Baxter mutually agreed to terminate the Hylenex Collaboration and the
associated agreements. On July&nbsp;18, 2011, we and Baxter entered into an agreement (the &#147;Transition Agreement&#148;) setting forth certain rights, data and assets to be transferred by Baxter to us during a transition period. Effective
July&nbsp;18, 2011, we had no future performance obligations to Baxter in connection with the Hylenex Collaboration. Therefore, we recognized the unamortized deferred revenue of approximately $9.3 million relating to the prepaid product-based
payments and the unamortized deferred revenue of approximately $7.6 million relating to deferred upfront payment from the Hylenex Collaboration as revenues under collaborative agreements for the three months ended September&nbsp;30, 2011. For the
nine months ended September&nbsp;30, 2011, we recognized revenues under the Hylenex Collaboration from the upfront payment of approximately $7.8 million and from the product-based payments of approximately $9.3 million. There were no deferred
revenues relating to the Hylenex Collaboration at September&nbsp;30, 2012 and 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, pursuant to the terms of the
Transition Agreement, Baxter no longer had the right to return the <I>Hylenex </I>recombinant API previously delivered to Baxter. Accordingly, we recognized approximately $991,000 of deferred revenue related to such <I>Hylenex </I>recombinant API as
product sales revenue during the three and nine months ended September&nbsp;30, 2011. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Net Income (Loss) Per Share </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted
average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted-average number of
common shares outstanding and potentially dilutive common shares outstanding. Potentially dilutive common shares outstanding, determined using the treasury stock method, principally include shares that may be issued under our stock options,
restricted stock awards (&#147;RSAs&#148;) and RSUs. Stock options, unvested RSAs and unvested RSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when their effect is dilutive.
For the three and nine months ended September&nbsp;30, 2012, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 7.3&nbsp;million were excluded from the calculation of diluted net loss per common share because their
effect is anti-dilutive. For the three and nine months ended September&nbsp;30, 2011, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 1.9&nbsp;million and 5.9&nbsp;million, respectively, were excluded from the
calculation of diluted net loss per common share because their effect is anti-dilutive. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Income (Loss) - Numerator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) for basic and diluted EPS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,005,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,165,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,146,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,354,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares - Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average shares for basic EPS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,305,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,223,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,658,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,282,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of dilutive stock options, RSAs and RSUs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,785,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average shares for diluted EPS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,305,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,009,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,658,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,282,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net income (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Stockholders&#146; Equity </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended September&nbsp;30, 2012 and 2011, we issued an aggregate of 426,277 and 2,713,573 shares
of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $4.56 and $1.70 per share, respectively, for net proceeds of approximately $1.9 million and $4.1 million, respectively. In
addition, for the nine months ended September&nbsp;30, 2012, we issued 81,070 shares of common stock upon vesting of certain RSUs. The RSU holders surrendered 46,930 RSUs to pay for minimum withholding taxes totaling approximately $347,000. Options
and RSUs to purchase approximately 6.9&nbsp;million and 6.0&nbsp;million shares of our common stock were outstanding as of September&nbsp;30, 2012 and December&nbsp;31, 2011, respectively. In addition, we issued 375,908 shares of common stock, net
of RSAs canceled, in connection with the grants of RSAs during the nine months ended September&nbsp;30, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;15, 2012, we completed an underwritten public offering and issued 7,820,000 shares of common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriter. All of the shares
were offered at a public offering price of $10.61 per share, generating approximately $81.5 million in net proceeds. Randal J. Kirk, a member of our board of directors, through his affiliates, purchased 1,360,000 shares of common stock in this
offering at the public offering price of $10.61 per share for a total of approximately $14.4 million. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Commitments and Contingencies </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations
in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny
coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial
position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#146;s opinion, individually or in the
aggregate, would have a material adverse effect on our consolidated results of operations or financial position. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_7"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>As used in this report, unless the context suggests otherwise, the terms &#147;we,&#148; &#147;our,&#148; &#147;ours,&#148; and
&#147;us&#148; refer to Halozyme Therapeutics, Inc., and its wholly owned subsidiary, Halozyme, Inc., which are sometimes collectively referred to herein as the &#147;Company.&#148; </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and
notes thereto included in Item&nbsp;1 of this Quarterly Report on Form 10-Q. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate
results or future period trends. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Except for the historical information contained herein, this report contains
&#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management&#146;s current forecast of certain aspects of our future. Words such as &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; &#147;think,&#148; &#147;may,&#148; &#147;could,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;continue,&#148; &#147;potential,&#148; &#147;likely,&#148; &#147;opportunity&#148; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of indentifying
forward-looking statements in this report. Additionally, statements concerning future matters such as the development or regulatory approval of new products, enhancements of existing products or technologies, third party performance under key
collaboration agreements, revenue and expense levels and other statements regarding matters that are not historical are forward-looking statements. Such statements are based on currently available operating, financial and competitive information and
are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set
forth below under the section entitled &#147;Risks Factors&#148; and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company dedicated to developing and
commercializing innovative products that advance patient care. Our research targets the extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell
migration, signaling and survival. Over many years, we have developed unique scientific expertise that allows us to pursue this target-rich environment for the development of future therapies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research focuses primarily on human enzymes that alter the extracellular matrix. Our lead enzyme, recombinant
human hyaluronidase (rHuPH20), temporarily degrades hyaluronan (HA), a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. We are also developing novel enzymes that may target other matrix structures for
therapeutic benefit. Our Enhanze</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> technology is the
platform for the delivery of proprietary small and large molecules. We apply our research to develop products in collaboration with other companies as well as for our own proprietary pipeline in therapeutic areas with significant unmet medical need,
such as diabetes, oncology and dermatology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operations to date have involved: (i)&nbsp;organizing
and staffing our operating subsidiary, Halozyme, Inc.; (ii)&nbsp;acquiring, developing and securing our technology; (iii)&nbsp;undertaking product development for our existing products and a limited number of product candidates; (iv)&nbsp;supporting
the development of collaboration product candidates; and (v)&nbsp;selling <I>Hylenex</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> recombinant
(hyaluronidase human injection). We continue to increase our focus on our proprietary product pipeline and have expanded investments in our proprietary product candidates. We currently have multiple proprietary programs in various stages of research
and development. In addition, we currently have license and collaborative agreements with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon
Corporation (Intrexon) to apply Enhanze technology to the collaborators&#146; biological therapeutic compounds. Currently, we have received only limited revenue from the sales of <I>Hylenex </I>recombinant, in addition to other revenues from our
collaborations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our collaborators have product candidates in the research, preclinical and clinical stages, but future
revenues from the sales and/or royalties of these product candidates will depend on our collaborators&#146; abilities and our ability to develop, manufacture, obtain regulatory approvals for and successfully commercialize product
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidates. It may be years, if ever, before we and our collaborators are able to obtain regulatory approvals for these product candidates. We have incurred net operating losses each year since
inception, with an accumulated deficit of approximately $294.2 million as of September&nbsp;30, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product and Product Candidates
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have one marketed product and multiple product candidates targeting several indications in various stages of
development. The following table summarizes our proprietary product and product candidates as well as our collaboration product candidates: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:140pt"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product and Product Candidates</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Therapeutic<BR>Area</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Use /<BR>Indication(s)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Research/</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pre-<BR>Clinical</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Phase&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Phase&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Phase&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed for<BR>Approval</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Approved<BR>Product</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="29"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Proprietary Product and Product Candidates</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Hylenex</I> recombinant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Various</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peptide,&nbsp;small</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(hyaluronidase human injection)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">molecule and fluid delivery</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Analog Insulin-PH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Endocrinology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diabetes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEGPH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Solid tumors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HTI-501</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dermatology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aesthetic</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">medicine,</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Collaboration Product Candidates</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roche (up to 8 targets):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcutaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breast cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT>
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcutaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MabThera<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT>
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hodgkin&#146;s</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">lymphoma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcutaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rheumatoid</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Actemra<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT>
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inflammatory</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">arthritis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter BioScience</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immunology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Primary</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HyQ</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">immuno-</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(GAMMAGARD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">deficiency</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LIQUID<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT>
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">with rHuPH20)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ViroPharma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immunology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hereditary</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cinryze<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
with</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">angioedema</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">rHuPH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intrexon</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immunology</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hereditary</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#666666"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alpha 1-antitrypsin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">emphysema</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">with rHuPH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>More Physiologic (Ultrafast) Insulin Program </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead proprietary program focuses on using rHuPH20 with prandial (mealtime or rapid-acting) insulin for the
treatment of diabetes mellitus. Diabetes mellitus is an increasingly prevalent, costly condition associated with substantial morbidity and mortality. Attaining and maintaining normal blood sugar levels to minimize the long-term clinical risks is a
key treatment goal for people living with diabetes. We have combined rHuPH20 with a rapid acting analog insulin, e.g., insulin lispro (Humalog<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) (Lispro-PH20), insulin aspart
(Novolog<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) (Aspart-PH20), and insulin glulisine (Apidra<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>), (each such combination, Analog-PH20), to accelerate their action. We have also studied the pre-administration of <I>Hylenex</I> recombinant in analog insulin pump
therapy at infusion site change (once every 48-72 hours). These Analog-PH20 combinations facilitate faster insulin dispersion in, and absorption from, the subcutaneous space into the vascular compartment, leading to faster insulin response. By
making mealtime insulin onset faster, i.e., providing earlier insulin to the blood and thus earlier glucose lowering activity, Analog-PH20 may yield a better profile of insulin effect, more like that found in healthy, non-diabetic people.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary goal of our more physiologic insulin program is to develop a best-in-class insulin product, with demonstrated
clinical benefits for type 1 and 2 diabetes mellitus patients, in comparison to the current standard of care analog insulin products. With a more rapidly absorbed, faster acting insulin product, we seek to demonstrate one or more significant
improvements relative to existing treatment, such as improved glycemic control, less hypoglycemia, and less weight gain. A number of clinical trials investigating the various attributes of our insulin candidates have been completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We view the multiple daily injection (MDI) market and the continuous subcutaneous insulin infusion (CSII) or pump market as distinct
product opportunities that could be pursued separately.&nbsp;Based on the data we have seen thus far, we believe that a large biotech or pharmaceutical company with global access to the primary care markets would be best positioned to maximize the
value of the MDI market and, therefore, entering into a collaboration would be an attractive option for us to leverage this opportunity.&nbsp;We believe that the pre-administration of <I>Hylenex</I> recombinant could be the best product offering for
the CSII market.&nbsp;We are currently evaluating a variety of strategic options for pursuing this opportunity commercially.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the American Diabetes Association&#146;s (ADA) annual conference in June 2012, we presented three clinical studies from our more
physiologic insulin program for two distinct markets &#150; the MDI market and the CSII market. With regard to MDI opportunity, we presented data from two treatment studies &#150; one in type 1 diabetes patients and one in type 2 diabetes patients.
Both studies met their primary endpoints of A1C non-inferiority (A1C is a measure of average blood sugar over three months) and improved post-prandial glucose control, compared to patients who were treated with analog insulin alone. Additionally,
data from the type 1 diabetes treatment study indicated that Analog-PH20 formulations reduced hypoglycemia compared to analog insulin alone. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the CSII market, we presented interim data from a study evaluating the use of <I>Hylenex</I> recombinant in analog insulin pump therapy that showed pre-administration of <I>Hylenex</I> recombinant
provided a &#147;faster-on faster-off&#148; more physiologic profile than current rapid insulin analogs. Data from the double-blind cross-over study showed that pre-administration of <I>Hylenex</I> recombinant, at the time of infusion set change,
not only accelerated the absorption and action of mealtime insulin, but also provided a more consistent insulin action profile over the three days of the infusion set life which resulted in improved post-prandial glucose control. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PEGPH20 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
developing an investigational PEGylated form of rHuPH20 (PEGPH20), a new molecular entity, as a candidate for the systemic treatment of tumors that accumulate HA. PEGylation refers to the attachment of polyethylene glycol to rHuPH20, thereby
creating PEGPH20. One of the novel properties of PEGPH20 is that it has an extended serum half-life and therefore can be used to treat systemic disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Approximately 25% of all solid malignancies accumulate HA, including pancreatic, lung, breast, colon and prostate cancers. Aberrant accumulation of this component of the tumor&#146;s infrastructure
supports a protective network that surrounds certain tumors. This pathologic accumulation of HA along with other matrix components creates a unique microenvironment for the growth of tumor cells compared to normal cells. We believe that depleting
the HA component of the tumor architecture with PEGPH20 disrupts the tumor microenvironment and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
opens the previously constricted vessels to allow anti-cancer therapies to have greater access to the tumor, which may enhance the chemotherapy&#146;s treatment effect. Increased blood flow may
also enhance radiotherapy treatment effect. We have generated data showing that disrupting the specialized environment around tumors will directly inhibit the growth. Because HA accumulates in about 25% of all solid tumors, we believe that PEGPH20
has the potential to help patients with many different kinds of cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently conducting clinical trials with
PEGPH20 in the treatment of solid tumors. The trials incorporate the use of oral dexamethasone as prophylactic treatment for all patients prior to receiving intravenous administration of PEGPH20 and subsequent post-dose oral dexamethasone.
Dexamethasone minimizes the side effect of PEGPH20. Our Phase 2 clinical trial, with a Phase 1b run-in period, for patients with metastatic pancreatic cancer is currently ongoing. In the Phase 1b run-in period of the trial, patients receive PEGPH20
in combination with gemcitabine. The objective of Phase 1b is to identify the recommended Phase 2 dose of PEGPH20 in combination with gemcitabine. The Phase 2 portion of the trial will be a randomized, double-blind, placebo-controlled study to
assess safety, tolerability, and efficacy of PEGPH20 in combination with certain chemotherapeutic agents versus the chemotherapeutic agents alone. We expect to specify the chemotherapeutic agents we will use in the Phase 2 portion of the trial
pending our determination of the chemotherapeutic agents that are most relevant in the treatment of pancreatic cancer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>HTI-501
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">HTI-501, a recombinant human proteinase known as cathepsin L, is a lysosomal proteinase that acts by degrading
collagen and is our first conditionally-active biologic. Collagen is an abundant protein in the body, particularly in connective tissue, and is present in high amounts in the extracellular matrix in the form of collagen fibers. Collagens are a class
of helical proteins that are assembled into macromolecular fibrils and fibers. The collagen fiber network provides a structural scaffolding framework in the extracellular matrix. In the skin, these collagen fibers connect the superficial epithelial
tissues to the underlying connective tissues. Collagen abnormalities contribute to a number of conditions, including frozen shoulder, Dupuytren&#146;s contracture, Peyronie&#146;s disease and cellulite. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A conditionally active biologic is a molecule that is only active under certain physiological conditions. HTI-501 is active under mildly
acidic conditions and inactive at the pH normally found in the tissue. The enzyme is combined with a low pH buffer and injected in its active state. The enzyme is only active locally and for a short period of time. Once the mildly acidic conditions
of the HTI-501 administration have been neutralized by the body, the enzyme becomes inactive. We intend to harness this conditional activity to exert control over the duration and location of the enzyme&#146;s therapeutic activity, potentially
improving the efficacy or safety of this product candidate for both medical and aesthetic conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exploring
HTI-501 as an approach to the treatment of edematous fibrosclerotic panniculopathy, also known as cellulite. The condition affects the great majority of post-adolescent women and is prevalent in all races. We believe that the collagen fibers
(fibrous septa) anchor the epidermis against the swelling of subcutaneous fat, which creates the dimpled appearance associated with the condition. We believe that HTI-501 acts by releasing the tension in the collagenous fibrous septa and smoothing
the dimpled appearance of the skin. HTI-501 has the potential to be studied as a treatment for other conditions involving collagen, such as frozen shoulder, Dupuytren&#146;s contracture, Peyronie&#146;s disease, keloids and hypertrophic scarring.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2011, we initiated a Phase 1/2 clinical trial of HTI-501 in women with moderate to severe
cellulite. The Phase 1 dose escalation portion of the trial evaluated a single injection of different HTI-501 formulations into dimpled lesions of the skin followed by a Phase 2 portion of the trial where multiple lesions are targeted with the
optimal dose and formulation. Up to 48 and 76 subjects may be enrolled in the Phase 1 and Phase 2 portions of the trial, respectively. The interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 were presented at
the 8</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> World Congress of the International Academy of
Cosmetic Dermatology in Cancun, Mexico, which was held from January&nbsp;31 to February&nbsp;3, 2012. In the Phase 1 portion of the clinical trial, no serious or severe adverse events were reported and the injection was well tolerated. The most
common adverse event was mild to moderate pain at the injection site that was generally bilateral (present at both investigational drug and buffer control injection sites), lasted a few minutes and did not require treatment. Data from this study
supported commencement of the Phase 2 portion of the clinical trial, which is currently underway. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Enhanze Technology </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Enhanze technology is a proprietary delivery platform using rHuPH20.&nbsp;This enzyme temporarily degrades HA. We believe this temporary degradation creates an opportunistic window for the improved
subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. The HA reconstitutes its normal density within several days and, therefore, we anticipate that
any effect of rHuPH20 on the architecture of the subcutaneous space is temporary. By using our rHuPH20 enzyme, many therapeutics that could normally only be injected intravenously can now be administered subcutaneously. This change in the route of
delivery to subcutaneous from intravenous (IV), can often improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle and reduce cost. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently have Enhanze technology collaborations with Roche, Baxter, ViroPharma and Intrexon. We are currently pursuing additional collaborations with biopharmaceutical companies that market drugs
requiring or benefiting from injection via the subcutaneous route of administration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Roche Collaboration
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December&nbsp;2006, we and Roche entered into an agreement under which Roche obtained a worldwide, exclusive
license to develop and commercialize product combinations of rHuPH20 with up to thirteen Roche target compounds (the Roche Collaboration). Roche initially had the exclusive right to apply rHuPH20 to only three pre-defined Roche biologic targets with
the option to exclusively develop and commercialize rHuPH20 with ten additional targets. As of September&nbsp;30, 2012, Roche has elected a total of five exclusive targets and retains the option to develop and commercialize rHuPH20 with three
additional targets through the payment of annual license maintenance fees. Pending the successful completion of various clinical, regulatory and sales events, Roche will be obligated to make milestone payments to us, as well as royalty payments on
the sales of products that result from the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2012, Roche submitted a Line
Extension Application to the European Medicines Agency for a compound, directed at one of the five Roche excusive targets, formulated with rHuPH20 (subcutaneous Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>). In addition, clinical trials have commenced for compounds directed at two other Roche exclusive targets under the Roche Collaboration. One compound formulated with
rHuPH20 (subcutaneous MabThera<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) is in a Phase 3 clinical trial and one compound formulated with rHuPH20
(subcutaneous Actemra<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) has completed a Phase 1 clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011, Roche announced positive top line results from the Phase 3 clinical trial in women with early HER2-positive breast
cancer who received a fixed dose of a new subcutaneously delivered version of Roche&#146;s anticancer biologic, Herceptin (trastuzumab) (Herceptin SC). In the study, the subcutaneous formulation showed comparable results to Herceptin given as an IV
infusion (Herceptin IV). Herceptin SC takes about 5 minutes to administer whereas Herceptin IV takes about 30-90 minutes to infuse. Roche is also developing an auto-injector device that should further simplify the process and could enable patients
to be dosed at home or in the doctor&#146;s office rather than at an infusion clinic or hospital. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required. This Phase 3 clinical trial was
an open-label trial involving 596 women with HER2-positive early breast cancer. The trial was designed to compare trastuzumab concentration in the blood (pharmacokinetics), efficacy (pathologic complete response) and safety of Herceptin SC to that
of Herceptin IV. The trial met its co-primary endpoints including trastuzumab concentration in the blood (serum concentrations) and efficacy. No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Herceptin
is approved to treat HER2-positive breast cancer and currently is given intravenously. Breast cancer is the most common cancer among women worldwide. Each year, more than 1.4&nbsp;million new cases of breast cancer are diagnosed worldwide, and
nearly 450,000 people will die of the disease annually. In HER2-positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumor cells. This is known as &#145;HER2 positivity&#146; and affects approximately
15-20% of people with breast cancer. Roche recently announced that data from this trial was presented at the European Breast Cancer Conference in Vienna, which was held in March 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2011, Roche began a Phase 3 clinical trial for a subcutaneous formulation of MabThera (rituximab) (MabThera SC). The study
investigates pharmacokinetics, efficacy and safety of MabThera SC. IV administered MabThera is approved for the treatment of non-Hodgkin&#146;s lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), types of cancer that affect lymphocytes (white
blood cells). An estimated 66,000 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
new cases of NHL were diagnosed in the U.S. in 2009 with approximately 125,000 new cases reported worldwide. Roche has stated that they will present data from the program in 2012 and they expect
to file a marketing application to regulatory authorities in the European Union in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2009, Roche completed a Phase 1
clinical trial for a subcutaneous formulation of Actemra. This trial investigated the safety and pharmacokinetics of subcutaneous Actemra in patients with rheumatoid arthritis. The results from this Phase 1 trial suggest that further exploration may
be warranted. Actemra administered intravenously is approved for the treatment of rheumatoid arthritis. Roche is separately developing a subcutaneous form of Actemra that does not use rHuPH20 and is being investigated for weekly or biweekly
administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional information about the Phase 3 subcutaneous Herceptin and Phase 3 subcutaneous MabThera clinical
trials can be found at www.clinicaltrials.gov and www.roche-trials.com. Information available on these websites is not incorporated into this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Baxter Gammagard Collaboration </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GAMMAGARD LIQUID is a Baxter product
that is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system. In September 2007, we and Baxter entered into an agreement under which Baxter obtained a worldwide, exclusive license to develop
and commercialize a product candidate (HyQ) consisting of rHuPH20 combined with GAMMAGARD LIQUID (the Gammagard Collaboration). Pending the successful completion of various regulatory and sales milestones, Baxter is obligated to make milestone
payments to us, as well as royalty payments on the sales of products that result from the collaboration. Baxter is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs under the Gammagard Collaboration,
while we are responsible for the supply of rHuPH20. We perform research and development activities at the request of Baxter, which are reimbursed by Baxter under the terms of the Gammagard Collaboration. In addition, Baxter has certain product
development and commercialization obligations in major markets identified in the Gammagard License. In September 2011, Baxter submitted an application to the European Medicines Agency&#146;s Committee for Human Medicinal Products seeking marketing
approval for HyQ. Baxter filed a biologic license application (BLA) for HyQ in the U.S. in the second quarter of 2011. On August&nbsp;1, 2012, we announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug
Administration (FDA) has issued a complete response letter (CRL) for Baxter&#146;s HyQ BLA. The CRL requested additional preclinical data to support the BLA. The primary issues raised in the CRL focused on non-neutralizing antibodies generated
against rHuPh20 and the possible effects of these antibodies on reproduction, development and fertility. Elevated anti-rHuPH20 antibody titers were detected in the registration trial, but have not been associated with any adverse events. Pending
Baxter and us providing additional preclinical data sufficient to address the regulatory questions, CBER has requested that patients should no longer be dosed with rHuPH20 in the Baxter HyQ program. Baxter has announced that individuals enrolling in
ongoing HyQ clinical studies in the U.S. will now be treated with Baxter&#146;s immune globulin therapy without rHuPH20.&nbsp;We and Baxter expect these requests will require additional time to complete and will delay the companies&#146; anticipated
regulatory review and approval timelines. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>ViroPharma Collaboration </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective May&nbsp;10, 2011, we and ViroPharma entered into a license and collaborative agreement under which
ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 in the development of a subcutaneous injectable formulation of ViroPharma&#146;s commercialized product, Cinryze<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (C1 esterase inhibitor [human]) (the ViroPharma Collaboration). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and to the
hereditary angioedema indication, along with three additional orphan indications. ViroPharma is solely responsible for the development, manufacturing, regulatory approval and marketing of any products resulting from the collaboration. We are
entitled to receive payments for research and development services and supply of bulk formulation of rHuPH20 (active pharmaceutical ingredient or API), if requested by ViroPharma. We are also entitled to receive milestone payments and royalties on
product sales by ViroPharma. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2012, ViroPharma reported positive data from ViroPharma&#146;s Phase 2 subcutaneous
trial of Cinryze in combination with Enhanze technology in patients with hereditary angioedema, a rare, debilitating and potentially fatal genetic disease. These data demonstrate that subcutaneous co-administration of Cinryze with rHuPH20 was easy
to administer, well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations. This innovative combination administered subcutaneously as a single injection will be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
further evaluated for the prevention of hereditary angioedema attacks. The results were presented at the 2012 annual meeting of the American Academy of Allergy Asthma&nbsp;&amp; Immunology, held
in March 2012 in Orlando, Florida. The open-label, multiple-dose Phase 2 clinical trial was conducted in 12 subjects with hereditary angioedema. The study was designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous
administration of Cinryze in combination with rHuPH20. We believe this product candidate could improve flexibility and convenience, and potentially allow prevention-minded patients living with hereditary angioedema to self administer every three or
four days, just as they do today with the current IV formulation, but with a single subcutaneous injection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;1,
2012, ViroPharma announced that the FDA had requested that studies of the combination of Cinryze and rHuPH20 be placed on temporary clinical hold pending the FDA&#146;s evaluation of potential safety concerns with Halozyme&#146;s rHuPH20 enzyme
raised by the presence of anti-rHuPH20 non-neutralizing antibodies that were detected in Baxter&#146;s HyQ program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
September&nbsp;21, 2012, ViroPharma and we announced that the FDA has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. The FDA informed ViroPharma that based
on their ongoing assessment, the FDA believes the potential safety signals regarding antibodies to rHuPH20 that were detected in Baxter&#146;s HyQ clinical development program are limited to that specific program. The FDA has advised ViroPharma to
amend the study protocol, allowing for increased laboratory sampling to monitor anti-rHuPH20 antibody levels, and keep the FDA informed of elevated antibody levels during the treatment phase of the study. ViroPharma announced that it plans to
initiate a larger Phase 2 clinical trial with the combination of Cinryze and rHuPH20 shortly. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intrexon Collaboration
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective June&nbsp;6, 2011, we and Intrexon entered into a license and collaborative agreement under which Intrexon
obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon&#146;s recombinant human alpha 1-antitrypsin (rHuA1AT) (the Intrexon Collaboration). In addition, the
license provides Intrexon with exclusivity for a defined indication (Exclusive Field). Intrexon is solely responsible for the development, manufacturing, regulatory approval and marketing of any products resulting from this collaboration. We are
entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. We are also entitled to receive milestone payments and royalties on product sales. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Hylenex Recombinant </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><I>Hylenex </I><B></B>recombinant is a formulation of rHuPH20 that has received FDA approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and
absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. <B> </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate revenues from product sales and collaborative agreements. Revenue from product sales depends on our ability to
develop, manufacture, obtain regulatory approvals for and successfully commercialize our products and product candidates. Payments received under collaborative agreements may include nonrefundable payments at the inception of the arrangement,
license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, reimbursements of research and development services, payments for the manufacture of bulk formulation of rHuPH20 for
collaborators and/or royalties, as applicable, on sales of products resulting from collaborative agreements. We analyze each element of our collaborative agreements and consider a variety of factors in determining the appropriate method of revenue
recognition. See &#147;<I>Critical Accounting Policies and Estimates &#150; Revenue Recognition &#150; Revenues Under Collaborative Agreements</I>&#148; below for our revenue recognition policies for payments received under collaborative agreements.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Costs and Expenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Product Sales. </I>Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead
costs associated with the production of our products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development.</I> Research and development expenses include salaries and benefits, research related manufacturing services, clinical trials, contract research services, supplies and
materials, facilities and other overhead costs and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future
uses. Our research and development activities are primarily focused on the development of our various product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception in 1998 through September&nbsp;30, 2012, we have incurred research and development expenses of $310.6 million. From
January&nbsp;1, 2009 through September&nbsp;30, 2012, approximately 25% and 16% of our research and development expenses were associated with the development of our ultrafast insulin and PEGPH20 product candidates, respectively. Research and
development expenses incurred for the nine months ended September&nbsp;30, 2012 and 2011 were as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Programs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product Candidates:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PEGPH20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,085,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,833,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HYLENEX</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,402,986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,638,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ultrafast Insulin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,886,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,926,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HTI-501</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,582,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,368,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhanze partnerships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,466,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,054,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">rHuPH20 platform (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,676,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,917,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,375,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,908,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,476,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,647,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes research, development and manufacturing expenses related to our proprietary recombinant human PH20 enzyme, rHuPH20. These expenses were not designated to a
specific program at the time the expenses were incurred. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the uncertainty in obtaining FDA and other
regulatory approvals, our reliance on third parties and competitive pressures, we are unable to estimate with any certainty the additional costs we will incur in the continued development of our proprietary product candidates for commercialization.
However, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical development timelines, likelihood of success and total costs vary widely. We anticipate that we will make ongoing determinations as to which research and development projects to pursue and how
much funding to direct to each project on an ongoing basis in response to existing resource levels, the scientific and clinical progress of each product candidate, and other market and regulatory developments. We plan on focusing our resources on
those proprietary and collaboration product candidates that represent the most valuable economic and strategic opportunities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product candidate completion dates and costs vary significantly for each product candidate
and are difficult to estimate. The lengthy process of seeking regulatory approvals and the subsequent compliance with applicable regulations require the expenditure of substantial resources. Any failure by us to obtain, or any delay in obtaining,
regulatory approvals could cause our research and development expenditures to increase and, in turn, have a material adverse effect on our results of operations. We cannot be certain when, or if, our product candidates will receive regulatory
approval or whether any net cash inflow from our other product candidates, or development projects, will commence. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative (SG&amp;A). </I>Through the second quarter of 2011, our selling expenses, which include sales and
marketing costs, primarily consisted of compensation, consulting fees and costs of market research studies related to our product and product candidates. In the third and fourth quarters of 2011, we expanded our commercial infrastructure, including
hiring of sales and marketing management and sales representatives. In addition, we began incurring costs related to advertising, marketing and logistics services for <I>Hylenex</I> recombinant in connection with the reintroduction of <I>Hylenex</I>
recombinant in December 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our general and administrative expenses consist primarily of compensation and other expenses
related to our corporate operations and administrative employees, accounting and legal fees, other professional services expenses, as well as other expenses associated with operating as a publicly traded company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our discussion and analysis of our financial position and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted
accounting principles (U.S. GAAP). The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of
contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following accounting policies to be critical to the judgments
and estimates used in the preparation of our consolidated financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
resulting from collaborative arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue in accordance with the authoritative guidance on revenue
recognition. Revenue is recognized when all of the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the seller&#146;s price to the buyer is
fixed or determinable; and (4)&nbsp;collectibility is reasonably assured. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product Sales </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we reintroduced <I>Hylenex</I> recombinant to the market, shipped initial orders to our wholesaler customers and began
promoting <I>Hylenex</I> recombinant through our sales force. We sell <I>Hylenex</I> recombinant in the United States to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. The wholesale
distributors take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales; however, we allow the
wholesale distributors to return product that is damaged or received in error. In addition, we allow for product to be returned beginning six months prior to and ending twelve months following product expiration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given our limited history of selling <I>Hylenex</I> recombinant and the lengthy return period, we currently cannot reliably estimate
expected returns and chargebacks of <I>Hylenex</I> recombinant at the time the product is received by the wholesale distributors. Therefore, we do not recognize revenue upon delivery of <I>Hylenex </I>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recombinant to the wholesale distributor until the point at which we can reliably estimate expected product returns and chargebacks from the wholesale distributors. Shipments of <I>Hylenex</I>
recombinant are recorded as deferred revenue until evidence exists to confirm that pull-through sales to the hospitals or other end-user customers have occurred. We recognize revenue when the product is sold through from the distributors to the
distributors&#146; customers. In addition, the costs of manufacturing <I>Hylenex</I> recombinant associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is
recognized. We estimate sell-through revenue and certain gross to net sales adjustments based on analysis of third-party information including information obtained from certain distributors with respect to their inventory levels and sell-through to
the distributors&#146; customers. At the time we can reliably estimate product returns and chargebacks from the wholesale distributors, we will record a one-time increase in net product sales revenue related to the recognition of product sales
revenue previously deferred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize product sales allowances as a reduction of product sales in the same period the
related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with wholesaler customers, hospitals and the levels of
inventory within the distribution channels that may result in future discounts taken. We must make significant judgments in determining these allowances. If actual results differ from our estimates, we will be required to make an adjustment to these
allowances in the future, which could have an effect on product sales revenue in the period of adjustment. Our product sales allowances include: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Distribution Fees</I>. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesale distributors for distribution services they
provide with respect to <I>Hylenex</I> recombinant. At the time the sale is made to the respective wholesale distributors, we record an allowance for distribution fees by reducing our accounts receivable and deferred revenue associated with such
product sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prompt Payment Discounts</I>. We offer cash discounts to certain wholesale distributors as an incentive to
meet certain payment terms. We expect our customers to take advantage of this discount. Therefore, at the time the sale is made to the respective wholesale distributors, we accrue the entire prompt payment discount, based on the gross amount of the
invoice by reducing our accounts receivable and deferred revenue associated with such product sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Chargebacks</I>. We
provide discounts to end-user members of certain group purchasing organizations (&#147;GPO&#148;) under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals who are members of the GPOs with which we
do not have contracts. The end-user members purchase products from the wholesale distributors at a contracted discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the
end users paid for the product. Given our lack of historical sales data, we recognize chargebacks in the same period the related product sales revenue is recognized and reduce our accounts receivable accordingly. The GPO fee we incur for these
transactions is also recorded in the same period the related product sales revenue is recognized and is included in accrued expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Product Returns</I>. The product returns reserve is based on management&#146;s best estimate of the product sales recognized as revenue during the period that are anticipated to be returned. The
product returns reserve is recorded as a reduction of product sales revenue in the same period the related product sales revenue is recognized and is included in accrued expenses. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues under Collaborative Agreements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into license and collaboration agreements under which the collaborators obtained worldwide exclusive rights for the use of our proprietary rHuPH20 enzyme in the development and
commercialization of the collaborators&#146; biologic compounds. The collaborative agreements contain multiple elements including nonrefundable payments at the inception of the arrangements, license fees, exclusivity fees, payments based on
achievement of specified milestones designated in the collaborative agreements, reimbursements of research and development services, payments for supply of rHuPH20 API for the collaborator and/or royalties on sales of products resulting from
collaborative agreements. We analyze each element of the collaborative agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the adoption of ASU No.&nbsp;2009-13, <I>Multiple-Deliverable Revenue
Arrangements</I>, on January&nbsp;1, 2011, in order for a delivered item to be accounted for separately from other deliverables in a multiple-element arrangement, the following three criteria had to be met: (i)&nbsp;the delivered item had standalone
value to the customer, (ii)&nbsp;there was objective and reliable evidence of fair value of the undelivered items, and (iii)&nbsp;if the arrangement included a general right of return relative to the delivered item, delivery or performance of the
undelivered items was considered probable and substantially in the control of the vendor. For the collaborative agreements entered into prior to January&nbsp;1, 2011, there was no objective and reliable evidence of fair value of the undelivered
items. Thus, the delivered licenses did not meet all of the required criteria to be accounted for separately from undelivered items. Therefore, we recognized revenue on nonrefundable upfront payments and license fees from these collaborative
agreements over the period of significant involvement under the related agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For new collaborative agreements or
material modifications of existing collaborative agreements entered into after December&nbsp;31, 2010, we follow the provisions of ASU No.&nbsp;2009-13. In order to account for the multiple-element arrangements, we identify the deliverables included
within the agreement and evaluate which deliverables represent units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to
use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&nbsp;the license to rHuPH20 technology, (ii)&nbsp;at the collaborator&#146;s request, research and development services which are
reimbursed at contractually determined rates, and (iii)&nbsp;at the collaborator&#146;s request, supply of rHuPH20 API which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered
item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the collaborator and the
availability of research expertise in this field in the general marketplace. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrangement consideration is allocated at the
inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (VSOE) of selling price or third-party
evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to
amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales
price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Nonrefundable upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally
include research and development services and the manufacture of rHuPH20 API, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the
collaborator is fixed or determinable and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the
period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The terms of our collaborative agreements provide for milestone payments upon achievement of certain development and regulatory events and/or specified sales volumes of commercialized products by the
collaborator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2011, we adopted on a prospective basis the Milestone Method. Under the Milestone
Method, we recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered
substantive when it meets all of the following criteria: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration is commensurate with either the entity&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a
result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration relates solely to past performance, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A milestone is defined as an event (i)&nbsp;that can only be achieved based in whole or in
part on either the entity&#146;s performance or on the occurrence of a specific outcome resulting from the vendor&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the date the arrangement is entered into that the event
will be achieved, and (iii)&nbsp;that would result in additional payments being due to the vendor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursements of research
and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is
probable. Revenue from the manufacture of rHuPH20 API is recognized when the API has met all specifications required for the collaborator&#146;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control
when any collaborator will request research and development services or supply of rHuPH20 API; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of rHuPH20 API. Royalties to
be received based on sales of licensed products by our collaborators incorporating rHuPH20 will be recognized as earned. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
collaborative agreements typically provide the collaborators the right to terminate such agreements in whole or on a product-by-product or target-by-target basis at any time upon 90 days prior written notice to us. There are no performance,
cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Roche Collaboration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December&nbsp;2006, we and Roche entered into the
Roche Collaboration under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with up to thirteen Roche target compounds. As of September&nbsp;30, 2012, we have received $57 million from
Roche, including the $20 million upfront license fee payment for the application of rHuPH20 to the initial three Roche exclusive targets, $20 million in connection with Roche&#146;s election of two additional exclusive targets and annual license
maintenance fees for the right to designate the remaining targets as exclusive targets, $13 million in clinical development milestone payments and a $4 million regulatory milestone payment. If Roche successfully develops all five exclusive targets
and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $178 million, including up to $17 million for the achievement of clinical development milestones, up to $16 million for the achievement of regulatory
milestones and up to $145 million for the achievement of sales-based milestones. Under the terms of the Roche Collaboration, Roche will also pay us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent
of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&#146;s obligation to pay royalties. Roche has the obligation to pay royalties with
respect to each product in each country, during the period equal to the longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the
product in such country or (b)&nbsp;ten years following the date of the first commercial sale of such product in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roche currently retains the option to develop and commercialize rHuPH20 with three additional targets under the Roche Collaboration,
provided that it continues to pay annual maintenance fees to us. For products developed for each of the additional targets, Roche may pay us upfront and milestone payments of up to $47 million per target, as well as royalties on product sales, for
each of the additional targets consisting of a mid-single digit percent of the net sales of such products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to our
continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of
the Roche Collaboration. We have determined that the clinical and regulatory milestones are substantive; therefore, we expect to recognize such clinical and regulatory milestone payments as revenue upon achievement. In addition, we have determined
that the sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, we will recognize such sales-based milestone payments as revenue upon
achievement of the milestone. For the three months ended September&nbsp;30, 2012 and 2011, we recognized no milestone payments as revenues under collaborative agreements in accordance with the Milestone Method. For the nine months ended
September&nbsp;30, 2012 and 2011, we recognized $4 million and $5 million, respectively, as revenues under collaborative agreements in accordance with the Milestone Method related to the achievement of certain clinical and regulatory milestones
pursuant to the terms of the Roche Collaboration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gammagard Collaboration </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2007, we and Baxter entered into the Gammagard Collaboration under which Baxter obtained a worldwide, exclusive license to
develop and commercialize HyQ. As of September&nbsp;30, 2012, we have received $13 million under the Gammagard Collaboration, including the $10 million upfront license fee payment and a $3 million regulatory milestone payment. If Baxter successfully
receives marketing approval for the licensed product candidate and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $34 million for the achievement of sales-based milestones. In addition, Baxter will pay us
a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. The Gammagard Collaboration is applicable to both kit and formulation combinations. Baxter assumes all
development, manufacturing, clinical, regulatory, sales and marketing costs under the Gammagard Collaboration, while we are responsible for the supply of the rHuPH20 enzyme. We perform research and development activities at the request of Baxter,
which are reimbursed by Baxter under the terms of the Gammagard Collaboration. In addition, Baxter has certain product development and commercialization obligations in major markets identified in the Gammagard Collaboration. Unless terminated
earlier in accordance with its terms, the Gammagard Collaboration continues in effect until the expiration of Baxter&#146;s obligation to pay royalties. Baxter has the obligation to pay royalties, with respect to each product in each country, during
the period equal to the longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years
following the date of the first commercial sale of such product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to our continuing involvement
obligations (for example, support activities associated with rHuPH20), revenue from the upfront payment was deferred and are being recognized over the term of the Gammagard Collaboration. We have determined that sales-based milestone payments are
similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, such payments will be recognized as revenue upon achievement of the milestone. For the three and nine months ended
September&nbsp;30, 2012, we recognized no milestone payments as revenue in accordance with the Milestone Method of revenue recognition. For the three and nine months ended September&nbsp;30, 2011, we recognized zero and $3 million, respectively, as
revenues under collaborative agreements in accordance with the Milestone Method of revenue recognition upon achievement of certain regulatory milestone under the terms of the Gammagard Collaboration. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ViroPharma and Intrexon Collaborations </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective May 2011, we and ViroPharma entered into the ViroPharma Collaboration. As of September&nbsp;30, 2012, we have received $13 million from ViroPharma, including the $9 million nonrefundable upfront
license fee payment, a $3 million clinical development milestone payment and a $1 million annual exclusivity payment. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41
million for the achievement of development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive an annual exclusivity fee of $1 million which commenced May 2012 and on each anniversary of the
effective date of the agreement thereafter until a certain development event occurs. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to
receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to
receive a royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the ViroPharma Collaboration continues in effect until the later
of (i)&nbsp;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and
(ii)&nbsp;expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Collaboration, with respect to each country, consists of the period equal to the
longer of: (a)&nbsp;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the
first commercial sale of such product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective June 2011, we and Intrexon entered into the Intrexon
Collaboration. As of September&nbsp;30, 2012, we have received a nonrefundable upfront license fee payment of $9 million and an annual exclusivity fee of $1 million from Intrexon. If Intrexon successfully develops the licensed product candidate and
achieves the pre-agreed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
sales target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the
achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive an annual exclusivity fee of $1 million which commenced in June 2012 and on each anniversary of the effective date of the
agreement thereafter until a certain development event occurs. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to receive additional cash
payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive a royalty on each product commercialized under the agreement
consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. Unless terminated earlier in accordance with its terms, the Intrexon Collaboration continues in effect until the later of
(i)&nbsp;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii)&nbsp;expiration
of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Collaboration, with respect to each country, consists of the period equal to the longer of: (a)&nbsp;the
duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&nbsp;ten years following the date of the first commercial sale of
such product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We identified the deliverables at the inception of the ViroPharma and Intrexon Collaborations
which are the license, research and development services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has
standalone value. The estimated selling prices for these units of accounting were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and
entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the collaborators. The arrangement
consideration was allocated to the deliverables based on the relative selling price method. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount allocable to the
delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, we excluded from the allocable
arrangement consideration the milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the $9 million upfront license fee received from ViroPharma to the
license fee deliverable under the ViroPharma arrangement and the $9 million upfront fee received from Intrexon to the license fee deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the
worldwide exclusive right to our technology to the collaborator in both the ViroPharma Collaboration and Intrexon Collaboration. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Collaboration and $9 million
upfront license fee received under the Intrexon Collaboration as revenues under collaborative agreements upon the receipt of such upfront license fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recognize the annual exclusivity fees as revenues under collaborative agreements when they are due and payable on each anniversary of the effective date and such amounts are included in the allocable
arrangement consideration and recognized based on the relative selling price allocation. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We
recognize amounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We
cannot predict the timing of delivery of research and development services and API as they are at the collaborators&#146; requests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are eligible to receive additional cash payments upon the achievement by the collaborators of specified development, regulatory and sales-based milestones. We have determined that each of the
development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In
addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone Method of revenue recognition; therefore, we will recognize the sales-based milestone
payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the three and nine months ended September&nbsp;30, 2011, we recognized a $3 million
milestone payment as revenues under collaborative agreements in accordance with the Milestone Method related to the achievement of a development milestone pursuant to the terms of the ViroPharma Collaboration. There were no milestone payments
recognized as revenues under collaborative agreements associated with the ViroPharma Collaboration for the three and nine months ended September&nbsp;30, 2012. There were no milestone payments recognized as revenues under collaborative agreements
associated with the Intrexon Collaboration for the three and nine months ended September&nbsp;30, 2012 and 2011. We recognized the annual exclusivity fee of zero and $1 million as revenues under collaborative agreements associated with each of the
ViroPharma and Intrexon Collaborations for the three and nine months ended September&nbsp;30, 2012, respectively. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based Payments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We use the fair value method to account for share-based payments in accordance with the authoritative guidance for share-based compensation. The fair value of each option award is estimated on the date of
grant using a Black-Scholes-Merton option pricing model (Black-Scholes model), that uses assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility, actual
and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. Expected volatilities are based on the historical volatility of our common stock. The expected term of options granted is based on analyses of
historical employee termination rates and option exercises. The risk-free interest rates are based on the U.S. Treasury yields in effect at the time of the grant. Since we do not expect to pay dividends on our common stock in the foreseeable future,
we estimated the dividend yield to be 0%. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate pre-vesting forfeitures based on our historical
experience. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If factors change and we employ different assumptions for determination of fair value in future periods, the
share-based compensation expense that we record may differ significantly from what we have recorded in the current period. There is a high degree of subjectivity involved when using option pricing models to estimate share-based compensation. Certain
share-based payments, such as employee stock options, may expire worthless or otherwise result in zero intrinsic value as compared to the fair values originally estimated on the grant date and reported in our consolidated financial statements.
Alternatively, values may be realized from these instruments that are significantly in excess of the fair values originally estimated on the grant date and reported in our consolidated financial statements. There is currently no market-based
mechanism or other practical application to verify the reliability and accuracy of the estimates stemming from these valuation models, nor is there a means to compare and adjust the estimates to actual values. Although the fair value of employee
share-based awards is determined in accordance with authoritative guidance on share-based payments using an option-pricing model, such value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses include salaries and benefits, facilities and other overhead expenses, clinical trial expenses, research related manufacturing services, contract services and other
outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and
development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the goods to be delivered or services
to be performed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone payments that we make in connection with in-licensed technology or product candidates are expensed
as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product candidates to be uncertain until such
licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all of our licensed technology or product
candidates to be uncertain and has expensed these amounts as incurred. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments made in connection with our clinical trials are often made under contracts with
multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally,
these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time-and-material basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of
other clinical trial milestones. Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient
studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial
protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in scope of contract are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
Because of the uncertainty of possible future changes to the scope of work in clinical trial contracts, we are unable to quantify an estimate of the reasonably likely effect of any such changes on our consolidated results of operations or financial
position. Historically, we have had no material changes in our clinical trial expense accruals that would have had a material impact on our consolidated results of operations or financial position. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inventories </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
compared with historical cost and the remaining shelf life of goods on hand. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials inventories consist of raw
materials used in the manufacture of our bulk drug material for <I>Hylenex</I> recombinant product. Work-in-process inventories consist of in-process <I>Hylenex</I> recombinant. Finished goods inventories consist of finished <I>Hylenex</I>
recombinant product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expense costs relating to the purchase and production of pre-approval inventories for which the sole
use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
by regulatory bodies such as the FDA, inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or comparable regulatory agencies in foreign countries,
costs related to purchases of the API and the manufacturing of the product candidate are recorded as research and development expense. All direct manufacturing costs incurred after approval are capitalized as inventory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment
of a particular transaction is specifically dictated by U.S. GAAP. There are also areas in which management&#146;s judgment in selecting any available alternative would not produce a materially different result. Please see our audited consolidated
financial statements and notes thereto included in Part II, Item&nbsp;8 of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, which contain accounting policies and other disclosures required by U.S. GAAP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Three
Months Ended September&nbsp;30, 2012 Compared to Three Months Ended September&nbsp;30, 2011 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I>Product
Sales, Net </I><B><I></I></B><B>&#150; </B><B><I></I></B>Product sales, net were $715,000 for the three months ended September&nbsp;30, 2012 compared to $1.2 million for the three months ended September&nbsp;30, 2011. The decrease of $442,000 in
product sales, net was primarily due to the recognition of approximately $991,000 of deferred revenue in the three months ended September&nbsp;30, 2011 associated with the termination of the collaboration with Baxter for the marketing rights of
<B><I></I></B><I>Hylenex</I><B><I></I></B> recombinant (the Hylenex Collaboration). The decrease was partially offset by the increase in product sales of <B><I></I></B><I>Hylenex</I><B><I></I></B> recombinant in the current period. Based on the
reintroduction of <B><I></I></B><I>Hylenex</I><B><I></I></B> recombinant in December 2011, we expect product sales to increase in 2012 as compared to 2011.<B><I> </I></B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenues Under Collaborative Agreements</I> &#150; Revenues under collaborative
agreements were $4.6 million for the three months ended September&nbsp;30, 2012 compared to $21.8 million for the three months ended September&nbsp;30, 2011. Revenues under collaborative agreements consisted of recognition of license fees and
milestone payments received from our collaborators of approximately $624,000 and $20.5 million for the three months ended September&nbsp;30, 2012 and 2011, respectively. The decrease in revenues from license fees and milestone payments of $19.9
million was mainly due to the recognition in the prior period of approximately $16.9 million of the deferred upfront license fee and deferred product-based payments associated with the termination of the Hylenex Collaboration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues under collaborative agreements also included reimbursements for research and development services from our collaborators of
approximately $4.0 million and $1.3 million for the three months ended September&nbsp;30, 2012 and 2011, respectively. The increase of $2.7 million in reimbursements for research and development services was primarily due to an increase in the
manufacturing activities to support potential launches of our collaboration product candidates by Roche. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount
of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to fluctuate in future periods based on our collaborators&#146;
abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Product Sales </I><B>&#150; </B>Cost of product sales were $227,000 for the three months ended September&nbsp;30, 2012 compared to $12,000 for the three months ended September&nbsp;30, 2011.
The increase of $215,000 in cost of product sales was due to the increased product sales of <I>Hylenex</I> recombinant. Based on the reintroduction of <I>Hylenex</I> recombinant in December 2011, we expect cost of product sales to increase in 2012
as compared to 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development</I><B> &#150; </B>Research and development expenses were $19.5 million for
the three months ended September&nbsp;30, 2012 compared to $13.5 million for the three months ended September&nbsp;30, 2011. The increase of $6.0 million, or 44%, was primarily due to an increase in manufacturing activities to support potential
launches of our collaboration product candidates by the collaborators. We expect research and development costs to increase in 2012 as compared to 2011 based on increased manufacturing and other research and development activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative</I><B> &#150; </B>SG&amp;A expenses were $5.6 million for the three months ended
September&nbsp;30, 2012 compared to $4.3 million for the three months ended September&nbsp;30, 2011. The increase of $1.3 million, or 30%, was primarily due to an increase of $831,000 in compensation costs, including a $141,000 increase in
stock-based compensation, primarily due to the increased headcount resulting from the expansion of our commercial department. In connection with the reintroduction of <I>Hylenex</I> recombinant in December 2011, we expect SG&amp;A expenses to
increase in 2012 as compared to 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Net Income (Loss)</I><B> &#150; </B>Net loss for the three months ended
September&nbsp;30, 2012 was $(20.0) million, or $(0.18) per common share, compared to net income of $5.2 million, or $0.05 per common share, for the three months ended September&nbsp;30, 2011. The increase in net loss was primarily due to the
decrease in revenues under collaborative agreements resulting from the recognition of the deferred upfront license fee, deferred product based payments and deferred product sales in connection with the termination of the Hylenex Collaboration
totaling $17.9 million in the prior period and an increase in operating expenses for the three months ended September&nbsp;30, 2012 as compared to the same period in 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nine Months Ended September&nbsp;30, 2012 Compared to Nine Months Ended September&nbsp;30, 2011 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Product Sales, Net </I><B>&#150; </B>Product sales, net were $1.4 million for the nine months ended September&nbsp;30, 2012 compared to $1.5 million for the nine months ended September&nbsp;30, 2011.
The decrease of $60,000 in product sales, net was primarily due to the recognition of approximately $991,000 of deferred revenue in the three months ended September&nbsp;30, 2011 associated with the termination of the Hylenex Collaboration. The
decrease was partially offset by the increase in product sales of <I>Hylenex</I> recombinant in the current period. Based on the reintroduction of <I>Hylenex</I> recombinant in December 2011, we expect product sales to increase in 2012 as compared
to 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenues Under Collaborative Agreements</I> &#150; Revenues under collaborative
agreements were $19.1 million for the nine months ended September&nbsp;30, 2012 compared to $52.2 million for the nine months ended September&nbsp;30, 2011. Revenues under collaborative agreements consisted of the recognition of license fees and
milestone payments received from our collaborators of approximately $8.3 million and $48.0 million for the nine months ended September&nbsp;30, 2012 and 2011, respectively. The decrease in revenues from license fees and milestone payments of $39.7
million was primarily due to the recognition in the prior period of $18.0 million in one-time upfront payments we received from the ViroPharma and Intrexon Collaborations and approximately $17.1 million of the deferred upfront license fee and
deferred product-based payments associated with the termination of the Hylenex Collaboration. The decrease was also due to a $5.0 million decrease in milestone payments recognized from our collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues under collaborative agreements also included reimbursements for research and development services from our collaborators of
approximately $10.8 million and $4.2 million for the nine months ended September&nbsp;30, 2012 and 2011, respectively. The increase of $6.6 million in reimbursements for research and development services was primarily due to an increase in
manufacturing activities to support potential launches of our collaboration product candidates by Baxter and Roche. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore,
the amount of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to fluctuate in future periods based on our
collaborators&#146; abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Product Sales </I><B>&#150; </B>Cost of product sales were $441,000 for the nine months ended September&nbsp;30, 2012 compared to $202,000 for the nine months ended September&nbsp;30, 2011. The
increase of $239,000 was mainly due to the increased product sales of <I>Hylenex</I> recombinant. The increase was partially offset by the $166,000 write-off of obsolete API inventory for <I>Hylenex</I> recombinant in the prior period. Based on the
reintroduction of <I>Hylenex</I> recombinant in December 2011, we expect cost of product sales to increase in 2012 as compared to 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development</I><B> &#150; </B>Research and development expenses were $51.5 million for the nine months ended September&nbsp;30, 2012 compared to $42.6 million for the nine months ended
September&nbsp;30, 2011. The increase of $8.9 million, or 21%, was primarily due to an increase in manufacturing activities to support potential launches of our collaboration product candidates by the collaborators. We expect research and
development costs to increase in 2012 as compared to 2011 based on increased manufacturing activities and other research and development activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative</I><B> &#150; </B>SG&amp;A expenses were $17.8 million for the nine months ended September&nbsp;30, 2012 compared to $12.2 million for the nine months ended
September&nbsp;30, 2011. The increase of $5.6 million, or 46%, was primarily due to a $4.1 million increase in compensation costs, including a $1.1 million increase in stock-based compensation, and a $1.0 million increase in sales and marketing
expenses mainly associated with the reintroduction of <I>Hylenex</I> recombinant in December 2011. The increase in compensation costs was due to an increase in headcount resulting from the expansion of our commercial department. In connection with
the reintroduction of <I>Hylenex</I> recombinant in December 2011, we expect SG&amp;A expenses to increase in 2012 as compared to 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Net Loss</I><B> &#150; </B>Net loss for the nine months ended September&nbsp;30, 2012 was $49.1 million, or $0.44 per common share, compared to $1.4 million, or $0.01 per common share for the nine
months ended September&nbsp;30, 2011. The increase in net loss was primarily due to the decrease in revenues under collaborative agreements resulting from the recognition in the prior period of $18.0 million in one-time upfront payments associated
with the ViroPharma and Intrexon Collaborations and $17.9 million of the deferred upfront license fee, deferred product-based payments and deferred product sales in connection with the termination of the Hylenex Collaboration. The increase in net
loss was also due to an increase in operating expenses for the nine months ended September&nbsp;30, 2012 as compared to the same period in 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal sources of liquidity are our existing cash and cash equivalents. As of September&nbsp;30, 2012, we had cash and cash
equivalents of approximately $87.6 million. We will continue to have significant cash </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements to support product development activities. The amount and timing of cash requirements will depend on the success of our clinical development programs, regulatory and market
acceptance, and the resources we devote to research and other commercialization activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our current cash
and cash equivalents will be sufficient to fund our operations for at least the next twelve months. Currently, we anticipate total net cash burn of approximately $60 to $65 million for the year ending December&nbsp;31, 2012, depending on the
progress of various preclinical and clinical programs, the timing of our manufacturing scale up and the achievement of various milestones under our existing collaborative agreements. We do not expect our revenues to be sufficient to fund operations
until 2014, at the earliest. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may finance future cash needs
through any one of the following financing vehicles: (i)&nbsp;the public offering of securities; (ii)&nbsp;new collaborative agreements; (iii)&nbsp;expansions or revisions to existing collaborative relationships; (iv)&nbsp;private financings; and/or
(v)&nbsp;other equity or debt financings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently a &#147;Well-Known Seasoned Issuer&#148; and may file automatic
shelf registration statements at any time with the SEC. In February 2012, we filed an automatic shelf registration statement on Form S-3 (Registration No.&nbsp;333-179444) with the SEC. On February&nbsp;15, 2012, we sold approximately
7.8&nbsp;million shares of our common stock at a public offering price of $10.61 per share, generating approximately $81.5 million in net proceeds. We may, in the future, offer and sell equity, debt securities and warrants to purchase any of such
securities, either individually or in units to raise capital to fund the continued development of our product candidates, the commercialization of our products or for other general corporate purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our existing cash and cash equivalents may not be adequate to fund our operations until we become cash flow positive, if ever. We cannot
be certain that additional financing will be available when needed or, if available, financing will be obtained on favorable terms. If we are unable to raise sufficient funds, we may need to delay, scale back or eliminate some or all of our research
and development programs, delay the launch of our product candidates, if approved, and/or restructure our operations. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders could result. If we raise
additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, the issuance of warrants that may ultimately dilute existing stockholders when exercised and covenants that may restrict our
ability to operate our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operations was $47.4 million during the nine months ended September&nbsp;30, 2012 compared to $20.8 million during the nine months ended September&nbsp;30, 2011. This change was primarily
due to the increase in net loss of $47.8 million adjusted for non-cash items including stock-based compensation and depreciation and amortization, in addition to changes in working capital for the nine months ended September&nbsp;30, 2012 as
compared to the same period in 2011. The increase in net loss was due to the decrease in revenues under collaborative agreements resulting from the recognition in the prior period of $18.0 million in one-time upfront payments associated with the
ViroPharma and Intrexon Collaborations and $17.9 million of the deferred upfront license fee, deferred product-based payments and deferred product sales in connection with the termination of the Hylenex Collaboration and an increase in operating
expenses for the nine months ended September&nbsp;30, 2012 as compared to the same period in 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing
activities was $873,000 during the nine months ended September&nbsp;30, 2012 compared to net cash used in investing activities of $272,000 during the nine months ended September&nbsp;30, 2011. This was due to an increase in purchases of property and
equipment during the nine months ended September&nbsp;30, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities was $83.1 million
during the nine months ended September, 2012 compared to $4.1 million during the nine months ended September&nbsp;30, 2011. Net cash provided by financing activities for the nine months ended September&nbsp;30, 2012 consisted of $81.5 million in net
proceeds from the sale of our common stock in February 2012 and $1.9 million in net proceeds from stock option exercises. Net cash provided by financing activities for the nine months ended September&nbsp;30, 2011 consisted of proceeds from stock
option exercises. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Off-Balance Sheet Arrangements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2012, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities
often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we did not engage
in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">See Note 2, <I>Summary of Significant Accounting Policies &#150; Adoption of Recent Accounting Pronouncements</I>, in the Notes to Condensed Consolidated Financial Statements for a discussion of recent
accounting pronouncements and their effect, if any, on us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Factors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risks Related To Our Business </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We have generated only minimal revenue from
product sales to date; we have a history of net losses and negative cash flow, and we may never achieve or maintain profitability. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Relative to expenses incurred in our operations, we have generated only minimal revenues from product sales, licensing fees, milestone payments and research reimbursements to date and we may never
generate sufficient revenues from future product sales, licensing fees and milestone payments to offset expenses. Even if we ultimately do achieve significant revenues from product sales, licensing fees, research reimbursements and/or milestone
payments, we expect to incur significant operating losses over the next few years. We have never been profitable, and we may never become profitable. Through September&nbsp;30, 2012, we have incurred aggregate net losses of approximately $294.2
million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If our product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner,
such failure or delay would substantially impair our ability to generate revenues. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval from the FDA is necessary to
manufacture and market pharmaceutical products in the United States, and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming,
risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our product candidates, or that the timing of any such approval will be appropriate for the
desired product launch schedule for a product candidate. We, and our collaborators, attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our
collaborators expect or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our product candidates for failure to collect sufficient clinical or animal safety data and require us or our collaborators to conduct
additional clinical or animal safety studies which may cause lengthy delays and increased costs to our programs. For example, we announced on August&nbsp;1, 2012 that the FDA has issued a CRL for Baxter&#146;s HyQ BLA. The CRL requested additional
preclinical data to support the BLA. The primary issues raised in the letter focused on non-neutralizing antibodies generated against rHuPH20 and the possible effects of these antibodies on reproduction, development and fertility. Elevated
anti-rHuPH20 antibody titers were detected in the registration trial, but have not been associated with any adverse events. Pending Baxter and us providing additional preclinical data sufficient to address the regulatory questions, the FDA has
requested that patients should no longer be dosed with rHuPH20 in the Baxter clinical studies. In view of the issues raised in the HyQ CRL, we have contacted the FDA regarding the impact on <I>Hylenex</I> recombinant. After reviewing the applicable
data submitted by us, FDA has confirmed that there is no need for actions against <I>Hylenex</I> recombinant or clinical programs in the <I>Hylenex </I>recombinant investigational new drug. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that Baxter and we will be able to resolve the issues raised by the FDA in a timely manner which could result
in a delay or failure to gain regulatory approval for the HyQ product candidate. Furthermore, although we do not believe at this time that the issues raised by the FDA with respect to the HyQ BLA will have a significant impact on our proprietary and
other collaboration product candidates, there can be no assurance that these concerns will not also be raised by the FDA or other health authorities in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Only two of our collaboration product candidates are currently in the regulatory
approval process and there are no proprietary product candidates currently in the regulatory approval process. We and our collaborators may not be successful in obtaining such approvals for any potential products in a timely manner, or at all. See
risk factor titled &#147;<B></B><I>Our proprietary and collaboration product candidates may not receive regulatory approvals for a variety of reasons, including unsuccessful clinical trials</I><B></B>&#148; for additional information relating to the
approval of product candidates.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, in order to continue to manufacture and market pharmaceutical products,
we must maintain our regulatory approvals. If we or any of our collaborators are unsuccessful in maintaining our regulatory approvals, our ability to generate revenues would be adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If our contract manufacturers are unable to manufacture and supply to us API in the quantity and quality required by us or our collaborators for use
in our products and product candidates, our product development and commercialization efforts could be delayed or stopped and our collaborations could be damaged. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Cook Pharmica LLC (Cook) to produce bulk API.&nbsp;These manufacturers each produce
API under current Good Manufacturing Practices (cGMP) for clinical uses.&nbsp;In addition, Avid currently produces API for <B></B><I>Hylenex</I><B></B> recombinant.&nbsp;In addition to supply obligations, Avid and Cook will also provide support for
the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We rely on their ability to successfully manufacture these batches according to product specifications, and Cook has relatively limited experience manufacturing
our API. In addition, as a result of our contractual obligations to Roche, we have been required to significantly scale up our commercial API production at Cook during the last two years. If Cook is unable to obtain status as a cGMP-approved
manufacturing facility, or if either Avid or Cook: (i)&nbsp;is unable to retain status as cGMP-approved manufacturing facilities; (ii)&nbsp;is unable to otherwise successfully scale up our API production; (iii)&nbsp;fails to manufacture and supply
API in the quantity and quality required by us or our collaborators for use in our proprietary and collaboration products and product candidates for any other reason, or (iv)&nbsp;provides the necessary support for the chemistry, manufacturing and
controls sections for FDA and other regulatory filings, our business will be adversely affected. In addition, a significant change in such parties&#146; business or financial condition could adversely affect their abilities to fulfill their
contractual obligations to us. In particular, due to announced adverse clinical results, Avid&#146;s parent, Peregrine Pharmaceuticals, Inc., has recently experienced a significant decline in its stock price, a lender has recently recalled a loan to
the company, and the company is currently party to multiple securities lawsuits. We have not established, and may not be able to establish, favorable arrangements with additional API manufacturers and suppliers of the ingredients necessary to
manufacture the API should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable to adequately perform their responsibilities. We have attempted to mitigate the impact of
supply interruption through the establishment of excess API inventory, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by Avid
and/or Cook. Any delays, interruptions or other problems regarding the ability of Avid and/or Cook to supply API on a timely basis could: (i)&nbsp;cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of
proprietary or collaboration product candidates; (ii)&nbsp;delay or prevent the effective commercialization of proprietary or collaboration products; and/or (iii)&nbsp;cause us to breach contractual obligations to deliver API to our collaborators.
Such delays would likely damage our relationship with our collaborators under our key collaboration agreements, and they would have a material adverse effect on our business and financial condition.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If any party to a key collaboration agreement, including us, fails to perform material obligations under such agreement, or if&nbsp;a key
collaboration agreement, or any other collaboration agreement, is terminated for any reason, our business could significantly suffer. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of maintenance fees, milestone payments and royalties. In the event that a party
fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could delay or suspend our product development activities for some of our product candidates,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
as well as our commercialization efforts for some or all of our products. In addition, the termination of a key collaboration agreement by one of our collaborators could materially impact our
ability to enter into additional collaboration agreements with new collaborators on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going
forward and reevaluate the applications and value of our technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Most of our current proprietary and collaboration products and
product candidates rely on the rHuPH20 enzyme. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">rHuPH20 is a key technological component of Enhanze technology and our
most advanced proprietary and collaboration products and product candidates, including the product candidates under our Roche, Baxter, ViroPharma and Intrexon collaborations, our ultrafast insulin program, our PEGPH20 program and <I>Hylenex
</I>recombinant. An adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to
rHuPH20 or if we discover negative characteristics of rHuPH20) would substantially impact multiple areas of our business, including current and potential collaborations, as well as proprietary programs. For example, we announced on August&nbsp;1,
2012 that the FDA has issued a CRL for Baxter&#146;s HyQ BLA. The CRL requested additional preclinical data to support the BLA. The primary issues raised in the letter focused on non-neutralizing antibodies generated against rHuPH20 and the possible
effects of these antibodies on reproduction, development and fertility. Elevated anti-rHuPH20 antibody titers were detected in the registration trial, but have not been associated with any adverse events. Pending Baxter and us providing additional
preclinical data sufficient to address the regulatory questions, the FDA has requested that patients should no longer be dosed with rHuPH20 in the Baxter clinical studies. Although we do not believe at this time that the issues raised by the FDA
with respect to the HyQ BLA will have a significant impact on our proprietary and other collaboration product candidates, there can be no assurance that these concerns will not also be raised by the FDA or other health authorities in the future.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our proprietary and collaboration product candidates may not receive regulatory approvals for a variety of reasons, including unsuccessful
clinical trials. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure
or delay of a clinical trial can occur at any stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, we or our collaborators may obtain different results in subsequent trials or studies that
fail to show the desired levels of safety and efficacy, or we may not, or our collaborators may not, obtain applicable regulatory approval for a variety of other reasons. Preclinical, nonclinical, and clinical trials for any of our proprietary or
collaboration product candidates could be unsuccessful, which would delay or prohibit regulatory approval and commercialization of the product candidates. In the United States and other jurisdictions, regulatory approval can be delayed, limited or
not granted for many reasons, including, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory review may not find a product candidate safe or effective enough to merit either continued testing or final approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory review may not find that the data from preclinical testing and clinical trials justifies approval, or they may require additional studies
that would significantly delay or make continued pursuit of approval commercially unattractive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue regulatory
approval for such a product; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our collaborators, our contract
manufacturers or our raw material suppliers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or
facilities of our collaborators, our contract manufacturers or our raw material suppliers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or
raise new issues or concerns late in the approval process; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage,
which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If a proprietary or collaboration product candidate is not approved in a timely fashion on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays
encountered in the regulatory approval process, it could have a material adverse impact on our business, and we will become more dependent on the development of other proprietary or collaboration product candidates and/or our ability to successfully
acquire other products and technologies. There can be no assurances that any proprietary or collaboration product candidate will receive regulatory approval in a timely manner, or at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that certain proprietary and collaboration products will be marketed, and perhaps manufactured, in foreign countries. The
process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and
jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does
not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our third party collaborators are responsible for providing certain proprietary materials that are essential components of our
collaboration product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these collaboration product candidates and/or damage our collaborations. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our development and commercialization collaborators are responsible for providing certain proprietary materials that are essential
components of our collaboration product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous product candidates and Baxter is responsible for producing the GAMMAGARD LIQUID for its
product candidate. If a collaborator, or any applicable third party service provider of a collaborator, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the collaboration product candidate or component of
such product candidate, such difficulties could (i)&nbsp;cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of collaboration product candidates; and/or (ii)&nbsp;delay or prevent the effective commercialization
of collaboration products. Such delays could have a material adverse effect on our business and financial condition. For example, Baxter received a Warning Letter from the FDA in January 2010 regarding Baxter&#146;s GAMMAGARD LIQUID manufacturing
facility in Lessines, Belgium. The FDA indicated in March 2010 that the issues raised in the Warning Letter had been addressed by Baxter, and we do not expect these issues to impact the development of the GAMMAGARD LIQUID product candidate.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We rely on third parties to prepare, fill, finish and package our products and product candidates, and if such third parties should fail
to perform, our commercialization and development efforts for our products and product candidates could be delayed or stopped. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We rely on third parties to store and ship API on our behalf and to also prepare, fill, finish and package our products and product candidates prior to their distribution. If we are unable to locate third
parties to perform these functions on terms that are acceptable to us, or if the third parties we identify fail to perform their obligations, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
</B>progress of clinical trials could be delayed or even suspended and the commercialization of approved product candidates could be delayed or prevented. For example, <B></B><I>Hylenex
</I><B></B>recombinant was voluntarily recalled in May 2010 because a portion of the <B></B><I>Hylenex </I><B></B>recombinant manufactured by Baxter was not in compliance with the requirements of the underlying <B></B><I>Hylenex
</I><B></B>recombinant agreements. During the second quarter of 2011, we submitted the data that the FDA had requested to support the reintroduction of <B></B><I>Hylenex </I><B></B>recombinant. The FDA approved the submitted data and granted the
reintroduction of <B></B><I>Hylenex </I><B></B>recombinant, and we reintroduced <B></B><I>Hylenex </I><B></B>recombinant to the market in December 2011. In June 2011, we entered into a commercial manufacturing and supply agreement with Baxter, under
which Baxter will fill, finish and package <B></B><I>Hylenex </I><B></B>recombinant product for us<B>. </B>Under our commercial manufacturing and supply agreement with Baxter, Baxter has agreed to fill and finish <B></B><I>Hylenex
</I><B></B>recombinant product for us for a limited period of time. The initial term of the commercial manufacturing and supply agreement with Baxter expires on December&nbsp;31, 2013. However, upon regulatory approval of a second filling line, the
initial term will automatically be extended to December&nbsp;31, 2015, subject to further extensions in accordance with the terms and conditions of the agreement. In June 2011, we entered into a services agreement with a third party manufacturer for
the technology transfer and manufacture of <B></B><I>Hylenex </I><B></B>recombinant. While we expect to enter into a commercial manufacturing and supply agreement with a new manufacturer of <B></B><I>Hylenex </I><B></B>recombinant, if we are unable
to find a suitable manufacturer of <B></B><I>Hylenex </I><B></B>recombinant prior to the expiration of the commercial manufacturing and supply agreement with Baxter or if a new manufacturer encounters difficulties in the manufacture, fill, finish or
packaging of <B></B><I>Hylenex </I><B></B>recombinant, our business and financial condition could be adversely effected. <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we are
unable to sufficiently develop our sales, marketing and distribution capabilities or enter into successful agreements with third parties to perform these functions, we will not be able to fully commercialize our products. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be successful in marketing and promoting our approved product, <I>Hylenex</I> recombinant or any other products we develop or
acquire in the future. Our sales, marketing and distribution capabilities are very limited. In order to commercialize any products successfully, we must internally develop substantial sales, marketing and distribution capabilities or establish
collaborations or other arrangements with third parties to perform these services. We do not have extensive experience in these areas, and we may not be able to establish adequate in-house sales, marketing and distribution capabilities or engage and
effectively manage relationships with third parties to perform any or all of such services. To the extent that we enter into co-promotion or other licensing arrangements, our product revenues are likely to be lower than if we directly marketed and
sold our products, and any revenues we receive will depend upon the efforts of third parties, whose efforts may not meet our expectations or be successful. These third parties would be largely responsible for the speed and scope of sales and
marketing efforts, and may not dedicate the resources necessary to maximize product opportunities. Our ability to cause these third parties to increase the speed and scope of their efforts may also be limited. In addition, sales and marketing
efforts could be negatively impacted by the delay or failure to obtain additional supportive clinical trial data for our products. In some cases, third party collaborators are responsible for conducting these additional clinical trials, and our
ability to increase the efforts and resources allocated to these trials may be limited. For example, in January 2011, we and Baxter mutually agreed to terminate the Hylenex Collaboration and the associated agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we or our collaborators fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products,
regulatory agencies may take action against us or them, which could significantly harm our business. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any approved
products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies.
Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our collaborators and our respective contractors, suppliers and vendors, will be subject to
ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP
regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping
requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes
or new requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In particular, regulatory requirements applicable to pharmaceutical products make the
substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, entirely dependent on contract manufacturers and suppliers for the manufacture of our
products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in
obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay clinical trials or otherwise inhibit our ability to bring approved products to market, which would have a material adverse
effect on our business and financial condition. Likewise, if we, our collaborators and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example
off-label or false or misleading promotion, this could materially harm our business and financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to
comply with regulatory requirements, may result in any of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on our products or manufacturing processes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of the products from the market; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voluntary or mandatory recall; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fines; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or termination of any of our ongoing clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to permit the import or export of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to approve pending applications or supplements to approved applications that we submit; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>We may wish to raise additional capital in the next twelve months and there can be no assurance that we will be able to obtain such funds. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the next twelve months, we may wish to raise additional capital to continue the development of our product candidates or for other
current corporate purposes. Our current cash reserves and expected revenues during the next few years may not be sufficient for us to continue the development of our proprietary product candidates, to fund general operations and conduct our
business. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more
financing vehicles that may be available to us including (i)&nbsp;the public or private issuance of securities; (ii)&nbsp;new collaborative agreements; and/or (iii)&nbsp;expansions or revisions to existing collaborative relationships. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In view of our stage of development, business prospects, the nature of our capital structure and general market conditions, if we are
required to raise additional capital in the future, the additional financing may not be available on favorable terms, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse
terms or significantly reduce operating expenses through the restructuring of our operations. If we raise additional capital, a substantial number of additional shares may be issued, and these shares will dilute the ownership interest of our current
investors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If proprietary or collaboration product candidates are approved for marketing but do not gain market
acceptance, our business may suffer and we may not be able to fund future operations. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assuming that our proprietary or
collaboration product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these existing product candidates or any other products which are developed or acquired in the
future, including, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the price of products relative to other therapies for the same or similar treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their
prescribed treatments relative to other therapies for the same or similar treatments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to fund our sales and marketing efforts and the ability and willingness of our collaborators to fund sales and marketing efforts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the degree to which the use of these products is restricted by the approved product label; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effectiveness of our sales and marketing efforts and the effectiveness of the sales and marketing efforts of our collaborators;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the introduction of generic competitors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which reimbursement for our products and related treatments will be available from third party payors including government insurance
programs (Medicare and Medicaid) and private insurers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If these products do not gain market acceptance, we
may not be able to fund future operations, including the development or acquisition of new product candidates and/or our sales and marketing efforts for our approved products, which would cause our business to suffer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our proprietary and collaboration product candidates will be restricted to the labels approved by FDA and applicable
regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Developing and marketing pharmaceutical products for human use involves significant product liability risks for which we currently have limited
insurance coverage. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The testing, marketing and sale of pharmaceutical products involves the risk of product liability
claims by consumers and other third parties. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If
product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is
successful, then the lack or insufficiency of insurance coverage could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance
coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose
additional costs on us. In addition, since many of our collaboration product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability
claims against us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends on the performance of key management and scientific employees with relevant experience. We depend
substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team. Particularly in view of the small number of employees on our staff
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to cover our numerous programs and key functions, if we are unable to retain existing personnel or identify or hire additional personnel, we may not be able to research, develop, commercialize or
market our products and product candidates as expected or on a timely basis and we may not be able to adequately support current and future alliances with strategic collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, if we were to lose key management personnel, such as Gregory Frost, Ph.D., our President and Chief Executive Officer, we
would likely lose some portion of our institutional knowledge and technical know-how, potentially causing a substantial delay in one or more of our development programs until adequate replacement personnel could be hired and trained. For example,
Dr.&nbsp;Frost has been with us from soon after our inception, and he possesses a substantial amount of knowledge about our development efforts and business. If we were to lose his services, we would experience delays in meeting our product
development schedules. We currently have a severance policy applicable to all employees and a change in control policy applicable to senior executives. We have not adopted any other policies or entered into any other agreements specifically designed
to motivate officers or other employees to remain with us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have key man life insurance policies on the lives of any
of our employees, including Dr.&nbsp;Frost. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our operations might be interrupted by the occurrence of a natural disaster or other
catastrophic event. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operations, including laboratories, offices and other research facilities, are located in three
buildings in San Diego, California. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, interruptions in the supply of natural
resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our collaborators, contractors and vendors. Even
though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that
exceed the coverage available under our and our contractors&#146; insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and
financial results. Moreover, any such event could delay our research and development programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If we or our collaborators do not achieve
projected development, clinical or regulatory goals in the timeframes we publicly announce or otherwise expect, the commercialization of our products and the development of our product candidates may be delayed and, as a result, our stock price may
decline, and we may face lawsuits relating to such declines. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may publicly articulate the estimated
timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any
number of reasons both within and outside of our control. If scientific, regulatory, strategic or other factors cause us to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly.
Such stock price decline may trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection
with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and
costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed
from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation
significantly diverts management&#146;s attention from our operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the consistent failure to meet publicly
announced milestones may erode the credibility of our management team with respect to future milestone estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Future acquisitions could disrupt our business and harm our financial condition. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to augment our product pipeline or otherwise strengthen our business, we may decide to acquire additional businesses, products
and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks,
including, but not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may have to issue convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect
the market price of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and
other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we
acquire; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain acquisitions may impact our relationship with existing or potential collaborators who are competitive with the acquired business, products or
technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to
justify acquisition costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">key personnel of an acquired company may decide not to work for us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance
that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will
not view such acquisitions positively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risks Related To Ownership of Our Common Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our stock price is subject to significant volatility. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. As a result, our high and low sales
prices of our common stock during the twelve months ended September&nbsp;30, 2012 were $13.50 and $3.86, respectively. We expect our stock price to continue to be subject to significant volatility and, in addition to the other risks and
uncertainties described elsewhere in this quarterly report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop
in our stock price: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a dispute regarding our failure, or the failure of one of our third party collaborators, to comply with the terms of a collaboration agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the termination, for any reason, of any of our collaboration agreements; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board
of Directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the resignation, or other departure, of members of management or our Board of Directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general negative conditions in the healthcare industry; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general negative conditions in the financial markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure, for any reason, to obtain regulatory approval for any of our proprietary or collaboration product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure, for any reason, to secure or defend our intellectual property position; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for those products that are not yet approved for commercial sale, the failure or delay of applicable regulatory bodies to approve such products;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identification of safety or patient tolerability issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of clinical trials to meet efficacy endpoints; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspensions or delays in the conduct of clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure, or the failure of our third party collaborators, to successfully commercialize products approved by applicable regulatory bodies such as
the FDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure, or the failure of our third party collaborators, to generate product revenues anticipated by investors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems with an API contract manufacturer or a fill and finish manufacturer for any product or product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sale of additional debt and/or equity securities by us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure to obtain financing on acceptable terms; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a restructuring of our operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Future transactions where we raise capital may negatively affect our stock price. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are currently a &#147;Well-Known Seasoned Issuer&#148; and may file automatic shelf registration statements at any time with the SEC. In addition, we currently have the ability to offer and sell
additional equity, debt securities and warrants to purchase such securities, either individually or in units, under an effective automatic shelf registration statement. Sales of substantial amounts of shares of our common stock or other securities
under our shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. In the future, we may issue additional options, warrants or other derivative
securities convertible into our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Trading in our stock has historically been limited, so investors may not be able to sell as
much stock as they want to at prevailing market prices. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stock has historically traded at a low daily trading volume.
If low trading volume continues, it may be difficult for stockholders to sell their shares in the public market at any given time at prevailing prices. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risks Related To Our Industry </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or
cancellation of product sales, introductions or modifications. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Extensive industry regulation has had, and will continue
to have, a significant impact on our business. All pharmaceutical companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug
substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and
foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products. We are dependent on receiving FDA and
other governmental approvals prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities will not approve our products or may impose onerous, costly and
time-consuming requirements such as additional clinical or animal testing. The FDA or other foreign regulatory agency may, at any time, halt our and our collaborators&#146; development and commercialization activities due to safety concerns. In
addition, even if our products are approved, regulatory agencies may also take post-approval action limiting or revoking our ability to sell our products. Any of these regulatory actions may adversely affect the economic benefit we may derive from
our products and therefore harm our financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under certain of these regulations, we and our contract suppliers
and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and
our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers&#146; and
manufacturers&#146; processes, are in compliance with cGMP and other FDA regulations. If we, or our contract supplier, fail these inspections, we may not be able to commercialize our product in a timely manner without incurring significant
additional costs, or at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the FDA imposes a number of complex regulatory requirements on entities that
advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving
the internet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result
in substantial expense, delay and/or cessation of the development and commercialization of our products. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We primarily
rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we will be able to obtain patent protection for our products and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the
patents are asserted against others. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently own or license several patents and also have pending patent applications
applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will
provide us with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. A European patent, EP1603541, claiming rHuPH20
was granted to us on November&nbsp;11, 2009 with claims to the human PH20 glycoprotein, PEGylated variants, a method of producing the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including
antibodies, insulins, cytokines, a chemotherapeutic agent and additional therapeutic classes.&nbsp;A third party opposed this patent in the European Patent Office in 2010; however, the opposition has been resolved with claims maintained in amended
form. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued
patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial
condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings
in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also rely on trademarks to protect the names of our products (e.g. <I>Hylenex </I>recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition,
product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by
regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with
confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be
able to resolve these disputes in our favor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to protecting our own intellectual property rights, third parties
may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to
treble damages, attorneys&#146; fees and costs, for past infringement if it is ultimately determined that our products infringe a third party&#146;s intellectual property rights. Even if infringement claims against us are without merit, defending a
lawsuit takes significant time, may be expensive and may divert management&#146;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of
the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws changes,
our competitors may be able to develop and commercialize products based on our discoveries. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent protection for
protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and
biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the
requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could
make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent
priority from &#147;first to invent&#148; to &#147;first to file,&#148; implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant
uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There also have been, and continue to be, policy discussions concerning the scope of patent
protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins may
lead to narrower patent protection, or narrower claim interpretation, for genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a
great deal of uncertainty outside the United States, and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents,
and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If third
party reimbursement and customer contracts are not available, our products may not be accepted in the market. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability
to earn sufficient returns on our products will depend in part on the extent to which reimbursement for our products and related treatments will be available from government health administration authorities, private health insurers, managed care
organizations and other healthcare providers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third-party payors are increasingly attempting to limit both the coverage and
the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of
reimbursement for the products that we commercialize, which could limit their market acceptance and result in a material adverse effect on our financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical
differentiation. If our products are compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our
financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures that
could cause us to sell our products at lower prices, resulting in less revenue to us. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of the proprietary or
collaboration products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations
and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the United States, the growth of such organizations, and various legislative proposals and
enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003, could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting
in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In March 2010, the United States adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the Healthcare Reform Act). This law
substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that are expected to impact our business
and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse and enforcement. These changes will
impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional provisions of the Healthcare Reform Act, some of which became effective in 2011, may negatively affect our revenues in the
future. For example, the Healthcare Reform Act imposes a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs that we believe will impact our revenues from our
products. In addition, as part of the Healthcare Reform Act&#146;s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will also be required to provide a 50% discount on branded prescription drugs dispensed to beneficiaries under this prescription drug program. We expect that the Healthcare Reform Act and other
healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or successfully commercialize our product candidates or could
limit or eliminate our future spending on development projects. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, individual states have become increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other
countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar
regulatory and legislative issues in most other countries outside the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We face intense competition and rapid technological
change that could result in the development of products by others that are superior to our proprietary and collaboration products under development. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Our proprietary and collaboration products have numerous competitors in the United States and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities
and other research institutions that have developed competing products. The competitors for <B></B><I>Hylenex </I><B></B>recombinant include, but are not limited to Bausch &amp; Lomb Inc. For our Analog-PH20 product candidates, such competitors may
include Biodel Inc., Eli Lily, Sanofi Aventis, Novo Nordisk Inc. and Mannkind Corporation. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and
collaboration product candidates or that could render our technologies and product candidates obsolete or noncompetitive. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and
capabilities than we do. In addition, many of our competitors have significantly greater experience than we do in undertaking preclinical testing and clinical trials of pharmaceutical product candidates and obtaining FDA and other regulatory
approvals of products and therapies for use in healthcare.<B> </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_8"></A>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures About Market Risk </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in
short-term marketable securities. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Some of the securities
may be subject to market risk. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest
rate later rises, the value of our investment will probably decline. To minimize this risk, we typically invest all, or substantially all, of our cash in money market funds that invest primarily in government securities. Our investment policy also
permits investments in a variety of securities including commercial paper and government and non-government debt securities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the
prevailing interest rate. As of September&nbsp;30, 2012, we did not have any holdings of derivative financial or commodity instruments, or any foreign currency denominated transactions, and all of our cash and cash equivalents were in money market
mutual funds and other investments that we believe to be highly liquid. If a 10% change in interest rates were to have occurred on September&nbsp;30, 2012, this change would not have had a material effect on the fair value of our investment
portfolio as of that date or on our net loss for the three months then ended. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_9"></A>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Controls and Procedures </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Evaluation
of Disclosure Controls and Procedures </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#146;s rules and forms, and that such information is
accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no
matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the supervision and with the participation of our
management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act
of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on
Form 10-Q. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in Internal Control Over Financial Reporting </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no changes in our internal control over financial reporting that occurred during the quarter ended September&nbsp;30, 2012
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_10"></A>PART II &#150; OTHER INFORMATION </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_11"></A>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From
time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that
we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any
such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to
any legal proceedings, the adverse outcome of which, in management&#146;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_12"></A>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Factors </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
provided updated Risk Factors in the section labeled &#147;Risk Factors&#148; in Part&nbsp;I, Item&nbsp;2, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;. The &#147;Risk Factors&#148; section
provides updated information in certain areas, particularly with respect to uncertainties regarding the regulatory approval of proprietary and collaboration product candidates. We do not believe the updates have materially changed the type or
magnitude of the risks we face in comparison to the disclosure provided in our most recent Annual Report on Form 10-K. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_13"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_14"></A>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Defaults Upon Senior Securities </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_15"></A>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mine Safety Disclosures </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_16"></A>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Information </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not
applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_17"></A>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, dated November 14, 2007, by and between the Registrant and the Registrant&#146;s predecessor Nevada corporation (1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on October 7, 2007 (2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Designation, Preferences and Rights of the terms of the Series A Preferred Stock (1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bylaws, as amended (2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from the Halozyme Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in eXtensible Business Reporting
Language (XBRL): (i)&nbsp;the Condensed Consolidated Balance Sheets, (ii)&nbsp;the Condensed Consolidated Statements of Comprehensive Loss, (iii)&nbsp;the Condensed Consolidated Statements of Cash Flows and (iv)&nbsp;related notes, tagged as block
of text*.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;*</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section&nbsp;18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those
sections. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Registrant&#146;s Current Report on Form 8-K, filed November&nbsp;20, 2007 (File No.&nbsp;001-32335). </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Registrant&#146;s Current Report on Form 8-K, filed December&nbsp;12, 2011 (File No.&nbsp;001-32335). </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx398930_18"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Halozyme Therapeutics, Inc.,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November 8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory I. Frost, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory I. Frost, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November 8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kurt A. Gustafson</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kurt A. Gustafson</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d398930dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Gregory I. Frost, Ph.D., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluated the effectiveness of the Registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">disclosed in this report any change in the Registrant&#146;s internal control over financial reporting that occurred during the Registrant&#146;s most recent fiscal
quarter (the Registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Registrant&#146;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
Registrant&#146;s auditors and the audit committee of the Registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory I. Frost, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory I. Frost, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d398930dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Kurt A. Gustafson, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluated the effectiveness of the Registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">disclosed in this report any change in the Registrant&#146;s internal control over financial reporting that occurred during the Registrant&#146;s most recent fiscal
quarter (the Registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Registrant&#146;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
Registrant&#146;s auditors and the audit committee of the Registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kurt A. Gustafson</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kurt A. Gustafson</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>d398930dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PURSUANT TO 18 U.S.C. SECTION 1350, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#147;Registrant&#148;) on Form 10-Q for the quarter ended
September&nbsp;30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Gregory I. Frost, Ph.D., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as
adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory I. Frost, Ph.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory I. Frost, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#147;Registrant&#148;) on Form 10-Q for the
quarter ended September&nbsp;30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Kurt A. Gustafson, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C.
Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kurt A. Gustafson</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kurt A. Gustafson</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>halo-20120930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.187; Copyright (C) RR Donnelley-->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:halo="http://halozyme.com/20120930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="halo-20120930.xsd" />
  <!-- Context Section -->
  <context id="ThreeMonthsEnded_30Sep2012_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Gammagard_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Roche_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Leasehold_Improvements_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Research_Equipment_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Computer_And_Office_Equipment_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Leasehold_Improvements_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Research_Equipment_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Computer_And_Office_Equipment_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Gammagard_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Roche_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Gammagard_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Gammagard_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Collaborative_Arrangement_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Product_Sales_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:ProductSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Collaborative_Arrangement_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Product_Sales_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:ProductSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Cash_Equivalents_Member_Fair_Value_Inputs_Level1_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Cash_Equivalents_Member_Fair_Value_Inputs_Level1_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Selling_General_And_Administrative_Expenses_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Selling_General_And_Administrative_Expenses_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Selling_General_And_Administrative_Expenses_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Restricted_Stock_Units_R_S_U_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Stock_Options_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Selling_General_And_Administrative_Expenses_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Restricted_Stock_Units_R_S_U_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Research_And_Development_Expense_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Hylenex_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:HylenexPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Hylenex_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:HylenexPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Roche_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_15Feb2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2012-02-15</instant>
    </period>
  </context>
  <context id="OneMonthEnded_29Feb2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Roche_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Gammagard_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Roche_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_06Jun2012_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-06-06</instant>
    </period>
  </context>
  <context id="BalanceAsOf_10May2012_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-05-10</instant>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Sep2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_30Sep2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member_2">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:GammagardPartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Roche_Partnership_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:RochePartnershipMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:ViropharmaPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">halo:IntrexonPartnershipsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Sep2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Oct2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="Jan-01-2012_Sep-30-2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:NatureOfOperations contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;
   &lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;1. Organization and Business &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Halozyme Therapeutics, Inc. (referred to as &amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;Halozyme&amp;#8221; or the
   &amp;#8220;Company&amp;#8221;) is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. Our research targets the extracellular matrix, an area outside the cell that provides structural support
   in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique scientific expertise that allows us to pursue this target-rich environment for the
   development of future therapies. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Our research focuses primarily on human enzymes that alter the
   extracellular matrix. Our lead enzyme, recombinant human hyaluronidase (&amp;#8220;rHuPH20&amp;#8221;), temporarily degrades hyaluronan, a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. We are also developing
   novel enzymes that may target other matrix structures for therapeutic benefit. Our Enhanze&lt;/font&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:times new roman" size="2"&gt;
    technology is the platform for the delivery of proprietary small and large molecules. We apply our research products in collaboration with other companies as well as for our own proprietary pipeline in
   therapeutic areas with significant unmet medical need, such as diabetes, oncology and dermatology. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Our
   operations to date have involved: (i)&amp;#160;organizing and staffing our operating subsidiary, Halozyme, Inc.; (ii)&amp;#160;acquiring, developing and securing our technology; (iii)&amp;#160;undertaking product development for our existing product and a
   limited number of product candidates; (iv)&amp;#160;supporting the development of collaboration product candidates and (v)&amp;#160;selling &lt;i&gt;Hylenex&lt;/i&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;
   &amp;reg;&lt;/sup&gt;&lt;/font&gt; recombinant (hyaluronidase human injection). We continue to increase our focus on our proprietary product pipeline and have expanded investments in our proprietary
   product candidates. We currently have multiple proprietary programs in various stages of research and development. In addition, we currently have license and collaborative agreements with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.
   (&amp;#8220;Roche&amp;#8221;), Baxter Healthcare Corporation (&amp;#8220;Baxter&amp;#8221;), ViroPharma Incorporated (&amp;#8220;ViroPharma&amp;#8221;), and Intrexon Corporation (&amp;#8220;Intrexon&amp;#8221;), to apply Enhanze technology to these collaborators&amp;#8217; biological
   therapeutic compounds. Currently, we have received only limited revenue from the sales of &lt;i&gt;Hylenex &lt;/i&gt;recombinant, in addition to other revenues from our collaborations. &lt;/font&gt;&lt;/p&gt;
</us-gaap:NatureOfOperations>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;2. Summary of Significant Accounting Policies &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States
   generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of
   the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated
   financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2011, filed with the SEC on March&amp;#160;12, 2012. The unaudited financial information for the interim periods presented herein
   reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring
   adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc. All intercompany accounts and transactions have been
   eliminated. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
   estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management
   believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#8217;s estimates. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Adoption of Recent Accounting Pronouncements &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effective January&amp;#160;1, 2012, we adopted Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting Standards Update
   (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2011-05, Comprehensive Income (Topic 220): &lt;i&gt;Presentation of Comprehensive Income&lt;/i&gt; and ASU No.&amp;#160;2011-12, &lt;i&gt;Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of
   Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU No.&amp;#160;2011-5&lt;/i&gt;. In these updates, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other
   comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each
   component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No.&amp;#160;2011-05 eliminates the option to present the components of other comprehensive income as part of the
   statement of changes in stockholders&amp;#8217; equity. The amendments in ASU No.&amp;#160;2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.
   The amendments in these updates are effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2011. The adoption of ASU Nos. 2011-05 and 2011-12 did not have a material impact on our consolidated financial
   position or results of operations. We have presented comprehensive income (loss) in our condensed consolidated statements of comprehensive income (loss). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Effective January&amp;#160;1, 2012, we prospectively adopted FASB&amp;#8217;s ASU No.&amp;#160;2011-04, &lt;i&gt;&amp;#8220;Fair Value Measurement (Topic 820) &amp;#8212; Amendments to Achieve Common Fair Value Measurement and
   Disclosure Requirements in U.S. GAAP and IFRS&amp;#8221;. &lt;/i&gt;The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;). Consequently, the
   amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This pronouncement is effective for fiscal years, and interim periods within
   those years, beginning after December&amp;#160;15, 2011. The adoption of ASU No.&amp;#160;2011-04 did not have a material effect on our consolidated financial position or results of operations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Inventories &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
   evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
   compared with historical cost and the remaining shelf life of goods on hand. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Raw materials inventories consist of raw
   materials used in the manufacture of our bulk drug material for &lt;i&gt;Hylenex&lt;/i&gt; recombinant product. Work-in-process inventories consist of in-process &lt;i&gt;Hylenex&lt;/i&gt; recombinant. Finished goods inventories consist of finished &lt;i&gt;Hylenex&lt;/i&gt;
   recombinant product. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We expense costs relating to the purchase and production of pre-approval inventories for which the sole
   use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
   by regulatory bodies such as the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;), inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or
   comparable regulatory agencies in foreign countries, costs related to purchases of the active pharmaceutical ingredients (&amp;#8220;API&amp;#8221;) and the manufacturing of the product candidate are recorded as research and development expense. All direct
   manufacturing costs incurred after approval are capitalized as inventory. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
   nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
   resulting from collaborative arrangements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We recognize revenue in accordance with the authoritative guidance on revenue
   recognition. Revenue is recognized when all of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the seller&amp;#8217;s price to the buyer is
   fixed or determinable; and (4)&amp;#160;collectibility is reasonably assured. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;&lt;/i&gt;&lt;b&gt;&lt;i&gt;Product Sales &lt;/i&gt;&lt;/b&gt;&lt;i&gt;&amp;#8211; Hylenex&lt;/i&gt; recombinant was approved for marketing by the FDA in
   December 2005. From 2005 through January&amp;#160;7, 2011, Baxter had the worldwide market rights for &lt;i&gt;Hylenex&lt;/i&gt; recombinant under the terms of the amended and restated development and supply agreement with Baxter (&amp;#8220;Hylenex
   Collaboration&amp;#8221;). Baxter commercially launched &lt;i&gt;Hylenex&lt;/i&gt; recombinant in October 2009. However, &lt;i&gt;Hylenex&lt;/i&gt; recombinant was voluntarily recalled in May 2010 because a portion of the product manufactured by Baxter was not in compliance
   with the requirements of the underlying collaboration. Effective January&amp;#160;7, 2011, we and Baxter mutually agreed to terminate the Hylenex Collaboration. During the second quarter of 2011, we submitted the data that the FDA had requested to
   support the reintroduction of &lt;i&gt;Hylenex&lt;/i&gt; recombinant to the market. The FDA approved the submitted data and granted the reintroduction of &lt;i&gt;Hylenex&lt;/i&gt; recombinant. &lt;i&gt; &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In December 2011, we reintroduced &lt;i&gt;Hylenex&lt;/i&gt; recombinant to the market, shipped initial orders to our wholesaler customers and began
   promoting &lt;i&gt;Hylenex&lt;/i&gt; recombinant through our sales force. We sell &lt;i&gt;Hylenex&lt;/i&gt; recombinant in the United States to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. The wholesale
   distributors take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales; however, we do allow the
   wholesale distributors to return product that is damaged or received in error. In addition, we allow for product to be returned beginning six months prior to and ending twelve months following product expiration. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Given our limited history of selling &lt;i&gt;Hylenex&lt;/i&gt; recombinant and the lengthy return period, we currently cannot reliably estimate
   expected returns and chargebacks of &lt;i&gt;Hylenex&lt;/i&gt; recombinant at the time the product is received by the wholesale distributors. Therefore, we do not recognize revenue upon delivery of &lt;i&gt;Hylenex&lt;/i&gt; recombinant to the wholesale distributor until
   the point at which we can reliably estimate expected product returns and chargebacks from the wholesale distributors. Shipments of &lt;i&gt;Hylenex&lt;/i&gt; recombinant are recorded as deferred revenue until evidence exists to confirm that pull-through sales
   to the hospitals or other end-user customers have occurred. We recognize revenue when the product is sold through from the distributors to the distributors&amp;#8217; customers. In addition, the costs of manufacturing &lt;i&gt;Hylenex&lt;/i&gt; recombinant
   associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized. We estimate sell-through revenue and certain gross to net sales adjustments based on
   analysis of third-party information including information obtained from certain distributors with respect to their inventory levels and sell-through to the distributors&amp;#8217; customers. At the time we can reliably estimate product returns and
   chargebacks from the wholesale distributors, we will record a one-time increase in net product sales revenue related to the recognition of product sales revenue previously deferred. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales
   allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with wholesale distributors and hospitals and the levels of inventory within the distribution channels
   that may result in future discounts taken. We must make significant judgments in determining these allowances. If actual results differ from our estimates, we will be required to make an adjustment to these allowances in the future, which could have
   an effect on product sales revenue in the period of adjustment. Our product sales allowances include: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Distribution
   Fees&lt;/i&gt;. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesale distributors for distribution services they provide with respect to &lt;i&gt;Hylenex&lt;/i&gt; recombinant. At the time
   the sale is made to the respective wholesale distributors, we record an allowance for distribution fees by reducing our accounts receivable and deferred revenue associated with such product sales. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Prompt Payment
   Discounts&lt;/i&gt;. We offer cash discounts to certain wholesale distributors as an incentive to meet certain payment terms. We expect our customers will take advantage of this discount; therefore, at the time the sale is made to the respective wholesale
   distributors, we accrue the entire prompt payment discount, based on the gross amount of each invoice, by reducing our accounts receivable and deferred revenue associated with such product sales. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Chargebacks&lt;/i&gt;. We provide discounts to end-user members of certain group purchasing organizations (&amp;#8220;GPO&amp;#8221;) under collective
   purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals who are members of the GPOs with which we do not have contracts. The end-user members purchase products from the wholesale distributors at a contracted
   discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the end users paid for the product. Given our lack of historical sales data, we recognize chargebacks in the same
   period the related product sales revenue is recognized and reduce our accounts receivable accordingly. A GPO fee we incur for these transactions is also recorded in the same period the related product sales revenue is recognized and is included in
   accrued expenses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Product Returns&lt;/i&gt;. The product returns reserve is based on management&amp;#8217;s best estimate of the
   product sales recognized as revenue during the period that are anticipated to be returned. The product returns reserve is recorded as a reduction of product sales revenue in the same period the related product sales revenue is recognized and is
   included in accrued expenses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenues under Collaborative Agreements &lt;/i&gt;&lt;/b&gt;&lt;i&gt;&amp;#8211; &lt;/i&gt;We have entered into
   license and collaboration agreements under which the collaborators obtained worldwide exclusive rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of the collaborators&amp;#8217; biologic compounds. The
   collaborative agreements contain multiple elements, including nonrefundable payments at the inception of the arrangements, license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative
   agreements, reimbursements of research and development services, payments for supply of rHuPH20 API for the collaborator and/or royalties on sales of products resulting from collaborative agreements. We analyze each element of the collaborative
   agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Prior to the adoption of ASU No.&amp;#160;2009-13, &lt;i&gt;Multiple-Deliverable Revenue Arrangements&lt;/i&gt;, on January&amp;#160;1, 2011, in order for a
   delivered item to be accounted for separately from other deliverables in a multiple-element arrangement, the following three criteria had to be met: (i)&amp;#160;the delivered item had standalone value to the customer, (ii)&amp;#160;there was objective and
   reliable evidence of fair value of the undelivered items, and (iii)&amp;#160;if the arrangement included a general right of return relative to the delivered item, delivery or performance of the undelivered items was considered probable and substantially
   in the control of the vendor. For the collaborative agreements entered into prior to January&amp;#160;1, 2011, there was no objective and reliable evidence of fair value of the undelivered items. Thus, the delivered licenses did not meet all of the
   required criteria to be accounted for separately from undelivered items. Therefore, we recognized revenue on nonrefundable upfront payments and license fees from these collaborative agreements over the period of significant involvement under the
   related agreements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;For new collaborative agreements or material modifications of existing collaborative agreements entered
   into after December&amp;#160;31, 2010, we follow the provisions of ASU No.&amp;#160;2009-13. In order to account for the multiple-element arrangements, we identify the deliverables included within the agreement and evaluate which deliverables represent
   units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The
   deliverables under our collaborative agreements include (i)&amp;#160;the license to rHuPH20 technology, (ii)&amp;#160;at the collaborator&amp;#8217;s request, research and development services which are reimbursed at contractually determined rates, and
   (iii)&amp;#160;at the collaborator&amp;#8217;s request, supply of rHuPH20 API which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone
   basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the collaborator and the availability of research expertise in this field in
   the general marketplace. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Arrangement
   consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence
   (&amp;#8220;VSOE&amp;#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of
   allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the
   separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Nonrefundable upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the
   license has standalone value from the undelivered items, which generally include research and development services and the manufacture of rHuPH20 API, the relative selling price allocation of the license is equal to or exceeds the upfront license
   fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does
   not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The terms of our collaborative agreements provide for milestone payments upon achievement of certain development and regulatory events
   and/or specified sales volumes of commercialized products by the collaborator. Effective January&amp;#160;1, 2011, we adopted on a prospective basis the Milestone Method. Under the Milestone Method, we recognize consideration that is contingent upon the
   achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The consideration is commensurate with either the entity&amp;#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a
   result of a specific outcome resulting from the entity&amp;#8217;s performance to achieve the milestone, &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The consideration relates solely to past performance, and &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;A milestone is defined as an event (i)&amp;#160;that can only be achieved based in whole or in part on either the entity&amp;#8217;s performance
   or on the occurrence of a specific outcome resulting from the vendor&amp;#8217;s performance, (ii)&amp;#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&amp;#160;that would
   result in additional payments being due to the vendor. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Reimbursements of research and development services are recognized as
   revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is probable. Revenue from the manufacture of rHuPH20
   API is recognized when the API has met all specifications required for the collaborator&amp;#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and
   development services or supply of rHuPH20 API; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of rHuPH20 API. Royalties to be received based on sales of licensed products
   by our collaborators incorporating rHuPH20 will be recognized as earned. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The collaborative agreements typically provide the
   collaborators the right to terminate such agreements in whole or on a product-by-product or target-by-target basis at any time upon 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any
   of our collaborative agreements that contain material financial consequences to us. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Cost of Product Sales &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal
   costs and manufacturing overhead associated with the production of &lt;i&gt;Hylenex &lt;/i&gt;recombinant. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses,
   research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no
   alternative future uses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Advance payments, including nonrefundable amounts, for goods or services that will be used or
   rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the
   goods to be delivered or services to be performed. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Milestone payments that we make in connection with in-licensed technology
   or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product
   candidates to be uncertain until such licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all
   of our licensed technology or product candidates to be uncertain and has expensed these amounts as incurred. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work
   performed, including actual level of patient enrollment, completion of patient studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts
   are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period
   in which the facts that give rise to the revision become reasonably certain. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total share-based compensation expense related to all of our share-based awards was allocated as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;913,946&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;890,276&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,279,940&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,944,552&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Selling, general and administrative&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,008,447&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;867,083&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,082,432&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,971,777&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense per basic and diluted share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.06&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.04&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense from:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,164,973&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;806,078&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,491,220&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,318,728&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Restricted stock awards and restricted stock units&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;757,420&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;951,281&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,871,152&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,597,601&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Since we have a net operating loss carryforward as of September&amp;#160;30, 2012, no excess tax benefits for the tax
   deductions related to share-based awards were recognized in the interim unaudited condensed consolidated statements of comprehensive loss for the three and nine months ended September&amp;#160;30, 2012. For the three months ended September&amp;#160;30, 2012 and 2011, employees exercised stock options to
   purchase 7,055 and 38,511 shares of common stock, respectively, for aggregate proceeds of approximately $39,000 and $79,000, respectively. For the nine months ended September&amp;#160;30, 2012 and 2011, employees exercised stock options to purchase
   426,277 and 2,713,573 shares of common stock, respectively, for aggregate proceeds of approximately $1.9 million and $4.1 million, respectively. In addition, for the nine months ended September&amp;#160;30, 2012, upon vesting of 128,000 restricted stock
   units (&amp;#8220;RSUs&amp;#8221;), the RSU holders received net settlement of 81,070 shares of common stock and surrendered 46,930 RSUs to pay for the minimum withholding taxes totaling approximately $347,000. There were no RSUs vested for the three months
   ended September&amp;#160;30, 2012 or the three and nine months ended September&amp;#160;30, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As of September&amp;#160;30, 2012,
   total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock awards and restricted stock units granted prior to that date was approximately $9.6 million and $7.0 million, respectively, which is
   expected to be recognized over a weighted-average period of approximately 2.7 years and 3.6 years, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We follow the authoritative guidance for fair value measurements and disclosures which, among other things, defines fair value,
   establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price that would be
   received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
   pricing an asset or liability. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The framework for measuring fair value provides a hierarchy that prioritizes the inputs to
   valuation techniques used in measuring fair value as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;div align="right"&gt;
   &lt;table cellspacing="0" cellpadding="0" width="96%" border="0" style="border-collapse:collapse; text-align: left"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td width="91%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities,&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, and&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants
   would use in pricing.&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Our financial instruments include cash and cash equivalents, accounts receivable, prepaid expenses,
   accounts payable and accrued expenses. The carrying amounts of financial instruments approximate their fair values due to their short maturities. Cash equivalents of approximately $85.0 million and $51.8 million at September&amp;#160;30, 2012 and
   December&amp;#160;31, 2011, respectively, are carried at fair value and are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices for identical securities. We have no instruments that are classified
   within Level 2 and Level 3. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Segment Information &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We operate our business in one segment, which includes all activities related to the research, development and commercialization of human
   enzymes that either transiently modify tissue to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. This segment also includes revenues and expenses related to (i)&amp;#160;research and development
   activities conducted under our collaborative agreements with third parties and (ii)&amp;#160;product sales of &lt;i&gt;Hylenex&lt;/i&gt; recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations
   as a single operating segment. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;3. Collaborative Agreements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Roche Collaboration &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In December 2006, we and Roche entered into a license and collaborative agreement under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and
   up to thirteen Roche target compounds (the &amp;#8220;Roche Collaboration&amp;#8221;). As of September&amp;#160;30, 2012, Roche has elected a total of five exclusive targets and retains the option to develop and commercialize rHuPH20 with three additional
   targets, provided that Roche continues to pay annual maintenance fees to us. As of September&amp;#160;30, 2012, we have received $57 million from Roche, including the $20 million upfront license fee payment for the application of rHuPH20 to the initial
   three Roche exclusive targets, $20 million in connection with Roche&amp;#8217;s election of two additional exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets, $13 million in
   clinical development milestone payments and a $4 million regulatory milestone payment. If Roche successfully develops all five exclusive targets and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $178
   million, including up to $17 million for the achievement of clinical development milestones, up to $16 million for the achievement of regulatory milestones and up to $145 million for the achievement of sales-based milestones. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Under the terms of the Roche Collaboration, Roche will also pay us a royalty on each product commercialized under the agreement
   consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&amp;#8217;s obligation to pay royalties. Roche
   has the obligation to pay royalties with respect to each product in each country, during the period equal to the longer of: (a)&amp;#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the
   collaboration which valid claim covers the product in such country or (b)&amp;#160;ten years following the date of the first commercial sale of such product in such country. For products developed for each of the additional targets, Roche may pay us
   upfront and milestone payments of up to $47 million per target, as well as royalties on product sales for each of the additional targets consisting of a mid-single digit percent of the net sales of such products. Additionally, Roche will obtain
   access to our expertise in developing and applying rHuPH20 to Roche targets. Under the terms of the Roche Collaboration, we were obligated to scale up the production of rHuPH20 and to identify a second source manufacturer that would help meet
   anticipated production obligations arising from the Roche Collaboration. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Due to our continuing involvement obligations (for
   example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We have
   determined that the clinical and regulatory milestones are substantive; therefore, we expect to recognize such clinical and regulatory milestone payments as revenue upon achievement of the milestones. In addition, we have determined that the
   sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, we will recognize such sales-based milestone payments as revenue upon achievement
   of the milestones. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;There were no milestone payments recognized as revenues under collaborative agreements under the Roche
   Collaboration for the three months ended September&amp;#160;30, 2012 and 2011. For the nine months ended September&amp;#160;30, 2012 and 2011, we recognized $4 million and $5 million, respectively, as revenues under collaborative agreements in accordance
   with the Milestone Method related to the achievement of certain regulatory and clinical milestones pursuant to the terms of the Roche Collaboration. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Gammagard Collaboration &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In September 2007, we entered
   into a license and collaborative agreement with Baxter, under which Baxter obtained a worldwide, exclusive license to develop and commercialize a product candidate (currently named HyQ) consisting of rHuPH20 combined with a current Baxter product,
   GAMMAGARD LIQUID&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;&amp;reg;&lt;/sup&gt;&lt;/font&gt; (the &amp;#8220;Gammagard Collaboration&amp;#8221;). As of September&amp;#160;30, 2012, we have received $13
   million under the Gammagard Collaboration, including the $10 million upfront license fee payment and a $3 million regulatory milestone payment. If Baxter successfully receives marketing approval for the licensed product candidate and achieves
   pre-agreed sales targets, we could receive additional milestone payments of up to $34 million for the achievement of sales-based milestones. In addition, Baxter will pay us a royalty on each product commercialized under the agreement consisting of a
   mid-single digit percent of the net sales of such product. The Gammagard Collaboration is applicable to both kit and formulation combinations. Baxter assumes all development, manufacturing, clinical,
   regulatory, sales and marketing costs under the Gammagard Collaboration, while we are responsible for the supply of rHuPH20 enzyme. We perform research and development activities at the request of Baxter, which are reimbursed by Baxter under the
   terms of the Gammagard Collaboration. In addition, Baxter has certain product development and commercialization obligations in major markets identified in the Gammagard Collaboration. Unless terminated earlier in accordance with its terms, the
   Gammagard Collaboration continues in effect until the expiration of Baxter&amp;#8217;s obligation to pay royalties. Baxter has the obligation to pay royalties, with respect to each product in each country, during the period equal to the longer of:
   (a)&amp;#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&amp;#160;ten years following the date of the first
   commercial sale of such product in such country. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Due to our continuing involvement obligations (for example, support
   activities associated with rHuPH20 enzyme), the upfront payment was deferred and is being recognized over the term of the Gammagard Collaboration. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   We have determined that sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, such payments
   will be recognized as revenue upon achievement of the milestones. There were no milestone payments recognized as revenues under collaborative agreements under the Gammagard Collaboration for the three and nine months ended September&amp;#160;30, 2012.
   For the three and nine months ended September&amp;#160;30, 2011, we recognized zero and $3 million, respectively, as revenues under collaborative agreements under the Gammagard Collaboration in accordance with the Milestone Method. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;ViroPharma and Intrexon Collaborations &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effective May&amp;#160;10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which
   ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma&amp;#8217;s commercialized product, Cinryze&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;
   &amp;reg;&lt;/sup&gt;&lt;/font&gt; (C1 esterase inhibitor [human]) (the &amp;#8220;ViroPharma Collaboration&amp;#8221;). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and
   to the hereditary angioedema indication, along with three additional orphan indications. As of September&amp;#160;30, 2012, we have received $13 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment, a $3 million
   clinical development milestone payment and a $1 million annual exclusivity fee. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of
   development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million which commenced on May&amp;#160;10, 2012 and on each anniversary of the effective
   date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for
   research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory
   milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive a royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such
   product. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unless terminated earlier in accordance with its terms, the ViroPharma Collaboration continues in effect until the
   later of (i)&amp;#160;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and
   (ii)&amp;#160;expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Collaboration, with respect to each country, consists of the period equal to the
   longer of: (a)&amp;#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&amp;#160;ten years following the date of the
   first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us.&amp;#160;Upon any such termination, the license
   granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effective June&amp;#160;6,
   2011, we and Intrexon entered into a collaboration and license agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon&amp;#8217;s
   recombinant human alpha 1-antitrypsin (rHuA1AT) (the &amp;#8220;Intrexon Collaboration&amp;#8221;). In addition, the license provides Intrexon with exclusivity for a defined indication (&amp;#8220;Exclusive Field&amp;#8221;). As of September&amp;#160;30, 2012, we have
   received $10 million from Intrexon, including a nonrefundable upfront license fee payment of $9 million and a $1 million annual exclusivity fee. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales
   target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as
   the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million which commenced on June&amp;#160;6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development
   event occurs. Intrexon is solely responsible for the development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for research and development services and supply of rHuPH20 API if
   requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also
   entitled to receive a royalty on each product commercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unless terminated earlier in accordance with its terms, the Intrexon Collaboration continues in effect until the later of
   (i)&amp;#160;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii)&amp;#160;expiration
   of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Collaboration, with respect to each country, consists of the period equal to the longer of: (a)&amp;#160;the
   duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&amp;#160;ten years following the date of the first commercial sale of
   such product in such country. Intrexon may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with
   respect to the terminated product, as applicable) will terminate. Intrexon&amp;#8217;s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development
   services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these
   units of accounting were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous
   collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the collaborators. The arrangement consideration was allocated to the deliverables based on the
   relative selling price method. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The amount allocable to the delivered unit or units of accounting is limited to the amount
   that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, we excluded from the allocable arrangement consideration the milestone payments, annual exclusivity
   fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the $9 million upfront license fee received from ViroPharma to the license fee deliverable under the ViroPharma arrangement and the $9
   million upfront fee received from Intrexon to the license fee deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in
   both the ViroPharma Collaboration and Intrexon Collaboration. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Collaboration and the $9 million upfront license fee received under the Intrexon Collaboration
   as revenues under collaborative agreements upon receipt of the upfront license fees. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We recognize the annual exclusivity fees
   as revenues under collaborative agreements when they are due and payable on each anniversary of the effective date and such amounts are included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the
   related services are performed. We recognize amounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the collaborators and the related title and risk of loss and damages
   have passed to the collaborators. We cannot predict the timing of delivery of research and development services and API as they are at the collaborators&amp;#8217; requests. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   We are eligible to receive additional cash payments upon the achievement by the collaborators of specified development, regulatory and sales-based milestones. We have determined that each of the
   development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In
   addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone Method of revenue recognition; therefore, we will recognize the sales-based milestone
   payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   For the three and nine months ended September&amp;#160;30, 2011, we recognized a $3 million milestone payment as revenues under collaborative agreements in accordance with the Milestone Method related to the
   achievement of a development milestone pursuant to the terms of the ViroPharma Collaboration. There were no milestone payments recognized as revenues under collaborative agreements associated with the ViroPharma Collaboration for the three and nine
   months ended September&amp;#160;30, 2012. There were no milestone payments recognized as revenues under collaborative agreements associated with the Intrexon Collaboration for the three and nine months ended September&amp;#160;30, 2012 and 2011. We
   recognized the annual exclusivity fee of zero and $1 million as revenues under collaborative agreements associated with each the ViroPharma and Intrexon Collaborations for the three and nine months ended September&amp;#160;30, 2012, respectively.
   &lt;/font&gt;&lt;/p&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:InventoryDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:InventoryDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;4. Inventories &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Inventories consist of the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;962,751&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;201,822&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;715,241&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;290,647&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;508,071&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;74,794&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,186,063&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;567,263&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;5. Property and Equipment, Net &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Property and equipment, net consist of the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research equipment&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,207,401&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,231,763&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Computer and office equipment&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,524,340&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,266,041&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,137,187&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,019,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,868,928&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,516,951&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(6,505,278&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(5,745,903&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,363,650&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,771,048&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Depreciation and amortization expense totaled approximately $286,000 and $239,000 for the three months ended
   September&amp;#160;30, 2012 and 2011, respectively, and approximately $796,000 and $852,000 for the nine months ended September&amp;#160;30, 2012 and 2011, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <halo:AccruedExpensesCurrentTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - halo:AccruedExpensesCurrentTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;6. Accrued Expenses &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued expenses consist of the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued outsourced research and development expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,735,396&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,910,273&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued compensation and payroll taxes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,339,791&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,223,936&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;966,486&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;481,365&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,041,673&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,615,574&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</halo:AccruedExpensesCurrentTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:DeferredRevenueDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;7. Deferred Revenue &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred revenue consists of the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Collaborative agreements&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;44,034,015&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;40,716,806&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Product sales&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;319,367&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;167,184&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total deferred revenue&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;44,353,382&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;40,883,990&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Less current portion&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;9,470,247&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,129,407&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred revenue, net of current portion&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;34,883,135&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;36,754,583&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Roche Collaboration. &lt;/i&gt;&lt;/b&gt;Under the terms of the Roche Collaboration, Roche paid $20 million to us in December
   2006 as an initial upfront payment for the application of rHuPH20 to three pre-defined Roche biologic targets. As of September&amp;#160;30, 2012, Roche has paid an aggregate of $20 million in connection with Roche&amp;#8217;s election of two additional
   exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets. Roche currently retains the option to develop and commercialize rHuPH20 with three additional targets, provided that Roche
   continues to pay annual license maintenance fees to us. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Due to our continuing involvement obligations (for example, support
   activities associated with rHuPH20 enzyme), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We recognized revenue from
   the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration in the amounts of approximately $503,000 and $491,000 for the three months ended September&amp;#160;30, 2012 and 2011, respectively, and
   approximately $1.5 million for the nine months ended September&amp;#160;30, 2012 and 2011. Deferred revenue relating to the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration was $30.1 million
   and $31.7 million as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the nine months ended
   September&amp;#160;30, 2012, we received approximately $7.0 million in deferred revenue relating to the manufacture of rHuPH20 API for Roche. We recognized approximately $334,000 as revenues under collaborative agreements from deferred revenue relating
   to the manufacture of rHuPH20 API for the three and nine months ended September&amp;#160;30, 2012. Deferred revenue relating to the manufacture of rHuPH20 API under the Roche Collaboration was $6.7 million and zero as of September&amp;#160;30, 2012 and
   December&amp;#160;31, 2011, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Gammagard Collaboration. &lt;/i&gt;&lt;/b&gt;Under the terms of the Gammagard Collaboration,
   Baxter paid us a nonrefundable upfront payment of $10 million. Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the $10&amp;#160;million upfront payment was deferred and is being recognized
   over the term of the Gammagard Collaboration. We recognized revenue from the upfront payment under the Gammagard Collaboration in the amounts of approximately $121,000 for each of the three months ended September&amp;#160;30, 2012 and 2011 and
   approximately $362,000 for the nine months ended September&amp;#160;30, 2012 and 2011. Deferred revenue relating to the upfront payment under the Gammagard Collaboration was $7.2 million and $7.6 million as of September&amp;#160;30, 2012 and
   December&amp;#160;31, 2011, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Hylenex
   Collaboration&lt;/i&gt;&lt;/b&gt;. In February 2007, we and Baxter amended certain existing agreements for &lt;i&gt;Hylenex &lt;/i&gt;recombinant and entered into the Hylenex Collaboration for kits and formulations with rHuPH20. Effective January&amp;#160;7, 2011, we and
   Baxter mutually agreed to terminate the Hylenex Collaboration and the associated agreements. On July&amp;#160;18, 2011, we and Baxter entered into an agreement (the &amp;#8220;Transition Agreement&amp;#8221;) setting forth certain rights, data and assets to be
   transferred by Baxter to us during a transition period. Effective July&amp;#160;18, 2011, we had no future performance obligations to Baxter in connection with the Hylenex Collaboration. Therefore, we recognized the unamortized deferred revenue of
   approximately $9.3 million relating to the prepaid product-based payments and the unamortized deferred revenue of approximately $7.6 million relating to deferred upfront payment from the Hylenex Collaboration as revenues under collaborative
   agreements for the three months ended September&amp;#160;30, 2011. For the nine months ended September&amp;#160;30, 2011, we recognized revenues under the Hylenex Collaboration from the upfront payment of approximately $7.8 million and from the
   product-based payments of approximately $9.3 million. There were no deferred revenues relating to the Hylenex Collaboration at September&amp;#160;30, 2012 and 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In addition, pursuant to the terms of the Transition Agreement, Baxter no longer had the right to return the &lt;i&gt;Hylenex &lt;/i&gt;recombinant API previously delivered to Baxter. Accordingly, we recognized
   approximately $991,000 of deferred revenue related to such &lt;i&gt;Hylenex &lt;/i&gt;recombinant API as product sales revenue during the three and nine months ended September&amp;#160;30, 2011. &lt;/font&gt;&lt;/p&gt;
</us-gaap:DeferredRevenueDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EarningsPerShareTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;8. Net Income (Loss) Per Share &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted
   average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted-average number of
   common shares outstanding and potentially dilutive common shares outstanding. Potentially dilutive common shares outstanding, determined using the treasury stock method, principally include shares that may be issued under our stock options,
   restricted stock awards (&amp;#8220;RSAs&amp;#8221;) and RSUs. Stock options, unvested RSAs and unvested RSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when their effect is dilutive.
   For the three and nine months ended September&amp;#160;30, 2012, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 7.3&amp;#160;million were excluded from the calculation of diluted net loss per common share because their
   effect is anti-dilutive. For the three and nine months ended September&amp;#160;30, 2011, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 1.9&amp;#160;million and 5.9&amp;#160;million, respectively, were excluded from the
   calculation of diluted net loss per common share because their effect is anti-dilutive. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="50%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Income (Loss) - Numerator:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net income (loss) for basic and diluted EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(20,005,846&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,165,193&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(49,146,146&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1,354,237&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Shares - Denominator:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted-average shares for basic EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;112,305,002&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;103,223,352&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;110,658,757&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;102,282,904&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effect of dilutive stock options, RSAs and RSUs&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,785,837&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted-average shares for diluted EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;112,305,002&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;105,009,189&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;110,658,757&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;102,282,904&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Basic and diluted net income (loss) per share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.05&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.44&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.01&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;9. Stockholders&amp;#8217; Equity &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the nine months ended September&amp;#160;30, 2012 and 2011, we issued an aggregate of 426,277 and 2,713,573 shares
   of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $4.56 and $1.70 per share, respectively, for net proceeds of approximately $1.9 million and $4.1 million, respectively. In
   addition, for the nine months ended September&amp;#160;30, 2012, we issued 81,070 shares of common stock upon vesting of certain RSUs. The RSU holders surrendered 46,930 RSUs to pay for minimum withholding taxes totaling approximately $347,000. Options
   and RSUs to purchase approximately 6.9&amp;#160;million and 6.0&amp;#160;million shares of our common stock were outstanding as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011, respectively. In addition, we issued 375,908 shares of common stock, net
   of RSAs canceled, in connection with the grants of RSAs during the nine months ended September&amp;#160;30, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On
   February&amp;#160;15, 2012, we completed an underwritten public offering and issued 7,820,000 shares of common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriter. All of the shares
   were offered at a public offering price of $10.61 per share, generating approximately $81.5 million in net proceeds. Randal J. Kirk, a member of our board of directors, through his affiliates, purchased 1,360,000 shares of common stock in this
   offering at the public offering price of $10.61 per share for a total of approximately $14.4 million. &lt;/font&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;10. Commitments and Contingencies &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations
   in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny
   coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial
   position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&amp;#8217;s opinion, individually or in the
   aggregate, would have a material adverse effect on our consolidated results of operations or financial position. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table1-->
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table1 - us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock--&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States
   generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of
   the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated
   financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2011, filed with the SEC on March&amp;#160;12, 2012. The unaudited financial information for the interim periods presented herein
   reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring
   adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc. All intercompany accounts and transactions have been
   eliminated. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
   estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management
   believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#8217;s estimates. &lt;/font&gt;&lt;/p&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table1-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table2-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table2 - us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Adoption of Recent Accounting Pronouncements &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effective January&amp;#160;1, 2012, we adopted Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting Standards Update
   (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2011-05, Comprehensive Income (Topic 220): &lt;i&gt;Presentation of Comprehensive Income&lt;/i&gt; and ASU No.&amp;#160;2011-12, &lt;i&gt;Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of
   Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU No.&amp;#160;2011-5&lt;/i&gt;. In these updates, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other
   comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each
   component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No.&amp;#160;2011-05 eliminates the option to present the components of other comprehensive income as part of the
   statement of changes in stockholders&amp;#8217; equity. The amendments in ASU No.&amp;#160;2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.
   The amendments in these updates are effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2011. The adoption of ASU Nos. 2011-05 and 2011-12 did not have a material impact on our consolidated financial
   position or results of operations. We have presented comprehensive income (loss) in our condensed consolidated statements of comprehensive income (loss). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Effective January&amp;#160;1, 2012, we prospectively adopted FASB&amp;#8217;s ASU No.&amp;#160;2011-04, &lt;i&gt;&amp;#8220;Fair Value Measurement (Topic 820) &amp;#8212; Amendments to Achieve Common Fair Value Measurement and
   Disclosure Requirements in U.S. GAAP and IFRS&amp;#8221;. &lt;/i&gt;The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;). Consequently, the
   amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This pronouncement is effective for fiscal years, and interim periods within
   those years, beginning after December&amp;#160;15, 2011. The adoption of ASU No.&amp;#160;2011-04 did not have a material effect on our consolidated financial position or results of operations. &lt;/font&gt;&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table2-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table3-->
  <us-gaap:InventoryPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table3 - us-gaap:InventoryPolicyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Inventories &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
   evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
   compared with historical cost and the remaining shelf life of goods on hand. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Raw materials inventories consist of raw
   materials used in the manufacture of our bulk drug material for &lt;i&gt;Hylenex&lt;/i&gt; recombinant product. Work-in-process inventories consist of in-process &lt;i&gt;Hylenex&lt;/i&gt; recombinant. Finished goods inventories consist of finished &lt;i&gt;Hylenex&lt;/i&gt;
   recombinant product. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We expense costs relating to the purchase and production of pre-approval inventories for which the sole
   use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
   by regulatory bodies such as the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;), inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or
   comparable regulatory agencies in foreign countries, costs related to purchases of the active pharmaceutical ingredients (&amp;#8220;API&amp;#8221;) and the manufacturing of the product candidate are recorded as research and development expense. All direct
   manufacturing costs incurred after approval are capitalized as inventory. &lt;/font&gt;&lt;/p&gt;
</us-gaap:InventoryPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table3-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table4-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table4 - us-gaap:RevenueRecognitionPolicyTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
   nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
   resulting from collaborative arrangements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We recognize revenue in accordance with the authoritative guidance on revenue
   recognition. Revenue is recognized when all of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the seller&amp;#8217;s price to the buyer is
   fixed or determinable; and (4)&amp;#160;collectibility is reasonably assured. &lt;/font&gt;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table4-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table5-->
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table5 - us-gaap:CostOfSalesPolicyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Cost of Product Sales &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal
   costs and manufacturing overhead associated with the production of &lt;i&gt;Hylenex &lt;/i&gt;recombinant. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CostOfSalesPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table5-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table6-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table6 - us-gaap:ResearchAndDevelopmentExpensePolicy--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses,
   research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no
   alternative future uses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Advance payments, including nonrefundable amounts, for goods or services that will be used or
   rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the
   goods to be delivered or services to be performed. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Milestone payments that we make in connection with in-licensed technology
   or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product
   candidates to be uncertain until such licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all
   of our licensed technology or product candidates to be uncertain and has expensed these amounts as incurred. &lt;/font&gt;&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table6-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table7-->
  <halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table7 - halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work
   performed, including actual level of patient enrollment, completion of patient studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts
   are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period
   in which the facts that give rise to the revision become reasonably certain. &lt;/font&gt;&lt;/p&gt;
</halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table7-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table8-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table8 - us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total share-based compensation expense related to all of our share-based awards was allocated as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;913,946&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;890,276&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,279,940&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,944,552&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Selling, general and administrative&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,008,447&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;867,083&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,082,432&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,971,777&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense per basic and diluted share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.06&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.04&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense from:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,164,973&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;806,078&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,491,220&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,318,728&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Restricted stock awards and restricted stock units&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;757,420&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;951,281&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,871,152&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,597,601&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Since we have a net operating loss carryforward as of September&amp;#160;30, 2012, no excess tax benefits for the tax
   deductions related to share-based awards were recognized in the interim unaudited condensed consolidated statements of comprehensive loss for the three and nine months ended September&amp;#160;30, 2012. For the three months ended September&amp;#160;30, 2012 and 2011, employees exercised stock options to
   purchase 7,055 and 38,511 shares of common stock, respectively, for aggregate proceeds of approximately $39,000 and $79,000, respectively. For the nine months ended September&amp;#160;30, 2012 and 2011, employees exercised stock options to purchase
   426,277 and 2,713,573 shares of common stock, respectively, for aggregate proceeds of approximately $1.9 million and $4.1 million, respectively. In addition, for the nine months ended September&amp;#160;30, 2012, upon vesting of 128,000 restricted stock
   units (&amp;#8220;RSUs&amp;#8221;), the RSU holders received net settlement of 81,070 shares of common stock and surrendered 46,930 RSUs to pay for the minimum withholding taxes totaling approximately $347,000. There were no RSUs vested for the three months
   ended September&amp;#160;30, 2012 or the three and nine months ended September&amp;#160;30, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As of September&amp;#160;30, 2012,
   total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock awards and restricted stock units granted prior to that date was approximately $9.6 million and $7.0 million, respectively, which is
   expected to be recognized over a weighted-average period of approximately 2.7 years and 3.6 years, respectively. &lt;/font&gt;&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table8-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table9-->
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table9 - us-gaap:FairValueOfFinancialInstrumentsPolicy--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We follow the authoritative guidance for fair value measurements and disclosures which, among other things, defines fair value,
   establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price that would be
   received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
   pricing an asset or liability. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The framework for measuring fair value provides a hierarchy that prioritizes the inputs to
   valuation techniques used in measuring fair value as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;div align="right"&gt;
   &lt;table cellspacing="0" cellpadding="0" width="96%" border="0" style="border-collapse:collapse; text-align: left"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td width="91%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities,&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, and&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="2"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants
   would use in pricing.&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Our financial instruments include cash and cash equivalents, accounts receivable, prepaid expenses,
   accounts payable and accrued expenses. The carrying amounts of financial instruments approximate their fair values due to their short maturities. Cash equivalents of approximately $85.0 million and $51.8 million at September&amp;#160;30, 2012 and
   December&amp;#160;31, 2011, respectively, are carried at fair value and are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices for identical securities. We have no instruments that are classified
   within Level 2 and Level 3. &lt;/font&gt;&lt;/p&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table9-->
  <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table10-->
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table10 - us-gaap:SegmentReportingPolicyPolicyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Segment Information &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We operate our business in one segment, which includes all activities related to the research, development and commercialization of human
   enzymes that either transiently modify tissue to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. This segment also includes revenues and expenses related to (i)&amp;#160;research and development
   activities conducted under our collaborative agreements with third parties and (ii)&amp;#160;product sales of &lt;i&gt;Hylenex&lt;/i&gt; recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations
   as a single operating segment. &lt;/font&gt;&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <!-- End Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table10-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note2_table1-->
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note2_table1 - us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;913,946&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;890,276&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,279,940&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,944,552&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Selling, general and administrative&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,008,447&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;867,083&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,082,432&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,971,777&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense per basic and diluted share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.02&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.06&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.04&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Share-based compensation expense from:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,164,973&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;806,078&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,491,220&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,318,728&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Restricted stock awards and restricted stock units&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;757,420&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;951,281&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,871,152&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,597,601&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,922,393&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,757,359&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,362,372&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,916,329&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note2_table1-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note4_table1-->
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note4_table1 - us-gaap:ScheduleOfInventoryCurrentTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;962,751&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;201,822&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;715,241&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;290,647&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;508,071&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;74,794&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,186,063&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;567,263&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note4_table1-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note5_table1-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note5_table1 - us-gaap:PropertyPlantAndEquipmentTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research equipment&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,207,401&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,231,763&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Computer and office equipment&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,524,340&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,266,041&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,137,187&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,019,147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,868,928&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,516,951&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(6,505,278&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(5,745,903&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,363,650&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,771,048&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note5_table1-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note6_table1-->
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note6_table1 - us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued outsourced research and development expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,735,396&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,910,273&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued compensation and payroll taxes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,339,791&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,223,936&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;966,486&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;481,365&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,041,673&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,615,574&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note6_table1-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note7_table1-->
  <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note7_table1 - us-gaap:DeferredRevenueByArrangementDisclosureTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Collaborative agreements&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;44,034,015&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;40,716,806&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Product sales&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;319,367&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;167,184&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total deferred revenue&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;44,353,382&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;40,883,990&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Less current portion&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;9,470,247&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,129,407&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred revenue, net of current portion&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;34,883,135&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;36,754,583&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note7_table1-->
  <!-- Begin Block Tagged Note Table: halo-20120930_note8_table1-->
  <us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock contextRef="Jan-01-2012_Sep-30-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note Table: halo-20120930_note8_table1 - us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock--&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="50%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Income (Loss) - Numerator:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net income (loss) for basic and diluted EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(20,005,846&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,165,193&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(49,146,146&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1,354,237&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Shares - Denominator:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted-average shares for basic EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;112,305,002&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;103,223,352&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;110,658,757&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;102,282,904&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effect of dilutive stock options, RSAs and RSUs&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,785,837&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted-average shares for diluted EPS&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;112,305,002&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;105,009,189&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;110,658,757&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;102,282,904&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Basic and diluted net income (loss) per share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.05&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.44&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.01&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock>
  <!-- End Block Tagged Note Table: halo-20120930_note8_table1-->
  <dei:AmendmentFlag contextRef="Jan-01-2012_Sep-30-2012">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Jan-01-2012_Sep-30-2012">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Jan-01-2012_Sep-30-2012">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Jan-01-2012_Sep-30-2012">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Jan-01-2012_Sep-30-2012">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Jan-01-2012_Sep-30-2012">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Jan-01-2012_Sep-30-2012">0001159036</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_31Oct2012" unitRef="Shares" decimals="INF">112705092</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Jan-01-2012_Sep-30-2012">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Jan-01-2012_Sep-30-2012">HALOZYME THERAPEUTICS INC</dei:EntityRegistrantName>
  <halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">1910273</halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent>
  <halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">3735396</halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent>
  <halo:AchievementOfDevelopmentAndRegulatoryMilestones contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">44000000</halo:AchievementOfDevelopmentAndRegulatoryMilestones>
  <halo:AchievementOfDevelopmentAndRegulatoryMilestones contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">41000000</halo:AchievementOfDevelopmentAndRegulatoryMilestones>
  <halo:AdditionalAchievementOfDevelopmentAndRegulatoryMilestones contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">10000000</halo:AdditionalAchievementOfDevelopmentAndRegulatoryMilestones>
  <halo:AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="-6">10000000</halo:AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications>
  <halo:AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">10000000</halo:AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">54000000</halo:AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">17000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">16000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="-6">34000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">10000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">145000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones>
  <halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">178000000</halo:AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets>
  <halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">0.04</halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted>
  <halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">0.02</halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted>
  <halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted contextRef="Jan-01-2012_Sep-30-2012" unitRef="USDEPS" decimals="2">0.06</halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted>
  <halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USDEPS" decimals="2">0.02</halo:AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted>
  <halo:AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">9000000</halo:AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement>
  <halo:AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">9000000</halo:AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement>
  <halo:AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="USD" decimals="0">347000</halo:AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod>
  <halo:AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">20000000</halo:AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement>
  <halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_10May2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement>
  <halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_06Jun2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement>
  <halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement>
  <halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeesReceivedUnderCollaborativeAgreement>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="NineMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="NineMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="ThreeMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="ThreeMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">1000000</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="ThreeMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:AnnualExclusivityFeeUnderCollaborativeAgreements contextRef="ThreeMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:AnnualExclusivityFeeUnderCollaborativeAgreements>
  <halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">13000000</halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement>
  <halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">3000000</halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement>
  <halo:DeferredRevenueRelatingToReimbursableResearchAndDevelopment contextRef="BalanceAsOf_31Dec2011_Roche_Partnership_Member" unitRef="USD" decimals="-6">0</halo:DeferredRevenueRelatingToReimbursableResearchAndDevelopment>
  <halo:DeferredRevenueRelatingToReimbursableResearchAndDevelopment contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member_2" unitRef="USD" decimals="-5">6700000</halo:DeferredRevenueRelatingToReimbursableResearchAndDevelopment>
  <halo:DeferredRevenueRelatingToUpfrontPayment contextRef="BalanceAsOf_31Dec2011_Gammagard_Partnership_Member" unitRef="USD" decimals="-5">7600000</halo:DeferredRevenueRelatingToUpfrontPayment>
  <halo:DeferredRevenueRelatingToUpfrontPayment contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member" unitRef="USD" decimals="-5">7200000</halo:DeferredRevenueRelatingToUpfrontPayment>
  <halo:DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees contextRef="BalanceAsOf_31Dec2011_Roche_Partnership_Member" unitRef="USD" decimals="-5">31700000</halo:DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees>
  <halo:DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member_2" unitRef="USD" decimals="-5">30100000</halo:DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees>
  <halo:DeferredRevenueToBeRecognizedOverTerm contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member" unitRef="USD" decimals="-6">10000000</halo:DeferredRevenueToBeRecognizedOverTerm>
  <halo:DurationOfRoyaltyReceivable contextRef="NineMonthsEnded_30Sep2012_Gammagard_Partnership_Member">P10Y</halo:DurationOfRoyaltyReceivable>
  <halo:DurationOfRoyaltyReceivable contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member">P10Y</halo:DurationOfRoyaltyReceivable>
  <halo:DurationOfRoyaltyReceivable contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member_2">P10Y</halo:DurationOfRoyaltyReceivable>
  <halo:DurationOfRoyaltyReceivable contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member">P10Y</halo:DurationOfRoyaltyReceivable>
  <halo:IncreaseDecreaseInDeferredRent contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">89453</halo:IncreaseDecreaseInDeferredRent>
  <halo:IncreaseDecreaseInDeferredRent contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">62385</halo:IncreaseDecreaseInDeferredRent>
  <halo:InitialUpfrontPayment contextRef="BalanceAsOf_31Dec2006_Roche_Partnership_Member" unitRef="USD" decimals="-6">20000000</halo:InitialUpfrontPayment>
  <halo:MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">47000000</halo:MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget>
  <halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="-6">10000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
  <halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">9000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
  <halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">20000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
  <halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">9000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
  <halo:NonrefundableUpfrontPayment contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member" unitRef="USD" decimals="-6">10000000</halo:NonrefundableUpfrontPayment>
  <halo:NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="Shares" decimals="INF">46930</halo:NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes>
  <halo:NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="Shares" decimals="INF">81070</halo:NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes>
  <halo:PercentageOfRoyaltyEntitledToReceiveOfNetSales contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="Pure" decimals="2">0.10</halo:PercentageOfRoyaltyEntitledToReceiveOfNetSales>
  <halo:PeriodForTermination contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member">P90D</halo:PeriodForTermination>
  <halo:PeriodForTermination contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member">P90D</halo:PeriodForTermination>
  <halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="-6">13000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
  <halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">10000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
  <halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">57000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
  <halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">13000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
  <halo:PublicOfferingPricePerShare contextRef="OneMonthEnded_29Feb2012" unitRef="USDEPS" decimals="2">10.61</halo:PublicOfferingPricePerShare>
  <halo:PurchaseOfCommonStockByAffiliates contextRef="BalanceAsOf_15Feb2012" unitRef="Shares" decimals="INF">1360000</halo:PurchaseOfCommonStockByAffiliates>
  <halo:PurchaseOfCommonStockByAffiliatesAmount contextRef="BalanceAsOf_15Feb2012" unitRef="USD" decimals="-5">14400000</halo:PurchaseOfCommonStockByAffiliatesAmount>
  <halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-5">7000000</halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment>
  <halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="INF">334000</halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements>
  <halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements contextRef="ThreeMonthsEnded_30Sep2012_Roche_Partnership_Member_2" unitRef="USD" decimals="INF">334000</halo:RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="NineMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="NineMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">3000000</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="ThreeMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="ThreeMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">3000000</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="ThreeMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement contextRef="ThreeMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</halo:RecognizedPaymentOfRevenueUnderCollaborativeAgreement>
  <halo:RecognizedRevenuesRelatedToProductBasedPayment contextRef="NineMonthsEnded_30Sep2011_Hylenex_Partnership_Member">9.3</halo:RecognizedRevenuesRelatedToProductBasedPayment>
  <halo:RecognizedRevenuesRelatedToUpfrontPayment contextRef="NineMonthsEnded_30Sep2011_Hylenex_Partnership_Member" unitRef="USD" decimals="-5">7800000</halo:RecognizedRevenuesRelatedToUpfrontPayment>
  <halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="-6">3000000</halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement>
  <halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="BalanceAsOf_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">4000000</halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement>
  <halo:StockIssuedDuringPeriodSharesNewIssuesToUnderwriter contextRef="OneMonthEnded_29Feb2012" unitRef="Shares" decimals="INF">1020000</halo:StockIssuedDuringPeriodSharesNewIssuesToUnderwriter>
  <halo:UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment contextRef="ThreeMonthsEnded_30Sep2011_Hylenex_Partnership_Member" unitRef="USD" decimals="-5">7600000</halo:UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment>
  <halo:UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments contextRef="ThreeMonthsEnded_30Sep2011_Hylenex_Partnership_Member" unitRef="USD" decimals="-5">9300000</halo:UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">7556859</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">3526839</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">2262465</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">4464273</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">5615574</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">8041673</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">5745903</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">6505278</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">255817772</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">345244876</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">3916329</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2011_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">1944552</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2011_Restricted_Stock_Units_R_S_U_Member" unitRef="USD" decimals="0">1597601</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2011_Selling_General_And_Administrative_Expenses_Member" unitRef="USD" decimals="0">1971777</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2011_Stock_Options_Member" unitRef="USD" decimals="0">2318728</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">1757359</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2011_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">890276</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2011_Restricted_Stock_Units_R_S_U_Member" unitRef="USD" decimals="0">951281</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2011_Selling_General_And_Administrative_Expenses_Member" unitRef="USD" decimals="0">867083</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2011_Stock_Options_Member" unitRef="USD" decimals="0">806078</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">6362372</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2012_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">3279940</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="USD" decimals="0">2871152</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2012_Selling_General_And_Administrative_Expenses_Member" unitRef="USD" decimals="0">3082432</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="NineMonthsEnded_30Sep2012_Stock_Options_Member" unitRef="USD" decimals="0">3491220</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">1922393</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2012_Research_And_Development_Expense_Member" unitRef="USD" decimals="0">913946</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="USD" decimals="0">757420</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2012_Selling_General_And_Administrative_Expenses_Member" unitRef="USD" decimals="0">1008447</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="ThreeMonthsEnded_30Sep2012_Stock_Options_Member" unitRef="USD" decimals="0">1164973</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="-5">5900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="-5">1900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" decimals="-5">7300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" decimals="-5">7300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">65758545</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">107982219</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">63987497</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">105618569</us-gaap:AssetsCurrent>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">6954</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">508990</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="0">83255848</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="0">66329358</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">52825527</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">87614891</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="BalanceAsOf_31Dec2011_Cash_Equivalents_Member_Fair_Value_Inputs_Level1_Member" unitRef="USD" decimals="-5">51800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="BalanceAsOf_30Sep2012_Cash_Equivalents_Member_Fair_Value_Inputs_Level1_Member" unitRef="USD" decimals="-5">85000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-16926490</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">34789364</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_30Sep2012" unitRef="USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2012" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">103989272</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">112692527</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">103989272</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">112692527</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">103990</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">112693</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-1354237</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">5165193</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-49146146</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">-20005846</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CostOfGoodsSold contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">201675</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">11723</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">440516</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">226635</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">55086092</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">17789595</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">69750010</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">25364160</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">802006</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">870548</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">40883990</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_31Dec2011_Product_Sales_Member" unitRef="USD" decimals="0">167184</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_31Dec2011_Collaborative_Arrangement_Member" unitRef="USD" decimals="0">40716806</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">44353382</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_30Sep2012_Product_Sales_Member" unitRef="USD" decimals="0">319367</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="BalanceAsOf_30Sep2012_Collaborative_Arrangement_Member" unitRef="USD" decimals="0">44034015</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">4129407</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">9470247</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">36754583</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">34883135</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Gammagard_Partnership_Member_2" unitRef="USD" decimals="0">362000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Hylenex_Partnership_Member" unitRef="USD" decimals="0">991000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Roche_Partnership_Member" unitRef="USD" decimals="-5">1500000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Gammagard_Partnership_Member_2" unitRef="USD" decimals="0">121000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Hylenex_Partnership_Member" unitRef="USD" decimals="0">991000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Roche_Partnership_Member_2" unitRef="USD" decimals="0">491000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="0">362000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-5">1500000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Gammagard_Partnership_Member" unitRef="USD" decimals="0">121000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Roche_Partnership_Member_2" unitRef="USD" decimals="0">503000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DepreciationAndAmortization contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">852000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">239000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">796000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">286000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">851613</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">796163</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-01-2012_Sep-30-2012" unitRef="USDEPS" decimals="2">-0.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USDEPS" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">3223936</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">3339791</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="NineMonthsEnded_30Sep2012_Stock_Options_Member">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="-5">7000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="-5">9600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">992</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">6610</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-2183864</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-2106754</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">3909636</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">2201808</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-17718311</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">3469392</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-89979</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">1618800</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">576918</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">3021100</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements xsi:nil="true" contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" />
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="INF">1785837</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements xsi:nil="true" contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" />
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements xsi:nil="true" contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" />
  <us-gaap:InventoryFinishedGoods contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">74794</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">508071</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">567263</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">2186063</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterials contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">201822</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryRawMaterials contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">962751</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryWorkInProcess contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">290647</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryWorkInProcess contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">715241</us-gaap:InventoryWorkInProcess>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">65758545</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">107982219</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">17301840</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">21038759</us-gaap:LiabilitiesCurrent>
  <us-gaap:LicenseAndMaintenanceRevenue contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">20000000</us-gaap:LicenseAndMaintenanceRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">52187447</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">21785525</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">19103970</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">4618969</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">4141615</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">83073435</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-271521</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-873165</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-20796584</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-47410906</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-1354237</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">5165193</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-49146146</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">-20005846</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">-1410823</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">5152833</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">-49218333</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">-20029837</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">481365</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">966486</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">56586</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">12360</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">72187</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">23991</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">271521</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">873165</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2012" unitRef="USDEPS" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="USD" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_30Sep2012" unitRef="USD" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">8332242</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">11353342</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">0</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">81476845</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="OneMonthEnded_29Feb2012" unitRef="USD" decimals="-5">81500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">4141615</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">1596590</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_30Sep2011_Stock_Options_Member" unitRef="USD" decimals="-5">4100000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="ThreeMonthsEnded_30Sep2011_Stock_Options_Member" unitRef="USD" decimals="0">79000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_30Sep2012_Stock_Options_Member" unitRef="USD" decimals="-5">1900000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="ThreeMonthsEnded_30Sep2012_Stock_Options_Member" unitRef="USD" decimals="0">39000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">7516951</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_31Dec2011_Computer_And_Office_Equipment_Member" unitRef="USD" decimals="0">1266041</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_31Dec2011_Research_Equipment_Member" unitRef="USD" decimals="0">5231763</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_31Dec2011_Leasehold_Improvements_Member" unitRef="USD" decimals="0">1019147</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">8868928</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_30Sep2012_Computer_And_Office_Equipment_Member" unitRef="USD" decimals="0">1524340</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_30Sep2012_Research_Equipment_Member" unitRef="USD" decimals="0">6207401</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_30Sep2012_Leasehold_Improvements_Member" unitRef="USD" decimals="0">1137187</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">1771048</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">2363650</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">42647265</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">13514352</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">51476329</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">19503491</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">-245021646</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">-294167792</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Gammagard_Partnership_Member" unitRef="USD" decimals="-6">3000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Roche_Partnership_Member_2" unitRef="USD" decimals="-6">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Gammagard_Partnership_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Roche_Partnership_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2011_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Gammagard_Partnership_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Roche_Partnership_Member_2" unitRef="USD" decimals="-6">4000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="NineMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Gammagard_Partnership_Member_2" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Intrexon_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Roche_Partnership_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="ThreeMonthsEnded_30Sep2012_Viropharma_Partnerships_Member" unitRef="USD" decimals="-6">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:Revenues contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">53675269</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">22942428</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">20531677</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">5334323</us-gaap:Revenues>
  <us-gaap:SalesRevenueGoodsNet contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">1487822</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">1156903</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">1427707</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">715354</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">12237152</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="0">4263520</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">17833165</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2012" unitRef="USD" decimals="0">5634034</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="0">3916329</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-01-2012_Sep-30-2012" unitRef="USD" decimals="0">6362372</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="NineMonthsEnded_30Sep2011_Restricted_Stock_Units_R_S_U_Member" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="NineMonthsEnded_30Sep2012_Restricted_Stock_Units_R_S_U_Member" unitRef="Shares" decimals="INF">128000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="-5">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="BalanceAsOf_30Sep2012" unitRef="Shares" decimals="-5">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="NineMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="3">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Jan-01-2012_Sep-30-2012" unitRef="USDEPS" decimals="3">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="0">10900116</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Sep2012" unitRef="USD" decimals="0">51189777</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="OneMonthEnded_29Feb2012" unitRef="Shares" decimals="INF">7820000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" decimals="INF">375908</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="INF">2713573</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="INF">38511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" decimals="INF">426277</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" decimals="INF">7055</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">102282904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">105009189</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" decimals="0">110658757</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" decimals="0">112305002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">102282904</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">103223352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Jan-01-2012_Sep-30-2012" unitRef="Shares" decimals="0">110658757</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Sep2012" unitRef="Shares" decimals="0">112305002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>halo-20120930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.187; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://halozyme.com/20120930" xmlns:halo="http://halozyme.com/20120930" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://halozyme.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>0609 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual" id="NetIncomeLossPerShareDetailsTextual">
        <link:definition>06081 - Disclosure - Net Income (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetails" id="NetIncomeLossPerShareDetails">
        <link:definition>0608 - Disclosure - Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/NetIncomeLossPerShareTables" id="NetIncomeLossPerShareTables">
        <link:definition>0508 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/DeferredRevenueDetailsTextual" id="DeferredRevenueDetailsTextual">
        <link:definition>06071 - Disclosure - Deferred Revenue (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/DeferredRevenueDetails" id="DeferredRevenueDetails">
        <link:definition>0607 - Disclosure - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/DeferredRevenueTables" id="DeferredRevenueTables">
        <link:definition>0507 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <link:definition>0606 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>0506 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual" id="PropertyAndEquipmentNetDetailsTextual">
        <link:definition>06051 - Disclosure - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>0605 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>0505 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/InventoriesTables" id="InventoriesTables">
        <link:definition>0504 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/InventoriesDetails" id="InventoriesDetails">
        <link:definition>0604 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/CollaborativeAgreementsDetails" id="CollaborativeAgreementsDetails">
        <link:definition>0603 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0502 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>0602 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0402 - Disclosure - Summary of Significant Accounting Policies [Policies]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/StatementsOfComprehensiveIncome" id="StatementsOfComprehensiveIncome">
        <link:definition>0120 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>0201 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0202 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/CollaborativeAgreements" id="CollaborativeAgreements">
        <link:definition>0203 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/Inventories" id="Inventories">
        <link:definition>0204 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>0205 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>0206 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/DeferredRevenue" id="DeferredRevenue">
        <link:definition>0207 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/NetIncomeLossPerShare" id="NetIncomeLossPerShare">
        <link:definition>0208 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>0209 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://halozyme.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0210 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="halo-20120930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="halo-20120930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="halo-20120930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="halo-20120930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <!-- elements -->
  <element name="DocumentAndEntityInformationAbstract" id="halo_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
  <element name="IncreaseDecreaseInDeferredRent" id="halo_IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="AccruedExpensesCurrentTextBlock" id="halo_AccruedExpensesCurrentTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" name="SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" name="SummaryOfSignificantAccountingPoliciesTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_CollaborativeAgreementsTextualAbstract" name="CollaborativeAgreementsTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_GammagardPartnershipMember" name="GammagardPartnershipMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_RochePartnershipMember" name="RochePartnershipMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_PeriodForTermination" name="PeriodForTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_ViropharmaPartnershipsMember" name="ViropharmaPartnershipsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_IntrexonPartnershipsMember" name="IntrexonPartnershipsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_AchievementOfDevelopmentAndRegulatoryMilestones" name="AchievementOfDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_ResearchEquipmentMember" name="ResearchEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_PropertyAndEquipmentNetTextualAbstract" name="PropertyAndEquipmentNetTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" name="AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="halo_ProductSalesMember" name="ProductSalesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_DeferredRevenueTextualAbstract" name="DeferredRevenueTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_InitialUpfrontPayment" name="InitialUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_DeferredRevenueRelatingToUpfrontPayment" name="DeferredRevenueRelatingToUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="halo_NonrefundableUpfrontPayment" name="NonrefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_NetIncomeLossPerShareTextualAbstract" name="NetIncomeLossPerShareTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_StockholdersEquityTextualAbstract" name="StockholdersEquityTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_PurchaseOfCommonStockByAffiliates" name="PurchaseOfCommonStockByAffiliates" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="halo_PurchaseOfCommonStockByAffiliatesAmount" name="PurchaseOfCommonStockByAffiliatesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" name="AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" name="SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" name="ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" name="AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" name="AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" name="AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" name="AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" name="MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_DeferredRevenueToBeRecognizedOverTerm" name="DeferredRevenueToBeRecognizedOverTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" name="CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" name="StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_PublicOfferingPricePerShare" name="PublicOfferingPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" name="NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" name="AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" name="ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" name="RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" name="AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" name="DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" name="AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" name="DeferredRevenueRelatingToReimbursableResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="halo_StockholdersEquityAdditionalTextualAbstract" name="StockholdersEquityAdditionalTextualAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" name="NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" name="NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" name="AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" name="AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" name="AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" name="DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" name="RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" name="RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" name="RecognizedPaymentOfRevenueUnderCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" name="AnnualExclusivityFeeUnderCollaborativeAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_HylenexPartnershipMember" name="HylenexPartnershipMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" name="UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" name="UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="halo_RecognizedRevenuesRelatedToUpfrontPayment" name="RecognizedRevenuesRelatedToUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="halo_RecognizedRevenuesRelatedToProductBasedPayment" name="RecognizedRevenuesRelatedToProductBasedPayment" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_DurationOfRoyaltyReceivable" name="DurationOfRoyaltyReceivable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" name="PercentageOfRoyaltyEntitledToReceiveOfNetSales" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" name="AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>halo-20120930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.187; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DocumentAndEntityInformation" roleURI="http://halozyme.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CollaborativeAgreementsDetails" roleURI="http://halozyme.com/role/CollaborativeAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#InventoriesDetails" roleURI="http://halozyme.com/role/InventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#InventoriesTables" roleURI="http://halozyme.com/role/InventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetTables" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetDetails" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpensesTables" roleURI="http://halozyme.com/role/AccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpensesDetails" roleURI="http://halozyme.com/role/AccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueTables" roleURI="http://halozyme.com/role/DeferredRevenueTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetails" roleURI="http://halozyme.com/role/DeferredRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetailsTextual" roleURI="http://halozyme.com/role/DeferredRevenueDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareTables" roleURI="http://halozyme.com/role/NetIncomeLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareDetails" roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareDetailsTextual" roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StockholdersEquityDetails" roleURI="http://halozyme.com/role/StockholdersEquityDetails" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <roleRef roleURI="http://halozyme.com/role/BalanceSheets" xlink:href="halo-20120930.xsd#BalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://halozyme.com/role/BalanceSheetsParenthetical" xlink:href="halo-20120930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://halozyme.com/role/StatementsOfComprehensiveIncome" xlink:href="halo-20120930.xsd#StatementsOfComprehensiveIncome" xlink:type="simple" />
  <roleRef roleURI="http://halozyme.com/role/StatementsOfCashFlows" xlink:href="halo-20120930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:role="http://halozyme.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_AccountsReceivableNetCurrent" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_InventoryNet" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_LiabilitiesCurrent" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_DeferredRevenueNoncurrent" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_DeferredRentCreditNoncurrent" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="16" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="17" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://halozyme.com/role/StatementsOfComprehensiveIncome" xlink:title="0120 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="loc_Revenues" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Revenues" xlink:to="loc_SalesRevenueGoodsNet" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Revenues" xlink:to="loc_LicenseAndServicesRevenue" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_Revenues" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_CostOfGoodsSold" order="21" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="22" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="23" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_CostsAndExpenses" order="24" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OperatingIncomeLoss" order="25" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="25.5" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://halozyme.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="27" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="28" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="29" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment" order="30" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="31" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_IncreaseDecreaseInInventories" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInInventories" order="32" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="33" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="34" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IncreaseDecreaseInDeferredRent" xlink:label="halo_IncreaseDecreaseInDeferredRent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="halo_IncreaseDecreaseInDeferredRent" order="35" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="36" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="37" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="39" use="optional" weight="-1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="43" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="21" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="82" use="optional" weight="1" priority="1" />
  </calculationLink>
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#OrganizationAndBusiness" roleURI="http://halozyme.com/role/OrganizationAndBusiness" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/OrganizationAndBusiness" xlink:title="0201 - Disclosure - Organization and Business" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPolicies" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Summary of Significant Accounting Policies" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CollaborativeAgreements" roleURI="http://halozyme.com/role/CollaborativeAgreements" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreements" xlink:title="0203 - Disclosure - Collaborative Agreements" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#Inventories" roleURI="http://halozyme.com/role/Inventories" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/Inventories" xlink:title="0204 - Disclosure - Inventories" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNet" roleURI="http://halozyme.com/role/PropertyAndEquipmentNet" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNet" xlink:title="0205 - Disclosure - Property and Equipment, Net" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpenses" roleURI="http://halozyme.com/role/AccruedExpenses" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpenses" xlink:title="0206 - Disclosure - Accrued Expenses" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenue" roleURI="http://halozyme.com/role/DeferredRevenue" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenue" xlink:title="0207 - Disclosure - Deferred Revenue" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShare" roleURI="http://halozyme.com/role/NetIncomeLossPerShare" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShare" xlink:title="0208 - Disclosure - Net Income (Loss) Per Share" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StockholdersEquity" roleURI="http://halozyme.com/role/StockholdersEquity" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquity" xlink:title="0209 - Disclosure - Stockholders' Equity" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CommitmentsAndContingencies" roleURI="http://halozyme.com/role/CommitmentsAndContingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CommitmentsAndContingencies" xlink:title="0210 - Disclosure - Commitments and Contingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0402 - Disclosure - Summary of Significant Accounting Policies [Policies]" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="0502 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/InventoriesDetails" xlink:title="0604 - Disclosure - Inventories (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_InventoryFinishedGoods" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryFinishedGoods" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_InventoryWorkInProcess" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryWorkInProcess" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_InventoryRawMaterials" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_InventoryNet" xlink:to="loc_InventoryRawMaterials" order="5" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/InventoriesTables" xlink:title="0504 - Disclosure - Inventories (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetTables" xlink:title="0505 - Disclosure - Property and Equipment, Net (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PropertyPlantAndEquipmentNet" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="7.5" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual" xlink:title="06051 - Disclosure - Property and Equipment, Net (Details Textual)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpensesTables" xlink:title="0506 - Disclosure - Accrued Expenses (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpensesDetails" xlink:title="0606 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_OtherAccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AccruedLiabilitiesCurrent" xlink:to="loc_OtherAccruedLiabilitiesCurrent" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AccruedLiabilitiesCurrent" xlink:to="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_EmployeeRelatedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AccruedLiabilitiesCurrent" xlink:to="loc_EmployeeRelatedLiabilitiesCurrent" order="7.5" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueTables" xlink:title="0507 - Disclosure - Deferred Revenue (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_DeferredRevenue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_DeferredRevenue" xlink:to="loc_DeferredRevenueCurrent" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_DeferredRevenue" xlink:to="loc_DeferredRevenueNoncurrent" order="40" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareTables" xlink:title="0508 - Disclosure - Net Income (Loss) Per Share (Tables)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareDetails" xlink:title="0608 - Disclosure - Net Income (Loss) Per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic" order="10" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual" xlink:title="06081 - Disclosure - Net Income (Loss) Per Share (Details Textual)" />
  <calculationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>halo-20120930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.199; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<link:linkbase xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CollaborativeAgreementsDetails" roleURI="http://halozyme.com/role/CollaborativeAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetDetails" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetails" roleURI="http://halozyme.com/role/DeferredRevenueDetails" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetailsTextual" roleURI="http://halozyme.com/role/DeferredRevenueDetailsTextual" />
  <link:roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StockholdersEquityDetails" roleURI="http://halozyme.com/role/StockholdersEquityDetails" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" order="3" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_AwardTypeAxis" order="3" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RochePartnershipMember" xlink:label="halo_RochePartnershipMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_GammagardPartnershipMember" xlink:label="halo_GammagardPartnershipMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ViropharmaPartnershipsMember" xlink:label="halo_ViropharmaPartnershipsMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IntrexonPartnershipsMember" xlink:label="halo_IntrexonPartnershipsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_RochePartnershipMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_GammagardPartnershipMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_ViropharmaPartnershipsMember" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_IntrexonPartnershipsMember" order="4" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="halo_CollaborativeAgreementsTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="halo_DurationOfRoyaltyReceivable" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueToBeRecognizedOverTerm" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PeriodForTermination" xlink:label="halo_PeriodForTermination" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeeUnderCollaborativeAgreements" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_DurationOfRoyaltyReceivable" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" order="8" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" order="9" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" order="10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" order="11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" order="12" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" order="13" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" order="14" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" order="15" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="16" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_DeferredRevenueToBeRecognizedOverTerm" order="17" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" order="18" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AchievementOfDevelopmentAndRegulatoryMilestones" order="19" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_PeriodForTermination" order="20" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" order="21" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" order="22" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" order="23" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" order="24" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ResearchEquipmentMember" xlink:label="halo_ResearchEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ComputerAndOfficeEquipmentMember" xlink:label="halo_ComputerAndOfficeEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="halo_ResearchEquipmentMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="halo_ComputerAndOfficeEquipmentMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:PropertyPlantAndEquipmentLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProductSalesMember" xlink:label="halo_ProductSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_CollaborativeArrangementMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="halo_ProductSalesMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:DeferredRevenueArrangementLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueAbstract" xlink:label="us-gaap_DeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="4" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RochePartnershipMember" xlink:label="halo_RochePartnershipMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_GammagardPartnershipMember" xlink:label="halo_GammagardPartnershipMember" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_HylenexPartnershipMember" xlink:label="halo_HylenexPartnershipMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="halo_RochePartnershipMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="halo_GammagardPartnershipMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="halo_HylenexPartnershipMember" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:DeferredRevenueArrangementLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="halo_DeferredRevenueTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_InitialUpfrontPayment" xlink:label="halo_InitialUpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndMaintenanceRevenue" xlink:label="us-gaap_LicenseAndMaintenanceRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontPayment" xlink:label="halo_NonrefundableUpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueToBeRecognizedOverTerm" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPayment" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToUpfrontPayment" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToProductBasedPayment" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_InitialUpfrontPayment" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_LicenseAndMaintenanceRevenue" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_NonrefundableUpfrontPayment" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_DeferredRevenueToBeRecognizedOverTerm" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_DeferredRevenueRelatingToUpfrontPayment" order="8" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" order="9" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" order="10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" order="11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" order="12" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" order="13" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_RecognizedRevenuesRelatedToUpfrontPayment" order="14" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="halo_RecognizedRevenuesRelatedToProductBasedPayment" order="15" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionsMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockholdersEquityTextualAbstract" xlink:label="halo_StockholdersEquityTextualAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" />
    <link:loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" order="5" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>halo-20120930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.187; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="halo_DocumentAndEntityInformationAbstract" xlink:href="halo-20120930.xsd#halo_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="halo_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:label="halo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US">Revenues under collaborative agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US">License and Services Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of product sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and Expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposals of equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IncreaseDecreaseInDeferredRent" xlink:label="halo_IncreaseDecreaseInDeferredRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_IncreaseDecreaseInDeferredRent" xlink:to="halo_IncreaseDecreaseInDeferredRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Increase Decrease in Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Accounts payable for purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Business and Collaborative Agreements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AccruedExpensesCurrentTextBlock" xlink:label="halo_AccruedExpensesCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AccruedExpensesCurrentTextBlock" xlink:to="halo_AccruedExpensesCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AccruedExpensesCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AccruedExpensesCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AccruedExpensesCurrentTextBlock_lbl" xml:lang="en-US">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Revenue Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US">Deferred Revenue [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Income (Loss) Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" xlink:label="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" xlink:to="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Shares Used in Computing Basic and Diluted Net Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Shares used in computing net income (loss) per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Shares used in computing basic and diluted net loss per share.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="lab_InventoryPolicyTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InventoryPolicyTextBlock" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_RevenueRecognitionPolicyTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_FairValueOfFinancialInstrumentsPolicy" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_AllocatedShareBasedCompensationExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_SellingGeneralAndAdministrativeExpensesMember" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based compensation expense related to all of our share-based awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionsMember" xlink:to="lab_StockOptionsMember" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_RestrictedStockUnitsRSUMember" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Summary of significant accounting policies.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total unrecognized estimated compensation cost related to non-vested stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted-average period of non-vested stock options and non-vested restricted stock awards and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based compensation expense related to all of our share-based awards</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="halo_CollaborativeAgreementsTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_CollaborativeAgreementsTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_CollaborativeAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaborative Agreements (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_CollaborativeAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaborative agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_CollaborativeAgreementsTextualAbstract_lbl" xml:lang="en-US">Collaborative Agreements (Textual) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_GammagardPartnershipMember" xlink:label="halo_GammagardPartnershipMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_GammagardPartnershipMember" xlink:to="halo_GammagardPartnershipMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_GammagardPartnershipMember_lbl" xml:lang="en-US">Gammagard Partnership [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_GammagardPartnershipMember_lbl" xml:lang="en-US">Gammagard Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_GammagardPartnershipMember_lbl" xml:lang="en-US">Gammagard partnership.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RochePartnershipMember" xlink:label="halo_RochePartnershipMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RochePartnershipMember" xlink:to="halo_RochePartnershipMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RochePartnershipMember_lbl" xml:lang="en-US">Roche Partnership [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="halo_RochePartnershipMember_lbl" xml:lang="en-US">Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RochePartnershipMember_lbl" xml:lang="en-US">Roche Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RochePartnershipMember_lbl" xml:lang="en-US">Roche partnership.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PeriodForTermination" xlink:label="halo_PeriodForTermination" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PeriodForTermination" xlink:to="halo_PeriodForTermination_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PeriodForTermination_lbl" xml:lang="en-US">Period for Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PeriodForTermination_lbl" xml:lang="en-US">Time period to provide prior notice to terminate collaborative agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PeriodForTermination_lbl" xml:lang="en-US">Period for termination.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ViropharmaPartnershipsMember" xlink:label="halo_ViropharmaPartnershipsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ViropharmaPartnershipsMember" xlink:to="halo_ViropharmaPartnershipsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ViropharmaPartnershipsMember_lbl" xml:lang="en-US">Viropharma Partnerships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ViropharmaPartnershipsMember_lbl" xml:lang="en-US">ViroPharma Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ViropharmaPartnershipsMember_lbl" xml:lang="en-US">Viropharma partnerships.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IntrexonPartnershipsMember" xlink:label="halo_IntrexonPartnershipsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_IntrexonPartnershipsMember" xlink:to="halo_IntrexonPartnershipsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_IntrexonPartnershipsMember_lbl" xml:lang="en-US">Intrexon Partnerships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_IntrexonPartnershipsMember_lbl" xml:lang="en-US">Intrexon Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_IntrexonPartnershipsMember_lbl" xml:lang="en-US">Intrexon partnerships.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="halo_AchievementOfDevelopmentAndRegulatoryMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Achievement of Development and Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Additional maximum payments upon achievement of development and regulatory milestone under collaborative agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Achievement of development and regulatory milestones.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="lab_AwardTypeAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="lab_InventoryRawMaterials" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InventoryRawMaterials" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="lab_InventoryWorkInProcess" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InventoryWorkInProcess" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InventoryWorkInProcess" xml:lang="en-US">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="lab_InventoryFinishedGoods" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_PropertyPlantAndEquipmentTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="lab_InventoryNetAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_InventoryNetAbstract" xml:lang="en-US">Inventory, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_InventoryNetAbstract" xml:lang="en-US">Summary of Inventories</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ResearchEquipmentMember" xlink:label="halo_ResearchEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ResearchEquipmentMember" xlink:to="halo_ResearchEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ResearchEquipmentMember_lbl" xml:lang="en-US">Research Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ResearchEquipmentMember_lbl" xml:lang="en-US">Research equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ResearchEquipmentMember_lbl" xml:lang="en-US">Research equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ComputerAndOfficeEquipmentMember" xlink:label="halo_ComputerAndOfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ComputerAndOfficeEquipmentMember" xlink:to="halo_ComputerAndOfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer and Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PropertyAndEquipmentNetTextualAbstract" xlink:label="halo_PropertyAndEquipmentNetTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PropertyAndEquipmentNetTextualAbstract" xlink:to="halo_PropertyAndEquipmentNetTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PropertyAndEquipmentNetTextualAbstract_lbl" xml:lang="en-US">Property and Equipment Net (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PropertyAndEquipmentNetTextualAbstract_lbl" xml:lang="en-US">Property and Equipment, Net (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PropertyAndEquipmentNetTextualAbstract_lbl" xml:lang="en-US">Property and equipment, net.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:to="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued Outsourced Research and Development Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued outsourced research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued outsourced research and development expenses current.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProductSalesMember" xlink:label="halo_ProductSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ProductSalesMember" xlink:to="halo_ProductSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ProductSalesMember_lbl" xml:lang="en-US">Product Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ProductSalesMember_lbl" xml:lang="en-US">Product sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ProductSalesMember_lbl" xml:lang="en-US">Product sales.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="lab_DeferredRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_DeferredRevenue" xml:lang="en-US">Total deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DeferredRevenue" xml:lang="en-US">Deferred revenues relating to Hylenex Collaboration</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="halo_DeferredRevenueTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_DeferredRevenueTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DeferredRevenueTextualAbstract_lbl" xml:lang="en-US">Deferred Revenue (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DeferredRevenueTextualAbstract_lbl" xml:lang="en-US">Deferred Revenue (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DeferredRevenueTextualAbstract_lbl" xml:lang="en-US">Deferred revenue.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_InitialUpfrontPayment" xlink:label="halo_InitialUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_InitialUpfrontPayment" xlink:to="halo_InitialUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_InitialUpfrontPayment_lbl" xml:lang="en-US">Initial Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_InitialUpfrontPayment_lbl" xml:lang="en-US">Initial upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_InitialUpfrontPayment_lbl" xml:lang="en-US">Initial upfront payment</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPayment" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DeferredRevenueRelatingToUpfrontPayment" xlink:to="halo_DeferredRevenueRelatingToUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment_lbl" xml:lang="en-US">Deferred Revenue Relating to Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment_lbl" xml:lang="en-US">Deferred revenue relating to the upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment_lbl" xml:lang="en-US">Deferred revenue relating to the upfront payment.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndMaintenanceRevenue" xlink:label="us-gaap_LicenseAndMaintenanceRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceRevenue" xlink:to="lab_LicenseAndMaintenanceRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LicenseAndMaintenanceRevenue" xml:lang="en-US">License and Maintenance Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LicenseAndMaintenanceRevenue" xml:lang="en-US">License and annual maintenance fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized" xlink:to="lab_DeferredRevenueRevenueRecognized" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueRevenueRecognized" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_DeferredRevenueRevenueRecognized" xml:lang="en-US">Deferred revenue related to Hylenex recombinant API as product sales revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DeferredRevenueRevenueRecognized" xml:lang="en-US">Designation fees and license maintenance fees</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontPayment" xlink:label="halo_NonrefundableUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_NonrefundableUpfrontPayment" xlink:to="halo_NonrefundableUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_NonrefundableUpfrontPayment_lbl" xml:lang="en-US">Nonrefundable Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_NonrefundableUpfrontPayment_lbl" xml:lang="en-US">Nonrefundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_NonrefundableUpfrontPayment_lbl" xml:lang="en-US">Nonrefundable upfront payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="lab_DeferredRevenueByArrangementDisclosureTextBlock" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:to="lab_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xml:lang="en-US">Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xml:lang="en-US">Reconciliation of Basic and Diluted Earnings (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="lab_NetIncomeLossAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) - Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for basic and diluted EPS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_EarningsPerShareBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_WeightedAverageNumberOfSharesOutstandingBasic" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares for basic EPS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Effect of dilutive options, RSAs and RSUs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares for diluted EPS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xml:lang="en-US">Shares - Denominator:</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NetIncomeLossPerShareTextualAbstract" xlink:label="halo_NetIncomeLossPerShareTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_NetIncomeLossPerShareTextualAbstract" xlink:to="halo_NetIncomeLossPerShareTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_NetIncomeLossPerShareTextualAbstract_lbl" xml:lang="en-US">Net Income (Loss) Per Share (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_NetIncomeLossPerShareTextualAbstract_lbl" xml:lang="en-US">Net income (loss) per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_NetIncomeLossPerShareTextualAbstract_lbl" xml:lang="en-US">Net Income (Loss) Per Share (Textual) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Outstanding stock options, outstanding RSUs and unvested RSAs totaling</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockholdersEquityTextualAbstract" xlink:label="halo_StockholdersEquityTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_StockholdersEquityTextualAbstract" xlink:to="halo_StockholdersEquityTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders Equity (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders' equity.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PurchaseOfCommonStockByAffiliates" xlink:label="halo_PurchaseOfCommonStockByAffiliates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PurchaseOfCommonStockByAffiliates" xlink:to="halo_PurchaseOfCommonStockByAffiliates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PurchaseOfCommonStockByAffiliates_lbl" xml:lang="en-US">Purchase of Common Stock by Affiliates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PurchaseOfCommonStockByAffiliates_lbl" xml:lang="en-US">Purchase of common stock by affiliates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PurchaseOfCommonStockByAffiliates_lbl" xml:lang="en-US">Purchase of common stock by affiliates</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PurchaseOfCommonStockByAffiliatesAmount" xlink:label="halo_PurchaseOfCommonStockByAffiliatesAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PurchaseOfCommonStockByAffiliatesAmount" xlink:to="halo_PurchaseOfCommonStockByAffiliatesAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PurchaseOfCommonStockByAffiliatesAmount_lbl" xml:lang="en-US">Purchase of Common Stock by Affiliates Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PurchaseOfCommonStockByAffiliatesAmount_lbl" xml:lang="en-US">Purchase of common stock by affiliates amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PurchaseOfCommonStockByAffiliatesAmount_lbl" xml:lang="en-US">Purchase of common stock by affiliates amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_PropertyPlantAndEquipmentByTypeAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_PropertyPlantAndEquipmentTypeDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="lab_LeaseholdImprovementsMember" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_PropertyPlantAndEquipmentLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_DeferredRevenueArrangementByTypeTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueArrangementByTypeTable" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_DeferredRevenueArrangementTypeAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueArrangementTypeAxis" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_DeferredRevenueArrangementTypeDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueArrangementTypeDomain" xml:lang="en-US">Deferred Revenue Arrangement Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_DeferredRevenueArrangementLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueArrangementLineItems" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueAbstract" xlink:label="us-gaap_DeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="lab_DeferredRevenueAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueAbstract" xml:lang="en-US">Deferred Revenue [ Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DeferredRevenueAbstract" xml:lang="en-US">Summary of Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" xlink:to="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense Per Share Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted_lbl" xml:lang="en-US">Share-based compensation expense per basic and diluted share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted_lbl" xml:lang="en-US">Allocated share based compensation expense per share basic and diluted.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:label="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:to="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Additional Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Additional Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract_lbl" xml:lang="en-US">Summary of significant accounting policies.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_CashAndCashEquivalentsFairValueDisclosure" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="lab_FairValueInputsLevel1Member" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="lab_CashEquivalentsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CashEquivalentsMember" xml:lang="en-US">Cash equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:to="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_lbl" xml:lang="en-US">Proceeds from Partner of License and Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_lbl" xml:lang="en-US">Total proceeds received from partner under license and collaborative agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_lbl" xml:lang="en-US">Proceeds from partner of license and collaborative agreement.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets_lbl" xml:lang="en-US">Additional Maximum Proceeds Receivable from Partner of License and Collaborative Agreement Upon Achievement of Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets_lbl" xml:lang="en-US">Additional maximum proceeds receivable from Roche if the partner successfully develops all five exclusive targets and achieves pre-agreed sales targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets_lbl" xml:lang="en-US">Additional maximum proceeds receivable from Roche if the partner successfully develops all five exclusive targets and achieves pre-agreed sales targets.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones_lbl" xml:lang="en-US">Additional Maximum Proceeds Receivable from Partner of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones_lbl" xml:lang="en-US">Additional maximum payments upon achievement of clinical development milestones under collaborative agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones_lbl" xml:lang="en-US">Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of clinical development milestones.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones_lbl" xml:lang="en-US">Additional Maximum Proceeds Receivable from Partner of License and Collaborative Agreement Upon Achievement of Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones_lbl" xml:lang="en-US">Additional maximum payments upon achievement of regulatory milestones under collaborative agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones_lbl" xml:lang="en-US">Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of regulatory milestones.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones_lbl" xml:lang="en-US">Additional Maximum Proceeds Receivable from Partner of License and Collaborative Agreement Upon Achievement of Sales Based Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones_lbl" xml:lang="en-US">Maximum payments upon achievement of sales-based milestones under collaborative agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones_lbl" xml:lang="en-US">Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of sales based milestones.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" xlink:to="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget_lbl" xml:lang="en-US">Maximum Proceeds Receivable from Partner of License and Collaborative Agreement Upfront and Milestone Payments Per Target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget_lbl" xml:lang="en-US">Potential additional upfront and milestone payments for each additional target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget_lbl" xml:lang="en-US">Maximum proceeds receivable from partner of license and collaborative agreement upfront and milestone payments per target.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueToBeRecognizedOverTerm" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DeferredRevenueToBeRecognizedOverTerm" xlink:to="halo_DeferredRevenueToBeRecognizedOverTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm_lbl" xml:lang="en-US">Deferred Revenue to be Recognized Over Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm_lbl" xml:lang="en-US">Deferred upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm_lbl" xml:lang="en-US">Deferred revenue to be recognized over term.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="lab_DepreciationAndAmortization" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense totaled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_AccruedLiabilitiesCurrentAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Summary of Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_EmployeeRelatedLiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued compensation and payroll taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="lab_FairValueByAssetClassAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Fair Value by Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_FairValueByFairValueHierarchyLevelAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="lab_CollaborativeArrangementMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementMember" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CollaborativeArrangementMember" xml:lang="en-US">Collaborative agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:label="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:to="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US">Calculation of Earnings Per Share Basic and Diluted Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US">Reconciliation of Basic and Diluted Earnings (Loss) Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US">Calculation of earnings per share basic and diluted earnings per share.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock options weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Underwritten public offering and issued shares</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" xlink:label="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" xlink:to="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues to Underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter_lbl" xml:lang="en-US">Shares sold to underwriter pursuant to the full exercise of an over-allotment option granted to the underwriter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter_lbl" xml:lang="en-US">Stock issued during period shares new issues to underwriter.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PublicOfferingPricePerShare" xlink:label="halo_PublicOfferingPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PublicOfferingPricePerShare" xlink:to="halo_PublicOfferingPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PublicOfferingPricePerShare_lbl" xml:lang="en-US">Public Offering Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PublicOfferingPricePerShare_lbl" xml:lang="en-US">Public offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PublicOfferingPricePerShare_lbl" xml:lang="en-US">Public offering price per share.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Total unrecognized estimated compensation cost of non-vested restricted stock awards and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_CostOfSalesPolicyTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Product Sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_ResearchAndDevelopmentExpensePolicy" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:to="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Nonrefundable upfront license fee payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Nonrefundable upfront license fee payment received under collaborative agreement.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:to="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_lbl" xml:lang="en-US">Amount Received For Additional Exclusive Targets And Annual License Maintenance Fees Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_lbl" xml:lang="en-US">Amount received from Roche for additional exclusive targets and annual license maintenance fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_lbl" xml:lang="en-US">Amount received from Roche for additional exclusive targets and annual license maintenance fees.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:to="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Clinical Development Milestone Payments Received Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Clinical development milestone payments received under collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Clinical development milestone payments received under collaborative agreement</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:to="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Regulatory Milestone Payments Received Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Regulatory milestone payments received under collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Regulatory milestone payments received under collaborative agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" xlink:to="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Annual Exclusivity Fees Received Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Annual exclusivity fees received under collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement_lbl" xml:lang="en-US">Annual exclusivity fees received under collaborative agreement</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" xlink:to="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees_lbl" xml:lang="en-US">Deferred Revenue Relating To Upfront Payment License Fees And Annual Maintenance Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees_lbl" xml:lang="en-US">Deferred revenue relating to the upfront payment, designated fees and annual license maintenance fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees_lbl" xml:lang="en-US">Deferred revenue relating to the upfront payment, license fees and annual maintenance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Additional Achievement of Development and Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Additional maximum cash payments receivable upon achievement of development and regulatory milestones for each product for use outside of Exclusive Field</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US">Additional maximum cash payments receivable upon achievement of development and regulatory milestones for each product for use outside of Exclusive Field.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:to="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Revenue Relating to Reimbursable Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Deferred revenue relating to reimbursable research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Deferred revenue relating to reimbursable research and development.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Restricted stock units (RSUs) vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, general and administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockOptionsMember" xml:lang="en-US">Stock options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:to="lab_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xml:lang="en-US">Proceeds and Excess Tax Benefit from Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xml:lang="en-US">Excess tax benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted stock awards and restricted stock units [Member]</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockholdersEquityAdditionalTextualAbstract" xlink:label="halo_StockholdersEquityAdditionalTextualAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="halo_StockholdersEquityAdditionalTextualAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_StockholdersEquityAdditionalTextualAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Additional Textual) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_StockholdersEquityAdditionalTextualAbstract_lbl" xml:lang="en-US">Stockholders equity.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 11)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_OtherNonoperatingIncomeExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherNonoperatingIncomeExpense" xml:lang="en-US">Interest and other income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from issuance of common shares under equity incentive plans, net</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:to="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes_lbl" xml:lang="en-US">Number of Shares of Common Stock Issued Related to R S Us Net of R S Us Surrendered as Payment for Withholding Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes_lbl" xml:lang="en-US">Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes_lbl" xml:lang="en-US">Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:to="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes_lbl" xml:lang="en-US">Number of R S Us Surrendered to Pay for Minimum Withholding Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes_lbl" xml:lang="en-US">Number of RSUs surrendered to pay for minimum withholding taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes_lbl" xml:lang="en-US">Number of RSUs surrendered to pay for minimum withholding taxes.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:to="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod_lbl" xml:lang="en-US">Amount of Withholding Taxes Associated With R S Us Vested During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod_lbl" xml:lang="en-US">Amount of withholding taxes associated with RSUs vested during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod_lbl" xml:lang="en-US">Amount of withholding taxes associated with RSUs vested during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Common stock issued in connection with the exercises of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of shares of common stock issued as a result of stock option exercises</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget_lbl" xml:lang="en-US">Additional Maximum Proceeds Receivable from Partner if the Partner Successfully Develops the Licensed Product Candidate and Achieves Pre Agreed Sales Target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget_lbl" xml:lang="en-US">Additional maximum proceeds receivable from Intrexon if the partner successfully develops the licensed product candidate and achieves pre-agreed sales target.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget_lbl" xml:lang="en-US">Additional maximum proceeds receivable from Intrexon if the partner successfully develops the licensed product candidate and achieves pre-agreed sales target</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" xlink:to="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications_lbl" xml:lang="en-US">Additional Maximum Payments Upon Achievement of Development and Regulatory Milestones for Each Product Targeting the Treatment of any of the Three Orphan Indications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications_lbl" xml:lang="en-US">Additional maximum payments upon achievement of development and regulatory milestones for each product targeting the treatment of any of the three orphan indications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications_lbl" xml:lang="en-US">Additional maximum payments upon achievement of development and regulatory milestones for each product targeting the treatment of any of the three orphan indications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding stock options and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" xlink:label="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" xlink:to="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of Accounting Policy for Clinical Trial Expenses Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for clinical trial expenses.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_SegmentReportingPolicyPolicyTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Adoption of Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net proceeds received from stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net proceeds from stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Shares issued related to restricted stock awards, net of any shares forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_PropertyPlantAndEquipmentGross" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Sales Revenue, Goods, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product sales, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Recognized Deferred Revenue Relating To Reimbursable Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Recognized deferred revenue relating to reimbursable research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment_lbl" xml:lang="en-US">Deferred revenue relating to reimbursable research and development.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements_lbl" xml:lang="en-US">Recognized Deferred Revenue Relating To Reimbursable Research And Development Under Collaborative Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements_lbl" xml:lang="en-US">Recognized deferred revenues relating to reimbursable research and development under collaborative agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements_lbl" xml:lang="en-US">Recognized deferred revenue relating to reimbursable research and development under collaborative agreements.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" xlink:to="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement_lbl" xml:lang="en-US">Recognized Payment Of Revenue Under Collaborative Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement_lbl" xml:lang="en-US">Recognized payment of revenues under collaborative agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement_lbl" xml:lang="en-US">Recognized payment of revenue under collaborative agreement.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeeUnderCollaborativeAgreements" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" xlink:to="halo_AnnualExclusivityFeeUnderCollaborativeAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements_lbl" xml:lang="en-US">Annual Exclusivity Fee Under The Collaborative Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements_lbl" xml:lang="en-US">Annual exclusivity fee under the collaborative agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements_lbl" xml:lang="en-US">Annual exclusivity fee under the collaborative agreements.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_HylenexPartnershipMember" xlink:label="halo_HylenexPartnershipMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_HylenexPartnershipMember" xlink:to="halo_HylenexPartnershipMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_HylenexPartnershipMember_lbl" xml:lang="en-US">Hylenex Partnership Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="halo_HylenexPartnershipMember_lbl" xml:lang="en-US">Hylenex Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_HylenexPartnershipMember_lbl" xml:lang="en-US">Hylenex Partnership [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_HylenexPartnershipMember_lbl" xml:lang="en-US">Hylenex partnership.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" xlink:to="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments_lbl" xml:lang="en-US">Unamortized Deferred Revenue Relating to Prepaid Product Based Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments_lbl" xml:lang="en-US">Unamortized deferred revenue relating to prepaid product-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments_lbl" xml:lang="en-US">Unamortized deferred revenue relating to prepaid product based payments.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" xlink:to="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment_lbl" xml:lang="en-US">Unamortized Deferred Revenue Relating to Deferred Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment_lbl" xml:lang="en-US">Unamortized deferred revenue relating to deferred upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment_lbl" xml:lang="en-US">Unamortized deferred revenue relating to deferred upfront payment.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToUpfrontPayment" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RecognizedRevenuesRelatedToUpfrontPayment" xlink:to="halo_RecognizedRevenuesRelatedToUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment_lbl" xml:lang="en-US">Recognized Revenues Related to Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment_lbl" xml:lang="en-US">Recognized revenues related to upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment_lbl" xml:lang="en-US">Recognized revenues related to upfront payment.</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToProductBasedPayment" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_RecognizedRevenuesRelatedToProductBasedPayment" xlink:to="halo_RecognizedRevenuesRelatedToProductBasedPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment_lbl" xml:lang="en-US">Recognized Revenues Related to Product Based Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment_lbl" xml:lang="en-US">Recognized revenues related to product-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment_lbl" xml:lang="en-US">Recognized revenues related to product based payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Less current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue, current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.001 par value; 150,000,000 shares authorized; 112,692,527 and 103,989,272 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="halo_DurationOfRoyaltyReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_DurationOfRoyaltyReceivable" xlink:to="halo_DurationOfRoyaltyReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_DurationOfRoyaltyReceivable_lbl" xml:lang="en-US">Duration of Royalty Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_DurationOfRoyaltyReceivable_lbl" xml:lang="en-US">Duration of royalty receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_DurationOfRoyaltyReceivable_lbl" xml:lang="en-US">Royalty receivable, Duration</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" xlink:to="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales_lbl" xml:lang="en-US">Percentage of Royalty Entitled To Receive Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales_lbl" xml:lang="en-US">Percentage of royalty entitled to receive of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales_lbl" xml:lang="en-US">Percentage of royalty entitled to receive of net sales</label>
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" xlink:to="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement_lbl" xml:lang="en-US">Allocation of License Fee Received to License Fee Deliverable under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement_lbl" xml:lang="en-US">Allocation of license fee received to license fee deliverable under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement_lbl" xml:lang="en-US">Allocation of license fee received to license fee deliverable under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Milestone payments recognized as revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DeferredRevenueByArrangementDisclosureTextBlock" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DeferredRevenueByArrangementDisclosureTextBlock" xml:lang="en-US">Summary of Deferred revenue</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>halo-20120930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.187; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://halozyme.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="halo-20120930.xsd#DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#OrganizationAndBusiness" roleURI="http://halozyme.com/role/OrganizationAndBusiness" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CollaborativeAgreements" roleURI="http://halozyme.com/role/CollaborativeAgreements" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#Inventories" roleURI="http://halozyme.com/role/Inventories" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNet" roleURI="http://halozyme.com/role/PropertyAndEquipmentNet" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpenses" roleURI="http://halozyme.com/role/AccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenue" roleURI="http://halozyme.com/role/DeferredRevenue" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShare" roleURI="http://halozyme.com/role/NetIncomeLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StockholdersEquity" roleURI="http://halozyme.com/role/StockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CommitmentsAndContingencies" roleURI="http://halozyme.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#CollaborativeAgreementsDetails" roleURI="http://halozyme.com/role/CollaborativeAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#InventoriesDetails" roleURI="http://halozyme.com/role/InventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#InventoriesTables" roleURI="http://halozyme.com/role/InventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetTables" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetDetails" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpensesTables" roleURI="http://halozyme.com/role/AccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#AccruedExpensesDetails" roleURI="http://halozyme.com/role/AccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueTables" roleURI="http://halozyme.com/role/DeferredRevenueTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetails" roleURI="http://halozyme.com/role/DeferredRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#DeferredRevenueDetailsTextual" roleURI="http://halozyme.com/role/DeferredRevenueDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareTables" roleURI="http://halozyme.com/role/NetIncomeLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareDetails" roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#NetIncomeLossPerShareDetailsTextual" roleURI="http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StockholdersEquityDetails" roleURI="http://halozyme.com/role/StockholdersEquityDetails" />
  <presentationLink xlink:role="http://halozyme.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DocumentAndEntityInformationAbstract" xlink:label="halo_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
  </presentationLink>
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#BalanceSheets" roleURI="http://halozyme.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#BalanceSheetsParenthetical" roleURI="http://halozyme.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StatementsOfComprehensiveIncome" roleURI="http://halozyme.com/role/StatementsOfComprehensiveIncome" />
  <roleRef xlink:type="simple" xlink:href="halo-20120930.xsd#StatementsOfCashFlows" roleURI="http://halozyme.com/role/StatementsOfCashFlows" />
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="1." use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AccountsReceivableNetCurrent" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_InventoryNet" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="10.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="11.2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="16" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRentCreditNoncurrent" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="18.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="20.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="20.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesIssued" order="20.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="20.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="21.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="21.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesIssued" order="21.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="21.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StatementsOfComprehensiveIncome" xlink:title="0120 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_RevenuesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_RevenuesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="loc_SalesRevenueGoodsNet" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="loc_LicenseAndServicesRevenue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="loc_Revenues" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="loc_Revenues" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_CostsAndExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_CostsAndExpensesAbstract" order="5.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostOfGoodsSold" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostsAndExpenses" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_OperatingIncomeLoss" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_NetIncomeLoss" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" xlink:label="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" order="12.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_ComprehensiveIncomeNetOfTax" order="12.875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract" xlink:to="loc_WeightedAverageNumberOfDilutedSharesOutstanding" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12.125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment" order="6" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="7.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="8" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_IncreaseDecreaseInInventories" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInInventories" order="9" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" use="optional" priority="1" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IncreaseDecreaseInDeferredRent" xlink:label="halo_IncreaseDecreaseInDeferredRent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="halo_IncreaseDecreaseInDeferredRent" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="15.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="17" use="optional" priority="1" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="19.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="23" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="26.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_CapitalExpendituresIncurredButNotYetPaid" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_CapitalExpendituresIncurredButNotYetPaid" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="7.875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="3.9375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/OrganizationAndBusiness" xlink:title="0201 - Disclosure - Organization and Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_NatureOfOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_NatureOfOperations" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_SignificantAccountingPoliciesTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_SignificantAccountingPoliciesTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreements" xlink:title="0203 - Disclosure - Collaborative Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/Inventories" xlink:title="0204 - Disclosure - Inventories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_InventoryDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryDisclosureAbstract" xlink:to="loc_InventoryDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNet" xlink:title="0205 - Disclosure - Property and Equipment, Net">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentAbstract" xlink:to="loc_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpenses" xlink:title="0206 - Disclosure - Accrued Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AccruedExpensesCurrentTextBlock" xlink:label="halo_AccruedExpensesCurrentTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="halo_AccruedExpensesCurrentTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenue" xlink:title="0207 - Disclosure - Deferred Revenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_DeferredRevenueDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="loc_DeferredRevenueDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueDisclosureAbstract" xlink:to="loc_DeferredRevenueDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShare" xlink:title="0208 - Disclosure - Net Income (Loss) Per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_EarningsPerShareTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquity" xlink:title="0209 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CommitmentsAndContingencies" xlink:title="0210 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0402 - Disclosure - Summary of Significant Accounting Policies [Policies]">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_InventoryPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_InventoryPolicyTextBlock" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_RevenueRecognitionPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_RevenueRecognitionPolicyTextBlock" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_FairValueOfFinancialInstrumentsPolicy" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_FairValueOfFinancialInstrumentsPolicy" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="85" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="96.25" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" xlink:label="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" order="98.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="125" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="35" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="0602 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_ResearchAndDevelopmentExpenseMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="loc_ResearchAndDevelopmentExpenseMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_SellingGeneralAndAdministrativeExpensesMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="loc_SellingGeneralAndAdministrativeExpensesMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_AllocatedShareBasedCompensationExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_AllocatedShareBasedCompensationExpense" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_AwardTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_AwardTypeAxis" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AwardTypeAxis" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="loc_StockOptionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_StockOptionsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_RestrictedStockUnitsRSUMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RestrictedStockUnitsRSUMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" xlink:label="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_FairValueByAssetClassAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_FairValueByAssetClassAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueByAssetClassAxis" xlink:to="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_CashEquivalentsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CashEquivalentsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_FairValueByFairValueHierarchyLevelAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_FairValueByFairValueHierarchyLevelAxis" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueByFairValueHierarchyLevelAxis" xlink:to="loc_FairValueMeasurementsFairValueHierarchyDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_FairValueInputsLevel1Member" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_FairValueInputsLevel1Member" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:label="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_CashAndCashEquivalentsFairValueDisclosure" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_CashAndCashEquivalentsFairValueDisclosure" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_AwardTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_AwardTypeAxis" order="50" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AwardTypeAxis" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="loc_StockOptionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_StockOptionsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_RestrictedStockUnitsRSUMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RestrictedStockUnitsRSUMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="67.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="82.265625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract" xlink:to="loc_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" order="83.496095" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" order="83.759765" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" order="84.067385" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="0502 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/CollaborativeAgreementsDetails" xlink:title="0603 - Disclosure - Collaborative Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_GammagardPartnershipMember" xlink:label="halo_GammagardPartnershipMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_GammagardPartnershipMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RochePartnershipMember" xlink:label="halo_RochePartnershipMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_RochePartnershipMember" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="halo_CollaborativeAgreementsTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="halo_CollaborativeAgreementsTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ViropharmaPartnershipsMember" xlink:label="halo_ViropharmaPartnershipsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_ViropharmaPartnershipsMember" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_IntrexonPartnershipsMember" xlink:label="halo_IntrexonPartnershipsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="halo_IntrexonPartnershipsMember" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets" order="19.375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones" order="19.6875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones" order="19.84375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones" order="19.921875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" xlink:label="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget" order="19.9609375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueToBeRecognizedOverTerm" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_DeferredRevenueToBeRecognizedOverTerm" order="19.990234375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AchievementOfDevelopmentAndRegulatoryMilestones" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AchievementOfDevelopmentAndRegulatoryMilestones" order="19.99755859375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PeriodForTermination" xlink:label="halo_PeriodForTermination" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_PeriodForTermination" order="19.998779296875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" order="16.25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" order="18.125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" order="18.90625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" order="19.21875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="19.98535" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" xlink:label="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement" order="19.99634" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones" order="39.99878" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" xlink:label="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget" order="19.53125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" xlink:label="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications" order="19.902345" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" xlink:label="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement" order="59.99878" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AnnualExclusivityFeeUnderCollaborativeAgreements" xlink:label="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AnnualExclusivityFeeUnderCollaborativeAgreements" order="79.99878" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="halo_DurationOfRoyaltyReceivable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_DurationOfRoyaltyReceivable" order="19.296875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" xlink:label="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales" order="19.3359375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" xlink:label="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CollaborativeAgreementsTextualAbstract" xlink:to="halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement" order="29.99878" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/InventoriesDetails" xlink:title="0604 - Disclosure - Inventories (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_InventoryNetAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryDisclosureAbstract" xlink:to="loc_InventoryNetAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryNetAbstract" xlink:to="loc_InventoryNet" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_InventoryFinishedGoods" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryNetAbstract" xlink:to="loc_InventoryFinishedGoods" order="65" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_InventoryWorkInProcess" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryNetAbstract" xlink:to="loc_InventoryWorkInProcess" order="62.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_InventoryRawMaterials" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryNetAbstract" xlink:to="loc_InventoryRawMaterials" order="61.25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/InventoriesTables" xlink:title="0504 - Disclosure - Inventories (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InventoryDisclosureAbstract" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetTables" xlink:title="0505 - Disclosure - Property and Equipment, Net (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_PropertyPlantAndEquipmentTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentAbstract" xlink:to="loc_PropertyPlantAndEquipmentTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetails" xlink:title="0605 - Disclosure - Property and Equipment, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentAbstract" xlink:to="loc_ScheduleOfPropertyPlantAndEquipmentTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_PropertyPlantAndEquipmentByTypeAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_PropertyPlantAndEquipmentTypeDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_LeaseholdImprovementsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentTypeDomain" xlink:to="loc_LeaseholdImprovementsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ResearchEquipmentMember" xlink:label="halo_ResearchEquipmentMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentTypeDomain" xlink:to="halo_ResearchEquipmentMember" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ComputerAndOfficeEquipmentMember" xlink:label="halo_ComputerAndOfficeEquipmentMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentTypeDomain" xlink:to="halo_ComputerAndOfficeEquipmentMember" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_PropertyPlantAndEquipmentLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_PropertyPlantAndEquipmentLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentLineItems" xlink:to="loc_PropertyPlantAndEquipmentNetByTypeAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="45" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="44.375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual" xlink:title="06051 - Disclosure - Property and Equipment, Net (Details Textual)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PropertyAndEquipmentNetTextualAbstract" xlink:label="halo_PropertyAndEquipmentNetTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PropertyPlantAndEquipmentAbstract" xlink:to="halo_PropertyAndEquipmentNetTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_DepreciationAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_PropertyAndEquipmentNetTextualAbstract" xlink:to="loc_DepreciationAndAmortization" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpensesTables" xlink:title="0506 - Disclosure - Accrued Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="loc_ScheduleOfAccruedLiabilitiesTableTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/AccruedExpensesDetails" xlink:title="0606 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_AccruedLiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="loc_AccruedLiabilitiesCurrentAbstract" order="5.3125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccruedLiabilitiesCurrentAbstract" xlink:to="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_OtherAccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccruedLiabilitiesCurrentAbstract" xlink:to="loc_OtherAccruedLiabilitiesCurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccruedLiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_EmployeeRelatedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccruedLiabilitiesCurrentAbstract" xlink:to="loc_EmployeeRelatedLiabilitiesCurrent" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueTables" xlink:title="0507 - Disclosure - Deferred Revenue (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_DeferredRevenueDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_DeferredRevenueByArrangementDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueDisclosureAbstract" xlink:to="loc_DeferredRevenueByArrangementDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetails" xlink:title="0607 - Disclosure - Deferred Revenue (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_DeferredRevenueDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_DeferredRevenueArrangementByTypeTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueDisclosureAbstract" xlink:to="loc_DeferredRevenueArrangementByTypeTable" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_DeferredRevenueArrangementTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementByTypeTable" xlink:to="loc_DeferredRevenueArrangementTypeAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_DeferredRevenueArrangementTypeDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeAxis" xlink:to="loc_DeferredRevenueArrangementTypeDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_DeferredRevenueArrangementLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementByTypeTable" xlink:to="loc_DeferredRevenueArrangementLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueAbstract" xlink:label="loc_DeferredRevenueAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementLineItems" xlink:to="loc_DeferredRevenueAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_ProductSalesMember" xlink:label="halo_ProductSalesMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeDomain" xlink:to="halo_ProductSalesMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_CollaborativeArrangementMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeDomain" xlink:to="loc_CollaborativeArrangementMember" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_DeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueAbstract" xlink:to="loc_DeferredRevenue" order="10.625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueAbstract" xlink:to="loc_DeferredRevenueCurrent" order="11.5625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="12.03125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/DeferredRevenueDetailsTextual" xlink:title="06071 - Disclosure - Deferred Revenue (Details Textual)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_DeferredRevenueDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_DeferredRevenueArrangementByTypeTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueDisclosureAbstract" xlink:to="loc_DeferredRevenueArrangementByTypeTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_DeferredRevenueArrangementLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementByTypeTable" xlink:to="loc_DeferredRevenueArrangementLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="halo_DeferredRevenueTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementLineItems" xlink:to="halo_DeferredRevenueTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_InitialUpfrontPayment" xlink:label="halo_InitialUpfrontPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_InitialUpfrontPayment" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndMaintenanceRevenue" xlink:label="loc_LicenseAndMaintenanceRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="loc_LicenseAndMaintenanceRevenue" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_DeferredRevenueRevenueRecognized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="loc_DeferredRevenueRevenueRecognized" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NonrefundableUpfrontPayment" xlink:label="halo_NonrefundableUpfrontPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_NonrefundableUpfrontPayment" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_DeferredRevenueArrangementTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementByTypeTable" xlink:to="loc_DeferredRevenueArrangementTypeAxis" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_DeferredRevenueArrangementTypeDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeAxis" xlink:to="loc_DeferredRevenueArrangementTypeDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RochePartnershipMember" xlink:label="halo_RochePartnershipMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeDomain" xlink:to="halo_RochePartnershipMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_GammagardPartnershipMember" xlink:label="halo_GammagardPartnershipMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeDomain" xlink:to="halo_GammagardPartnershipMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueToBeRecognizedOverTerm" xlink:label="halo_DeferredRevenueToBeRecognizedOverTerm" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_DeferredRevenueToBeRecognizedOverTerm" order="95" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" xlink:label="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToUpfrontPayment" xlink:label="halo_DeferredRevenueRelatingToUpfrontPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_DeferredRevenueRelatingToUpfrontPayment" order="115" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment" order="135" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment" order="155" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" xlink:label="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements" order="175" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_HylenexPartnershipMember" xlink:label="halo_HylenexPartnershipMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DeferredRevenueArrangementTypeDomain" xlink:to="halo_HylenexPartnershipMember" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" xlink:label="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments" order="195" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" xlink:label="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment" order="215" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToUpfrontPayment" xlink:label="halo_RecognizedRevenuesRelatedToUpfrontPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_RecognizedRevenuesRelatedToUpfrontPayment" order="235" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_RecognizedRevenuesRelatedToProductBasedPayment" xlink:label="halo_RecognizedRevenuesRelatedToProductBasedPayment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="halo_RecognizedRevenuesRelatedToProductBasedPayment" order="255" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_DeferredRevenueTextualAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="295" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareTables" xlink:title="0508 - Disclosure - Net Income (Loss) Per Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:label="loc_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareDetails" xlink:title="0608 - Disclosure - Net Income (Loss) Per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:label="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_NetIncomeLossAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:to="loc_NetIncomeLossAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetIncomeLossAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_CalculationOfEarningsPerShareBasicAndDilutedEarningsPerShareAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_WeightedAverageNumberOfDilutedSharesOutstanding" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="45" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual" xlink:title="06081 - Disclosure - Net Income (Loss) Per Share (Details Textual)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NetIncomeLossPerShareTextualAbstract" xlink:label="halo_NetIncomeLossPerShareTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="halo_NetIncomeLossPerShareTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_NetIncomeLossPerShareTextualAbstract" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://halozyme.com/role/StockholdersEquityDetails" xlink:title="0609 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_AwardTypeAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_AwardTypeAxis" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AwardTypeAxis" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="loc_StockOptionsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_StockOptionsMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_RestrictedStockUnitsRSUMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RestrictedStockUnitsRSUMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockholdersEquityTextualAbstract" xlink:label="halo_StockholdersEquityTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="halo_StockholdersEquityTextualAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityTextualAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockholdersEquityAdditionalTextualAbstract" xlink:label="halo_StockholdersEquityAdditionalTextualAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="halo_StockholdersEquityAdditionalTextualAbstract" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" xlink:label="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PublicOfferingPricePerShare" xlink:label="halo_PublicOfferingPricePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="halo_PublicOfferingPricePerShare" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PurchaseOfCommonStockByAffiliates" xlink:label="halo_PurchaseOfCommonStockByAffiliates" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="halo_PurchaseOfCommonStockByAffiliates" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_PurchaseOfCommonStockByAffiliatesAmount" xlink:label="halo_PurchaseOfCommonStockByAffiliatesAmount" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="halo_PurchaseOfCommonStockByAffiliatesAmount" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" xlink:label="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityTextualAbstract" xlink:to="halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod" order="48.984375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" xlink:label="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityTextualAbstract" xlink:to="halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes" order="46.83594" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="halo-20120930.xsd#halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" xlink:label="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityTextualAbstract" xlink:to="halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes" order="47.91016" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="halo_StockholdersEquityAdditionalTextualAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Income (Loss) Per Share (Details Textual)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NetIncomeLossPerShareTextualAbstract', window );"><strong>Net Income (Loss) Per Share (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding stock options, outstanding RSUs and unvested RSAs totaling</a></td>
        <td class="nump">7.3<span></span></td>
        <td class="nump">1.9<span></span></td>
        <td class="nump">7.3<span></span></td>
        <td class="nump">5.9<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NetIncomeLossPerShareTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NetIncomeLossPerShareTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBLBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaborative Agreements (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Roche Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Roche Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Roche Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Roche Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Gammagard Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Gammagard Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Gammagard Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Gammagard Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>ViroPharma Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>ViroPharma Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>ViroPharma Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>ViroPharma Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>May 10, 2012

</div>
          <div>ViroPharma Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Intrexon Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Intrexon Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Intrexon Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Intrexon Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 06, 2012

</div>
          <div>Intrexon Collaboration [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTextualAbstract', window );"><strong>Collaborative Agreements (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total proceeds received from partner under license and collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Nonrefundable upfront license fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement', window );">Amount received from Roche for additional exclusive targets and annual license maintenance fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement', window );">Clinical development milestone payments received under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement', window );">Regulatory milestone payments received under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Royalty receivable, Duration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales', window );">Percentage of royalty entitled to receive of net sales</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets', window );">Additional maximum proceeds receivable from Roche if the partner successfully develops all five exclusive targets and achieves pre-agreed sales targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">178<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">178<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget', window );">Additional maximum proceeds receivable from Intrexon if the partner successfully develops the licensed product candidate and achieves pre-agreed sales target</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones', window );">Additional maximum payments upon achievement of clinical development milestones under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones', window );">Additional maximum payments upon achievement of regulatory milestones under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications', window );">Additional maximum payments upon achievement of development and regulatory milestones for each product targeting the treatment of any of the three orphan indications</a></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones', window );">Maximum payments upon achievement of sales-based milestones under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget', window );">Potential additional upfront and milestone payments for each additional target</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payments recognized as revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement', window );">Annual exclusivity fees received under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AchievementOfDevelopmentAndRegulatoryMilestones', window );">Additional maximum payments upon achievement of development and regulatory milestone under collaborative agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Time period to provide prior notice to terminate collaborative agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement', window );">Allocation of license fee received to license fee deliverable under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones', window );">Additional maximum cash payments receivable upon achievement of development and regulatory milestones for each product for use outside of Exclusive Field</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement', window );">Recognized payment of revenues under collaborative agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AnnualExclusivityFeeUnderCollaborativeAgreements', window );">Annual exclusivity fee under the collaborative agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AchievementOfDevelopmentAndRegulatoryMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Achievement of development and regulatory milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AchievementOfDevelopmentAndRegulatoryMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum cash payments receivable upon achievement of development and regulatory milestones for each product for use outside of Exclusive Field.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalAchievementOfDevelopmentAndRegulatoryMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum payments upon achievement of development and regulatory milestones for each product targeting the treatment of any of the three orphan indications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumPaymentsUponAchievementOfDevelopmentAndRegulatoryMilestonesForEachProductTargetingTreatmentOfAnyOfThreeOrphanIndications</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum proceeds receivable from Intrexon if the partner successfully develops the licensed product candidate and achieves pre-agreed sales target.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumProceedsReceivableFromPartnerIfPartnerSuccessfullyDevelopsLicensedProductCandidateAndAchievesPreAgreedSalesTarget</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of clinical development milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of regulatory milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfRegulatoryMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum proceeds receivable from partner of license and collaborative agreement upon achievement of sales based milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfSalesBasedMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional maximum proceeds receivable from Roche if the partner successfully develops all five exclusive targets and achieves pre-agreed sales targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation of license fee received to license fee deliverable under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AllocationOfLicenseFeeReceivedToLicenseFeeDeliverableUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount received from Roche for additional exclusive targets and annual license maintenance fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual exclusivity fees received under collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AnnualExclusivityFeesReceivedUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualExclusivityFeeUnderCollaborativeAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual exclusivity fee under the collaborative agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AnnualExclusivityFeeUnderCollaborativeAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical development milestone payments received under collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_CollaborativeAgreementsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_CollaborativeAgreementsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DurationOfRoyaltyReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Duration of royalty receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DurationOfRoyaltyReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum proceeds receivable from partner of license and collaborative agreement upfront and milestone payments per target.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_MaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUpfrontAndMilestonePaymentsPerTarget</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Nonrefundable upfront license fee payment received under collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalty entitled to receive of net sales.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PercentageOfRoyaltyEntitledToReceiveOfNetSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PeriodForTermination">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period for termination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PeriodForTermination</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from partner of license and collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized payment of revenue under collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RecognizedPaymentOfRevenueUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Regulatory milestone payments received under collaborative agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:InventoryDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>4. Inventories </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Inventories consist of the following: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Raw materials</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">962,751</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">201,822</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Work-in-process</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">715,241</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">290,647</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Finished goods</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">508,071</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">74,794</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,186,063</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">567,263</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A
M;FEZ871I;VY?86YD7T)U<VEN97-S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B
M;W)A=&EV95]!9W)E96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^26YV96YT;W)I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT7TYE=#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8W)U961?
M17AP96YS97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y$969E<G)E9%]2979E;G5E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3F5T7TEN8V]M95],;W-S7U!E<E]3:&%R93PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?
M06-C;W5N=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YV96YT;W)I97-?5&%B;&5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=%].971?5&%B/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^06-C<G5E9%]%>'!E;G-E<U]486)L97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$969E<G)E9%]2
M979E;G5E7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYE=%]);F-O;65?3&]S<U]097)?4VAA<F5?5&%B;#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG
M;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0T/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B;W)A
M=&EV95]!9W)E96UE;G1S7T1E=&%I/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^26YV96YT;W)I97-?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I
M<&UE;G1?3F5T7T1E=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?3F5T7T1E=#$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-R=65D7T5X<&5N
M<V5S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y$969E<G)E9%]2979E;G5E7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$969E<G)E9%]2979E;G5E7T1E=&%I
M;'-?5&5X='4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.971?26YC;VUE7TQO<W-?4&5R7U-H87)E7T1E=&$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?26YC;VUE7TQO<W-?4&5R
M7U-H87)E7T1E=&$Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]$971A:6QS/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X
M8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS
M:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C
M=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R
M;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X
M.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^
M/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P
M86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@
M;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?
M-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T,#$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5104%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M
M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I
M='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y(04Q/6EE-12!42$52
M05!%551)0U,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$Q-3DP,S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O
M8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I
M<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A
M<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ
M,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO
M;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3(L-S`U+#`Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?
M-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F
M8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S
M+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$50,4%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.#<L-C$T+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-3(L.#(U+#4R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L
M92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0V-"PR
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#(V,BPT-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#$X-BPP-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-C<L,C8S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S
M(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q+#,U,RPS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX+#,S,BPR-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`U+#8Q."PU-CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,RPY.#<L-#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S8S+#8U,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S<Q+#`T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`W+#DX,BPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-2PW-3@L-30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-3(V+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L-34V+#@U.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP-#$L-C<S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV,34L
M-3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E+"!C=7)R96YT('!O<G1I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#<P+#(T-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3(Y+#0P-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Q+#`S."PW-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS,#$L.#0P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E+"!N970@;V8@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-"PX.#,L,3,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L-S4T+#4X,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5N="P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#<P+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,BPP,#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S
M(&%N9"!C;VYT:6YG96YC:65S("A.;W1E(#$Q*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@+2`D,"XP
M,#$@<&%R('9A;'5E.R`R,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R!N
M;R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@+2`D,"XP,#$@<&%R('9A;'5E.R`Q-3`L,#`P+#`P,"!S
M:&%R97,@875T:&]R:7IE9#L@,3$R+#8Y,BPU,C<@86YD(#$P,RPY.#DL,C<R
M('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S
M,"P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$L(')E<W!E8W1I=F5L>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$R+#8Y,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,RPY.3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-#4L,C0T+#@W-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-2PX,3<L-S<R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L
M871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M.30L,38W+#<Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R-#4L,#(Q+#8T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G
M(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L,3@Y
M+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#DP,"PQ,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<R!A;F0@4W1O8VMH
M;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3`W+#DX,BPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8U+#<U."PU-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D
M7S0W8F,W9#=C8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M9F)B,3$X,%\Q8C8W7S0Y,S5?831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DY!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S
M("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYD96YS
M960@0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$R+#8Y,BPU,C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L.3@Y+#(W,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q,BPV.3(L-3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#DX.2PR-S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?
M-#DS-5]A-&9D7S0W8F,W9#=C8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E9F)B,3$X,%\Q8C8W7S0Y,S5?831F9%\T-V)C-V0W8V,P-V(O
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%349!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E
M;65N=',@;V8@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I("A5;F%U9&ET
M960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]D=6-T
M('-A;&5S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S$U+#,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PQ-38L.3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0R-RPW,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#@W+#@R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V
M96YU97,@=6YD97(@8V]L;&%B;W)A=&EV92!A9W)E96UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Q."PY-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PW.#4L-3(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL
M,3`S+#DW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4R+#$X-RPT-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS,S0L,S(S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L.30R+#0R.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4S
M,2PV-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,RPV-S4L,C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S
M="!O9B!P<F]D=6-T('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C8L-C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L-S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#0P+#4Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,2PV-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3DL-3`S+#0Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S+#4Q-"PS-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,2PT-S8L,S(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-C0W+#(V-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5L
M;&EN9RP@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-C,T+#`S-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C8S+#4R,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#@S,RPQ
M-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,BPR,S<L,34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PS-C0L,38P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-S@Y+#4Y
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8Y+#<U,"PP,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-2PP.#8L,#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&EN8V]M92`H;&]S
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P+#`R.2PX,S<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PQ-3(L.#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#DL,C$X+#,S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0Q,"PX,C,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A;F0@
M;W1H97(@:6YC;VUE+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S+#DY,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R+#,V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<R+#$X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#4X-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO
M<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"PP,#4L.#0V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,38U+#$Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0Y+#$T-BPQ-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-30L,C,W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I
M;'5T960@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0T*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F5S('5S960@:6X@8V]M<'5T:6YG(&YE="!I;F-O
M;64@*&QO<W,I('!E<B!S:&%R93H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%S:6,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q,BPS,#4L,#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#(R,RPS-3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L-C4X+#<U-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,BPR.#(L.3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,3(L,S`U+#`P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P-2PP,#DL,3@Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#8U."PW-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#(L,C@R
M+#DP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#(P+#`P-2PX-#8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#$V-2PQ.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#0Y+#$T-BPQ-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q+#,U-"PR,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P138U044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A
M<V@@1FQO=W,@*%5N875D:71E9"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&%C
M=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#0Y+#$T-BPQ-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q+#,U-"PR,S<I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE
M;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN
M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S8R+#,W,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3$V
M+#,R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y-BPQ-C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3$L-C$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N
M(&1I<W!O<V%L(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-BPV,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.3DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A
M=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,C`Q+#@P
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#DP.2PV,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PV,3@L.#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+#DW.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E
M<R!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S+#`R,2PQ,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3<V+#DQ."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD
M(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L,3`V+#<U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R+#$X,RPX-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPS.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.2PT-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#8Y+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$W+#<Q."PS,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-#<L-#$P+#DP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R,"PW.38L-3@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1I;F<@86-T
M:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@W,RPQ-C4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<Q+#4R,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!U<V5D(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-S,L,38U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W,2PU,C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,2PT-S8L.#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E
M(&]F(&-O;6UO;B!S:&%R97,@=6YD97(@97%U:71Y(&EN8V5N=&EV92!P;&%N
M<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Y-BPU
M.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#$T,2PV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L
M,#<S+#0S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L,30Q+#8Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S92`H9&5C<F5A<V4I(&EN
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,T+#<X.2PS-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPY,C8L-#DP*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@
M8V%S:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,BPX,C4L-3(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L,C4U+#@T
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@;V8@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RPV,30L.#DQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L
M,S(Y+#,U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@9&ES8VQO<W5R92!O9B!N
M;VXM8V%S:"!I;G9E<W1I;F<@86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE(&9O<B!P=7)C:&%S97,@;V8@<')O<&5R='D@86YD(&5Q
M=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#@L
M.3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS
M-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I
M;VX@86YD($)U<VEN97-S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!"=7-I;F5S<R!A
M;F0@0V]L;&%B;W)A=&EV92!!9W)E96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T
M:6]N(&%N9"!"=7-I;F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\
M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$@+2!U<RUG86%P.DYA='5R
M94]F3W!E<F%T:6]N<RTM/@T*("`@/"$M+2!X8G)L+&YS("TM/@T*("`@/"$M
M+2!X8G)L+&YX("TM/@T*("`@/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\+V(^/"]F;VYT/@T*("`@
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CX\8CX\+V(^/"]F;VYT/@T*("`@/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(#QB/CPO
M8CX\+V9O;G0^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C$N($]R9V%N:7IA=&EO;B!A;F0@
M0G5S:6YE<W,@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^2&%L;WIY;64@5&AE<F%P975T:6-S+"!);F,N("AR969E<G)E
M9"!T;R!A<R`F(S@R,C`[=V4L)B,X,C(Q.R`F(S@R,C`[=7,L)B,X,C(Q.R`F
M(S@R,C`[2&%L;WIY;64F(S@R,C$[(&]R('1H90T*("`@)B,X,C(P.T-O;7!A
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M('1A<F=E="UR:6-H(&5N=FER;VYM96YT(&9O<B!T:&4-"B`@(&1E=F5L;W!M
M96YT(&]F(&9U='5R92!T:&5R87!I97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C0E.W!A9&1I;F<M8F]T=&]M.C!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W5R
M(')E<V5A<F-H(&9O8W5S97,@<')I;6%R:6QY(&]N(&AU;6%N(&5N>GEM97,@
M=&AA="!A;'1E<B!T:&4-"B`@(&5X=')A8V5L;'5L87(@;6%T<FEX+B!/=7(@
M;&5A9"!E;GIY;64L(')E8V]M8FEN86YT(&AU;6%N(&AY86QU<F]N:61A<V4@
M*"8C.#(R,#MR2'502#(P)B,X,C(Q.RDL('1E;7!O<F%R:6QY(&1E9W)A9&5S
M(&AY86QU<F]N86XL(&$@;6%T<FEX(&-O;7!O;F5N="!I;B!T:&4@<VMI;BP@
M86YD(&9A8VEL:71A=&5S('1H92!D:7-P97)S:6]N(&%N9"!A8G-O<G!T:6]N
M(&]F(&1R=6=S(&%N9"!F;'5I9',N(%=E(&%R92!A;'-O(&1E=F5L;W!I;F<-
M"B`@(&YO=F5L(&5N>GEM97,@=&AA="!M87D@=&%R9V5T(&]T:&5R(&UA=')I
M>"!S=')U8W1U<F5S(&9O<B!T:&5R87!E=71I8R!B96YE9FET+B!/=7(@16YH
M86YZ93PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQS=7`^5$T\+W-U<#X\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX-"B`@("!T96-H;F]L;V=Y(&ES('1H92!P;&%T9F]R;2!F;W(@=&AE(&1E
M;&EV97)Y(&]F('!R;W!R:65T87)Y('-M86QL(&%N9"!L87)G92!M;VQE8W5L
M97,N(%=E(&%P<&QY(&]U<B!R97-E87)C:"!P<F]D=6-T<R!I;B!C;VQL86)O
M<F%T:6]N('=I=&@@;W1H97(@8V]M<&%N:65S(&%S('=E;&P@87,@9F]R(&]U
M<B!O=VX@<')O<')I971A<GD@<&EP96QI;F4@:6X-"B`@('1H97)A<&5U=&EC
M(&%R96%S('=I=&@@<VEG;FEF:6-A;G0@=6YM970@;65D:6-A;"!N965D+"!S
M=6-H(&%S(&1I86)E=&5S+"!O;F-O;&]G>2!A;F0@9&5R;6%T;VQO9WDN(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E.W!A9&1I;F<M8F]T=&]M
M.C!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^3W5R#0H@("!O<&5R871I;VYS('1O(&1A=&4@:&%V
M92!I;G9O;'9E9#H@*&DI)B,Q-C`[;W)G86YI>FEN9R!A;F0@<W1A9F9I;F<@
M;W5R(&]P97)A=&EN9R!S=6)S:61I87)Y+"!(86QO>GEM92P@26YC+CL@*&EI
M*28C,38P.V%C<75I<FEN9RP@9&5V96QO<&EN9R!A;F0@<V5C=7)I;F<@;W5R
M('1E8VAN;VQO9WD[("AI:6DI)B,Q-C`[=6YD97)T86MI;F<@<')O9'5C="!D
M979E;&]P;65N="!F;W(@;W5R(&5X:7-T:6YG('!R;V1U8W0@86YD(&$-"B`@
M(&QI;6ET960@;G5M8F5R(&]F('!R;V1U8W0@8V%N9&ED871E<SL@*&EV*28C
M,38P.W-U<'!O<G1I;F<@=&AE(&1E=F5L;W!M96YT(&]F(&-O;&QA8F]R871I
M;VX@<')O9'5C="!C86YD:61A=&5S(&%N9"`H=BDF(S$V,#MS96QL:6YG(#QI
M/DAY;&5N97@\+VD^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\<W5P/@T*("`@)G)E9SL\+W-U<#X\+V9O
M;G0^(')E8V]M8FEN86YT("AH>6%L=7)O;FED87-E(&AU;6%N(&EN:F5C=&EO
M;BDN(%=E(&-O;G1I;G5E('1O(&EN8W)E87-E(&]U<B!F;V-U<R!O;B!O=7(@
M<')O<')I971A<GD@<')O9'5C="!P:7!E;&EN92!A;F0@:&%V92!E>'!A;F1E
M9"!I;G9E<W1M96YT<R!I;B!O=7(@<')O<')I971A<GD-"B`@('!R;V1U8W0@
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M:&4L($EN8RX-"B`@("@F(S@R,C`[4F]C:&4F(S@R,C$[*2P@0F%X=&5R($AE
M86QT:&-A<F4@0V]R<&]R871I;VX@*"8C.#(R,#M"87AT97(F(S@R,C$[*2P@
M5FER;U!H87)M82!);F-O<G!O<F%T960@*"8C.#(R,#M6:7)O4&AA<FUA)B,X
M,C(Q.RDL(&%N9"!);G1R97AO;B!#;W)P;W)A=&EO;B`H)B,X,C(P.TEN=')E
M>&]N)B,X,C(Q.RDL('1O(&%P<&QY($5N:&%N>F4@=&5C:&YO;&]G>2!T;R!T
M:&5S92!C;VQL86)O<F%T;W)S)B,X,C$W.R!B:6]L;V=I8V%L#0H@("!T:&5R
M87!E=71I8R!C;VUP;W5N9',N($-U<G)E;G1L>2P@=V4@:&%V92!R96-E:79E
M9"!O;FQY(&QI;6ET960@<F5V96YU92!F<F]M('1H92!S86QE<R!O9B`\:3Y(
M>6QE;F5X(#PO:3YR96-O;6)I;F%N="P@:6X@861D:71I;VX@=&\@;W1H97(@
M<F5V96YU97,@9G)O;2!O=7(@8V]L;&%B;W)A=&EO;G,N(#PO9F]N=#X\+W`^
M#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F
M8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E9F)B,3$X,%\Q8C8W7S0Y,S5?831F9%\T
M-V)C-V0W8V,P-V(O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,B`M
M('5S+6=A87`Z4VEG;FEF:6-A;G1!8V-O=6YT:6YG4&]L:6-I97-497AT0FQO
M8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB
M;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^/&(^,BX@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA
M<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/D)A<VES(&]F(%!R97-E;G1A
M=&EO;B`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^5&AE(&%C8V]M<&%N>6EN9R!I;G1E<FEM('5N875D:71E9"!C
M;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA
M=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@56YI=&5D(%-T
M871E<PT*("`@9V5N97)A;&QY(&%C8V5P=&5D(&%C8V]U;G1I;F<@<')I;F-I
M<&QE<R`H)B,X,C(P.U4N4RX@1T%!4"8C.#(R,3LI(&%N9"!W:71H('1H92!R
M=6QE<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%4N4RX@4V5C=7)I=&EE<R!A
M;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H)B,X,C(P.U-%0R8C.#(R,3LI(')E
M;&%T960@=&\@82!Q=6%R=&5R;'D@<F5P;W)T(&]N($9O<FT@,3`M42X@06-C
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M9"!C;VYS;VQI9&%T960-"B`@(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!N
M;W1E<R!T:&5R971O(&EN8VQU9&5D(&EN(&]U<B!!;FYU86P@4F5P;W)T(&]N
M($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,2P@9FEL960@=VET:"!T:&4@4T5#(&]N($UA<F-H)B,Q-C`[,3(L
M(#(P,3(N(%1H92!U;F%U9&ET960@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&9O
M<B!T:&4@:6YT97)I;2!P97)I;V1S('!R97-E;G1E9"!H97)E:6X-"B`@(')E
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M(')E8W5R<FEN9PT*("`@861J=7-T;65N=',N($]P97)A=&EN9R!R97-U;'1S
M(&9O<B!I;G1E<FEM('!E<FEO9',@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I
M8V%T:79E(&]F('1H92!O<&5R871I;F<@<F5S=6QT<R!F;W(@86X@96YT:7)E
M(&9I<V-A;"!Y96%R+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CX-"B`@(%1H92!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE(&%C8V]U;G1S(&]F($AA
M;&]Z>6UE(%1H97)A<&5U=&EC<RP@26YC+B!A;F0@;W5R('=H;VQL>2!O=VYE
M9"!S=6)S:61I87)Y+"!(86QO>GEM92P@26YC+B!!;&P@:6YT97)C;VUP86YY
M(&%C8V]U;G1S(&%N9"!T<F%N<V%C=&EO;G,@:&%V92!B965N#0H@("!E;&EM
M:6YA=&5D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4:&4@<')E<&%R871I;VX@;V8@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:"!5+E,N($=!05`@<F5Q
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M870@;6%N86=E;65N=`T*("`@8F5L:65V97,@=&\@8F4@<F5A<V]N86)L92!U
M;F1E<B!T:&4@8VER8W5M<W1A;F-E<RX@0GD@=&AE:7(@;F%T=7)E+"!E<W1I
M;6%T97,@87)E('-U8FIE8W0@=&\@86X@:6YH97)E;G0@9&5G<F5E(&]F('5N
M8V5R=&%I;G1Y(&%N9"P@87,@<W5C:"P@86-T=6%L(')E<W5L=',@;6%Y(&1I
M9F9E<B!F<F]M(&UA;F%G96UE;G0F(S@R,3<[<R!E<W1I;6%T97,N(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN
M+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/D%D
M;W!T:6]N(&]F(%)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S(#PO
M:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
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M871E#0H@("`H)B,X,C(P.T%3528C.#(R,3LI($YO+B8C,38P.S(P,3$M,#4L
M($-O;7!R96AE;G-I=F4@26YC;VUE("A4;W!I8R`R,C`I.B`\:3Y0<F5S96YT
M871I;VX@;V8@0V]M<')E:&5N<VEV92!);F-O;64\+VD^(&%N9"!!4U4@3F\N
M)B,Q-C`[,C`Q,2TQ,BP@/&D^0V]M<')E:&5N<VEV92!);F-O;64@*%1O<&EC
M(#(R,"DZ($1E9F5R<F%L(&]F('1H92!%9F9E8W1I=F4@1&%T92!F;W(@06UE
M;F1M96YT<R!T;R!T:&4@4')E<V5N=&%T:6]N(&]F#0H@("!296-L87-S:69I
M8V%T:6]N<R!O9B!)=&5M<R!/=70@;V8@06-C=6UU;&%T960@3W1H97(@0V]M
M<')E:&5N<VEV92!);F-O;64@:6X@05-5($YO+B8C,38P.S(P,3$M-3PO:3XN
M($EN('1H97-E('5P9&%T97,L(&%N(&5N=&ET>2!H87,@=&AE(&]P=&EO;B!T
M;R!P<F5S96YT('1H92!T;W1A;"!O9B!C;VUP<F5H96YS:79E(&EN8V]M92P@
M=&AE(&-O;7!O;F5N=',@;V8@;F5T(&EN8V]M92P@86YD('1H92!C;VUP;VYE
M;G1S(&]F(&]T:&5R#0H@("!C;VUP<F5H96YS:79E(&EN8V]M92!E:71H97(@
M:6X@82!S:6YG;&4@8V]N=&EN=6]U<R!S=&%T96UE;G0@;V8@8V]M<')E:&5N
M<VEV92!I;F-O;64@;W(@:6X@='=O('-E<&%R871E(&)U="!C;VYS96-U=&EV
M92!S=&%T96UE;G1S+B!);B!B;W1H(&-H;VEC97,L(&%N(&5N=&ET>2!I<R!R
M97%U:7)E9"!T;R!P<F5S96YT(&5A8V@@8V]M<&]N96YT(&]F(&YE="!I;F-O
M;64@86QO;F<@=VET:"!T;W1A;"!N970@:6YC;VUE+"!E86-H#0H@("!C;VUP
M;VYE;G0@;V8@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@86QO;F<@=VET
M:"!A('1O=&%L(&9O<B!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92P@86YD
M(&$@=&]T86P@86UO=6YT(&9O<B!C;VUP<F5H96YS:79E(&EN8V]M92X@05-5
M($YO+B8C,38P.S(P,3$M,#4@96QI;6EN871E<R!T:&4@;W!T:6]N('1O('!R
M97-E;G0@=&AE(&-O;7!O;F5N=',@;V8@;W1H97(@8V]M<')E:&5N<VEV92!I
M;F-O;64@87,@<&%R="!O9B!T:&4-"B`@('-T871E;65N="!O9B!C:&%N9V5S
M(&EN('-T;V-K:&]L9&5R<R8C.#(Q-SL@97%U:71Y+B!4:&4@86UE;F1M96YT
M<R!I;B!!4U4@3F\N)B,Q-C`[,C`Q,2TP-2!D;R!N;W0@8VAA;F=E('1H92!I
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M<B8C,38P.S$U+"`R,#$Q+B!4:&4@861O<'1I;VX@;V8@05-5($YO<RX@,C`Q
M,2TP-2!A;F0@,C`Q,2TQ,B!D:60@;F]T(&AA=F4@82!M871E<FEA;"!I;7!A
M8W0@;VX@;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"B`@('!O<VET:6]N
M(&]R(')E<W5L=',@;V8@;W!E<F%T:6]N<RX@5V4@:&%V92!P<F5S96YT960@
M8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&EN(&]U<B!C;VYD96YS960@
M8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@8V]M<')E:&5N<VEV92!I;F-O
M;64@*&QO<W,I+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CX-"B`@($5F9F5C=&EV92!*86YU87)Y)B,Q-C`[,2P@,C`Q,BP@
M=V4@<')O<W!E8W1I=F5L>2!A9&]P=&5D($9!4T(F(S@R,3<[<R!!4U4@3F\N
M)B,Q-C`[,C`Q,2TP-"P@/&D^)B,X,C(P.T9A:7(@5F%L=64@365A<W5R96UE
M;G0@*%1O<&EC(#@R,"D@)B,X,C$R.R!!;65N9&UE;G1S('1O($%C:&EE=F4@
M0V]M;6]N($9A:7(@5F%L=64@365A<W5R96UE;G0@86YD#0H@("!$:7-C;&]S
M=7)E(%)E<75I<F5M96YT<R!I;B!5+E,N($=!05`@86YD($E&4E,F(S@R,C$[
M+B`\+VD^5&AE(&%M96YD;65N=',@:6X@05-5(#(P,3$M,#0@<F5S=6QT(&EN
M(&-O;6UO;B!F86ER('9A;'5E(&UE87-U<F5M96YT(&%N9"!D:7-C;&]S=7)E
M(')E<75I<F5M96YT<R!I;B!'04%0(&%N9"!);G1E<FYA=&EO;F%L($9I;F%N
M8VEA;"!297!O<G1I;F<@4W1A;F1A<F1S("@F(S@R,C`[24924R8C.#(R,3LI
M+B!#;VYS97%U96YT;'DL('1H90T*("`@86UE;F1M96YT<R!C:&%N9V4@=&AE
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M:6X-"B`@('1H;W-E('EE87)S+"!B96=I;FYI;F<@869T97(@1&5C96UB97(F
M(S$V,#LQ-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F($%352!.;RXF(S$V,#LR
M,#$Q+3`T(&1I9"!N;W0@:&%V92!A(&UA=&5R:6%L(&5F9F5C="!O;B!O=7(@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F
M(&]P97)A=&EO;G,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/CQB/CQI/DEN=F5N=&]R:65S(#PO:3X\+V(^/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($EN=F5N=&]R
M:65S(&%R92!S=&%T960@870@;&]W97(@;V8@8V]S="!O<B!M87)K970N($-O
M<W0@:7,@9&5T97)M:6YE9"!O;B!A(&9I<G-T+6EN+"!F:7)S="UO=70@8F%S
M:7,N($EN=F5N=&]R:65S(&%R92!R979I97=E9"!P97)I;V1I8V%L;'D@9F]R
M('!O=&5N=&EA;"!E>&-E<W,L(&1A=&5D(&]R(&]B<V]L971E('-T871U<RX@
M36%N86=E;65N=`T*("`@979A;'5A=&5S('1H92!C87)R>6EN9R!V86QU92!O
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M9B!L:69E(&]F(&=O;V1S(&]N(&AA;F0N(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E)A=R!M871E<FEA;',@:6YV96YT;W)I
M97,@8V]N<VES="!O9B!R87<-"B`@(&UA=&5R:6%L<R!U<V5D(&EN('1H92!M
M86YU9F%C='5R92!O9B!O=7(@8G5L:R!D<G5G(&UA=&5R:6%L(&9O<B`\:3Y(
M>6QE;F5X/"]I/B!R96-O;6)I;F%N="!P<F]D=6-T+B!7;W)K+6EN+7!R;V-E
M<W,@:6YV96YT;W)I97,@8V]N<VES="!O9B!I;BUP<F]C97-S(#QI/DAY;&5N
M97@\+VD^(')E8V]M8FEN86YT+B!&:6YI<VAE9"!G;V]D<R!I;G9E;G1O<FEE
M<R!C;VYS:7-T(&]F(&9I;FES:&5D(#QI/DAY;&5N97@\+VD^#0H@("!R96-O
M;6)I;F%N="!P<F]D=6-T+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N
M=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY792!E>'!E;G-E(&-O<W1S(')E;&%T:6YG('1O('1H
M92!P=7)C:&%S92!A;F0@<')O9'5C=&EO;B!O9B!P<F4M87!P<F]V86P@:6YV
M96YT;W)I97,@9F]R('=H:6-H('1H92!S;VQE#0H@("!U<V4@:7,@<')E+6%P
M<')O=F%L('!R;V1U8W1S(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M>'!E;G-E(&EN('1H92!P97)I;V0@:6YC=7)R960@=6YT:6P@<W5C:"!T:6UE
M(&%S('=E(&)E;&EE=F4@9G5T=7)E(&-O;6UE<F-I86QI>F%T:6]N(&ES('!R
M;V)A8FQE(&%N9"!F=71U<F4@96-O;F]M:6,@8F5N969I="!I<R!E>'!E8W1E
M9"!T;R!B92!R96%L:7IE9"X@1F]R('!R;V1U8W1S('1H870@:&%V92!B965N
M(&%P<')O=F5D#0H@("!B>2!R96=U;&%T;W)Y(&)O9&EE<R!S=6-H(&%S('1H
M92!5+E,N($9O;V0@86YD($1R=6<@061M:6YI<W1R871I;VX@*"8C.#(R,#M&
M1$$F(S@R,C$[*2P@:6YV96YT;W)I97,@=7-E9"!I;B!C;&EN:6-A;"!T<FEA
M;',@87)E(&5X<&5N<V5D(&%T('1H92!T:6UE('1H92!I;G9E;G1O<FEE<R!A
M<F4@<&%C:V%G960@9F]R('1H92!C;&EN:6-A;"!T<FEA;',N(%!R:6]R('1O
M(')E8V5I=FEN9R!A<'!R;W9A;"!F<F]M('1H92!&1$$@;W(-"B`@(&-O;7!A
M<F%B;&4@<F5G=6QA=&]R>2!A9V5N8VEE<R!I;B!F;W)E:6=N(&-O=6YT<FEE
M<RP@8V]S=',@<F5L871E9"!T;R!P=7)C:&%S97,@;V8@=&AE(&%C=&EV92!P
M:&%R;6%C975T:6-A;"!I;F=R961I96YT<R`H)B,X,C(P.T%0228C.#(R,3LI
M(&%N9"!T:&4@;6%N=69A8W1U<FEN9R!O9B!T:&4@<')O9'5C="!C86YD:61A
M=&4@87)E(')E8V]R9&5D(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M>'!E;G-E+B!!;&P@9&ER96-T#0H@("!M86YU9F%C='5R:6YG(&-O<W1S(&EN
M8W5R<F5D(&%F=&5R(&%P<')O=F%L(&%R92!C87!I=&%L:7IE9"!A<R!I;G9E
M;G1O<GDN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\:3Y2979E;G5E
M(%)E8V]G;FET:6]N(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN
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M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V4@<F5C
M;V=N:7IE(')E=F5N=64@:6X@86-C;W)D86YC92!W:71H('1H92!A=71H;W)I
M=&%T:79E(&=U:61A;F-E(&]N(')E=F5N=64-"B`@(')E8V]G;FET:6]N+B!2
M979E;G5E(&ES(')E8V]G;FEZ960@=VAE;B!A;&P@;V8@=&AE(&9O;&QO=VEN
M9R!C<FET97)I82!A<F4@;65T.B`H,2DF(S$V,#MP97)S=6%S:79E(&5V:61E
M;F-E(&]F(&%N(&%R<F%N9V5M96YT(&5X:7-T<SL@*#(I)B,Q-C`[9&5L:79E
M<GD@:&%S(&]C8W5R<F5D(&]R('-E<G9I8V5S(&AA=F4@8F5E;B!R96YD97)E
M9#L@*#,I)B,Q-C`[=&AE('-E;&QE<B8C.#(Q-SMS('!R:6-E('1O('1H92!B
M=7EE<B!I<PT*("`@9FEX960@;W(@9&5T97)M:6YA8FQE.R!A;F0@*#0I)B,Q
M-C`[8V]L;&5C=&EB:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+B`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3X\+VD^
M/&(^/&D^4')O9'5C="!386QE<R`\+VD^/"]B/CQI/B8C.#(Q,3L@2'EL96YE
M>#PO:3X@<F5C;VUB:6YA;G0@=V%S(&%P<')O=F5D(&9O<B!M87)K971I;F<@
M8GD@=&AE($9$02!I;@T*("`@1&5C96UB97(@,C`P-2X@1G)O;2`R,#`U('1H
M<F]U9V@@2F%N=6%R>28C,38P.S<L(#(P,3$L($)A>'1E<B!H860@=&AE('=O
M<FQD=VED92!M87)K970@<FEG:'1S(&9O<B`\:3Y(>6QE;F5X/"]I/B!R96-O
M;6)I;F%N="!U;F1E<B!T:&4@=&5R;7,@;V8@=&AE(&%M96YD960@86YD(')E
M<W1A=&5D(&1E=F5L;W!M96YT(&%N9"!S=7!P;'D@86=R965M96YT('=I=&@@
M0F%X=&5R("@F(S@R,C`[2'EL96YE>`T*("`@0V]L;&%B;W)A=&EO;B8C.#(R
M,3LI+B!"87AT97(@8V]M;65R8VEA;&QY(&QA=6YC:&5D(#QI/DAY;&5N97@\
M+VD^(')E8V]M8FEN86YT(&EN($]C=&]B97(@,C`P.2X@2&]W979E<BP@/&D^
M2'EL96YE>#PO:3X@<F5C;VUB:6YA;G0@=V%S('9O;'5N=&%R:6QY(')E8V%L
M;&5D(&EN($UA>2`R,#$P(&)E8V%U<V4@82!P;W)T:6]N(&]F('1H92!P<F]D
M=6-T(&UA;G5F86-T=7)E9"!B>2!"87AT97(@=V%S(&YO="!I;B!C;VUP;&EA
M;F-E#0H@("!W:71H('1H92!R97%U:7)E;65N=',@;V8@=&AE('5N9&5R;'EI
M;F<@8V]L;&%B;W)A=&EO;BX@169F96-T:79E($IA;G5A<GDF(S$V,#LW+"`R
M,#$Q+"!W92!A;F0@0F%X=&5R(&UU='5A;&QY(&%G<F5E9"!T;R!T97)M:6YA
M=&4@=&AE($AY;&5N97@@0V]L;&%B;W)A=&EO;BX@1'5R:6YG('1H92!S96-O
M;F0@<75A<G1E<B!O9B`R,#$Q+"!W92!S=6)M:71T960@=&AE(&1A=&$@=&AA
M="!T:&4@1D1!(&AA9"!R97%U97-T960@=&\-"B`@('-U<'!O<G0@=&AE(')E
M:6YT<F]D=6-T:6]N(&]F(#QI/DAY;&5N97@\+VD^(')E8V]M8FEN86YT('1O
M('1H92!M87)K970N(%1H92!&1$$@87!P<F]V960@=&AE('-U8FUI='1E9"!D
M871A(&%N9"!G<F%N=&5D('1H92!R96EN=')O9'5C=&EO;B!O9B`\:3Y(>6QE
M;F5X/"]I/B!R96-O;6)I;F%N="X@/&D^(#PO:3X\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!$96-E;6)E<B`R,#$Q+"!W
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M"B`@(&1I<W1R:6)U=&]R<R!T86ME('1I=&QE('1O('1H92!P<F]D=6-T+"!B
M96%R('1H92!R:7-K(&]F(&QO<W,@;V8@;W=N97)S:&EP(&%N9"!H879E(&5C
M;VYO;6EC('-U8G-T86YC92!T;R!T:&4@:6YV96YT;W)Y+B!&=7)T:&5R+"!W
M92!H879E(&YO('-I9VYI9FEC86YT(&]B;&EG871I;VYS(&9O<B!F=71U<F4@
M<&5R9F]R;6%N8V4@=&\@9V5N97)A=&4@<'5L;"UT:')O=6=H('-A;&5S.R!H
M;W=E=F5R+"!W92!D;R!A;&QO=R!T:&4-"B`@('=H;VQE<V%L92!D:7-T<FEB
M=71O<G,@=&\@<F5T=7)N('!R;V1U8W0@=&AA="!I<R!D86UA9V5D(&]R(')E
M8V5I=F5D(&EN(&5R<F]R+B!);B!A9&1I=&EO;BP@=V4@86QL;W<@9F]R('!R
M;V1U8W0@=&\@8F4@<F5T=7)N960@8F5G:6YN:6YG('-I>"!M;VYT:',@<')I
M;W(@=&\@86YD(&5N9&EN9R!T=V5L=F4@;6]N=&AS(&9O;&QO=VEN9R!P<F]D
M=6-T(&5X<&ER871I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D=I=F5N(&]U<B!L:6UI=&5D(&AI<W1O<GD@;V8@<V5L
M;&EN9R`\:3Y(>6QE;F5X/"]I/B!R96-O;6)I;F%N="!A;F0@=&AE(&QE;F=T
M:'D@<F5T=7)N('!E<FEO9"P@=V4@8W5R<F5N=&QY(&-A;FYO="!R96QI86)L
M>2!E<W1I;6%T90T*("`@97AP96-T960@<F5T=7)N<R!A;F0@8VAA<F=E8F%C
M:W,@;V8@/&D^2'EL96YE>#PO:3X@<F5C;VUB:6YA;G0@870@=&AE('1I;64@
M=&AE('!R;V1U8W0@:7,@<F5C96EV960@8GD@=&AE('=H;VQE<V%L92!D:7-T
M<FEB=71O<G,N(%1H97)E9F]R92P@=V4@9&\@;F]T(')E8V]G;FEZ92!R979E
M;G5E('5P;VX@9&5L:79E<GD@;V8@/&D^2'EL96YE>#PO:3X@<F5C;VUB:6YA
M;G0@=&\@=&AE('=H;VQE<V%L92!D:7-T<FEB=71O<B!U;G1I;`T*("`@=&AE
M('!O:6YT(&%T('=H:6-H('=E(&-A;B!R96QI86)L>2!E<W1I;6%T92!E>'!E
M8W1E9"!P<F]D=6-T(')E='5R;G,@86YD(&-H87)G96)A8VMS(&9R;VT@=&AE
M('=H;VQE<V%L92!D:7-T<FEB=71O<G,N(%-H:7!M96YT<R!O9B`\:3Y(>6QE
M;F5X/"]I/B!R96-O;6)I;F%N="!A<F4@<F5C;W)D960@87,@9&5F97)R960@
M<F5V96YU92!U;G1I;"!E=FED96YC92!E>&ES=',@=&\@8V]N9FER;2!T:&%T
M('!U;&PM=&AR;W5G:"!S86QE<PT*("`@=&\@=&AE(&AO<W!I=&%L<R!O<B!O
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M97,@861J=7-T;65N=',@8F%S960@;VX-"B`@(&%N86QY<VES(&]F('1H:7)D
M+7!A<G1Y(&EN9F]R;6%T:6]N(&EN8VQU9&EN9R!I;F9O<FUA=&EO;B!O8G1A
M:6YE9"!F<F]M(&-E<G1A:6X@9&ES=')I8G5T;W)S('=I=&@@<F5S<&5C="!T
M;R!T:&5I<B!I;G9E;G1O<GD@;&5V96QS(&%N9"!S96QL+71H<F]U9V@@=&\@
M=&AE(&1I<W1R:6)U=&]R<R8C.#(Q-SL@8W5S=&]M97)S+B!!="!T:&4@=&EM
M92!W92!C86X@<F5L:6%B;'D@97-T:6UA=&4@<')O9'5C="!R971U<FYS(&%N
M9`T*("`@8VAA<F=E8F%C:W,@9G)O;2!T:&4@=VAO;&5S86QE(&1I<W1R:6)U
M=&]R<RP@=V4@=VEL;"!R96-O<F0@82!O;F4M=&EM92!I;F-R96%S92!I;B!N
M970@<')O9'5C="!S86QE<R!R979E;G5E(')E;&%T960@=&\@=&AE(')E8V]G
M;FET:6]N(&]F('!R;V1U8W0@<V%L97,@<F5V96YU92!P<F5V:6]U<VQY(&1E
M9F5R<F5D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M="!S86QE<PT*("`@86QL;W=A;F-E<R!A<F4@8F%S960@;VX@86UO=6YT<R!O
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M('=H:6-H(&-O=6QD(&AA=F4-"B`@(&%N(&5F9F5C="!O;B!P<F]D=6-T('-A
M;&5S(')E=F5N=64@:6X@=&AE('!E<FEO9"!O9B!A9&IU<W1M96YT+B!/=7(@
M<')O9'5C="!S86QE<R!A;&QO=V%N8V5S(&EN8VQU9&4Z(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/D1I<W1R:6)U=&EO
M;@T*("`@1F5E<SPO:3XN(%1H92!D:7-T<FEB=71I;VX@9F5E<RP@8F%S960@
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M97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ<'@[
M;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y0<F]M<'0@4&%Y;65N
M=`T*("`@1&ES8V]U;G1S/"]I/BX@5V4@;V9F97(@8V%S:"!D:7-C;W5N=',@
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M86QE<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&D^0VAA<F=E8F%C:W,\+VD^+B!792!P<F]V:61E(&1I<V-O=6YT<R!T
M;R!E;F0M=7-E<B!M96UB97)S(&]F(&-E<G1A:6X@9W)O=7`@<'5R8VAA<VEN
M9R!O<F=A;FEZ871I;VYS("@F(S@R,C`[1U!/)B,X,C(Q.RD@=6YD97(@8V]L
M;&5C=&EV90T*("`@<'5R8VAA<VEN9R!C;VYT<F%C=',@8F5T=V5E;B!U<R!A
M;F0@=&AE($=03W,N(%=E(&%L<V\@<')O=FED92!D:7-C;W5N=',@=&\@8V5R
M=&%I;B!H;W-P:71A;',@=VAO(&%R92!M96UB97)S(&]F('1H92!'4$]S('=I
M=&@@=VAI8V@@=V4@9&\@;F]T(&AA=F4@8V]N=')A8W1S+B!4:&4@96YD+75S
M97(@;65M8F5R<R!P=7)C:&%S92!P<F]D=6-T<R!F<F]M('1H92!W:&]L97-A
M;&4@9&ES=')I8G5T;W)S(&%T(&$@8V]N=')A8W1E9`T*("`@9&ES8V]U;G1E
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M<R!I;B!T:&4@<V%M90T*("`@<&5R:6]D('1H92!R96QA=&5D('!R;V1U8W0@
M<V%L97,@<F5V96YU92!I<R!R96-O9VYI>F5D(&%N9"!R961U8V4@;W5R(&%C
M8V]U;G1S(')E8V5I=F%B;&4@86-C;W)D:6YG;'DN($$@1U!/(&9E92!W92!I
M;F-U<B!F;W(@=&AE<V4@=')A;G-A8W1I;VYS(&ES(&%L<V\@<F5C;W)D960@
M:6X@=&AE('-A;64@<&5R:6]D('1H92!R96QA=&5D('!R;V1U8W0@<V%L97,@
M<F5V96YU92!I<R!R96-O9VYI>F5D(&%N9"!I<R!I;F-L=61E9"!I;@T*("`@
M86-C<G5E9"!E>'!E;G-E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^/&D^4')O9'5C="!2971U<FYS/"]I/BX@5&AE('!R
M;V1U8W0@<F5T=7)N<R!R97-E<G9E(&ES(&)A<V5D(&]N(&UA;F%G96UE;G0F
M(S@R,3<[<R!B97-T(&5S=&EM871E(&]F('1H90T*("`@<')O9'5C="!S86QE
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M(&%N9"!I<PT*("`@:6YC;'5D960@:6X@86-C<G5E9"!E>'!E;G-E<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^
M4F5V96YU97,@=6YD97(@0V]L;&%B;W)A=&EV92!!9W)E96UE;G1S(#PO:3X\
M+V(^/&D^)B,X,C$Q.R`\+VD^5V4@:&%V92!E;G1E<F5D(&EN=&\-"B`@(&QI
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M8V]M<&]U;F1S+B!4:&4-"B`@(&-O;&QA8F]R871I=F4@86=R965M96YT<R!C
M;VYT86EN(&UU;'1I<&QE(&5L96UE;G1S+"!I;F-L=61I;F<@;F]N<F5F=6YD
M86)L92!P87EM96YT<R!A="!T:&4@:6YC97!T:6]N(&]F('1H92!A<G)A;F=E
M;65N=',L(&QI8V5N<V4@9F5E<RP@97AC;'5S:79I='D@9F5E<RP@<&%Y;65N
M=',@8F%S960@;VX@86-H:65V96UE;G0@;V8@<W!E8VEF:65D(&UI;&5S=&]N
M97,@9&5S:6=N871E9"!I;B!T:&4@8V]L;&%B;W)A=&EV90T*("`@86=R965M
M96YT<RP@<F5I;6)U<G-E;65N=',@;V8@<F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT('-E<G9I8V5S+"!P87EM96YT<R!F;W(@<W5P<&QY(&]F(')(=5!(,C`@
M05!)(&9O<B!T:&4@8V]L;&%B;W)A=&]R(&%N9"]O<B!R;WEA;'1I97,@;VX@
M<V%L97,@;V8@<')O9'5C=',@<F5S=6QT:6YG(&9R;VT@8V]L;&%B;W)A=&EV
M92!A9W)E96UE;G1S+B!792!A;F%L>7IE(&5A8V@@96QE;65N="!O9B!T:&4@
M8V]L;&%B;W)A=&EV90T*("`@86=R965M96YT<R!A;F0@8V]N<VED97(@82!V
M87)I971Y(&]F(&9A8W1O<G,@:6X@9&5T97)M:6YI;F<@=&AE(&%P<')O<')I
M871E(&UE=&AO9"!O9B!R979E;G5E(')E8V]G;FET:6]N(&]F(&5A8V@@96QE
M;65N="X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^4')I;W(@=&\@=&AE(&%D;W!T:6]N(&]F($%352!.;RXF(S$V,#LR,#`Y
M+3$S+"`\:3Y-=6QT:7!L92U$96QI=F5R86)L92!2979E;G5E($%R<F%N9V5M
M96YT<SPO:3XL(&]N($IA;G5A<GDF(S$V,#LQ+"`R,#$Q+"!I;B!O<F1E<B!F
M;W(@80T*("`@9&5L:79E<F5D(&ET96T@=&\@8F4@86-C;W5N=&5D(&9O<B!S
M97!A<F%T96QY(&9R;VT@;W1H97(@9&5L:79E<F%B;&5S(&EN(&$@;75L=&EP
M;&4M96QE;65N="!A<G)A;F=E;65N="P@=&AE(&9O;&QO=VEN9R!T:')E92!C
M<FET97)I82!H860@=&\@8F4@;65T.B`H:2DF(S$V,#MT:&4@9&5L:79E<F5D
M(&ET96T@:&%D('-T86YD86QO;F4@=F%L=64@=&\@=&AE(&-U<W1O;65R+"`H
M:6DI)B,Q-C`[=&AE<F4@=V%S(&]B:F5C=&EV92!A;F0-"B`@(')E;&EA8FQE
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M;F0@<W5B<W1A;G1I86QL>0T*("`@:6X@=&AE(&-O;G1R;VP@;V8@=&AE('9E
M;F1O<BX@1F]R('1H92!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@96YT97)E
M9"!I;G1O('!R:6]R('1O($IA;G5A<GDF(S$V,#LQ+"`R,#$Q+"!T:&5R92!W
M87,@;F\@;V)J96-T:79E(&%N9"!R96QI86)L92!E=FED96YC92!O9B!F86ER
M('9A;'5E(&]F('1H92!U;F1E;&EV97)E9"!I=&5M<RX@5&AU<RP@=&AE(&1E
M;&EV97)E9"!L:6-E;G-E<R!D:60@;F]T(&UE970@86QL(&]F('1H90T*("`@
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M;G9O;'9E;65N="!U;F1E<B!T:&4-"B`@(')E;&%T960@86=R965M96YT<RX@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1F]R
M(&YE=R!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@;W(@;6%T97)I86P@;6]D
M:69I8V%T:6]N<R!O9B!E>&ES=&EN9R!C;VQL86)O<F%T:79E(&%G<F5E;65N
M=',@96YT97)E9`T*("`@:6YT;R!A9G1E<B!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$P+"!W92!F;VQL;W<@=&AE('!R;W9I<VEO;G,@;V8@05-5($YO+B8C,38P
M.S(P,#DM,3,N($EN(&]R9&5R('1O(&%C8V]U;G0@9F]R('1H92!M=6QT:7!L
M92UE;&5M96YT(&%R<F%N9V5M96YT<RP@=V4@:61E;G1I9GD@=&AE(&1E;&EV
M97)A8FQE<R!I;F-L=61E9"!W:71H:6X@=&AE(&%G<F5E;65N="!A;F0@979A
M;'5A=&4@=VAI8V@@9&5L:79E<F%B;&5S(')E<')E<V5N=`T*("`@=6YI=',@
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M:6]N+B!4:&4-"B`@(&1E;&EV97)A8FQE<R!U;F1E<B!O=7(@8V]L;&%B;W)A
M=&EV92!A9W)E96UE;G1S(&EN8VQU9&4@*&DI)B,Q-C`[=&AE(&QI8V5N<V4@
M=&\@<DAU4$@R,"!T96-H;F]L;V=Y+"`H:6DI)B,Q-C`[870@=&AE(&-O;&QA
M8F]R871O<B8C.#(Q-SMS(')E<75E<W0L(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!S97)V:6-E<R!W:&EC:"!A<F4@<F5I;6)U<G-E9"!A="!C;VYT<F%C
M='5A;&QY(&1E=&5R;6EN960@<F%T97,L(&%N9`T*("`@*&EI:2DF(S$V,#MA
M="!T:&4@8V]L;&%B;W)A=&]R)B,X,C$W.W,@<F5Q=65S="P@<W5P<&QY(&]F
M(')(=5!(,C`@05!)('=H:6-H(&ES(')E:6UB=7)S960@870@;W5R(&-O<W0@
M<&QU<R!A(&UA<F=I;BX@02!D96QI=F5R960@:71E;2!I<R!C;VYS:61E<F5D
M(&$@<V5P87)A=&4@=6YI="!O9B!A8V-O=6YT:6YG('=H96X@=&AE(&1E;&EV
M97)E9"!I=&5M(&AA<R!V86QU92!T;R!T:&4@8V]L;&%B;W)A=&]R(&]N(&$@
M<W1A;F1A;&]N90T*("`@8F%S:7,@8F%S960@;VX@=&AE(&-O;G-I9&5R871I
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M:&4@9V5N97)A;"!M87)K971P;&%C92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O
M='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M('9E;F1O<B!S<&5C:69I8R!O8FIE8W1I=F4@979I9&5N8V4-"B`@("@F(S@R
M,C`[5E-/128C.#(R,3LI(&]F('-E;&QI;F<@<')I8V4@;W(@=&AI<F0M<&%R
M='D@979I9&5N8V4@;V8@<V5L;&EN9R!P<FEC92!I9B!64T]%(&1O97,@;F]T
M(&5X:7-T+B!)9B!N96ET:&5R(%933T4@;F]R('1H:7)D+7!A<G1Y(&5V:61E
M;F-E(&]F('-E;&QI;F<@<')I8V4@97AI<W1S+"!W92!U<V4@;W5R(&)E<W0@
M97-T:6UA=&4@;V8@=&AE('-E;&QI;F<@<')I8V4@9F]R('1H92!D96QI=F5R
M86)L92X@5&AE(&%M;W5N="!O9@T*("`@86QL;V-A8FQE(&%R<F%N9V5M96YT
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M("`@<V5P87)A=&4@=6YI=',N($-H86YG97,@:6X@=&AE(&%L;&]C871I;VX@
M;V8@=&AE('-A;&5S('!R:6-E(&)E='=E96X@9&5L:79E<F5D(&%N9"!U;F1E
M;&EV97)E9"!E;&5M96YT<R!C86X@:6UP86-T(')E=F5N=64@<F5C;V=N:71I
M;VX@8G5T(&1O(&YO="!C:&%N9V4@=&AE('1O=&%L(')E=F5N=64@<F5C;V=N
M:7IE9"!U;F1E<B!A;GD@86=R965M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@
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M"B`@(&9E92P@<&5R<W5A<VEV92!E=FED96YC92!O9B!A;B!A<G)A;F=E;65N
M="!E>&ES=',L(&]U<B!P<FEC92!T;R!T:&4@8V]L;&%B;W)A=&]R(&ES(&9I
M>&5D(&]R(&1E=&5R;6EN86)L92!A;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A
M<V]N86)L>2!A<W-U<F5D+B!5<&9R;VYT(&QI8V5N<V4@9F5E('!A>6UE;G1S
M(&%R92!D969E<G)E9"!I9B!F86-T<R!A;F0@8VER8W5M<W1A;F-E<R!D:6-T
M871E('1H870@=&AE(&QI8V5N<V4@9&]E<PT*("`@;F]T(&AA=F4@<W1A;F1A
M;&]N92!V86QU92X@5&AE(&1E=&5R;6EN871I;VX@;V8@=&AE(&QE;F=T:"!O
M9B!T:&4@<&5R:6]D(&]V97(@=VAI8V@@=&\@9&5F97(@<F5V96YU92!I<R!S
M=6)J96-T('1O(&IU9&=M96YT(&%N9"!E<W1I;6%T:6]N(&%N9"!C86X@:&%V
M92!A;B!I;7!A8W0@;VX@=&AE(&%M;W5N="!O9B!R979E;G5E(')E8V]G;FEZ
M960@:6X@82!G:79E;B!P97)I;V0N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
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M;&QA8F]R871O<BX@169F96-T:79E($IA;G5A<GDF(S$V,#LQ+"`R,#$Q+"!W
M92!A9&]P=&5D(&]N(&$@<')O<W!E8W1I=F4@8F%S:7,@=&AE($UI;&5S=&]N
M92!-971H;V0N(%5N9&5R('1H92!-:6QE<W1O;F4@365T:&]D+"!W92!R96-O
M9VYI>F4@8V]N<VED97)A=&EO;B!T:&%T(&ES(&-O;G1I;F=E;G0@=7!O;B!T
M:&4-"B`@(&%C:&EE=F5M96YT(&]F(&$@;6EL97-T;VYE(&EN(&ET<R!E;G1I
M<F5T>2!A<R!R979E;G5E(&EN('1H92!P97)I;V0@:6X@=VAI8V@@=&AE(&UI
M;&5S=&]N92!I<R!A8VAI979E9"!O;FQY(&EF('1H92!M:6QE<W1O;F4@:7,@
M<W5B<W1A;G1I=F4@:6X@:71S(&5N=&ER971Y+B!!(&UI;&5S=&]N92!I<R!C
M;VYS:61E<F5D('-U8G-T86YT:79E('=H96X@:70@;65E=',@86QL(&]F('1H
M92!F;VQL;W=I;F<@8W)I=&5R:6$Z#0H@("`\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB
M;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E
M<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS
M1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T:#TS1#0E
M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^5&AE(&-O;G-I9&5R871I;VX@:7,@8V]M;65N<W5R871E('=I=&@@96ET
M:&5R('1H92!E;G1I='DF(S@R,3<[<R!P97)F;W)M86YC92!T;R!A8VAI979E
M('1H92!M:6QE<W1O;F4@;W(@=&AE(&5N:&%N8V5M96YT(&]F('1H92!V86QU
M92!O9B!T:&4@9&5L:79E<F5D(&ET96TH<RD@87,@80T*("`@<F5S=6QT(&]F
M(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I;F<@9G)O;2!T:&4@96YT:71Y
M)B,X,C$W.W,@<&5R9F]R;6%N8V4@=&\@86-H:65V92!T:&4@;6EL97-T;VYE
M+"`\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@
M<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB
M;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E
M<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS
M1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T:#TS1#0E
M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^5&AE(&-O;G-I9&5R871I;VX@<F5L871E<R!S;VQE;'D@=&\@<&%S="!P
M97)F;W)M86YC92P@86YD(#PO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PO
M=&%B;&4^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O
M<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG
M;CH@;&5F="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('=I9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H
M/3-$-"4^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C,N/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY4:&4@8V]N<VED97)A=&EO;B!I<R!R96%S;VYA
M8FQE(')E;&%T:79E('1O(&%L;"!O9B!T:&4@9&5L:79E<F%B;&5S(&%N9"!P
M87EM96YT('1E<FUS('=I=&AI;B!T:&4@87)R86YG96UE;G0N(#PO9F]N=#X\
M+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D$@;6EL97-T;VYE(&ES(&1E9FEN960@87,@86X@979E
M;G0@*&DI)B,Q-C`[=&AA="!C86X@;VYL>2!B92!A8VAI979E9"!B87-E9"!I
M;B!W:&]L92!O<B!I;B!P87)T(&]N(&5I=&AE<B!T:&4@96YT:71Y)B,X,C$W
M.W,@<&5R9F]R;6%N8V4-"B`@(&]R(&]N('1H92!O8V-U<G)E;F-E(&]F(&$@
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M('9E;F1O<BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
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M8V]L;&%B;W)A=&]R('=I;&P@<F5Q=65S="!R97-E87)C:"!A;F0-"B`@(&1E
M=F5L;W!M96YT('-E<G9I8V5S(&]R('-U<'!L>2!O9B!R2'502#(P($%023L@
M=&AE<F5F;W)E+"!W92!C86YN;W0@<')E9&EC="!W:&5N('=E('=I;&P@<F5C
M;V=N:7IE(')E=F5N=65S(&EN(&-O;FYE8W1I;VX@=VET:"!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@<V5R=FEC97,@86YD('-U<'!L>2!O9B!R2'502#(P
M($%022X@4F]Y86QT:65S('1O(&)E(')E8V5I=F5D(&)A<V5D(&]N('-A;&5S
M(&]F(&QI8V5N<V5D('!R;V1U8W1S#0H@("!B>2!O=7(@8V]L;&%B;W)A=&]R
M<R!I;F-O<G!O<F%T:6YG(')(=5!(,C`@=VEL;"!B92!R96-O9VYI>F5D(&%S
M(&5A<FYE9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^5&AE(&-O;&QA8F]R871I=F4@86=R965M96YT<R!T>7!I8V%L;'D@
M<')O=FED92!T:&4-"B`@(&-O;&QA8F]R871O<G,@=&AE(')I9VAT('1O('1E
M<FUI;F%T92!S=6-H(&%G<F5E;65N=',@:6X@=VAO;&4@;W(@;VX@82!P<F]D
M=6-T+6)Y+7!R;V1U8W0@;W(@=&%R9V5T+6)Y+71A<F=E="!B87-I<R!A="!A
M;GD@=&EM92!U<&]N(#DP(&1A>7,@<')I;W(@=W)I='1E;B!N;W1I8V4@=&\@
M=7,N(%1H97)E(&%R92!N;R!P97)F;W)M86YC92P@8V%N8V5L;&%T:6]N+"!T
M97)M:6YA=&EO;B!O<B!R969U;F0@<')O=FES:6]N<R!I;B!A;GD-"B`@(&]F
M(&]U<B!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@=&AA="!C;VYT86EN(&UA
M=&5R:6%L(&9I;F%N8VEA;"!C;VYS97%U96YC97,@=&\@=7,N(#PO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O
M='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/D-O<W0@
M;V8@4')O9'5C="!386QE<R`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S
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M;VX@;V8@/&D^2'EL96YE>"`\+VD^<F5C;VUB:6YA;G0N($-O<W0@;V8@<')O
M9'5C="!S86QE<R!A;'-O(&-O;G-I<W1S(&]F('1H92!W<FET92UD;W=N(&]F
M(&5X8V5S<RP@9&%T960@86YD(&]B<V]L971E(&EN=F5N=&]R:65S+B`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT
M;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R
M9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT($5X<&5N<V5S(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M97AP96YS97,@:6YC;'5D92!S86QA<FEE<R!A;F0@8F5N969I=',L(&9A8VEL
M:71I97,@86YD(&]T:&5R(&]V97)H96%D(&5X<&5N<V5S+"!E>'1E<FYA;"!C
M;&EN:6-A;"!T<FEA;"!E>'!E;G-E<RP-"B`@(')E<V5A<F-H(')E;&%T960@
M;6%N=69A8W1U<FEN9R!S97)V:6-E<RP@8V]N=')A8W0@<V5R=FEC97,@86YD
M(&]T:&5R(&]U='-I9&4@97AP96YS97,N(%)E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E<R!A<F4@8VAA<F=E9"!T;R!O<&5R871I;VYS(&%S(&EN
M8W5R<F5D('=H96X@=&AE<V4@97AP96YD:71U<F5S(')E;&%T92!T;R!O=7(@
M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5F9F]R=',@86YD(&AA=F4@;F\-
M"B`@(&%L=&5R;F%T:79E(&9U='5R92!U<V5S+B`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!9'9A;F-E('!A>6UE;G1S+"!I
M;F-L=61I;F<@;F]N<F5F=6YD86)L92!A;6]U;G1S+"!F;W(@9V]O9',@;W(@
M<V5R=FEC97,@=&AA="!W:6QL(&)E('5S960@;W(-"B`@(')E;F1E<F5D(&9O
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M97AP96-T('1H90T*("`@9V]O9',@=&\@8F4@9&5L:79E<F5D(&]R('-E<G9I
M8V5S('1O(&)E('!E<F9O<FUE9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^36EL97-T;VYE('!A>6UE;G1S('1H870@=V4@
M;6%K92!I;B!C;VYN96-T:6]N('=I=&@@:6XM;&EC96YS960@=&5C:&YO;&]G
M>0T*("`@;W(@<')O9'5C="!C86YD:61A=&5S(&%R92!E>'!E;G-E9"!A<R!I
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M(&9O<B!A;&P-"B`@(&]F(&]U<B!L:6-E;G-E9"!T96-H;F]L;V=Y(&]R('!R
M;V1U8W0@8V%N9&ED871E<R!T;R!B92!U;F-E<G1A:6X@86YD(&AA<R!E>'!E
M;G-E9"!T:&5S92!A;6]U;G1S(&%S(&EN8W5R<F5D+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\:3Y#;&EN:6-A;"!4
M<FEA;"!%>'!E;G-E<R`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL
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M<F5G87)D:6YG('=O<FL-"B`@('!E<F9O<FUE9"P@:6YC;'5D:6YG(&%C='5A
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M9"!T;R!E>'!E;G-E(&EN('1H92!P97)I;V0-"B`@(&EN('=H:6-H('1H92!F
M86-T<R!T:&%T(&=I=F4@<FES92!T;R!T:&4@<F5V:7-I;VX@8F5C;VUE(')E
M87-O;F%B;'D@8V5R=&%I;BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE
M9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^/&(^/&D^4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N
M(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4;W1A;"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R
M96QA=&5D('1O(&%L;"!O9B!O=7(@<VAA<F4M8F%S960@87=A<F1S('=A<R!A
M;&QO8V%T960@87,@9F]L;&]W<SH@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#4V)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY4:')E92!-;VYT:',@16YD960\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CY.:6YE($UO;G1H<R!%;F1E9#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#8@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB97(F(S$V,#LS
M,"P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB97(F(S$V,#LS,"P\+V(^/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q
M,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^.3$S+#DT-CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C@Y,"PR-S8\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS+#(W.2PY-#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#DT-"PU-3(\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3
M96QL:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#`X+#0T-SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^.#8W+#`X,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPP.#(L-#,R/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ+#DW,2PW-S<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$L.3(R+#,Y,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$L-S4W+#,U.3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L,S8R
M+#,W,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C,L.3$V+#,R.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY3:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS
M92!P97(@8F%S:6,@86YD(&1I;'5T960@<VAA<F4\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,"XP,CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C`N,#(\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXP+C`V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,"XP-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3:&%R92UB87-E9"!C
M;VUP96YS871I;VX@97AP96YS92!F<F]M.CPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E-T;V-K(&]P=&EO;G,\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PQ-C0L.3<S/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^.#`V+#`W.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C,L-#DQ+#(R,#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L,S$X
M+#<R.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)E<W1R:6-T960@<W1O
M8VL@87=A<F1S(&%N9"!R97-T<FEC=&5D('-T;V-K('5N:71S/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-S4W+#0R,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^.34Q+#(X,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPX-S$L,34R/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ+#4Y-RPV,#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C$L.3(R+#,Y,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L-S4W+#,U.3PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C8L,S8R+#,W,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C,L.3$V+#,R.3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@
M("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4VEN
M8V4@=V4@:&%V92!A(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0@
M87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(L(&YO(&5X8V5S<R!T87@@
M8F5N969I=',@9F]R('1H92!T87@-"B`@(&1E9'5C=&EO;G,@<F5L871E9"!T
M;R!S:&%R92UB87-E9"!A=V%R9',@=V5R92!R96-O9VYI>F5D(&EN('1H92!I
M;G1E<FEM('5N875D:71E9"!C;VYD96YS960@8V]N<V]L:61A=&5D('-T871E
M;65N=',@;V8@8V]M<')E:&5N<VEV92!L;W-S(&9O<B!T:&4@=&AR964@86YD
M(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+B!&
M;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@
M,C`Q,B!A;F0@,C`Q,2P@96UP;&]Y965S(&5X97)C:7-E9"!S=&]C:R!O<'1I
M;VYS('1O#0H@("!P=7)C:&%S92`W+#`U-2!A;F0@,S@L-3$Q('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VLL(')E<W!E8W1I=F5L>2P@9F]R(&%G9W)E9V%T92!P
M<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0S.2PP,#`@86YD("0W.2PP,#`L
M(')E<W!E8W1I=F5L>2X@1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q,2P@96UP;&]Y965S(&5X97)C
M:7-E9"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E#0H@("`T,C8L,C<W(&%N
M9"`R+#<Q,RPU-S,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@<F5S<&5C=&EV
M96QY+"!F;W(@86=G<F5G871E('!R;V-E961S(&]F(&%P<')O>&EM871E;'D@
M)#$N.2!M:6QL:6]N(&%N9"`D-"XQ(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X@
M26X@861D:71I;VXL(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,3(L('5P;VX@=F5S=&EN9R!O9B`Q,C@L,#`P(')E
M<W1R:6-T960@<W1O8VL-"B`@('5N:71S("@F(S@R,C`[4E-5<R8C.#(R,3LI
M+"!T:&4@4E-5(&AO;&1E<G,@<F5C96EV960@;F5T('-E='1L96UE;G0@;V8@
M.#$L,#<P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@86YD('-U<G)E;F1E<F5D
M(#0V+#DS,"!24U5S('1O('!A>2!F;W(@=&AE(&UI;FEM=6T@=VET:&AO;&1I
M;F<@=&%X97,@=&]T86QI;F<@87!P<F]X:6UA=&5L>2`D,S0W+#`P,"X@5&AE
M<F4@=V5R92!N;R!24U5S('9E<W1E9"!F;W(@=&AE('1H<F5E(&UO;G1H<PT*
M("`@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@;W(@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(L#0H@("!T;W1A;"!U;G)E
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M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN
M+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/D9A
M:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S(#PO:3X\+V(^/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
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M<FEC:6YG(&%N(&%S<V5T(&]R(&QI86)I;&ET>2X@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE(&9R86UE=V]R:R!F;W(@
M;65A<W5R:6YG(&9A:7(@=F%L=64@<')O=FED97,@82!H:65R87)C:'D@=&AA
M="!P<FEO<FET:7IE<R!T:&4@:6YP=71S('1O#0H@("!V86QU871I;VX@=&5C
M:&YI<75E<R!U<V5D(&EN(&UE87-U<FEN9R!F86ER('9A;'5E(&%S(&9O;&QO
M=W,Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[
M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*
M("`@/&1I=B!A;&EG;CTS1')I9VAT/B`-"B`@(#QT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.38E(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N
M.B!L969T)SX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT
M<CX@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=VED=&@],T0Y
M,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(
M96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY,979E;"8C,38P.S$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY1=6]T960@<')I8V5S("AU;F%D:G5S=&5D*2!I;B!A
M8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI
M=&EE<RP\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/DQE=F5L(#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);G!U=',@;W1H97(@=&AA
M;B!Q=6]T960@<')I8V5S(&EN8VQU9&5D('=I=&AI;B!,979E;"`Q('1H870@
M87)E(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I<F5C=&QY(&]B<V5R=F%B;&4L
M(&%N9#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0R/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^3&5V96P@,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E5N;V)S97)V86)L92!I;G!U
M=',@:6X@=VAI8V@@;&ET=&QE(&]R(&YO(&UA<FME="!A8W1I=FET>2!E>&ES
M=',L('1H97)E9F]R92!R97%U:7)I;F<@86X@96YT:71Y('1O(&1E=F5L;W`@
M:71S(&]W;B!A<W-U;7!T:6]N<R!A8F]U="!T:&4@87-S=6UP=&EO;G,@=&AA
M="!M87)K970@<&%R=&EC:7!A;G1S#0H@("!W;W5L9"!U<V4@:6X@<')I8VEN
M9RX\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!"
M;V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN
M9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY/=7(@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&EN
M8VQU9&4@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@86-C;W5N=',@<F5C
M96EV86)L92P@<')E<&%I9"!E>'!E;G-E<RP-"B`@(&%C8V]U;G1S('!A>6%B
M;&4@86YD(&%C8W)U960@97AP96YS97,N(%1H92!C87)R>6EN9R!A;6]U;G1S
M(&]F(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!A<'!R;WAI;6%T92!T:&5I<B!F
M86ER('9A;'5E<R!D=64@=&\@=&AE:7(@<VAO<G0@;6%T=7)I=&EE<RX@0V%S
M:"!E<75I=F%L96YT<R!O9B!A<'!R;WAI;6%T96QY("0X-2XP(&UI;&QI;VX@
M86YD("0U,2XX(&UI;&QI;VX@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@
M86YD#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!R97-P96-T:79E;'DL
M(&%R92!C87)R:65D(&%T(&9A:7(@=F%L=64@86YD(&%R92!C;&%S<VEF:65D
M('=I=&AI;B!,979E;"`Q(&]F('1H92!F86ER('9A;'5E(&AI97)A<F-H>2!B
M96-A=7-E('1H97D@87)E('9A;'5E9"!B87-E9"!O;B!Q=6]T960@;6%R:V5T
M('!R:6-E<R!F;W(@:61E;G1I8V%L('-E8W5R:71I97,N(%=E(&AA=F4@;F\@
M:6YS=')U;65N=',@=&AA="!A<F4@8VQA<W-I9FEE9`T*("`@=VET:&EN($QE
M=F5L(#(@86YD($QE=F5L(#,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL
M969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/CQB/CQI/E-E9VUE;G0@26YF;W)M871I;VX@/"]I
M/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E=E(&]P97)A=&4@;W5R(&)U<VEN97-S(&EN(&]N92!S96=M96YT+"!W:&EC
M:"!I;F-L=61E<R!A;&P@86-T:79I=&EE<R!R96QA=&5D('1O('1H92!R97-E
M87)C:"P@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F(&AU
M;6%N#0H@("!E;GIY;65S('1H870@96ET:&5R('1R86YS:65N=&QY(&UO9&EF
M>2!T:7-S=64@=&\@9F%C:6QI=&%T92!I;FIE8W1I;VX@;V8@;W1H97(@=&AE
M<F%P:65S(&]R(&-O<G)E8W0@9&ES96%S960@=&ES<W5E('-T<G5C='5R97,@
M9F]R(&-L:6YI8V%L(&)E;F5F:70N(%1H:7,@<V5G;65N="!A;'-O(&EN8VQU
M9&5S(')E=F5N=65S(&%N9"!E>'!E;G-E<R!R96QA=&5D('1O("AI*28C,38P
M.W)E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*("`@86-T:79I=&EE<R!C;VYD
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M<F%T:6]N<PT*("`@87,@82!S:6YG;&4@;W!E<F%T:6YG('-E9VUE;G0N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ<'@[;6%R9VEN
M+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?
M,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C
M8S`W8B]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O<F%T:79E($%G<F5E;65N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<F=A;FEZ871I;VX@86YD($)U<VEN97-S(&%N9"!#;VQL86)O<F%T:79E
M($%G<F5E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:79E($%G<F5E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT
M;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L
M+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ
M+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!4
M86=G960@3F]T92`S("T@=7,M9V%A<#I#;VQL86)O<F%T:79E07)R86YG96UE
M;G1$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I
M;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,RX@0V]L
M;&%B;W)A=&EV92!!9W)E96UE;G1S(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA
M<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E)O8VAE($-O;&QA8F]R871I;VX@
M/"]I/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M#0H@("!);B!$96-E;6)E<B`R,#`V+"!W92!A;F0@4F]C:&4@96YT97)E9"!I
M;G1O(&$@;&EC96YS92!A;F0@8V]L;&%B;W)A=&EV92!A9W)E96UE;G0@=6YD
M97(@=VAI8V@@4F]C:&4@;V)T86EN960@82!W;W)L9'=I9&4L(&5X8VQU<VEV
M92!L:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@<')O9'5C
M="!C;VUB:6YA=&EO;G,@;V8@<DAU4$@R,"!A;F0-"B`@('5P('1O('1H:7)T
M965N(%)O8VAE('1A<F=E="!C;VUP;W5N9',@*'1H92`F(S@R,C`[4F]C:&4@
M0V]L;&%B;W)A=&EO;B8C.#(R,3LI+B!!<R!O9B!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,BP@4F]C:&4@:&%S(&5L96-T960@82!T;W1A;"!O9B!F:79E(&5X
M8VQU<VEV92!T87)G971S(&%N9"!R971A:6YS('1H92!O<'1I;VX@=&\@9&5V
M96QO<"!A;F0@8V]M;65R8VEA;&EZ92!R2'502#(P('=I=&@@=&AR964@861D
M:71I;VYA;`T*("`@=&%R9V5T<RP@<')O=FED960@=&AA="!2;V-H92!C;VYT
M:6YU97,@=&\@<&%Y(&%N;G5A;"!M86EN=&5N86YC92!F965S('1O('5S+B!!
M<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,BP@=V4@:&%V92!R96-E:79E
M9"`D-3<@;6EL;&EO;B!F<F]M(%)O8VAE+"!I;F-L=61I;F<@=&AE("0R,"!M
M:6QL:6]N('5P9G)O;G0@;&EC96YS92!F964@<&%Y;65N="!F;W(@=&AE(&%P
M<&QI8V%T:6]N(&]F(')(=5!(,C`@=&\@=&AE(&EN:71I86P-"B`@('1H<F5E
M(%)O8VAE(&5X8VQU<VEV92!T87)G971S+"`D,C`@;6EL;&EO;B!I;B!C;VYN
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M;F%L(&UI;&5S=&]N92!P87EM96YT<R!O9B!U<"!T;R`D,3<X#0H@("!M:6QL
M:6]N+"!I;F-L=61I;F<@=7`@=&\@)#$W(&UI;&QI;VX@9F]R('1H92!A8VAI
M979E;65N="!O9B!C;&EN:6-A;"!D979E;&]P;65N="!M:6QE<W1O;F5S+"!U
M<"!T;R`D,38@;6EL;&EO;B!F;W(@=&AE(&%C:&EE=F5M96YT(&]F(')E9W5L
M871O<GD@;6EL97-T;VYE<R!A;F0@=7`@=&\@)#$T-2!M:6QL:6]N(&9O<B!T
M:&4@86-H:65V96UE;G0@;V8@<V%L97,M8F%S960@;6EL97-T;VYE<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^56YD97(@
M=&AE('1E<FUS(&]F('1H92!2;V-H92!#;VQL86)O<F%T:6]N+"!2;V-H92!W
M:6QL(&%L<V\@<&%Y('5S(&$@<F]Y86QT>2!O;B!E86-H('!R;V1U8W0@8V]M
M;65R8VEA;&EZ960@=6YD97(@=&AE(&%G<F5E;65N=`T*("`@8V]N<VES=&EN
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M86QT:65S+B!2;V-H90T*("`@:&%S('1H92!O8FQI9V%T:6]N('1O('!A>2!R
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M="!I;B!S=6-H(&-O=6YT<GD@;W(@*&(I)B,Q-C`[=&5N('EE87)S(&9O;&QO
M=VEN9R!T:&4@9&%T92!O9B!T:&4@9FER<W0@8V]M;65R8VEA;"!S86QE(&]F
M('-U8V@@<')O9'5C="!I;B!S=6-H(&-O=6YT<GDN($9O<B!P<F]D=6-T<R!D
M979E;&]P960@9F]R(&5A8V@@;V8@=&AE(&%D9&ET:6]N86P@=&%R9V5T<RP@
M4F]C:&4@;6%Y('!A>2!U<PT*("`@=7!F<F]N="!A;F0@;6EL97-T;VYE('!A
M>6UE;G1S(&]F('5P('1O("0T-R!M:6QL:6]N('!E<B!T87)G970L(&%S('=E
M;&P@87,@<F]Y86QT:65S(&]N('!R;V1U8W0@<V%L97,@9F]R(&5A8V@@;V8@
M=&AE(&%D9&ET:6]N86P@=&%R9V5T<R!C;VYS:7-T:6YG(&]F(&$@;6ED+7-I
M;F=L92!D:6=I="!P97)C96YT(&]F('1H92!N970@<V%L97,@;V8@<W5C:"!P
M<F]D=6-T<RX@061D:71I;VYA;&QY+"!2;V-H92!W:6QL(&]B=&%I;@T*("`@
M86-C97-S('1O(&]U<B!E>'!E<G1I<V4@:6X@9&5V96QO<&EN9R!A;F0@87!P
M;'EI;F<@<DAU4$@R,"!T;R!2;V-H92!T87)G971S+B!5;F1E<B!T:&4@=&5R
M;7,@;V8@=&AE(%)O8VAE($-O;&QA8F]R871I;VXL('=E('=E<F4@;V)L:6=A
M=&5D('1O('-C86QE('5P('1H92!P<F]D=6-T:6]N(&]F(')(=5!(,C`@86YD
M('1O(&ED96YT:69Y(&$@<V5C;VYD('-O=7)C92!M86YU9F%C='5R97(@=&AA
M="!W;W5L9"!H96QP(&UE970-"B`@(&%N=&EC:7!A=&5D('!R;V1U8W1I;VX@
M;V)L:6=A=&EO;G,@87)I<VEN9R!F<F]M('1H92!2;V-H92!#;VQL86)O<F%T
M:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY$=64@=&\@;W5R(&-O;G1I;G5I;F<@:6YV;VQV96UE;G0@;V)L:6=A=&EO
M;G,@*&9O<@T*("`@97AA;7!L92P@<W5P<&]R="!A8W1I=FET:65S(&%S<V]C
M:6%T960@=VET:"!R2'502#(P*2P@<F5V96YU97,@9G)O;2!T:&4@=7!F<F]N
M="!P87EM96YT+"!E>&-L=7-I=F4@9&5S:6=N871I;VX@9F5E<R!A;F0@86YN
M=6%L(&QI8V5N<V4@;6%I;G1E;F%N8V4@9F5E<R!W97)E(&1E9F5R<F5D(&%N
M9"!A<F4@8F5I;F<@<F5C;V=N:7IE9"!O=F5R('1H92!T97)M(&]F('1H92!2
M;V-H92!#;VQL86)O<F%T:6]N+B!792!H879E#0H@("!D971E<FUI;F5D('1H
M870@=&AE(&-L:6YI8V%L(&%N9"!R96=U;&%T;W)Y(&UI;&5S=&]N97,@87)E
M('-U8G-T86YT:79E.R!T:&5R969O<F4L('=E(&5X<&5C="!T;R!R96-O9VYI
M>F4@<W5C:"!C;&EN:6-A;"!A;F0@<F5G=6QA=&]R>2!M:6QE<W1O;F4@<&%Y
M;65N=',@87,@<F5V96YU92!U<&]N(&%C:&EE=F5M96YT(&]F('1H92!M:6QE
M<W1O;F5S+B!);B!A9&1I=&EO;BP@=V4@:&%V92!D971E<FUI;F5D('1H870@
M=&AE#0H@("!S86QE<RUB87-E9"!M:6QE<W1O;F4@<&%Y;65N=',@87)E('-I
M;6EL87(@=&\@<F]Y86QT>2!P87EM96YT<R!A;F0@87)E(&YO="!C;VYS:61E
M<F5D(&UI;&5S=&]N92!P87EM96YT<R!U;F1E<B!T:&4@36EL97-T;VYE($UE
M=&AO9"!O9B!R979E;G5E(')E8V]G;FET:6]N.R!T:&5R969O<F4L('=E('=I
M;&P@<F5C;V=N:7IE('-U8V@@<V%L97,M8F%S960@;6EL97-T;VYE('!A>6UE
M;G1S(&%S(')E=F5N=64@=7!O;B!A8VAI979E;65N=`T*("`@;V8@=&AE(&UI
M;&5S=&]N97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1H97)E('=E<F4@;F\@;6EL97-T;VYE('!A>6UE;G1S(')E8V]G
M;FEZ960@87,@<F5V96YU97,@=6YD97(@8V]L;&%B;W)A=&EV92!A9W)E96UE
M;G1S('5N9&5R('1H92!2;V-H90T*("`@0V]L;&%B;W)A=&EO;B!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A
M;F0@,C`Q,2X@1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F
M(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q,2P@=V4@<F5C;V=N:7IE9"`D-"!M:6QL
M:6]N(&%N9"`D-2!M:6QL:6]N+"!R97-P96-T:79E;'DL(&%S(')E=F5N=65S
M('5N9&5R(&-O;&QA8F]R871I=F4@86=R965M96YT<R!I;B!A8V-O<F1A;F-E
M#0H@("!W:71H('1H92!-:6QE<W1O;F4@365T:&]D(')E;&%T960@=&\@=&AE
M(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@<F5G=6QA=&]R>2!A;F0@8VQI;FEC
M86P@;6EL97-T;VYE<R!P=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE(%)O
M8VAE($-O;&QA8F]R871I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL
M969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/@T*("`@/&D^1V%M;6%G87)D($-O;&QA8F]R871I
M;VX@/"]I/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4[<&%D9&EN
M9RUB;W1T;VTZ,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!397!T96UB97(@,C`P-RP@=V4@
M96YT97)E9`T*("`@:6YT;R!A(&QI8V5N<V4@86YD(&-O;&QA8F]R871I=F4@
M86=R965M96YT('=I=&@@0F%X=&5R+"!U;F1E<B!W:&EC:"!"87AT97(@;V)T
M86EN960@82!W;W)L9'=I9&4L(&5X8VQU<VEV92!L:6-E;G-E('1O(&1E=F5L
M;W`@86YD(&-O;6UE<F-I86QI>F4@82!P<F]D=6-T(&-A;F1I9&%T92`H8W5R
M<F5N=&QY(&YA;65D($AY42D@8V]N<VES=&EN9R!O9B!R2'502#(P(&-O;6)I
M;F5D('=I=&@@82!C=7)R96YT($)A>'1E<B!P<F]D=6-T+`T*("`@1T%-34%'
M05)$($Q)455)1#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#$^/'-U<#XF<F5G.SPO<W5P/CPO9F]N=#X@*'1H
M92`F(S@R,C`[1V%M;6%G87)D($-O;&QA8F]R871I;VXF(S@R,C$[*2X@07,@
M;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(L('=E(&AA=F4@<F5C96EV960@
M)#$S#0H@("!M:6QL:6]N('5N9&5R('1H92!'86UM86=A<F0@0V]L;&%B;W)A
M=&EO;BP@:6YC;'5D:6YG('1H92`D,3`@;6EL;&EO;B!U<&9R;VYT(&QI8V5N
M<V4@9F5E('!A>6UE;G0@86YD(&$@)#,@;6EL;&EO;B!R96=U;&%T;W)Y(&UI
M;&5S=&]N92!P87EM96YT+B!)9B!"87AT97(@<W5C8V5S<V9U;&QY(')E8V5I
M=F5S(&UA<FME=&EN9R!A<'!R;W9A;"!F;W(@=&AE(&QI8V5N<V5D('!R;V1U
M8W0@8V%N9&ED871E(&%N9"!A8VAI979E<PT*("`@<')E+6%G<F5E9"!S86QE
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M(&9O<B!T:&4@<W5P<&QY(&]F(')(=5!(,C`@96YZ>6UE+B!792!P97)F;W)M
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W1I=FET:65S(&%T('1H92!R
M97%U97-T(&]F($)A>'1E<BP@=VAI8V@@87)E(')E:6UB=7)S960@8GD@0F%X
M=&5R('5N9&5R('1H90T*("`@=&5R;7,@;V8@=&AE($=A;6UA9V%R9"!#;VQL
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M=&AE(&QO;F=E<B!O9CH-"B`@("AA*28C,38P.W1H92!D=7)A=&EO;B!O9B!A
M;GD@=F%L:60@8VQA:6T@;V8@;W5R('!A=&5N=',@8V]V97)I;F<@<DAU4$@R
M,"!O<B!O=&AE<B!S<&5C:69I960@<&%T96YT<R!D979E;&]P960@=6YD97(@
M=&AE(&-O;&QA8F]R871I;VX@=VAI8V@@=F%L:60@8VQA:6T@8V]V97)S('1H
M92!P<F]D=6-T(&EN('-U8V@@8V]U;G1R>2!O<B`H8BDF(S$V,#MT96X@>65A
M<G,@9F]L;&]W:6YG('1H92!D871E(&]F('1H92!F:7)S=`T*("`@8V]M;65R
M8VEA;"!S86QE(&]F('-U8V@@<')O9'5C="!I;B!S=6-H(&-O=6YT<GDN(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D1U92!T
M;R!O=7(@8V]N=&EN=6EN9R!I;G9O;'9E;65N="!O8FQI9V%T:6]N<R`H9F]R
M(&5X86UP;&4L('-U<'!O<G0-"B`@(&%C=&EV:71I97,@87-S;V-I871E9"!W
M:71H(')(=5!(,C`@96YZ>6UE*2P@=&AE('5P9G)O;G0@<&%Y;65N="!W87,@
M9&5F97)R960@86YD(&ES(&)E:6YG(')E8V]G;FEZ960@;W9E<B!T:&4@=&5R
M;2!O9B!T:&4@1V%M;6%G87)D($-O;&QA8F]R871I;VXN(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@5V4@:&%V92!D
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M;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(N#0H@
M("!&;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(F(S$V,#LS,"P@,C`Q,2P@=V4@<F5C;V=N:7IE9"!Z97)O(&%N9"`D,R!M
M:6QL:6]N+"!R97-P96-T:79E;'DL(&%S(')E=F5N=65S('5N9&5R(&-O;&QA
M8F]R871I=F4@86=R965M96YT<R!U;F1E<B!T:&4@1V%M;6%G87)D($-O;&QA
M8F]R871I;VX@:6X@86-C;W)D86YC92!W:71H('1H92!-:6QE<W1O;F4@365T
M:&]D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\:3Y6:7)O4&AA<FUA(&%N9"!);G1R97AO;B!#;VQL86)O<F%T:6]N<R`\
M+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)3MP861D:6YG+6)O
M='1O;3HP<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/D5F9F5C=&EV92!-87DF(S$V,#LQ,"P@,C`Q
M,2P@=V4@86YD(%9I<F]0:&%R;6$@96YT97)E9"!I;G1O(&$@8V]L;&%B;W)A
M=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0L('5N9&5R('=H:6-H#0H@("!6
M:7)O4&AA<FUA(&]B=&%I;F5D(&$@=V]R;&1W:61E(&5X8VQU<VEV92!L:6-E
M;G-E(&9O<B!T:&4@=7-E(&]F(')(=5!(,C`@96YZ>6UE(&EN('1H92!D979E
M;&]P;65N="!O9B!A('-U8F-U=&%N96]U<R!I;FIE8W1A8FQE(&9O<FUU;&%T
M:6]N(&]F(%9I<F]0:&%R;6$F(S@R,3<[<R!C;VUM97)C:6%L:7IE9"!P<F]D
M=6-T+"!#:6YR>7IE/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\<W5P/@T*("`@)G)E9SL\+W-U<#X\+V9O
M;G0^("A#,2!E<W1E<F%S92!I;FAI8FET;W(@6VAU;6%N72D@*'1H92`F(S@R
M,C`[5FER;U!H87)M82!#;VQL86)O<F%T:6]N)B,X,C(Q.RDN($EN(&%D9&ET
M:6]N+"!T:&4@;&EC96YS92!P<F]V:61E<R!6:7)O4&AA<FUA('=I=&@@97AC
M;'5S:79I='D@=&\@0S$@97-T97)A<V4@:6YH:6)I=&]R(&%N9`T*("`@=&\@
M=&AE(&AE<F5D:71A<GD@86YG:6]E9&5M82!I;F1I8V%T:6]N+"!A;&]N9R!W
M:71H('1H<F5E(&%D9&ET:6]N86P@;W)P:&%N(&EN9&EC871I;VYS+B!!<R!O
M9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,BP@=V4@:&%V92!R96-E:79E9"`D
M,3,@;6EL;&EO;B!F<F]M(%9I<F]0:&%R;6$L(&EN8VQU9&EN9R!T:&4@)#D@
M;6EL;&EO;B!N;VYR969U;F1A8FQE('5P9G)O;G0@;&EC96YS92!F964@<&%Y
M;65N="P@82`D,R!M:6QL:6]N#0H@("!C;&EN:6-A;"!D979E;&]P;65N="!M
M:6QE<W1O;F4@<&%Y;65N="!A;F0@82`D,2!M:6QL:6]N(&%N;G5A;"!E>&-L
M=7-I=FET>2!F964N($EF(%9I<F]0:&%R;6$@<W5C8V5S<V9U;&QY(&1E=F5L
M;W!S('1H92!L:6-E;G-E9"!P<F]D=6-T(&-A;F1I9&%T92P@=V4@8V]U;&0@
M<F5C96EV92!A9&1I=&EO;F%L(&UI;&5S=&]N92!P87EM96YT<R!O9B!U<"!T
M;R`D-#$@;6EL;&EO;B!F;W(@=&AE(&%C:&EE=F5M96YT(&]F#0H@("!D979E
M;&]P;65N="!A;F0@<F5G=6QA=&]R>2!M:6QE<W1O;F5S+B!);B!A9&1I=&EO
M;BP@<V\@;&]N9R!A<R!T:&4@86=R965M96YT(&ES(&EN(&5F9F5C="P@=V4@
M87)E(&5N=&ET;&5D('1O(')E8V5I=F4@82!N;VYR969U;F1A8FQE(&%N;G5A
M;"!E>&-L=7-I=FET>2!F964@;V8@)#$@;6EL;&EO;B!W:&EC:"!C;VUM96YC
M960@;VX@36%Y)B,Q-C`[,3`L(#(P,3(@86YD(&]N(&5A8V@@86YN:79E<G-A
M<GD@;V8@=&AE(&5F9F5C=&EV90T*("`@9&%T92!O9B!T:&4@86=R965M96YT
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M<@T*("`@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('-E<G9I8V5S(&%N9"!S
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M8V@-"B`@('!R;V1U8W0N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/E5N;&5S<R!T97)M:6YA=&5D(&5A<FQI97(@:6X@86-C
M;W)D86YC92!W:71H(&ET<R!T97)M<RP@=&AE(%9I<F]0:&%R;6$@0V]L;&%B
M;W)A=&EO;B!C;VYT:6YU97,@:6X@969F96-T('5N=&EL('1H90T*("`@;&%T
M97(@;V8@*&DI)B,Q-C`[97AP:7)A=&EO;B!O9B!T:&4@;&%S="!T;R!E>'!I
M<F4@;V8@=&AE('9A;&ED(&-L86EM<R!O9B!O=7(@<&%T96YT<R!C;W9E<FEN
M9R!R2'502#(P(&]R(&]T:&5R('-P96-I9FEE9"!P871E;G1S(&1E=F5L;W!E
M9"!U;F1E<B!T:&4@8V]L;&%B;W)A=&EO;B!W:&EC:"!V86QI9"!C;&%I;2!C
M;W9E<G,@82!P<F]D=6-T(&1E=F5L;W!E9"!U;F1E<B!T:&4@8V]L;&%B;W)A
M=&EO;BP@86YD#0H@("`H:6DI)B,Q-C`[97AP:7)A=&EO;B!O9B!T:&4@;&%S
M="!T;R!E>'!I<F4@<F]Y86QT>2!T97)M(&9O<B!A('!R;V1U8W0@9&5V96QO
M<&5D('5N9&5R('1H92!C;VQL86)O<F%T:6]N+B!4:&4@<F]Y86QT>2!T97)M
M(&]F(&$@<')O9'5C="!D979E;&]P960@=6YD97(@=&AE(%9I<F]0:&%R;6$@
M0V]L;&%B;W)A=&EO;BP@=VET:"!R97-P96-T('1O(&5A8V@@8V]U;G1R>2P@
M8V]N<VES=',@;V8@=&AE('!E<FEO9"!E<75A;"!T;R!T:&4-"B`@(&QO;F=E
M<B!O9CH@*&$I)B,Q-C`[=&AE(&1U<F%T:6]N(&]F(&%N>2!V86QI9"!C;&%I
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M<&]N(#DP(&1A>7,@<')I;W(@=W)I='1E;B!N;W1I8V4@=&\@=7,N)B,Q-C`[
M57!O;B!A;GD@<W5C:"!T97)M:6YA=&EO;BP@=&AE(&QI8V5N<V4-"B`@(&=R
M86YT960@=&\@5FER;U!H87)M82`H:6X@=&]T86P@;W(@=VET:"!R97-P96-T
M('1O('1H92!T97)M:6YA=&5D('!R;V1U8W0L(&%S(&%P<&QI8V%B;&4I('=I
M;&P@=&5R;6EN871E+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT
M+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#XF
M(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^169F96-T
M:79E($IU;F4F(S$V,#LV+`T*("`@,C`Q,2P@=V4@86YD($EN=')E>&]N(&5N
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M96-O;6)I;F%N="!H=6UA;B!A;'!H82`Q+6%N=&ET<GEP<VEN("AR2'5!,4%4
M*2`H=&AE("8C.#(R,#M);G1R97AO;B!#;VQL86)O<F%T:6]N)B,X,C(Q.RDN
M($EN(&%D9&ET:6]N+"!T:&4@;&EC96YS92!P<F]V:61E<R!);G1R97AO;B!W
M:71H(&5X8VQU<VEV:71Y(&9O<B!A(&1E9FEN960@:6YD:6-A=&EO;B`H)B,X
M,C(P.T5X8VQU<VEV92!&:65L9"8C.#(R,3LI+B!!<R!O9B!397!T96UB97(F
M(S$V,#LS,"P@,C`Q,BP@=V4@:&%V90T*("`@<F5C96EV960@)#$P(&UI;&QI
M;VX@9G)O;2!);G1R97AO;BP@:6YC;'5D:6YG(&$@;F]N<F5F=6YD86)L92!U
M<&9R;VYT(&QI8V5N<V4@9F5E('!A>6UE;G0@;V8@)#D@;6EL;&EO;B!A;F0@
M82`D,2!M:6QL:6]N(&%N;G5A;"!E>&-L=7-I=FET>2!F964N($EF($EN=')E
M>&]N('-U8V-E<W-F=6QL>2!D979E;&]P<R!T:&4@;&EC96YS960@<')O9'5C
M="!C86YD:61A=&4@86YD(&%C:&EE=F5S('1H92!P<F4M86=R965D('-A;&5S
M#0H@("!T87)G970L('=E(&-O=6QD(')E8V5I=F4@861D:71I;VYA;"!M:6QE
M<W1O;F4@<&%Y;65N=',@;V8@=7`@=&\@)#4T(&UI;&QI;VXL(&EN8VQU9&EN
M9R`D-#0@;6EL;&EO;B!F;W(@=&AE(&%C:&EE=F5M96YT(&]F(&1E=F5L;W!M
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M96QO<&UE;G0-"B`@(&5V96YT(&]C8W5R<RX@26YT<F5X;VX@:7,@<V]L96QY
M(')E<W!O;G-I8FQE(&9O<B!T:&4@9&5V96QO<&UE;G0L(&UA;G5F86-T=7)I
M;F<@86YD(&UA<FME=&EN9R!O9B!A;GD@<')O9'5C=',@<F5S=6QT:6YG(&9R
M;VT@=&AI<R!C;VQL86)O<F%T:6]N+B!792!A<F4@96YT:71L960@=&\@<F5C
M96EV92!P87EM96YT<R!F;W(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('-E
M<G9I8V5S(&%N9"!S=7!P;'D@;V8@<DAU4$@R,"!!4$D@:68-"B`@(')E<75E
M<W1E9"!B>2!);G1R97AO;BX@26X@861D:71I;VXL('=E(&%R92!E;G1I=&QE
M9"!T;R!R96-E:79E(&%D9&ET:6]N86P@8V%S:"!P87EM96YT<R!P;W1E;G1I
M86QL>2!T;W1A;&EN9R`D,3`@;6EL;&EO;B!F;W(@96%C:"!P<F]D=6-T(&9O
M<B!U<V4@;W5T<VED92!T:&4@17AC;'5S:79E($9I96QD('5P;VX@86-H:65V
M96UE;G0@;V8@9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL97-T;VYE
M<RX@5V4@87)E(&%L<V\-"B`@(&5N=&ET;&5D('1O(')E8V5I=F4@82!R;WEA
M;'1Y(&]N(&5A8V@@<')O9'5C="!C;VUM97)C:6%L:7IE9"!U;F1E<B!T:&4@
M86=R965M96YT(&-O;G-I<W1I;F<@;V8@82!P97)C96YT86=E(&]F('1H92!N
M970@<V%L97,@;V8@<W5C:"!P<F]D=6-T(')A;F=I;F<@9G)O;2!M:60M<VEN
M9VQE(&1I9VET<R!U<"!T;R!L;W<@9&]U8FQE+61I9VET('!E<F-E;G0N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E5N;&5S
M<R!T97)M:6YA=&5D(&5A<FQI97(@:6X@86-C;W)D86YC92!W:71H(&ET<R!T
M97)M<RP@=&AE($EN=')E>&]N($-O;&QA8F]R871I;VX@8V]N=&EN=65S(&EN
M(&5F9F5C="!U;G1I;"!T:&4@;&%T97(@;V8-"B`@("AI*28C,38P.V5X<&ER
M871I;VX@;V8@=&AE(&QA<W0@=&\@97AP:7)E(&]F('1H92!V86QI9"!C;&%I
M;7,@;V8@;W5R('!A=&5N=',@8V]V97)I;F<@<DAU4$@R,"!O<B!O=&AE<B!S
M<&5C:69I960@<&%T96YT<R!D979E;&]P960@=6YD97(@=&AE(&-O;&QA8F]R
M871I;VX@=VAI8V@@=F%L:60@8VQA:6T@8V]V97)S(&$@<')O9'5C="!D979E
M;&]P960@=6YD97(@=&AE(&-O;&QA8F]R871I;VXL(&%N9"`H:6DI)B,Q-C`[
M97AP:7)A=&EO;@T*("`@;V8@=&AE(&QA<W0@=&\@97AP:7)E(')O>6%L='D@
M=&5R;2!F;W(@82!P<F]D=6-T(&1E=F5L;W!E9"!U;F1E<B!T:&4@8V]L;&%B
M;W)A=&EO;BX@5&AE(')O>6%L='D@=&5R;2!O9B!A('!R;V1U8W0@9&5V96QO
M<&5D('5N9&5R('1H92!);G1R97AO;B!#;VQL86)O<F%T:6]N+"!W:71H(')E
M<W!E8W0@=&\@96%C:"!C;W5N=')Y+"!C;VYS:7-T<R!O9B!T:&4@<&5R:6]D
M(&5Q=6%L('1O('1H92!L;VYG97(@;V8Z("AA*28C,38P.W1H90T*("`@9'5R
M871I;VX@;V8@86YY('9A;&ED(&-L86EM(&]F(&]U<B!P871E;G1S(&-O=F5R
M:6YG(')(=5!(,C`@;W(@;W1H97(@<W!E8VEF:65D('!A=&5N=',@9&5V96QO
M<&5D('5N9&5R('1H92!C;VQL86)O<F%T:6]N('=H:6-H('9A;&ED(&-L86EM
M(&-O=F5R<R!T:&4@<')O9'5C="!I;B!S=6-H(&-O=6YT<GD@;W(@*&(I)B,Q
M-C`[=&5N('EE87)S(&9O;&QO=VEN9R!T:&4@9&%T92!O9B!T:&4@9FER<W0@
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M=&@-"B`@(')E<W!E8W0@=&\@=&AE('1E<FUI;F%T960@<')O9'5C="P@87,@
M87!P;&EC86)L92D@=VEL;"!T97)M:6YA=&4N($EN=')E>&]N)B,X,C$W.W,@
M8VAI968@97AE8W5T:79E(&]F9FEC97(L(&-H86ER;6%N(&]F(&ET<R!B;V%R
M9"!O9B!D:7)E8W1O<G,@86YD(&UA:F]R('-H87)E:&]L9&5R(&ES(&%L<V\@
M82!M96UB97(@;V8@;W5R(&)O87)D(&]F(&1I<F5C=&]R<RX@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V4@:61E;G1I9FEE
M9"!T:&4@9&5L:79E<F%B;&5S(&%T('1H92!I;F-E<'1I;VX@;V8@=&AE(%9I
M<F]0:&%R;6$@86YD($EN=')E>&]N(&%G<F5E;65N=',@=VAI8V@@87)E('1H
M92!L:6-E;G-E+"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0-"B`@('-E<G9I
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M;F<@<')I8V5S(&9O<B!T:&5S90T*("`@=6YI=',@;V8@86-C;W5N=&EN9R!W
M97)E(&1E=&5R;6EN960@8F%S960@;VX@;6%R:V5T(&-O;F1I=&EO;G,L('1H
M92!T97)M<R!O9B!C;VUP87)A8FQE(&-O;&QA8F]R871I=F4@87)R86YG96UE
M;G1S(&9O<B!S:6UI;&%R('1E8VAN;VQO9WD@:6X@=&AE('!H87)M86-E=71I
M8V%L(&%N9"!B:6]T96-H(&EN9'5S=')Y(&%N9"!E;G1I='DM<W!E8VEF:6,@
M9F%C=&]R<R!S=6-H(&%S('1H92!T97)M<R!O9B!O=7(@<')E=FEO=7,-"B`@
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M(&UE=&AO9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
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M<&5C:69I960@<&5R9F]R;6%N8V4@8V]N9&ET:6]N<R`H=&AE(&YO;F-O;G1I
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M96YT(&%N9"!T:&4@)#D-"B`@(&UI;&QI;VX@=7!F<F]N="!F964@<F5C96EV
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M('1H92`D.2!M:6QL:6]N('5P9G)O;G0@;&EC96YS92!F964@<F5C96EV960@
M=6YD97(@=&AE(%9I<F]0:&%R;6$@0V]L;&%B;W)A=&EO;B!A;F0@=&AE("0Y
M(&UI;&QI;VX@=7!F<F]N="!L:6-E;G-E(&9E92!R96-E:79E9"!U;F1E<B!T
M:&4@26YT<F5X;VX@0V]L;&%B;W)A=&EO;@T*("`@87,@<F5V96YU97,@=6YD
M97(@8V]L;&%B;W)A=&EV92!A9W)E96UE;G1S('5P;VX@<F5C96EP="!O9B!T
M:&4@=7!F<F]N="!L:6-E;G-E(&9E97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E=E(')E8V]G;FEZ92!T:&4@86YN=6%L
M(&5X8VQU<VEV:71Y(&9E97,-"B`@(&%S(')E=F5N=65S('5N9&5R(&-O;&QA
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M=65S=',N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/@T*("`@5V4@87)E(&5L:6=I8FQE('1O(')E8V5I=F4@861D:71I;VYA
M;"!C87-H('!A>6UE;G1S('5P;VX@=&AE(&%C:&EE=F5M96YT(&)Y('1H92!C
M;VQL86)O<F%T;W)S(&]F('-P96-I9FEE9"!D979E;&]P;65N="P@<F5G=6QA
M=&]R>2!A;F0@<V%L97,M8F%S960@;6EL97-T;VYE<RX@5V4@:&%V92!D971E
M<FUI;F5D('1H870@96%C:"!O9B!T:&4-"B`@(&1E=F5L;W!M96YT(&%N9"!R
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M87-S;V-I871E9"!W:71H('1H92!M:6QE<W1O;F4N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@1F]R('1H92!T:')E
M92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3$L('=E(')E8V]G;FEZ960@82`D,R!M:6QL:6]N(&UI;&5S=&]N92!P87EM
M96YT(&%S(')E=F5N=65S('5N9&5R(&-O;&QA8F]R871I=F4@86=R965M96YT
M<R!I;B!A8V-O<F1A;F-E('=I=&@@=&AE($UI;&5S=&]N92!-971H;V0@<F5L
M871E9"!T;R!T:&4-"B`@(&%C:&EE=F5M96YT(&]F(&$@9&5V96QO<&UE;G0@
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M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(N(%1H97)E('=E
M<F4@;F\@;6EL97-T;VYE('!A>6UE;G1S(')E8V]G;FEZ960@87,@<F5V96YU
M97,@=6YD97(@8V]L;&%B;W)A=&EV92!A9W)E96UE;G1S(&%S<V]C:6%T960@
M=VET:"!T:&4@26YT<F5X;VX@0V]L;&%B;W)A=&EO;B!F;W(@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,B!A;F0@,C`Q,2X@5V4-"B`@(')E8V]G;FEZ960@=&AE(&%N;G5A;"!E>&-L
M=7-I=FET>2!F964@;V8@>F5R;R!A;F0@)#$@;6EL;&EO;B!A<R!R979E;G5E
M<R!U;F1E<B!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@87-S;V-I871E9"!W
M:71H(&5A8V@@=&AE(%9I<F]0:&%R;6$@86YD($EN=')E>&]N($-O;&QA8F]R
M871I;VYS(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!R97-P96-T:79E;'DN#0H@("`\+V9O
M;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=F5N=&]R:65S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^26YV96YT;W)I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E
M(#0@+2!U<RUG86%P.DEN=F5N=&]R>41I<V-L;W-U<F5497AT0FQO8VLM+3X-
M"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ
M,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^/&(^-"X@26YV96YT;W)I97,@/"]B/CPO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26YV96YT;W)I97,@8V]N
M<VES="!O9B!T:&4@9F]L;&]W:6YG.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D97(],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F
M="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)A
M=R!M871E<FEA;',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^.38R+#<U,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C(P,2PX,C(\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY7;W)K+6EN
M+7!R;V-E<W,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXW,34L,C0Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR.3`L-C0W/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^1FEN:7-H960@9V]O9',\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU,#@L,#<Q/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXW-"PW.30\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXR+#$X-BPP-C,\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU-C<L,C8S/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L($YE=#QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(&%N
M9"!%<75I<&UE;G0L($YE="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE
M;G0L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN
M($)L;V-K(%1A9V=E9"!.;W1E(#4@+2!U<RUG86%P.E!R;W!E<G1Y4&QA;G1!
M;F1%<75I<&UE;G1$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/CQB/C4N(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L($YE="`\+V(^/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY0<F]P97)T>2!A
M;F0@97%U:7!M96YT+"!N970@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.B`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G
M:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\
M(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I
M9'1H/3-$-S(E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-E<'1E
M;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[
M,S$L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&5Q=6EP;65N=#PO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#(P-RPT,#$\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXU+#(S,2PW-C,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUP=71E<B!A;F0@;V9F:6-E(&5Q
M=6EP;65N=#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C$L-3(T+#,T,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PR-C8L,#0Q/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L
M,3,W+#$X-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PP,3DL,30W/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX+#@V."PY,C@\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C<L-3$V+#DU,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/D%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#8L-3`U+#(W.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@U+#<T-2PY,#,\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPS-C,L-C4P
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,2PW-S$L,#0X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^
M(`T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY$97!R96-I871I;VX@
M86YD(&%M;W)T:7IA=&EO;B!E>'!E;G-E('1O=&%L960@87!P<F]X:6UA=&5L
M>2`D,C@V+#`P,"!A;F0@)#(S.2PP,#`@9F]R('1H92!T:')E92!M;VYT:',@
M96YD960-"B`@(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R(&%N9"`R,#$Q+"!R
M97-P96-T:79E;'DL(&%N9"!A<'!R;WAI;6%T96QY("0W.38L,#`P(&%N9"`D
M.#4R+#`P,"!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C
M,38P.S,P+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN(#PO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ<'@[;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T
M.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7
M;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY!8V-R=65D($5X<&5N<V5S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!%>'!E
M;G-E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W)U960@17AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`V("T@
M:&%L;SI!8V-R=65D17AP96YS97-#=7)R96YT5&5X=$)L;V-K+2T^#0H@("`\
M<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^/&(^-BX@06-C<G5E9"!%>'!E;G-E<R`\+V(^/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!8V-R=65D(&5X<&5N<V5S
M(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9SH@/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN
M+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ
M(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(
M96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#<R)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB97(F(S$V,#LS,"P\+V(^
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C,38P.S,Q+#PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY!8V-R=65D(&]U='-O=7)C960@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&5X<&5N<V5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C,L-S,U+#,Y-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$L.3$P+#(W,SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%C8W)U
M960@8V]M<&5N<V%T:6]N(&%N9"!P87ER;VQL('1A>&5S/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPS,SDL-SDQ/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXS+#(R,RPY,S8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^.38V+#0X-CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M-#@Q+#,V-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C@L,#0Q+#8W,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C4L-C$U+#4W-#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S
M='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D
M-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P
M7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T
M,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M969E<G)E9"!2979E;G5E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@4F5V96YU92!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M9F5R<F5D(%)E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q
M+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH
M=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M
M+2!"96=I;B!";&]C:R!486=G960@3F]T92`W("T@=7,M9V%A<#I$969E<G)E
M9%)E=F5N=65$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS
M1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB
M/C<N($1E9F5R<F5D(%)E=F5N=64@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^1&5F97)R960@<F5V96YU92!C;VYS:7-T
M<R!O9B!T:&4@9F]L;&]W:6YG.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M
M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@
M86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^
M#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@
M5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;&QA
M8F]R871I=F4@86=R965M96YT<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXT-"PP,S0L,#$U/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#`L-S$V+#@P-CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E!R;V1U8W0@<V%L97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS,3DL,S8W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ-C<L
M,3@T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5&]T86P@9&5F97)R960@<F5V96YU93PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0T+#,U,RPS.#(\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C0P+#@X,RPY.3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY,97-S(&-U<G)E;G0@
M<&]R=&EO;CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CDL-#<P+#(T-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PQ,CDL-#`W/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^1&5F97)R960@<F5V96YU92P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS-"PX.#,L
M,3,U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,S8L-S4T+#4X,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A
M8FQE/B`-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^4F]C
M:&4@0V]L;&%B;W)A=&EO;BX@/"]I/CPO8CY5;F1E<B!T:&4@=&5R;7,@;V8@
M=&AE(%)O8VAE($-O;&QA8F]R871I;VXL(%)O8VAE('!A:60@)#(P(&UI;&QI
M;VX@=&\@=7,@:6X@1&5C96UB97(-"B`@(#(P,#8@87,@86X@:6YI=&EA;"!U
M<&9R;VYT('!A>6UE;G0@9F]R('1H92!A<'!L:6-A=&EO;B!O9B!R2'502#(P
M('1O('1H<F5E('!R92UD969I;F5D(%)O8VAE(&)I;VQO9VEC('1A<F=E=',N
M($%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!2;V-H92!H87,@<&%I
M9"!A;B!A9V=R96=A=&4@;V8@)#(P(&UI;&QI;VX@:6X@8V]N;F5C=&EO;B!W
M:71H(%)O8VAE)B,X,C$W.W,@96QE8W1I;VX@;V8@='=O(&%D9&ET:6]N86P-
M"B`@(&5X8VQU<VEV92!T87)G971S(&%N9"!A;FYU86P@;&EC96YS92!M86EN
M=&5N86YC92!F965S(&9O<B!T:&4@<FEG:'0@=&\@9&5S:6=N871E('1H92!R
M96UA:6YI;F<@=&%R9V5T<R!A<R!E>&-L=7-I=F4@=&%R9V5T<RX@4F]C:&4@
M8W5R<F5N=&QY(')E=&%I;G,@=&AE(&]P=&EO;B!T;R!D979E;&]P(&%N9"!C
M;VUM97)C:6%L:7IE(')(=5!(,C`@=VET:"!T:')E92!A9&1I=&EO;F%L('1A
M<F=E=',L('!R;W9I9&5D('1H870@4F]C:&4-"B`@(&-O;G1I;G5E<R!T;R!P
M87D@86YN=6%L(&QI8V5N<V4@;6%I;G1E;F%N8V4@9F5E<R!T;R!U<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1'5E('1O
M(&]U<B!C;VYT:6YU:6YG(&EN=F]L=F5M96YT(&]B;&EG871I;VYS("AF;W(@
M97AA;7!L92P@<W5P<&]R=`T*("`@86-T:79I=&EE<R!A<W-O8VEA=&5D('=I
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M9B!A<'!R;WAI;6%T96QY("0U,#,L,#`P(&%N9"`D-#DQ+#`P,"!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY+"!A;F0-"B`@(&%P<')O>&EM871E;'D@
M)#$N-2!M:6QL:6]N(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,3(@86YD(#(P,3$N($1E9F5R<F5D(')E=F5N=64@
M<F5L871I;F<@=&\@=&AE('5P9G)O;G0@<&%Y;65N="P@97AC;'5S:79E(&1E
M<VEG;F%T:6]N(&9E97,@86YD(&%N;G5A;"!L:6-E;G-E(&UA:6YT96YA;F-E
M(&9E97,@=6YD97(@=&AE(%)O8VAE($-O;&QA8F]R871I;VX@=V%S("0S,"XQ
M(&UI;&QI;VX-"B`@(&%N9"`D,S$N-R!M:6QL:6]N(&%S(&]F(%-E<'1E;6)E
M<B8C,38P.S,P+"`R,#$R(&%N9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!R
M97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960-"B`@(%-E
M<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!W92!R96-E:79E9"!A<'!R;WAI;6%T
M96QY("0W+C`@;6EL;&EO;B!I;B!D969E<G)E9"!R979E;G5E(')E;&%T:6YG
M('1O('1H92!M86YU9F%C='5R92!O9B!R2'502#(P($%022!F;W(@4F]C:&4N
M(%=E(')E8V]G;FEZ960@87!P<F]X:6UA=&5L>2`D,S,T+#`P,"!A<R!R979E
M;G5E<R!U;F1E<B!C;VQL86)O<F%T:79E(&%G<F5E;65N=',@9G)O;2!D969E
M<G)E9"!R979E;G5E(')E;&%T:6YG#0H@("!T;R!T:&4@;6%N=69A8W1U<F4@
M;V8@<DAU4$@R,"!!4$D@9F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(N($1E9F5R<F5D(')E=F5N
M=64@<F5L871I;F<@=&\@=&AE(&UA;G5F86-T=7)E(&]F(')(=5!(,C`@05!)
M('5N9&5R('1H92!2;V-H92!#;VQL86)O<F%T:6]N('=A<R`D-BXW(&UI;&QI
M;VX@86YD('IE<F\@87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@86YD
M#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!R97-P96-T:79E;'DN(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI
M/D=A;6UA9V%R9"!#;VQL86)O<F%T:6]N+B`\+VD^/"]B/E5N9&5R('1H92!T
M97)M<R!O9B!T:&4@1V%M;6%G87)D($-O;&QA8F]R871I;VXL#0H@("!"87AT
M97(@<&%I9"!U<R!A(&YO;G)E9G5N9&%B;&4@=7!F<F]N="!P87EM96YT(&]F
M("0Q,"!M:6QL:6]N+B!$=64@=&\@;W5R(&-O;G1I;G5I;F<@:6YV;VQV96UE
M;G0@;V)L:6=A=&EO;G,@*&9O<B!E>&%M<&QE+"!S=7!P;W)T(&%C=&EV:71I
M97,@87-S;V-I871E9"!W:71H(')(=5!(,C`@96YZ>6UE*2P@=&AE("0Q,"8C
M,38P.VUI;&QI;VX@=7!F<F]N="!P87EM96YT('=A<R!D969E<G)E9"!A;F0@
M:7,@8F5I;F<@<F5C;V=N:7IE9`T*("`@;W9E<B!T:&4@=&5R;2!O9B!T:&4@
M1V%M;6%G87)D($-O;&QA8F]R871I;VXN(%=E(')E8V]G;FEZ960@<F5V96YU
M92!F<F]M('1H92!U<&9R;VYT('!A>6UE;G0@=6YD97(@=&AE($=A;6UA9V%R
M9"!#;VQL86)O<F%T:6]N(&EN('1H92!A;6]U;G1S(&]F(&%P<')O>&EM871E
M;'D@)#$R,2PP,#`@9F]R(&5A8V@@;V8@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q,2!A;F0-"B`@(&%P
M<')O>&EM871E;'D@)#,V,BPP,#`@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q,2X@1&5F97)R960@
M<F5V96YU92!R96QA=&EN9R!T;R!T:&4@=7!F<F]N="!P87EM96YT('5N9&5R
M('1H92!'86UM86=A<F0@0V]L;&%B;W)A=&EO;B!W87,@)#<N,B!M:6QL:6]N
M(&%N9"`D-RXV(&UI;&QI;VX@87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3(@86YD#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!R97-P96-T:79E
M;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ<'@[
M;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ
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M(S$V,#LW+"`R,#$Q+"!W92!A;F0-"B`@($)A>'1E<B!M=71U86QL>2!A9W)E
M960@=&\@=&5R;6EN871E('1H92!(>6QE;F5X($-O;&QA8F]R871I;VX@86YD
M('1H92!A<W-O8VEA=&5D(&%G<F5E;65N=',N($]N($IU;'DF(S$V,#LQ."P@
M,C`Q,2P@=V4@86YD($)A>'1E<B!E;G1E<F5D(&EN=&\@86X@86=R965M96YT
M("AT:&4@)B,X,C(P.U1R86YS:71I;VX@06=R965M96YT)B,X,C(Q.RD@<V5T
M=&EN9R!F;W)T:"!C97)T86EN(')I9VAT<RP@9&%T82!A;F0@87-S971S('1O
M(&)E#0H@("!T<F%N<V9E<G)E9"!B>2!"87AT97(@=&\@=7,@9'5R:6YG(&$@
M=')A;G-I=&EO;B!P97)I;V0N($5F9F5C=&EV92!*=6QY)B,Q-C`[,3@L(#(P
M,3$L('=E(&AA9"!N;R!F=71U<F4@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,@
M=&\@0F%X=&5R(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@2'EL96YE>"!#;VQL
M86)O<F%T:6]N+B!4:&5R969O<F4L('=E(')E8V]G;FEZ960@=&AE('5N86UO
M<G1I>F5D(&1E9F5R<F5D(')E=F5N=64@;V8-"B`@(&%P<')O>&EM871E;'D@
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M90T*("`@86=R965M96YT<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(F(S$V,#LS,"P@,C`Q,2X@1F]R('1H92!N:6YE(&UO;G1H<R!E
M;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@=V4@<F5C;V=N:7IE9"!R
M979E;G5E<R!U;F1E<B!T:&4@2'EL96YE>"!#;VQL86)O<F%T:6]N(&9R;VT@
M=&AE('5P9G)O;G0@<&%Y;65N="!O9B!A<'!R;WAI;6%T96QY("0W+C@@;6EL
M;&EO;B!A;F0@9G)O;2!T:&4-"B`@('!R;V1U8W0M8F%S960@<&%Y;65N=',@
M;V8@87!P<F]X:6UA=&5L>2`D.2XS(&UI;&QI;VXN(%1H97)E('=E<F4@;F\@
M9&5F97)R960@<F5V96YU97,@<F5L871I;F<@=&\@=&AE($AY;&5N97@@0V]L
M;&%B;W)A=&EO;B!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A;F0@,C`Q
M,2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M#0H@("!);B!A9&1I=&EO;BP@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F('1H
M92!4<F%N<VET:6]N($%G<F5E;65N="P@0F%X=&5R(&YO(&QO;F=E<B!H860@
M=&AE(')I9VAT('1O(')E='5R;B!T:&4@/&D^2'EL96YE>"`\+VD^<F5C;VUB
M:6YA;G0@05!)('!R979I;W5S;'D@9&5L:79E<F5D('1O($)A>'1E<BX@06-C
M;W)D:6YG;'DL('=E(')E8V]G;FEZ960-"B`@(&%P<')O>&EM871E;'D@)#DY
M,2PP,#`@;V8@9&5F97)R960@<F5V96YU92!R96QA=&5D('1O('-U8V@@/&D^
M2'EL96YE>"`\+VD^<F5C;VUB:6YA;G0@05!)(&%S('!R;V1U8W0@<V%L97,@
M<F5V96YU92!D=7)I;F<@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2X@/"]F;VYT/CPO<#X-"CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?
M,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C
M8S`W8B]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@26YC;VUE("A,;W-S*2!097(@4VAA
M<F4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M26YC;VUE("A,;W-S*2!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14
M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM
M/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`X("T@=7,M9V%A
M<#I%87)N:6YG<U!E<E-H87)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS
M1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB
M/C@N($YE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R92`\+V(^/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY"87-I8R!N970@:6YC
M;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E(&ES(&-O;7!U=&5D(&)Y(&1I
M=FED:6YG(&YE="!I;F-O;64@*&QO<W,I(&9O<B!T:&4@<&5R:6]D(&)Y('1H
M92!W96EG:'1E9`T*("`@879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E
M<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('!E<FEO9"P@=VET:&]U="!C;VYS
M:61E<F%T:6]N(&9O<B!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',N($1I;'5T
M960@;F5T(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R92!I<R!C;VUP
M=71E9"!B>2!D:79I9&EN9R!N970@:6YC;VUE("AL;W-S*2!F;W(@=&AE('!E
M<FEO9"!B>2!T:&4@=V5I9VAT960M879E<F%G92!N=6UB97(@;V8-"B`@(&-O
M;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@86YD('!O=&5N=&EA;&QY(&1I;'5T
M:79E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<N(%!O=&5N=&EA;&QY(&1I
M;'5T:79E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<L(&1E=&5R;6EN960@
M=7-I;F<@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"P@<')I;F-I<&%L;'D@
M:6YC;'5D92!S:&%R97,@=&AA="!M87D@8F4@:7-S=65D('5N9&5R(&]U<B!S
M=&]C:R!O<'1I;VYS+`T*("`@<F5S=')I8W1E9"!S=&]C:R!A=V%R9',@*"8C
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M("`@1F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,3(L(&]U='-T86YD:6YG('-T;V-K(&]P=&EO;G,L
M(&]U='-T86YD:6YG(%)357,@86YD('5N=F5S=&5D(%)307,@=&]T86QI;F<@
M87!P<F]X:6UA=&5L>2`W+C,F(S$V,#MM:6QL:6]N('=E<F4@97AC;'5D960@
M9G)O;2!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S<R!P97(@
M8V]M;6]N('-H87)E(&)E8V%U<V4@=&AE:7(-"B`@(&5F9F5C="!I<R!A;G1I
M+61I;'5T:79E+B!&;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@;W5T<W1A;F1I;F<@<W1O8VL@
M;W!T:6]N<RP@;W5T<W1A;F1I;F<@4E-5<R!A;F0@=6YV97-T960@4E-!<R!T
M;W1A;&EN9R!A<'!R;WAI;6%T96QY(#$N.28C,38P.VUI;&QI;VX@86YD(#4N
M.28C,38P.VUI;&QI;VXL(')E<W!E8W1I=F5L>2P@=V5R92!E>&-L=61E9"!F
M<F]M('1H90T*("`@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S<R!P
M97(@8V]M;6]N('-H87)E(&)E8V%U<V4@=&AE:7(@969F96-T(&ES(&%N=&DM
M9&EL=71I=F4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ
M93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P
M.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$.3(E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E
M;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@
M#0H@("`\=&0@=VED=&@],T0U,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^5&AR964@36]N=&AS($5N9&5D/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^3FEN92!-
M;VYT:',@16YD960\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^4V5P=&5M8F5R)B,Q-C`[,S`L/"]B/CPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^4V5P=&5M8F5R)B,Q-C`[,S`L/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P
M,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@
M("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L
M92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T($EN8V]M
M92`H3&]S<RD@+2!.=6UE<F%T;W(Z/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@9F]R(&)A
M<VEC(&%N9"!D:6QU=&5D($504SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXH,C`L,#`U+#@T-CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+#$V-2PQ.3,\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXH-#DL,30V+#$T-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,2PS-30L,C,W/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY3:&%R97,@+2!$96YO;6EN871O<CH\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY796EG:'1E9"UA=F5R86=E('-H
M87)E<R!F;W(@8F%S:6,@15!3/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,3$R+#,P-2PP,#(\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$P
M,RPR,C,L,S4R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,3`L-C4X+#<U-SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^,3`R+#(X,BPY,#0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%9F9E
M8W0@;V8@9&EL=71I=F4@<W1O8VL@;W!T:6]N<RP@4E-!<R!A;F0@4E-5<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L-S@U+#@S-SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M5V5I9VAT960M879E<F%G92!S:&%R97,@9F]R(&1I;'5T960@15!3/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$R+#,P
M-2PP,#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$P-2PP,#DL,3@Y/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M,3`L-C4X+#<U-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3`R+#(X,BPY,#0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M0F%S:6,@86YD(&1I;'5T960@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@P+C$X
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C`N,#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,"XT-#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,"XP,3PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L
M92!";V1Y("TM/@T*("`@/"]T86)L93X@#0H@("`\<"!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C
M,38P.SPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS
M-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T,30N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VMH;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-
M3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12
M+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@
M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Y("T@=7,M9V%A<#I3=&]C
M:VAO;&1E<G-%<75I='E.;W1E1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@
M/'`@<W1Y;&4],T1M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQB/CDN(%-T;V-K:&]L9&5R<R8C.#(Q-SL@17%U:71Y(#PO8CX\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D1U<FEN
M9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3(@86YD(#(P,3$L('=E(&ES<W5E9"!A;B!A9V=R96=A=&4@;V8@-#(V+#(W
M-R!A;F0@,BPW,3,L-3<S('-H87)E<PT*("`@;V8@8V]M;6]N('-T;V-K+"!R
M97-P96-T:79E;'DL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE<F-I<V5S
M(&]F('-T;V-K(&]P=&EO;G,@870@82!W96EG:'1E9"!A=F5R86=E(&5X97)C
M:7-E('!R:6-E(&]F("0T+C4V(&%N9"`D,2XW,"!P97(@<VAA<F4L(')E<W!E
M8W1I=F5L>2P@9F]R(&YE="!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0Q
M+CD@;6EL;&EO;B!A;F0@)#0N,2!M:6QL:6]N+"!R97-P96-T:79E;'DN($EN
M#0H@("!A9&1I=&EO;BP@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,BP@=V4@:7-S=65D(#@Q+#`W,"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K('5P;VX@=F5S=&EN9R!O9B!C97)T86EN(%)357,N
M(%1H92!24U4@:&]L9&5R<R!S=7)R96YD97)E9"`T-BPY,S`@4E-5<R!T;R!P
M87D@9F]R(&UI;FEM=6T@=VET:&AO;&1I;F<@=&%X97,@=&]T86QI;F<@87!P
M<F]X:6UA=&5L>2`D,S0W+#`P,"X@3W!T:6]N<PT*("`@86YD(%)357,@=&\@
M<'5R8VAA<V4@87!P<F]X:6UA=&5L>2`V+CDF(S$V,#MM:6QL:6]N(&%N9"`V
M+C`F(S$V,#MM:6QL:6]N('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K('=E
M<F4@;W5T<W1A;F1I;F<@87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@
M86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(')E<W!E8W1I=F5L>2X@26X@
M861D:71I;VXL('=E(&ES<W5E9"`S-S4L.3`X('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VLL(&YE=`T*("`@;V8@4E-!<R!C86YC96QE9"P@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!G<F%N=',@;V8@4E-!<R!D=7)I;F<@=&AE(&YI;F4@;6]N
M=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;@T*("`@1F5B<G5A
M<GDF(S$V,#LQ-2P@,C`Q,BP@=V4@8V]M<&QE=&5D(&%N('5N9&5R=W)I='1E
M;B!P=6)L:6,@;V9F97)I;F<@86YD(&ES<W5E9"`W+#@R,"PP,#`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:RP@:6YC;'5D:6YG(#$L,#(P+#`P,"!S:&%R97,@
M<V]L9"!P=7)S=6%N="!T;R!T:&4@9G5L;"!E>&5R8VES92!O9B!A;B!O=F5R
M+6%L;&]T;65N="!O<'1I;VX@9W)A;G1E9"!T;R!T:&4@=6YD97)W<FET97(N
M($%L;"!O9B!T:&4@<VAA<F5S#0H@("!W97)E(&]F9F5R960@870@82!P=6)L
M:6,@;V9F97)I;F<@<')I8V4@;V8@)#$P+C8Q('!E<B!S:&%R92P@9V5N97)A
M=&EN9R!A<'!R;WAI;6%T96QY("0X,2XU(&UI;&QI;VX@:6X@;F5T('!R;V-E
M961S+B!286YD86P@2BX@2VER:RP@82!M96UB97(@;V8@;W5R(&)O87)D(&]F
M(&1I<F5C=&]R<RP@=&AR;W5G:"!H:7,@869F:6QI871E<RP@<'5R8VAA<V5D
M(#$L,S8P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN('1H:7,-"B`@
M(&]F9F5R:6YG(&%T('1H92!P=6)L:6,@;V9F97)I;F<@<')I8V4@;V8@)#$P
M+C8Q('!E<B!S:&%R92!F;W(@82!T;W1A;"!O9B!A<'!R;WAI;6%T96QY("0Q
M-"XT(&UI;&QI;VXN(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D
M7S0W8F,W9#=C8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M9F)B,3$X,%\Q8C8W7S0Y,S5?831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H965T
M<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M
M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA
M+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,3`@+2!U<RUG86%P.D-O;6UI
M=&UE;G1S06YD0V]N=&EN9V5N8VEE<T1I<V-L;W-U<F5497AT0FQO8VLM+3X-
M"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ
M,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^/&(^,3`N($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/D9R;VT@=&EM92!T;R!T:6UE+"!W92!M87D@8F4@:6YV;VQV960@:6X@
M9&ES<'5T97,L(&EN8VQU9&EN9R!L:71I9V%T:6]N+"!R96QA=&EN9R!T;R!C
M;&%I;7,@87)I<VEN9R!O=70@;V8@;W!E<F%T:6]N<PT*("`@:6X@=&AE(&YO
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M87D@9&5N>0T*("`@8V]V97)A9V4@;W(@;W5R('!O;&EC>2!L:6UI=',@;6%Y
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M9'5A;&QY(&]R(&EN('1H90T*("`@86=G<F5G871E+"!W;W5L9"!H879E(&$@
M;6%T97)I86P@861V97)S92!E9F9E8W0@;VX@;W5R(&-O;G-O;&ED871E9"!R
M97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@9FEN86YC:6%L('!O<VET:6]N+B`\
M+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P155*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M0;VQI8VEE
M<UT\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N
M=&EN9R!0;VQI8WDZ(&AA;&\M,C`Q,C`Y,S!?;F]T93)?86-C;W5N=&EN9U]P
M;VQI8WE?=&%B;&4Q("T@=7,M9V%A<#I"87-I<T]F4')E<V5N=&%T:6]N06YD
M4VEG;FEF:6-A;G1!8V-O=6YT:6YG4&]L:6-I97-497AT0FQO8VLM+3X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\:3Y"87-I<R!O9B!0<F5S
M96YT871I;VX@/"]I/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
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M9"!3=&%T97,-"B`@(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R
M:6YC:7!L97,@*"8C.#(R,#M5+E,N($=!05`F(S@R,C$[*2!A;F0@=VET:"!T
M:&4@<G5L97,@86YD(')E9W5L871I;VYS(&]F('1H92!5+E,N(%-E8W5R:71I
M97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*"8C.#(R,#M314,F(S@R,C$[
M*2!R96QA=&5D('1O(&$@<75A<G1E<FQY(')E<&]R="!O;B!&;W)M(#$P+5$N
M($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L;"!O9@T*("`@
M=&AE(&EN9F]R;6%T:6]N(&%N9"!D:7-C;&]S=7)E<R!R97%U:7)E9"!B>2!5
M+E,N($=!05`@9F]R(&$@8V]M<&QE=&4@<V5T(&]F(&9I;F%N8VEA;"!S=&%T
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M-C`[,S$L(#(P,3$L(&9I;&5D('=I=&@@=&AE(%-%0R!O;B!-87)C:"8C,38P
M.S$R+"`R,#$R+B!4:&4@=6YA=61I=&5D(&9I;F%N8VEA;"!I;F9O<FUA=&EO
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M<FUA;"!R96-U<G)I;F<-"B`@(&%D:G5S=&UE;G1S+B!/<&5R871I;F<@<F5S
M=6QT<R!F;W(@:6YT97)I;2!P97)I;V1S(&%R92!N;W0@;F5C97-S87)I;'D@
M:6YD:6-A=&EV92!O9B!T:&4@;W!E<F%T:6YG(')E<W5L=',@9F]R(&%N(&5N
M=&ER92!F:7-C86P@>65A<BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
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M<&%N>2!A8V-O=6YT<R!A;F0@=')A;G-A8W1I;VYS(&AA=F4@8F5E;@T*("`@
M96QI;6EN871E9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^5&AE('!R97!A<F%T:6]N(&]F(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@52Y3+B!'04%0
M(')E<75I<F5S(&UA;F%G96UE;G0@=&\@;6%K90T*("`@97-T:6UA=&5S(&%N
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M<R!T:&%T(&UA;F%G96UE;G0-"B`@(&)E;&EE=F5S('1O(&)E(')E87-O;F%B
M;&4@=6YD97(@=&AE(&-I<F-U;7-T86YC97,N($)Y('1H96ER(&YA='5R92P@
M97-T:6UA=&5S(&%R92!S=6)J96-T('1O(&%N(&EN:&5R96YT(&1E9W)E92!O
M9B!U;F-E<G1A:6YT>2!A;F0L(&%S('-U8V@L(&%C='5A;"!R97-U;'1S(&UA
M>2!D:69F97(@9G)O;2!M86YA9V5M96YT)B,X,C$W.W,@97-T:6UA=&5S+B`\
M+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9&]P=&EO;B!O9B!296-E;G0@06-C;W5N=&EN9R!0
M<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N
M,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT
M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM
M($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@:&%L;RTR
M,#$R,#DS,%]N;W1E,E]A8V-O=6YT:6YG7W!O;&EC>5]T86)L93(@+2!U<RUG
M86%P.DYE=T%C8V]U;G1I;F=0<F]N;W5N8V5M96YT<U!O;&EC>5!O;&EC>51E
M>'1";&]C:RTM/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\
M:3Y!9&]P=&EO;B!O9B!296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT
M<R`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^169F96-T:79E($IA;G5A<GDF(S$V,#LQ+"`R,#$R+"!W92!A9&]P
M=&5D($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"8C.#(Q
M-SMS("@F(S@R,C`[1D%30B8C.#(R,3LI($%C8V]U;G1I;F<@4W1A;F1A<F1S
M(%5P9&%T90T*("`@*"8C.#(R,#M!4U4F(S@R,C$[*2!.;RXF(S$V,#LR,#$Q
M+3`U+"!#;VUP<F5H96YS:79E($EN8V]M92`H5&]P:6,@,C(P*3H@/&D^4')E
M<V5N=&%T:6]N(&]F($-O;7!R96AE;G-I=F4@26YC;VUE/"]I/B!A;F0@05-5
M($YO+B8C,38P.S(P,3$M,3(L(#QI/D-O;7!R96AE;G-I=F4@26YC;VUE("A4
M;W!I8R`R,C`I.B!$969E<G)A;"!O9B!T:&4@169F96-T:79E($1A=&4@9F]R
M($%M96YD;65N=',@=&\@=&AE(%!R97-E;G1A=&EO;B!O9@T*("`@4F5C;&%S
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M<&]N96YT<R!O9B!O=&AE<@T*("`@8V]M<')E:&5N<VEV92!I;F-O;64@96ET
M:&5R(&EN(&$@<VEN9VQE(&-O;G1I;G5O=7,@<W1A=&5M96YT(&]F(&-O;7!R
M96AE;G-I=F4@:6YC;VUE(&]R(&EN('1W;R!S97!A<F%T92!B=70@8V]N<V5C
M=71I=F4@<W1A=&5M96YT<RX@26X@8F]T:"!C:&]I8V5S+"!A;B!E;G1I='D@
M:7,@<F5Q=6ER960@=&\@<')E<V5N="!E86-H(&-O;7!O;F5N="!O9B!N970@
M:6YC;VUE(&%L;VYG('=I=&@@=&]T86P@;F5T(&EN8V]M92P@96%C:`T*("`@
M8V]M<&]N96YT(&]F(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE(&%L;VYG
M('=I=&@@82!T;W1A;"!F;W(@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64L
M(&%N9"!A('1O=&%L(&%M;W5N="!F;W(@8V]M<')E:&5N<VEV92!I;F-O;64N
M($%352!.;RXF(S$V,#LR,#$Q+3`U(&5L:6UI;F%T97,@=&AE(&]P=&EO;B!T
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M:6YC;VUE+@T*("`@5&AE(&%M96YD;65N=',@:6X@=&AE<V4@=7!D871E<R!A
M<F4@969F96-T:79E(&9O<B!F:7-C86P@>65A<G,L(&%N9"!I;G1E<FEM('!E
M<FEO9',@=VET:&EN('1H;W-E('EE87)S+"!B96=I;FYI;F<@869T97(@1&5C
M96UB97(F(S$V,#LQ-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F($%352!.;W,N
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M:6YC;VUE("AL;W-S*2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z
M-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^#0H@("!%9F9E8W1I=F4@2F%N=6%R>28C,38P.S$L(#(P
M,3(L('=E('!R;W-P96-T:79E;'D@861O<'1E9"!&05-")B,X,C$W.W,@05-5
M($YO+B8C,38P.S(P,3$M,#0L(#QI/B8C.#(R,#M&86ER(%9A;'5E($UE87-U
M<F5M96YT("A4;W!I8R`X,C`I("8C.#(Q,CL@06UE;F1M96YT<R!T;R!!8VAI
M979E($-O;6UO;B!&86ER(%9A;'5E($UE87-U<F5M96YT(&%N9`T*("`@1&ES
M8VQO<W5R92!297%U:7)E;65N=',@:6X@52Y3+B!'04%0(&%N9"!)1E)3)B,X
M,C(Q.RX@/"]I/E1H92!A;65N9&UE;G1S(&EN($%352`R,#$Q+3`T(')E<W5L
M="!I;B!C;VUM;VX@9F%I<B!V86QU92!M96%S=7)E;65N="!A;F0@9&ES8VQO
M<W5R92!R97%U:7)E;65N=',@:6X@1T%!4"!A;F0@26YT97)N871I;VYA;"!&
M:6YA;F-I86P@4F5P;W)T:6YG(%-T86YD87)D<R`H)B,X,C(P.TE&4E,F(S@R
M,C$[*2X@0V]N<V5Q=65N=&QY+"!T:&4-"B`@(&%M96YD;65N=',@8VAA;F=E
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M8F5R)B,Q-C`[,34L(#(P,3$N(%1H92!A9&]P=&EO;B!O9B!!4U4@3F\N)B,Q
M-C`[,C`Q,2TP-"!D:60@;F]T(&AA=F4@82!M871E<FEA;"!E9F9E8W0@;VX@
M;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<&]S:71I;VX@;W(@<F5S=6QT
M<R!O9B!O<&5R871I;VYS+B`\+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A
M9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@:&%L;RTR,#$R,#DS,%]N;W1E,E]A
M8V-O=6YT:6YG7W!O;&EC>5]T86)L93,@+2!U<RUG86%P.DEN=F5N=&]R>5!O
M;&EC>51E>'1";&]C:RTM/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\8CX\:3Y);G9E;G1O<FEE<R`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\
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M;G0-"B`@(&5V86QU871E<R!T:&4@8V%R<GEI;F<@=F%L=64@;V8@:6YV96YT
M;W)I97,@;VX@82!R96=U;&%R(&)A<VES+"!T86MI;F<@:6YT;R!A8V-O=6YT
M('-U8V@@9F%C=&]R<R!A<R!H:7-T;W)I8V%L(&%N9"!A;G1I8VEP871E9"!F
M=71U<F4@<V%L97,@8V]M<&%R960@=&\@<75A;G1I=&EE<R!O;B!H86YD+"!T
M:&4@<')I8V4@:70@97AP96-T<R!T;R!O8G1A:6X@9F]R('!R;V1U8W1S(&EN
M('1H96ER(')E<W!E8W1I=F4@;6%R:V5T<PT*("`@8V]M<&%R960@=VET:"!H
M:7-T;W)I8V%L(&-O<W0@86YD('1H92!R96UA:6YI;F<@<VAE;&8@;&EF92!O
M9B!G;V]D<R!O;B!H86YD+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
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M=&]R:65S(&-O;G-I<W0@;V8@:6XM<')O8V5S<R`\:3Y(>6QE;F5X/"]I/B!R
M96-O;6)I;F%N="X@1FEN:7-H960@9V]O9',@:6YV96YT;W)I97,@8V]N<VES
M="!O9B!F:6YI<VAE9"`\:3Y(>6QE;F5X/"]I/@T*("`@<F5C;VUB:6YA;G0@
M<')O9'5C="X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^5V4@97AP96YS92!C;W-T<R!R96QA=&EN9R!T;R!T:&4@<'5R8VAA
M<V4@86YD('!R;V1U8W1I;VX@;V8@<')E+6%P<')O=F%L(&EN=F5N=&]R:65S
M(&9O<B!W:&EC:"!T:&4@<V]L90T*("`@=7-E(&ES('!R92UA<'!R;W9A;"!P
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M9`T*("`@8GD@<F5G=6QA=&]R>2!B;V1I97,@<W5C:"!A<R!T:&4@52Y3+B!&
M;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N("@F(S@R,C`[1D1!)B,X,C(Q
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M06QL(&1I<F5C=`T*("`@;6%N=69A8W1U<FEN9R!C;W-T<R!I;F-U<G)E9"!A
M9G1E<B!A<'!R;W9A;"!A<F4@8V%P:71A;&EZ960@87,@:6YV96YT;W)Y+B`\
M+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($%C8V]U
M;G1I;F<@4&]L:6-Y.B!H86QO+3(P,3(P.3,P7VYO=&4R7V%C8V]U;G1I;F=?
M<&]L:6-Y7W1A8FQE-"`M('5S+6=A87`Z4F5V96YU95)E8V]G;FET:6]N4&]L
M:6-Y5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M/&(^/&D^4F5V96YU92!296-O9VYI=&EO;B`\+VD^/"]B/CPO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V4@9V5N97)A=&4@<F5V
M96YU97,@9G)O;2!P<F]D=6-T('-A;&5S(&%N9"!C;VQL86)O<F%T:79E(&%G
M<F5E;65N=',N(%!A>6UE;G1S(')E8V5I=F5D('5N9&5R(&-O;&QA8F]R871I
M=F4@86=R965M96YT<R!M87D@:6YC;'5D90T*("`@;F]N<F5F=6YD86)L92!F
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M<F]D=6-T<PT*("`@<F5S=6QT:6YG(&9R;VT@8V]L;&%B;W)A=&EV92!A<G)A
M;F=E;65N=',N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
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M('1H92!F;VQL;W=I;F<@8W)I=&5R:6$@87)E(&UE=#H@*#$I)B,Q-C`[<&5R
M<W5A<VEV92!E=FED96YC92!O9B!A;B!A<G)A;F=E;65N="!E>&ES=',[("@R
M*28C,38P.V1E;&EV97)Y(&AA<R!O8V-U<G)E9"!O<B!S97)V:6-E<R!H879E
M(&)E96X@<F5N9&5R960[("@S*28C,38P.W1H92!S96QL97(F(S@R,3<[<R!P
M<FEC92!T;R!T:&4@8G5Y97(@:7,-"B`@(&9I>&5D(&]R(&1E=&5R;6EN86)L
M93L@86YD("@T*28C,38P.V-O;&QE8W1I8FEL:71Y(&ES(')E87-O;F%B;'D@
M87-S=7)E9"X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!0<F]D=6-T(%-A;&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H
M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA
M;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL
M,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@
M5&%G9V5D($%C8V]U;G1I;F<@4&]L:6-Y.B!H86QO+3(P,3(P.3,P7VYO=&4R
M7V%C8V]U;G1I;F=?<&]L:6-Y7W1A8FQE-2`M('5S+6=A87`Z0V]S=$]F4V%L
M97-0;VQI8WE497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^/&(^/&D^0V]S="!O9B!0<F]D=6-T(%-A;&5S(#PO:3X\+V(^/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W-T(&]F
M('!R;V1U8W0@<V%L97,@8V]N<VES=',@<')I;6%R:6QY(&]F(')A=R!M871E
M<FEA;',L('1H:7)D+7!A<G1Y(&UA;G5F86-T=7)I;F<@8V]S=',L(&9I;&P@
M86YD(&9I;FES:"!C;W-T<RP@9G)E:6=H="!C;W-T<RP@:6YT97)N86P-"B`@
M(&-O<W1S(&%N9"!M86YU9F%C='5R:6YG(&]V97)H96%D(&%S<V]C:6%T960@
M=VET:"!T:&4@<')O9'5C=&EO;B!O9B`\:3Y(>6QE;F5X(#PO:3YR96-O;6)I
M;F%N="X@0V]S="!O9B!P<F]D=6-T('-A;&5S(&%L<V\@8V]N<VES=',@;V8@
M=&AE('=R:71E+61O=VX@;V8@97AC97-S+"!D871E9"!A;F0@;V)S;VQE=&4@
M:6YV96YT;W)I97,N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E
M;&]P;65N="!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\
M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@:&%L
M;RTR,#$R,#DS,%]N;W1E,E]A8V-O=6YT:6YG7W!O;&EC>5]T86)L938@+2!U
M<RUG86%P.E)E<V5A<F-H06YD1&5V96QO<&UE;G1%>'!E;G-E4&]L:6-Y+2T^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($5X<&5N<V5S(#PO:3X\+V(^/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@97AP96YS97,@:6YC;'5D92!S86QA<FEE<R!A;F0@8F5N969I
M=',L(&9A8VEL:71I97,@86YD(&]T:&5R(&]V97)H96%D(&5X<&5N<V5S+"!E
M>'1E<FYA;"!C;&EN:6-A;"!T<FEA;"!E>'!E;G-E<RP-"B`@(')E<V5A<F-H
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M(&AA=F4@;F\-"B`@(&%L=&5R;F%T:79E(&9U='5R92!U<V5S+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!9'9A;F-E('!A
M>6UE;G1S+"!I;F-L=61I;F<@;F]N<F5F=6YD86)L92!A;6]U;G1S+"!F;W(@
M9V]O9',@;W(@<V5R=FEC97,@=&AA="!W:6QL(&)E('5S960@;W(-"B`@(')E
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M92!D;R!N;W0@97AP96-T('1H90T*("`@9V]O9',@=&\@8F4@9&5L:79E<F5D
M(&]R('-E<G9I8V5S('1O(&)E('!E<F9O<FUE9"X@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^36EL97-T;VYE('!A>6UE;G1S
M('1H870@=V4@;6%K92!I;B!C;VYN96-T:6]N('=I=&@@:6XM;&EC96YS960@
M=&5C:&YO;&]G>0T*("`@;W(@<')O9'5C="!C86YD:61A=&5S(&%R92!E>'!E
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M(&)E;F5F:71S(&9O<B!A;&P-"B`@(&]F(&]U<B!L:6-E;G-E9"!T96-H;F]L
M;V=Y(&]R('!R;V1U8W0@8V%N9&ED871E<R!T;R!B92!U;F-E<G1A:6X@86YD
M(&AA<R!E>'!E;G-E9"!T:&5S92!A;6]U;G1S(&%S(&EN8W5R<F5D+B`\+V9O
M;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;&EN:6-A;"!4<FEA;"!%>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O
M=6YT:6YG(%!O;&EC>3H@:&%L;RTR,#$R,#DS,%]N;W1E,E]A8V-O=6YT:6YG
M7W!O;&EC>5]T86)L93<@+2!H86QO.D1I<V-L;W-U<F5/9D%C8V]U;G1I;F=0
M;VQI8WE&;W)#;&EN:6-A;%1R:6%L17AP96YS97-0;VQI8WE497AT0FQO8VLM
M+3X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T
M=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^0VQI;FEC
M86P@5')I86P@17AP96YS97,@/"]I/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@
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M<PT*("`@87)E(&UO9&EF:65D("AF;W(@:6YS=&%N8V4L(&%S(&$@<F5S=6QT
M(&]F(&-H86YG97,@:6X@=&AE(&-L:6YI8V%L('1R:6%L('!R;W1O8V]L(&]R
M('-C;W!E(&]F('=O<FL@=&\@8F4@<&5R9F]R;65D*2P@=V4@;6]D:69Y(&]U
M<B!A8V-R=6%L<R!A8V-O<F1I;F=L>2!O;B!A('!R;W-P96-T:79E(&)A<VES
M+B!2979I<VEO;G,@:6X@=&AE('-C;W!E(&]F(&$@8V]N=')A8W0@87)E(&-H
M87)G960@=&\@97AP96YS92!I;B!T:&4@<&5R:6]D#0H@("!I;B!W:&EC:"!T
M:&4@9F%C=',@=&AA="!G:79E(')I<V4@=&\@=&AE(')E=FES:6]N(&)E8V]M
M92!R96%S;VYA8FQY(&-E<G1A:6XN(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+4)A
M<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\
M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@:&%L
M;RTR,#$R,#DS,%]N;W1E,E]A8V-O=6YT:6YG7W!O;&EC>5]T86)L93@@+2!U
M<RUG86%P.E-H87)E0F%S961#;VUP96YS871I;VY/<'1I;VY!;F1);F-E;G1I
M=F50;&%N<U!O;&EC>2TM/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\8CX\:3Y3:&%R92U"87-E9"!#;VUP96YS871I;VX@/"]I/CPO8CX\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN
M+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L('-H
M87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@86QL
M(&]F(&]U<B!S:&%R92UB87-E9"!A=V%R9',@=V%S(&%L;&]C871E9"!A<R!F
M;VQL;W=S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z
M,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\
M+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT
M97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*
M("`@/'1D('=I9'1H/3-$-38E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/E1H<F5E($UO;G1H<R!%;F1E9#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/DYI;F4@36]N
M=&AS($5N9&5D/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@
M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@
M0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXY,3,L.30V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^.#DP+#(W-CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L,C<Y
M+#DT,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C$L.30T+#4U,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E-E;&QI;F<L(&=E;F5R
M86P@86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PP,#@L-#0W/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX
M-C<L,#@S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS+#`X,BPT,S(\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L
M.3<Q+#<W-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PY,C(L,SDS
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,2PW-3<L,S4Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPS-C(L,S<R/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,RPY,38L,S(Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E('!E<B!B87-I8R!A
M;F0@9&EL=71E9"!S:&%R93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXP+C`R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,"XP,CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C`N,#8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXP+C`T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E(&9R;VTZ/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^4W1O8VL@;W!T:6]N<SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#$V-"PY-S,\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX,#8L,#<X
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,RPT.3$L,C(P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPS,3@L-S(X/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!A=V%R9',@86YD
M(')E<W1R:6-T960@<W1O8VL@=6YI=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW-3<L-#(P/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXY
M-3$L,C@Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXR+#@W,2PQ-3(\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L
M-3DW+#8P,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,2PY,C(L,SDS/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,2PW-3<L,S4Y/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPS-C(L,S<R
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,RPY,38L,S(Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3:6YC92!W92!H879E(&$@
M;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9"!A<R!O9B!397!T96UB
M97(F(S$V,#LS,"P@,C`Q,BP@;F\@97AC97-S('1A>"!B96YE9FET<R!F;W(@
M=&AE('1A>`T*("`@9&5D=6-T:6]N<R!R96QA=&5D('1O('-H87)E+6)A<V5D
M(&%W87)D<R!W97)E(')E8V]G;FEZ960@:6X@=&AE(&EN=&5R:6T@=6YA=61I
M=&5D(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!C;VUP
M<F5H96YS:79E(&QO<W,@9F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(N($9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R(&%N9"`R,#$Q
M+"!E;7!L;WEE97,@97AE<F-I<V5D('-T;V-K(&]P=&EO;G,@=&\-"B`@('!U
M<F-H87-E(#<L,#4U(&%N9"`S."PU,3$@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:RP@<F5S<&5C=&EV96QY+"!F;W(@86=G<F5G871E('!R;V-E961S(&]F(&%P
M<')O>&EM871E;'D@)#,Y+#`P,"!A;F0@)#<Y+#`P,"P@<F5S<&5C=&EV96QY
M+B!&;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P
M+"`R,#$R(&%N9"`R,#$Q+"!E;7!L;WEE97,@97AE<F-I<V5D('-T;V-K(&]P
M=&EO;G,@=&\@<'5R8VAA<V4-"B`@(#0R-BPR-S<@86YD(#(L-S$S+#4W,R!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K+"!R97-P96-T:79E;'DL(&9O<B!A9V=R
M96=A=&4@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D,2XY(&UI;&QI;VX@
M86YD("0T+C$@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!);B!A9&1I=&EO;BP@
M9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@
M,C`Q,BP@=7!O;B!V97-T:6YG(&]F(#$R."PP,#`@<F5S=')I8W1E9"!S=&]C
M:PT*("`@=6YI=',@*"8C.#(R,#M24U5S)B,X,C(Q.RDL('1H92!24U4@:&]L
M9&5R<R!R96-E:79E9"!N970@<V5T=&QE;65N="!O9B`X,2PP-S`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!A;F0@<W5R<F5N9&5R960@-#8L.3,P(%)357,@
M=&\@<&%Y(&9O<B!T:&4@;6EN:6UU;2!W:71H:&]L9&EN9R!T87AE<R!T;W1A
M;&EN9R!A<'!R;WAI;6%T96QY("0S-#<L,#`P+B!4:&5R92!W97)E(&YO(%)3
M57,@=F5S=&5D(&9O<B!T:&4@=&AR964@;6]N=&AS#0H@("!E;F1E9"!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,B!O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N
M=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!<R!O9B!397!T96UB
M97(F(S$V,#LS,"P@,C`Q,BP-"B`@('1O=&%L('5N<F5C;V=N:7IE9"!E<W1I
M;6%T960@8V]M<&5N<V%T:6]N(&-O<W0@<F5L871E9"!T;R!N;VXM=F5S=&5D
M('-T;V-K(&]P=&EO;G,@86YD(&YO;BUV97-T960@<F5S=')I8W1E9"!S=&]C
M:R!A=V%R9',@86YD(')E<W1R:6-T960@<W1O8VL@=6YI=',@9W)A;G1E9"!P
M<FEO<B!T;R!T:&%T(&1A=&4@=V%S(&%P<')O>&EM871E;'D@)#DN-B!M:6QL
M:6]N(&%N9"`D-RXP(&UI;&QI;VXL(')E<W!E8W1I=F5L>2P@=VAI8V@@:7,-
M"B`@(&5X<&5C=&5D('1O(&)E(')E8V]G;FEZ960@;W9E<B!A('=E:6=H=&5D
M+6%V97)A9V4@<&5R:6]D(&]F(&%P<')O>&EM871E;'D@,BXW('EE87)S(&%N
M9"`S+C8@>65A<G,L(')E<W!E8W1I=F5L>2X@/"]F;VYT/CPO<#X-"CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N
M=&EN9R!0;VQI8WDZ(&AA;&\M,C`Q,C`Y,S!?;F]T93)?86-C;W5N=&EN9U]P
M;VQI8WE?=&%B;&4Y("T@=7,M9V%A<#I&86ER5F%L=65/9D9I;F%N8VEA;$EN
M<W1R=6UE;G1S4&]L:6-Y+2T^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/CQB/CQI/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S
M(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY792!F;VQL;W<@=&AE(&%U=&AO<FET871I=F4@9W5I9&%N8V4@9F]R
M(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&%N9"!D:7-C;&]S=7)E<R!W:&EC
M:"P@86UO;F<@;W1H97(@=&AI;F=S+"!D969I;F5S(&9A:7(@=F%L=64L#0H@
M("!E<W1A8FQI<VAE<R!A(&-O;G-I<W1E;G0@9G)A;65W;W)K(&9O<B!M96%S
M=7)I;F<@9F%I<B!V86QU92!A;F0@97AP86YD<R!D:7-C;&]S=7)E(&9O<B!E
M86-H(&UA:F]R(&%S<V5T(&%N9"!L:6%B:6QI='D@8V%T96=O<GD@;65A<W5R
M960@870@9F%I<B!V86QU92!O;B!E:71H97(@82!R96-U<G)I;F<@;W(@;F]N
M<F5C=7)R:6YG(&)A<VES+B!&86ER('9A;'5E(&ES(&1E9FEN960@87,@86X@
M97AI="!P<FEC92!T:&%T('=O=6QD(&)E#0H@("!R96-E:79E9"!T;R!S96QL
M(&%N(&%S<V5T(&]R('!A:60@=&\@=')A;G-F97(@82!L:6%B:6QI='D@:6X@
M86X@;W)D97)L>2!T<F%N<V%C=&EO;B!B971W965N(&UA<FME="!P87)T:6-I
M<&%N=',N($%S('-U8V@L(&9A:7(@=F%L=64@:7,@82!M87)K970M8F%S960@
M;65A<W5R96UE;G0@=&AA="!S:&]U;&0@8F4@9&5T97)M:6YE9"!B87-E9"!O
M;B!A<W-U;7!T:6]N<R!T:&%T(&UA<FME="!P87)T:6-I<&%N=',@=V]U;&0@
M=7-E(&EN#0H@("!P<FEC:6YG(&%N(&%S<V5T(&]R(&QI86)I;&ET>2X@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
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M;'5E(&%S(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^
M)B,Q-C`[/"]P/@T*("`@/&1I=B!A;&EG;CTS1')I9VAT/B`-"B`@(#QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.38E
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!T97AT+6%L:6=N.B!L969T)SX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A
M9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=VED=&@],T0Y,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM
M($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y
M("TM/@T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY,
M979E;"8C,38P.S$\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY1=6]T960@<')I8V5S("AU;F%D
M:G5S=&5D*2!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T
M<R!O<B!L:6%B:6QI=&EE<RP\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/DQE=F5L(#(\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);G!U
M=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S(&EN8VQU9&5D('=I=&AI;B!,
M979E;"`Q('1H870@87)E(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I<F5C=&QY
M(&]B<V5R=F%B;&4L(&%N9#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^3&5V96P@,SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E5N;V)S
M97)V86)L92!I;G!U=',@:6X@=VAI8V@@;&ET=&QE(&]R(&YO(&UA<FME="!A
M8W1I=FET>2!E>&ES=',L('1H97)E9F]R92!R97%U:7)I;F<@86X@96YT:71Y
M('1O(&1E=F5L;W`@:71S(&]W;B!A<W-U;7!T:6]N<R!A8F]U="!T:&4@87-S
M=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A;G1S#0H@("!W;W5L9"!U
M<V4@:6X@<')I8VEN9RX\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM
M($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/=7(@9FEN86YC:6%L(&EN
M<W1R=6UE;G1S(&EN8VQU9&4@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@
M86-C;W5N=',@<F5C96EV86)L92P@<')E<&%I9"!E>'!E;G-E<RP-"B`@(&%C
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M-C`[,S`L(#(P,3(@86YD#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!R
M97-P96-T:79E;'DL(&%R92!C87)R:65D(&%T(&9A:7(@=F%L=64@86YD(&%R
M92!C;&%S<VEF:65D('=I=&AI;B!,979E;"`Q(&]F('1H92!F86ER('9A;'5E
M(&AI97)A<F-H>2!B96-A=7-E('1H97D@87)E('9A;'5E9"!B87-E9"!O;B!Q
M=6]T960@;6%R:V5T('!R:6-E<R!F;W(@:61E;G1I8V%L('-E8W5R:71I97,N
M(%=E(&AA=F4@;F\@:6YS=')U;65N=',@=&AA="!A<F4@8VQA<W-I9FEE9`T*
M("`@=VET:&EN($QE=F5L(#(@86YD($QE=F5L(#,N(#PO9F]N=#X\+W`^#0H\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E9VUE;G0@26YF;W)M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!8
M2%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G
M+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*
M("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ
M(&AA;&\M,C`Q,C`Y,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B;&4Q
M,"`M('5S+6=A87`Z4V5G;65N=%)E<&]R=&EN9U!O;&EC>5!O;&EC>51E>'1"
M;&]C:RTM/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\:3Y3
M96=M96YT($EN9F]R;6%T:6]N(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY792!O<&5R871E(&]U<B!B=7-I;F5S
M<R!I;B!O;F4@<V5G;65N="P@=VAI8V@@:6YC;'5D97,@86QL(&%C=&EV:71I
M97,@<F5L871E9"!T;R!T:&4@<F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!C
M;VUM97)C:6%L:7IA=&EO;B!O9B!H=6UA;@T*("`@96YZ>6UE<R!T:&%T(&5I
M=&AE<B!T<F%N<VEE;G1L>2!M;V1I9GD@=&ES<W5E('1O(&9A8VEL:71A=&4@
M:6YJ96-T:6]N(&]F(&]T:&5R('1H97)A<&EE<R!O<B!C;W)R96-T(&1I<V5A
M<V5D('1I<W-U92!S=')U8W1U<F5S(&9O<B!C;&EN:6-A;"!B96YE9FET+B!4
M:&ES('-E9VUE;G0@86QS;R!I;F-L=61E<R!R979E;G5E<R!A;F0@97AP96YS
M97,@<F5L871E9"!T;R`H:2DF(S$V,#MR97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0-"B`@(&%C=&EV:71I97,@8V]N9'5C=&5D('5N9&5R(&]U<B!C;VQL86)O
M<F%T:79E(&%G<F5E;65N=',@=VET:"!T:&ER9"!P87)T:65S(&%N9"`H:6DI
M)B,Q-C`[<')O9'5C="!S86QE<R!O9B`\:3Y(>6QE;F5X/"]I/B!R96-O;6)I
M;F%N="X@5&AE(&-H:65F(&]P97)A=&EN9R!D96-I<VEO;BUM86ME<B!R979I
M97=S('1H92!O<&5R871I;F<@<F5S=6QT<R!O;B!A;B!A9V=R96=A=&4@8F%S
M:7,@86YD(&UA;F%G97,@=&AE(&]P97)A=&EO;G,-"B`@(&%S(&$@<VEN9VQE
M(&]P97)A=&EN9R!S96=M96YT+B`\+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@86QL(&]F(&]U<B!S:&%R92UB
M87-E9"!A=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA
M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@
M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL
M,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"
M96=I;B!";&]C:R!486=G960@3F]T92!486)L93H@:&%L;RTR,#$R,#DS,%]N
M;W1E,E]T86)L93$@+2!U<RUG86%P.E-C:&5D=6QE3V9%;7!L;WEE95-E<G9I
M8V53:&%R94)A<V5D0V]M<&5N<V%T:6]N06QL;V-A=&EO;D]F4F5C;V=N:7IE
M9%!E<FEO9$-O<W1S5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG
M;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE
M($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-38E/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/E1H<F5E($UO;G1H<R!%;F1E9#PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0Q/CQB/DYI;F4@36]N=&AS($5N9&5D/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E
M<B8C,38P.S,P+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M-B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P
M+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P
M,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-
M"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R
M/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXY,3,L.30V/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M.#DP+#(W-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C,L,C<Y+#DT,#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L.30T+#4U,CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PP
M,#@L-#0W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXX-C<L,#@S/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#`X
M,BPT,S(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$L.3<Q+#<W-SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,2PY,C(L,SDS/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PW-3<L,S4Y/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-BPS-C(L,S<R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPY,38L,S(Y/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E('!E<B!B87-I8R!A;F0@9&EL=71E9"!S:&%R93PO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXP+C`R/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,"XP,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C`N,#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXP+C`T/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9R;VTZ/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P
M96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4W1O8VL@;W!T:6]N
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#$V
M-"PY-S,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXX,#8L,#<X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPT.3$L,C(P/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^,BPS,3@L-S(X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4F5S=')I
M8W1E9"!S=&]C:R!A=V%R9',@86YD(')E<W1R:6-T960@<W1O8VL@=6YI=',\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW
M-3<L-#(P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXY-3$L,C@Q/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#@W
M,2PQ-3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$L-3DW+#8P,3PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PY,C(L,SDS/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PW-3<L
M,S4Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-BPS-C(L,S<R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPY,38L,S(Y/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D
M>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DEN=F5N=&]R:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV96YT;W)I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6UM87)Y(&]F($EN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-
M"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@5&%B;&4Z(&AA;&\M
M,C`Q,C`Y,S!?;F]T931?=&%B;&4Q("T@=7,M9V%A<#I38VAE9'5L94]F26YV
M96YT;W)Y0W5R<F5N=%1A8FQE5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D
M97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X
M="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN
M(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-S(E
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P
M.S,P+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P
M,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-
M"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R
M/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E)A=R!M871E<FEA;',\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^.38R+#<U,3PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(P,2PX,C(\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY7;W)K+6EN+7!R;V-E<W,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXW,34L,C0Q/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR.3`L
M-C0W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1FEN:7-H960@9V]O9',\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU
M,#@L,#<Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXW-"PW.30\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F
M;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#$X-BPP-C,\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU
M-C<L,C8S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M
M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L($YE="`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L($YE="!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U;6UA<GD@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D
M($YO=&4@5&%B;&4Z(&AA;&\M,C`Q,C`Y,S!?;F]T935?=&%B;&4Q("T@=7,M
M9V%A<#I0<F]P97)T>5!L86YT06YD17%U:7!M96YT5&5X=$)L;V-K+2T^#0H@
M("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D
M('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-E
M<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q
M-C`[,S$L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@
M(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&5Q=6EP;65N=#PO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#(P-RPT,#$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXU+#(S,2PW-C,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUP=71E<B!A;F0@;V9F:6-E
M(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C$L-3(T+#,T,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PR-C8L,#0Q/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3&5A<V5H;VQD(&EM<')O=F5M96YT
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$L,3,W+#$X-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PP,3DL,30W/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX+#@V."PY
M,C@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C<L-3$V+#DU,3PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$
M(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T
M:6]N/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^*#8L-3`U+#(W.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@U+#<T-2PY,#,\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPS-C,L
M-C4P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,2PW-S$L,#0X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B
M;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8W)U960@17AP96YS
M97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!8V-R=65D($5X<&5N<V5S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R
M>2!O9B!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-
M"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@5&%B;&4Z(&AA;&\M
M,C`Q,C`Y,S!?;F]T939?=&%B;&4Q("T@=7,M9V%A<#I38VAE9'5L94]F06-C
M<G5E9$QI86)I;&ET:65S5&%B;&5497AT0FQO8VLM+3X-"B`@(#QT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T
M97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0W
M,B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^4V5P=&5M8F5R)B,Q
M-C`[,S`L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(S$V,#LS,2P\+V(^
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^
M,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM
M/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^06-C<G5E9"!O=71S;W5R8V5D(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!E>'!E;G-E<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXS+#<S-2PS.38\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#DQ,"PR-S,\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY!8V-R=65D(&-O;7!E;G-A=&EO;B!A;F0@<&%Y<F]L;"!T87AE<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L
M,S,Y+#<Y,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPR,C,L.3,V/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^3W1H97(@86-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CDV-BPT.#8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C0X,2PS-C4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z
M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXX+#`T,2PV-S,\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+#8Q-2PU-S0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!";V1Y("TM/@T*("`@/"]T86)L93X@#0H\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A
M-&9D7S0W8F,W9#=C8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E9F)B,3$X,%\Q8C8W7S0Y,S5?831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H
M965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^1&5F97)R960@4F5V96YU92`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D
M(%)E=F5N=64@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F($1E9F5R<F5D(')E=F5N=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT
M;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L
M+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ
M+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!4
M86=G960@3F]T92!486)L93H@:&%L;RTR,#$R,#DS,%]N;W1E-U]T86)L93$@
M+2!U<RUG86%P.D1E9F5R<F5D4F5V96YU94)Y07)R86YG96UE;G1$:7-C;&]S
M=7)E5&5X=$)L;V-K+2T^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@
M86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^
M#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C,38P.S,P+#PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@
M5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;&QA
M8F]R871I=F4@86=R965M96YT<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXT-"PP,S0L,#$U/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#`L-S$V+#@P-CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E!R;V1U8W0@<V%L97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS,3DL,S8W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ-C<L
M,3@T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5&]T86P@9&5F97)R960@<F5V96YU93PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0T+#,U,RPS.#(\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C0P+#@X,RPY.3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY,97-S(&-U<G)E;G0@
M<&]R=&EO;CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CDL-#<P+#(T-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PQ,CDL-#`W/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^1&5F97)R960@<F5V96YU92P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS-"PX.#,L
M,3,U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,S8L-S4T+#4X,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A
M8FQE/B`-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A
M-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@26YC;VUE("A,
M;W-S*2!097(@4VAA<F4@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@26YC;VUE("A,;W-S*2!0
M97(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-O;F-I;&EA=&EO;B!O9B!"87-I8R!A;F0@
M1&EL=71E9"!%87)N:6YG<R`H3&]S<RD@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@
M5&%B;&4Z(&AA;&\M,C`Q,C`Y,S!?;F]T93A?=&%B;&4Q("T@=7,M9V%A<#I3
M8VAE9'5L94]F0V%L8W5L871I;VY/9DYU;65R871O<D%N9$1E;F]M:6YA=&]R
M26Y%87)N:6YG<U!E<E-H87)E5&%B;&5497AT0FQO8VLM+3X-"B`@(#QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@]
M,T0U,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^5&AR964@36]N=&AS
M($5N9&5D/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^3FEN92!-;VYT:',@16YD960\+V(^
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^4V5P=&5M8F5R)B,Q-C`[,S`L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^4V5P=&5M
M8F5R)B,Q-C`[,S`L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L
M92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@
M/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T($EN8V]M92`H3&]S<RD@+2!.=6UE
M<F%T;W(Z/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@9F]R(&)A<VEC(&%N9"!D:6QU=&5D
M($504SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH
M,C`L,#`U+#@T-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXU+#$V-2PQ.3,\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH-#DL,30V
M+#$T-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXH,2PS-30L,C,W/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3:&%R97,@+2!$
M96YO;6EN871O<CH\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E
M;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY796EG:'1E9"UA=F5R86=E('-H87)E<R!F;W(@8F%S:6,@
M15!3/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^,3$R+#,P-2PP,#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$P,RPR,C,L,S4R/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXQ,3`L-C4X+#<U-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3`R+#(X,BPY,#0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%9F9E8W0@;V8@9&EL=71I=F4@
M<W1O8VL@;W!T:6]N<RP@4E-!<R!A;F0@4E-5<SPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C$L-S@U+#@S-SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V5I9VAT960M879E<F%G
M92!S:&%R97,@9F]R(&1I;'5T960@15!3/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$R+#,P-2PP,#(\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$P-2PP,#DL,3@Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,3`L-C4X+#<U-SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,3`R+#(X,BPY,#0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0F%S:6,@86YD(&1I;'5T
M960@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@P+C$X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C`N,#4\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXH,"XT-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,"XP,3PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*28C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@
M/"]T86)L93X@#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F)B,3$X,%\Q8C8W7S0Y
M,S5?831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%54Y!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@86QL(&]F(&]U<B!S:&%R92UB
M87-E9"!A=V%R9',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PY,C(L,SDS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<U
M-RPS-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8L,S8R+#,W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPY,38L,S(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP
M96YS871I;VX@97AP96YS92!P97(@8F%S:6,@86YD(&1I;'5T960@<VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@86QL(&]F(&]U<B!S:&%R
M92UB87-E9"!A=V%R9',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,38T+#DW,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P-BPP
M-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#0Y,2PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#,Q."PW,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@87=A<F1S
M(&%N9"!R97-T<FEC=&5D('-T;V-K('5N:71S(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!A;&P@;V8@;W5R('-H
M87)E+6)A<V5D(&%W87)D<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4W+#0R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU,2PR
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#@W,2PQ-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#4Y-RPV,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T
M960@=&\@86QL(&]F(&]U<B!S:&%R92UB87-E9"!A=V%R9',\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDQ,RPY-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.3`L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-SDL.30P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-#0L-34R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396QL
M:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A
M<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@86QL(&]F(&]U
M<B!S:&%R92UB87-E9"!A=V%R9',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP,#@L
M-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`X-C<L,#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S+#`X,BPT,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3<Q+#<W-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T
M.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7
M;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$57-4)'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY3=&]C:R!O<'1I
M;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3$\8G(^4W1O8VL@;W!T:6]N<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/E-T;V-K(&]P=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CY3=&]C:R!O<'1I;VYS(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^4F5S=')I8W1E9"!S=&]C:R!A=V%R9',@86YD(')E<W1R
M:6-T960@<W1O8VL@=6YI=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CY297-T<FEC=&5D('-T
M;V-K(&%W87)D<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/D-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\8G(^3&5V96P@,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/D-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\8G(^3&5V96P@,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%1E>'1U
M86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T('!R;V-E961S(')E8V5I=F5D(&9R;VT@<W1O8VL@
M;W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D('-T;V-K('5N:71S("A24U5S*2!V97-T960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(X+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!R96QA=&5D('1O(%)357,L
M(&YE="!O9B!24U5S('-U<G)E;F1E<F5D(&%S('!A>6UE;G0@9F]R('=I=&AH
M;VQD:6YG('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,2PP-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!24U5S('-U<G)E;F1E<F5D('1O('!A>2!F;W(@
M;6EN:6UU;2!W:71H:&]L9&EN9R!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#8L.3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@;V8@=VET:&AO;&1I;F<@=&%X
M97,@87-S;V-I871E9"!W:71H(%)357,@=F5S=&5D(&1U<FEN9R!T:&4@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#<L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3$L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M879E<F%G92!P97)I
M;V0@;V8@;F]N+79E<W1E9"!S=&]C:R!O<'1I;VYS(&%N9"!N;VXM=F5S=&5D
M(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&%N9"!R97-T<FEC=&5D('-T;V-K
M('5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR('EE87)S
M(#@@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XS('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@*$%D9&ET:6]N86P@5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-E<W,@=&%X(&)E
M;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@87,@82!R97-U
M;'0@;V8@<W1O8VL@;W!T:6]N(&5X97)C:7-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPP-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS."PU,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C8L,C<W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW,3,L-3<S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!U;G)E8V]G;FEZ960@97-T:6UA=&5D(&-O;7!E;G-A=&EO;B!C;W-T
M(')E;&%T960@=&\@;F]N+79E<W1E9"!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#8P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#8P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L('5N<F5C;V=N:7IE9"!E<W1I;6%T960@8V]M<&5N<V%T:6]N(&-O<W0@
M;V8@;F]N+79E<W1E9"!R97-T<FEC=&5D('-T;V-K(&%W87)D<R!A;F0@<F5S
M=')I8W1E9"!S=&]C:R!U;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`W+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T
M9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE
M971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"3$)+/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/D-O;&QA8F]R871I=F4@06=R965M96YT<R`H1&5T86EL<RD@
M*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^4F]C:&4@0V]L;&%B;W)A=&EO;B!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$Q/&)R/E)O8VAE($-O;&QA8F]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY2;V-H
M92!#;VQL86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^4F]C:&4@0V]L;&%B;W)A
M=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/D=A;6UA9V%R9"!#;VQL86)O<F%T:6]N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3$\8G(^1V%M;6%G87)D($-O;&QA8F]R871I;VX@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY'86UM86=A<F0@0V]L;&%B;W)A=&EO;B!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/D=A
M;6UA9V%R9"!#;VQL86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^5FER;U!H87)M
M82!#;VQL86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^5FER;U!H87)M82!#;VQL
M86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^5FER;U!H87)M82!#;VQL86)O<F%T
M:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3$\8G(^5FER;U!H87)M82!#;VQL86)O<F%T:6]N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q
M,"P@,C`Q,CQB<CY6:7)O4&AA<FUA($-O;&QA8F]R871I;VX@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY);G1R97AO;B!#;VQL86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^26YT
M<F5X;VX@0V]L;&%B;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/DEN=')E>&]N($-O
M;&QA8F]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CY);G1R97AO;B!#;VQL86)O<F%T
M:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,#8L(#(P,3(\8G(^26YT<F5X;VX@0V]L;&%B;W)A=&EO;B!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VQL86)O<F%T:79E($%G<F5E;65N=',@*%1E>'1U86PI(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@<')O8V5E9',@<F5C96EV960@9G)O;2!P87)T;F5R('5N9&5R
M(&QI8V5N<V4@86YD(&-O;&QA8F]R871I=F4@86=R965M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]N<F5F=6YD86)L92!U<&9R;VYT(&QI8V5N<V4@9F5E
M('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UO=6YT(')E8V5I=F5D(&9R;VT@4F]C:&4@9F]R(&%D9&ET
M:6]N86P@97AC;'5S:79E('1A<F=E=',@86YD(&%N;G5A;"!L:6-E;G-E(&UA
M:6YT96YA;F-E(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-L:6YI8V%L(&1E=F5L;W!M96YT(&UI;&5S=&]N92!P87EM96YT
M<R!R96-E:79E9"!U;F1E<B!C;VQL86)O<F%T:79E(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296=U;&%T;W)Y
M(&UI;&5S=&]N92!P87EM96YT<R!R96-E:79E9"!U;F1E<B!C;VQL86)O<F%T
M:79E(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F]Y86QT>2!R96-E:79A8FQE+"!$=7)A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<F]Y86QT>2!E;G1I=&QE9"!T;R!R
M96-E:79E(&]F(&YE="!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&UA>&EM=6T@<')O8V5E9',@<F5C
M96EV86)L92!F<F]M(%)O8VAE(&EF('1H92!P87)T;F5R('-U8V-E<W-F=6QL
M>2!D979E;&]P<R!A;&P@9FEV92!E>&-L=7-I=F4@=&%R9V5T<R!A;F0@86-H
M:65V97,@<')E+6%G<F5E9"!S86QE<R!T87)G971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@;6%X:6UU;2!P
M<F]C965D<R!R96-E:79A8FQE(&9R;VT@26YT<F5X;VX@:68@=&AE('!A<G1N
M97(@<W5C8V5S<V9U;&QY(&1E=F5L;W!S('1H92!L:6-E;G-E9"!P<F]D=6-T
M(&-A;F1I9&%T92!A;F0@86-H:65V97,@<')E+6%G<F5E9"!S86QE<R!T87)G
M970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET
M:6]N86P@;6%X:6UU;2!P87EM96YT<R!U<&]N(&%C:&EE=F5M96YT(&]F(&-L
M:6YI8V%L(&1E=F5L;W!M96YT(&UI;&5S=&]N97,@=6YD97(@8V]L;&%B;W)A
M=&EV92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%D9&ET:6]N86P@;6%X:6UU;2!P87EM96YT<R!U<&]N(&%C:&EE
M=F5M96YT(&]F(')E9W5L871O<GD@;6EL97-T;VYE<R!U;F1E<B!C;VQL86)O
M<F%T:79E(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^061D:71I;VYA;"!M87AI;75M('!A>6UE;G1S('5P;VX@86-H
M:65V96UE;G0@;V8@9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL97-T
M;VYE<R!F;W(@96%C:"!P<F]D=6-T('1A<F=E=&EN9R!T:&4@=')E871M96YT
M(&]F(&%N>2!O9B!T:&4@=&AR964@;W)P:&%N(&EN9&EC871I;VYS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<&%Y
M;65N=',@=7!O;B!A8VAI979E;65N="!O9B!S86QE<RUB87-E9"!M:6QE<W1O
M;F5S('5N9&5R(&-O;&QA8F]R871I=F4@86=R965M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L
M(&%D9&ET:6]N86P@=7!F<F]N="!A;F0@;6EL97-T;VYE('!A>6UE;G1S(&9O
M<B!E86-H(&%D9&ET:6]N86P@=&%R9V5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=',@<F5C;V=N:7IE
M9"!A<R!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06YN=6%L(&5X8VQU<VEV:71Y(&9E97,@<F5C
M96EV960@=6YD97(@8V]L;&%B;W)A=&EV92!A9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!M87AI
M;75M('!A>6UE;G1S('5P;VX@86-H:65V96UE;G0@;V8@9&5V96QO<&UE;G0@
M86YD(')E9W5L871O<GD@;6EL97-T;VYE('5N9&5R(&-O;&QA8F]R871I=F4@
M86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&EM92!P97)I;V0@=&\@<')O=FED92!P<FEO<B!N;W1I8V4@=&\@
M=&5R;6EN871E(&-O;&QA8F]R871I=F4@86=R965M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^.3`@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CDP(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]C871I
M;VX@;V8@;&EC96YS92!F964@<F5C96EV960@=&\@;&EC96YS92!F964@9&5L
M:79E<F%B;&4@=6YD97(@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!M87AI;75M(&-A<V@@<&%Y;65N
M=',@<F5C96EV86)L92!U<&]N(&%C:&EE=F5M96YT(&]F(&1E=F5L;W!M96YT
M(&%N9"!R96=U;&%T;W)Y(&UI;&5S=&]N97,@9F]R(&5A8V@@<')O9'5C="!F
M;W(@=7-E(&]U='-I9&4@;V8@17AC;'5S:79E($9I96QD/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI>F5D('!A>6UE;G0@
M;V8@<F5V96YU97,@=6YD97(@8V]L;&%B;W)A=&EV92!A9W)E96UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L
M(&5X8VQU<VEV:71Y(&9E92!U;F1E<B!T:&4@8V]L;&%B;W)A=&EV92!A9W)E
M96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C
M8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F)B,3$X,%\Q
M8C8W7S0Y,S5?831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H965T<R]3:&5E=#(V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%049!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY)
M;G9E;G1O<FEE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!);G9E;G1O<FEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y287<@;6%T97)I86QS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#DV,BPW-3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P,2PX,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=O<FLM:6XM
M<')O8V5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$U+#(T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Y,"PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9I;FES:&5D(&=O;V1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#@L,#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S0L-SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPQ.#8L,#8S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-C<L,C8S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P141/
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP
M;65N="P@3F5T("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM
M87)Y(&]F(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT(&=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#@L.#8X+#DR.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-RPU,38L.34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D97!R96-I
M871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-BPU,#4L,C<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4L-S0U+#DP,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,S8S+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-S<Q+#`T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@97%U:7!M96YT(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5M;6%R>2!O9B!0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@
M86YD(&5Q=6EP;65N="!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPR,#<L-#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PR,S$L-S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E<B!A;F0@;V9F:6-E
M(&5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4')O<&5R='D@86YD(&5Q=6EP
M;65N="P@;F5T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@9W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3(T+#,T,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C8V+#`T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A
M<V5H;VQD(&EM<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4')O<&5R='D@
M86YD(&5Q=6EP;65N="P@;F5T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@9W)O<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ,S<L,3@W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#`Q.2PQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F)B,3$X,%\Q8C8W7S0Y,S5?
M831F9%\T-V)C-V0W8V,P-V(O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%245!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A
M;F0@17%U:7!M96YT+"!.970@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="P@3F5T
M("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T
M:6]N(&5X<&5N<V4@=&]T86QE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R.#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W.38L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X-3(L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%&04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E<R`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!!8V-R=65D
M(&5X<&5N<V5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@;W5T<V]U<F-E9"!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPW,S4L,SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#DQ,"PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M<&5N<V%T:6]N
M(&%N9"!P87ER;VQL('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#,S.2PW.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#(R,RPY,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%C8W)U960@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV-BPT.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#$L
M,S8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X+#`T,2PV-S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-C$U+#4W-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V
M-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W
M8B]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$541D%%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D1E9F5R<F5D(%)E=F5N=64@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@1&5F97)R960@<F5V
M96YU93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@9&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T-"PS-3,L,S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,"PX.#,L.3DP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S(&-U
M<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PT-S`L,C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PQ,CDL-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E+"!N970@;V8@
M8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-"PX.#,L,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S8L-S4T+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EV92!A9W)E96UE
M;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5M;6%R>2!O9B!$969E<G)E9"!R979E;G5E/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!D969E
M<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-"PP,S0L,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`L-S$V+#@P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!S86QE<R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA
M<GD@;V8@1&5F97)R960@<F5V96YU93PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@9&5F97)R960@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,3DL,S8W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C<L
M,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14A%04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5F97)R960@4F5V96YU
M92`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#8\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O8VAE($-O
M;&QA8F]R871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!2979E;G5E("A497AT=6%L*2!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN:71I86P@=7!F<F]N="!P87EM96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@86YD(&%N
M;G5A;"!M86EN=&5N86YC92!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97-I9VYA=&EO;B!F965S(&%N9"!L:6-E
M;G-E(&UA:6YT96YA;F-E(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT.3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R979E;G5E(')E;&%T:6YG('1O('1H92!U<&9R;VYT('!A>6UE;G0L
M(&1E<VEG;F%T960@9F5E<R!A;F0@86YN=6%L(&QI8V5N<V4@;6%I;G1E;F%N
M8V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E(')E
M;&%T:6YG('1O(')E:6UB=7)S86)L92!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8V]G;FEZ960@9&5F97)R960@<F5V96YU92!R96QA=&EN
M9R!T;R!R96EM8G5R<V%B;&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G
M;FEZ960@9&5F97)R960@<F5V96YU97,@<F5L871I;F<@=&\@<F5I;6)U<G-A
M8FQE(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!U;F1E<B!C;VQL86)O<F%T
M:79E(&%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,S-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E(')E;&%T960@=&\@
M2'EL96YE>"!R96-O;6)I;F%N="!!4$D@87,@<')O9'5C="!S86QE<R!R979E
M;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#,L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DQ
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%M;6%G87)D($-O;&QA8F]R871I
M;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY$969E<G)E9"!2979E;G5E("A497AT=6%L*2!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<VEG;F%T:6]N(&9E97,@86YD(&QI8V5N<V4@;6%I;G1E;F%N8V4@9F5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S8R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]N<F5F=6YD86)L92!U<&9R;VYT('!A>6UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!U<&9R;VYT('!A>6UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R979E;G5E(')E;&%T:6YG('1O('1H92!U<&9R;VYT('!A>6UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92!R96QA=&5D('1O($AY
M;&5N97@@<F5C;VUB:6YA;G0@05!)(&%S('!R;V1U8W0@<V%L97,@<F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^2'EL96YE>"!#;VQL86)O<F%T:6]N(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5F97)R960@4F5V96YU92`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-I9VYA=&EO
M;B!F965S(&%N9"!L:6-E;G-E(&UA:6YT96YA;F-E(&9E97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDY,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.3$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F%M;W)T
M:7IE9"!D969E<G)E9"!R979E;G5E(')E;&%T:6YG('1O('!R97!A:60@<')O
M9'5C="UB87-E9"!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5;F%M;W)T:7IE9"!D969E<G)E9"!R979E;G5E
M(')E;&%T:6YG('1O(&1E9F5R<F5D('5P9G)O;G0@<&%Y;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI>F5D
M(')E=F5N=65S(')E;&%T960@=&\@=7!F<F]N="!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G;FEZ960@
M<F5V96YU97,@<F5L871E9"!T;R!P<F]D=6-T+6)A<V5D('!A>6UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CDN,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V
M96YU92!R96QA=&5D('1O($AY;&5N97@@<F5C;VUB:6YA;G0@05!)(&%S('!R
M;V1U8W0@<V%L97,@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Y.3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y.3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15I'044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H87)E("A$971A:6QS*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@26YC;VUE("A,;W-S*2`M
M($YU;65R871O<CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@9F]R(&)A<VEC(&%N9"!D:6QU
M=&5D($504SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R,"PP
M,#4L.#0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2PQ-C4L,3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@T.2PQ-#8L,30V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PS-30L,C,W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:&%R97,@+2!$96YO;6EN871O<CH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M879E<F%G92!S
M:&%R97,@9F]R(&)A<VEC($504SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$R+#,P-2PP,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#,L,C(S+#,U,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PV-3@L-S4W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R+#(X
M,BPY,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5F9F5C="!O9B!D:6QU=&EV92!O<'1I;VYS+"!24T%S(&%N9"!2
M4U5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#<X-2PX,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"UA=F5R86=E('-H87)E<R!F;W(@9&EL=71E9"!%4%,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q,BPS,#4L,#`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`U+#`P.2PQ.#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L
M-C4X+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,BPR.#(L.3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@:6YC
M;VUE("AL;W-S*2!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XQ."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-#0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?969B8C$Q.#!?,6(V-U\T
M.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8B]7
M;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)14%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R92`H
M1&5T86EL<R!497AT=6%L*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F5T($EN8V]M92`H3&]S
M<RD@4&5R(%-H87)E("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG('-T
M;V-K(&]P=&EO;G,L(&]U='-T86YD:6YG(%)357,@86YD('5N=F5S=&5D(%)3
M07,@=&]T86QI;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<N,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?969B8C$Q.#!?,6(V-U\T.3,U7V$T9F1?-#=B8S=D-V-C,#=B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5F8F(Q,3@P7S%B-C=?-#DS
M-5]A-&9D7S0W8F,W9#=C8S`W8B]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4Q,T)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L
M9&5R<R<@17%U:71Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1F5B+B`Q-2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A!9&1I=&EO
M;F%L(%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@:7-S=65D(&%S(&$@<F5S=6QT(&]F('-T;V-K(&]P=&EO;B!E
M>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S@L-3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#(V+#(W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-S$S+#4W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!W96EG:'1E
M9"!A=F5R86=E(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0N-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@<W1O8VL@;W!T
M:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R97,@:7-S=65D(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A
M=V%R9',L(&YE="!O9B!A;GD@<VAA<F5S(&9O<F9E:71E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S<U+#DP.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD97)W<FET=&5N('!U
M8FQI8R!O9F9E<FEN9R!A;F0@:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPX,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@<V]L9"!T;R!U
M;F1E<G=R:71E<B!P=7)S=6%N="!T;R!T:&4@9G5L;"!E>&5R8VES92!O9B!A
M;B!O=F5R+6%L;&]T;65N="!O<'1I;VX@9W)A;G1E9"!T;R!T:&4@=6YD97)W
M<FET97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4'5B;&EC(&]F9F5R:6YG('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"XV,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R
M;VT@8V]M;6]N('-T;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`X,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,2PT-S8L.#0U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O
M9B!C;VUM;VX@<W1O8VL@8GD@869F:6QI871E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PS-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!C;VUM;VX@
M<W1O8VL@8GD@869F:6QI871E<R!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G($5Q=6ET>2`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O
M8V5E9',@9G)O;2!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K(&%W87)D<R!A;F0@<F5S=')I8W1E
M9"!S=&]C:R!U;FET<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A497AT
M=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&ES<W5E9"!R96QA=&5D('1O(%)357,L(&YE="!O9B!24U5S('-U<G)E;F1E
M<F5D(&%S('!A>6UE;G0@9F]R('=I=&AH;VQD:6YG('1A>&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PP-S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!24U5S
M('-U<G)E;F1E<F5D('1O('!A>2!F;W(@;6EN:6UU;2!W:71H:&]L9&EN9R!T
M87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L.3,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]U;G0@;V8@=VET:&AO;&1I;F<@=&%X97,@87-S;V-I871E9"!W:71H(%)3
M57,@=F5S=&5D(&1U<FEN9R!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,T-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P7S%B-C=?-#DS-5]A-&9D7S0W
M8F,W9#=C8S`W8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E9F)B
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M965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S0N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V5F8F(Q,3@P
@7S%B-C=?-#DS-5]A-&9D7S0W8F,W9#=C8S`W8BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accrued Expenses (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Summary of Accrued expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent', window );">Accrued outsourced research and development expenses</a></td>
        <td class="nump">$ 3,735,396<span></span></td>
        <td class="nump">$ 1,910,273<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and payroll taxes</a></td>
        <td class="nump">3,339,791<span></span></td>
        <td class="nump">3,223,936<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump">966,486<span></span></td>
        <td class="nump">481,365<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
        <td class="nump">$ 8,041,673<span></span></td>
        <td class="nump">$ 5,615,574<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued outsourced research and development expenses current.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, Net (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PropertyAndEquipmentNetTextualAbstract', window );"><strong>Property and Equipment, Net (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense totaled</a></td>
        <td class="nump">$ 286,000<span></span></td>
        <td class="nump">$ 239,000<span></span></td>
        <td class="nump">$ 796,000<span></span></td>
        <td class="nump">$ 852,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyAndEquipmentNetTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PropertyAndEquipmentNetTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Deferred Revenue (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAbstract', window );"><strong>Summary of Deferred revenue</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
        <td class="nump">$ 44,353,382<span></span></td>
        <td class="nump">$ 40,883,990<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Less current portion</a></td>
        <td class="nump">9,470,247<span></span></td>
        <td class="nump">4,129,407<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump">34,883,135<span></span></td>
        <td class="nump">36,754,583<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Collaborative agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAbstract', window );"><strong>Summary of Deferred revenue</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
        <td class="nump">44,034,015<span></span></td>
        <td class="nump">40,716,806<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Product sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAbstract', window );"><strong>Summary of Deferred revenue</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
        <td class="nump">$ 319,367<span></span></td>
        <td class="nump">$ 167,184<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7, 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7, 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 48<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHEAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Deferred Revenue (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Roche Collaboration [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_InitialUpfrontPayment', window );">Initial upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndMaintenanceRevenue', window );">License and annual maintenance fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Designation fees and license maintenance fees</a></td>
        <td class="nump">503,000<span></span></td>
        <td class="nump">491,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees', window );">Deferred revenue relating to the upfront payment, designated fees and annual license maintenance fees</a></td>
        <td class="nump">30,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment', window );">Deferred revenue relating to reimbursable research and development</a></td>
        <td class="nump">6,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment', window );">Recognized deferred revenue relating to reimbursable research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements', window );">Recognized deferred revenues relating to reimbursable research and development under collaborative agreements</a></td>
        <td class="nump">334,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">334,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred revenue related to Hylenex recombinant API as product sales revenue</a></td>
        <td class="nump">503,000<span></span></td>
        <td class="nump">491,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gammagard Collaboration [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Designation fees and license maintenance fees</a></td>
        <td class="nump">121,000<span></span></td>
        <td class="nump">121,000<span></span></td>
        <td class="nump">362,000<span></span></td>
        <td class="nump">362,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueToBeRecognizedOverTerm', window );">Deferred upfront payment</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueRelatingToUpfrontPayment', window );">Deferred revenue relating to the upfront payment</a></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred revenue related to Hylenex recombinant API as product sales revenue</a></td>
        <td class="nump">121,000<span></span></td>
        <td class="nump">121,000<span></span></td>
        <td class="nump">362,000<span></span></td>
        <td class="nump">362,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Hylenex Collaboration [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Designation fees and license maintenance fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">991,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">991,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments', window );">Unamortized deferred revenue relating to prepaid product-based payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment', window );">Unamortized deferred revenue relating to deferred upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RecognizedRevenuesRelatedToUpfrontPayment', window );">Recognized revenues related to upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RecognizedRevenuesRelatedToProductBasedPayment', window );">Recognized revenues related to product-based payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">9.3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred revenue related to Hylenex recombinant API as product sales revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 991,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 991,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue relating to reimbursable research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueRelatingToUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue relating to the upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DeferredRevenueRelatingToUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue relating to the upfront payment, license fees and annual maintenance fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFeesAndAnnualMaintenanceFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DeferredRevenueTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueToBeRecognizedOverTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue to be recognized over term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DeferredRevenueToBeRecognizedOverTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_InitialUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_InitialUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NonrefundableUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Nonrefundable upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NonrefundableUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue relating to reimbursable research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized deferred revenue relating to reimbursable research and development under collaborative agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RecognizedDeferredRevenueRelatingToReimbursableResearchAndDevelopmentUnderCollaborativeAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RecognizedRevenuesRelatedToProductBasedPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized revenues related to product based payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RecognizedRevenuesRelatedToProductBasedPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RecognizedRevenuesRelatedToUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized revenues related to upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_RecognizedRevenuesRelatedToUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unamortized deferred revenue relating to deferred upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_UnamortizedDeferredRevenueRelatingToDeferredUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unamortized deferred revenue relating to prepaid product based payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_UnamortizedDeferredRevenueRelatingToPrepaidProductBasedPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndMaintenanceRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndMaintenanceRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business and Collaborative Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>3. Collaborative Agreements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Roche Collaboration </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In December 2006, we and Roche entered into a license and collaborative agreement under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and
   up to thirteen Roche target compounds (the &#8220;Roche Collaboration&#8221;). As of September&#160;30, 2012, Roche has elected a total of five exclusive targets and retains the option to develop and commercialize rHuPH20 with three additional
   targets, provided that Roche continues to pay annual maintenance fees to us. As of September&#160;30, 2012, we have received $57 million from Roche, including the $20 million upfront license fee payment for the application of rHuPH20 to the initial
   three Roche exclusive targets, $20 million in connection with Roche&#8217;s election of two additional exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets, $13 million in
   clinical development milestone payments and a $4 million regulatory milestone payment. If Roche successfully develops all five exclusive targets and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $178
   million, including up to $17 million for the achievement of clinical development milestones, up to $16 million for the achievement of regulatory milestones and up to $145 million for the achievement of sales-based milestones. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Under the terms of the Roche Collaboration, Roche will also pay us a royalty on each product commercialized under the agreement
   consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&#8217;s obligation to pay royalties. Roche
   has the obligation to pay royalties with respect to each product in each country, during the period equal to the longer of: (a)&#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the
   collaboration which valid claim covers the product in such country or (b)&#160;ten years following the date of the first commercial sale of such product in such country. For products developed for each of the additional targets, Roche may pay us
   upfront and milestone payments of up to $47 million per target, as well as royalties on product sales for each of the additional targets consisting of a mid-single digit percent of the net sales of such products. Additionally, Roche will obtain
   access to our expertise in developing and applying rHuPH20 to Roche targets. Under the terms of the Roche Collaboration, we were obligated to scale up the production of rHuPH20 and to identify a second source manufacturer that would help meet
   anticipated production obligations arising from the Roche Collaboration. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Due to our continuing involvement obligations (for
   example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We have
   determined that the clinical and regulatory milestones are substantive; therefore, we expect to recognize such clinical and regulatory milestone payments as revenue upon achievement of the milestones. In addition, we have determined that the
   sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, we will recognize such sales-based milestone payments as revenue upon achievement
   of the milestones. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">There were no milestone payments recognized as revenues under collaborative agreements under the Roche
   Collaboration for the three months ended September&#160;30, 2012 and 2011. For the nine months ended September&#160;30, 2012 and 2011, we recognized $4 million and $5 million, respectively, as revenues under collaborative agreements in accordance
   with the Milestone Method related to the achievement of certain regulatory and clinical milestones pursuant to the terms of the Roche Collaboration. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>Gammagard Collaboration </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">In September 2007, we entered
   into a license and collaborative agreement with Baxter, under which Baxter obtained a worldwide, exclusive license to develop and commercialize a product candidate (currently named HyQ) consisting of rHuPH20 combined with a current Baxter product,
   GAMMAGARD LIQUID<font style="font-family:times new roman" size="1"><sup>&reg;</sup></font> (the &#8220;Gammagard Collaboration&#8221;). As of September&#160;30, 2012, we have received $13
   million under the Gammagard Collaboration, including the $10 million upfront license fee payment and a $3 million regulatory milestone payment. If Baxter successfully receives marketing approval for the licensed product candidate and achieves
   pre-agreed sales targets, we could receive additional milestone payments of up to $34 million for the achievement of sales-based milestones. In addition, Baxter will pay us a royalty on each product commercialized under the agreement consisting of a
   mid-single digit percent of the net sales of such product. The Gammagard Collaboration is applicable to both kit and formulation combinations. Baxter assumes all development, manufacturing, clinical,
   regulatory, sales and marketing costs under the Gammagard Collaboration, while we are responsible for the supply of rHuPH20 enzyme. We perform research and development activities at the request of Baxter, which are reimbursed by Baxter under the
   terms of the Gammagard Collaboration. In addition, Baxter has certain product development and commercialization obligations in major markets identified in the Gammagard Collaboration. Unless terminated earlier in accordance with its terms, the
   Gammagard Collaboration continues in effect until the expiration of Baxter&#8217;s obligation to pay royalties. Baxter has the obligation to pay royalties, with respect to each product in each country, during the period equal to the longer of:
   (a)&#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&#160;ten years following the date of the first
   commercial sale of such product in such country. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Due to our continuing involvement obligations (for example, support
   activities associated with rHuPH20 enzyme), the upfront payment was deferred and is being recognized over the term of the Gammagard Collaboration. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   We have determined that sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, such payments
   will be recognized as revenue upon achievement of the milestones. There were no milestone payments recognized as revenues under collaborative agreements under the Gammagard Collaboration for the three and nine months ended September&#160;30, 2012.
   For the three and nine months ended September&#160;30, 2011, we recognized zero and $3 million, respectively, as revenues under collaborative agreements under the Gammagard Collaboration in accordance with the Milestone Method. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>ViroPharma and Intrexon Collaborations </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">Effective May&#160;10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which
   ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma&#8217;s commercialized product, Cinryze<font style="font-family:times new roman" size="1"><sup>
   &reg;</sup></font> (C1 esterase inhibitor [human]) (the &#8220;ViroPharma Collaboration&#8221;). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and
   to the hereditary angioedema indication, along with three additional orphan indications. As of September&#160;30, 2012, we have received $13 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment, a $3 million
   clinical development milestone payment and a $1 million annual exclusivity fee. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of
   development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million which commenced on May&#160;10, 2012 and on each anniversary of the effective
   date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for
   research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory
   milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive a royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such
   product. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Unless terminated earlier in accordance with its terms, the ViroPharma Collaboration continues in effect until the
   later of (i)&#160;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and
   (ii)&#160;expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Collaboration, with respect to each country, consists of the period equal to the
   longer of: (a)&#160;the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&#160;ten years following the date of the
   first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us.&#160;Upon any such termination, the license
   granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Effective June&#160;6,
   2011, we and Intrexon entered into a collaboration and license agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon&#8217;s
   recombinant human alpha 1-antitrypsin (rHuA1AT) (the &#8220;Intrexon Collaboration&#8221;). In addition, the license provides Intrexon with exclusivity for a defined indication (&#8220;Exclusive Field&#8221;). As of September&#160;30, 2012, we have
   received $10 million from Intrexon, including a nonrefundable upfront license fee payment of $9 million and a $1 million annual exclusivity fee. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales
   target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as
   the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million which commenced on June&#160;6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development
   event occurs. Intrexon is solely responsible for the development, manufacturing and marketing of any products resulting from this collaboration. We are entitled to receive payments for research and development services and supply of rHuPH20 API if
   requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also
   entitled to receive a royalty on each product commercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Unless terminated earlier in accordance with its terms, the Intrexon Collaboration continues in effect until the later of
   (i)&#160;expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii)&#160;expiration
   of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Collaboration, with respect to each country, consists of the period equal to the longer of: (a)&#160;the
   duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b)&#160;ten years following the date of the first commercial sale of
   such product in such country. Intrexon may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with
   respect to the terminated product, as applicable) will terminate. Intrexon&#8217;s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development
   services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these
   units of accounting were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous
   collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the collaborators. The arrangement consideration was allocated to the deliverables based on the
   relative selling price method. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The amount allocable to the delivered unit or units of accounting is limited to the amount
   that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, we excluded from the allocable arrangement consideration the milestone payments, annual exclusivity
   fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the $9 million upfront license fee received from ViroPharma to the license fee deliverable under the ViroPharma arrangement and the $9
   million upfront fee received from Intrexon to the license fee deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in
   both the ViroPharma Collaboration and Intrexon Collaboration. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Collaboration and the $9 million upfront license fee received under the Intrexon Collaboration
   as revenues under collaborative agreements upon receipt of the upfront license fees. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We recognize the annual exclusivity fees
   as revenues under collaborative agreements when they are due and payable on each anniversary of the effective date and such amounts are included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the
   related services are performed. We recognize amounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the collaborators and the related title and risk of loss and damages
   have passed to the collaborators. We cannot predict the timing of delivery of research and development services and API as they are at the collaborators&#8217; requests. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   We are eligible to receive additional cash payments upon the achievement by the collaborators of specified development, regulatory and sales-based milestones. We have determined that each of the
   development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In
   addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone Method of revenue recognition; therefore, we will recognize the sales-based milestone
   payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   For the three and nine months ended September&#160;30, 2011, we recognized a $3 million milestone payment as revenues under collaborative agreements in accordance with the Milestone Method related to the
   achievement of a development milestone pursuant to the terms of the ViroPharma Collaboration. There were no milestone payments recognized as revenues under collaborative agreements associated with the ViroPharma Collaboration for the three and nine
   months ended September&#160;30, 2012. There were no milestone payments recognized as revenues under collaborative agreements associated with the Intrexon Collaboration for the three and nine months ended September&#160;30, 2012 and 2011. We
   recognized the annual exclusivity fee of zero and $1 million as revenues under collaborative agreements associated with each the ViroPharma and Intrexon Collaborations for the three and nine months ended September&#160;30, 2012, respectively.
   </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-1<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Income (Loss) Per Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net Income (Loss) - Numerator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for basic and diluted EPS</a></td>
        <td class="num">$ (20,005,846)<span></span></td>
        <td class="nump">$ 5,165,193<span></span></td>
        <td class="num">$ (49,146,146)<span></span></td>
        <td class="num">$ (1,354,237)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Shares - Denominator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS</a></td>
        <td class="nump">112,305,002<span></span></td>
        <td class="nump">103,223,352<span></span></td>
        <td class="nump">110,658,757<span></span></td>
        <td class="nump">102,282,904<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive options, RSAs and RSUs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,785,837<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS</a></td>
        <td class="nump">112,305,002<span></span></td>
        <td class="nump">105,009,189<span></span></td>
        <td class="nump">110,658,757<span></span></td>
        <td class="nump">102,282,904<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net income (loss) per share</a></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="num">$ (0.44)<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1500-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 87,614,891<span></span></td>
        <td class="nump">$ 52,825,527<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump">4,464,273<span></span></td>
        <td class="nump">2,262,465<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">2,186,063<span></span></td>
        <td class="nump">567,263<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
        <td class="nump">11,353,342<span></span></td>
        <td class="nump">8,332,242<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">105,618,569<span></span></td>
        <td class="nump">63,987,497<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">2,363,650<span></span></td>
        <td class="nump">1,771,048<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">107,982,219<span></span></td>
        <td class="nump">65,758,545<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">3,526,839<span></span></td>
        <td class="nump">7,556,859<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">8,041,673<span></span></td>
        <td class="nump">5,615,574<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
        <td class="nump">9,470,247<span></span></td>
        <td class="nump">4,129,407<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">21,038,759<span></span></td>
        <td class="nump">17,301,840<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump">34,883,135<span></span></td>
        <td class="nump">36,754,583<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
        <td class="nump">870,548<span></span></td>
        <td class="nump">802,006<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 150,000,000 shares authorized; 112,692,527 and 103,989,272 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">112,693<span></span></td>
        <td class="nump">103,990<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">345,244,876<span></span></td>
        <td class="nump">255,817,772<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(294,167,792)<span></span></td>
        <td class="num">(245,021,646)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">51,189,777<span></span></td>
        <td class="nump">10,900,116<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 107,982,219<span></span></td>
        <td class="nump">$ 65,758,545<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Business<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business and Collaborative Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2">
   <b></b></font>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>1. Organization and Business </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Halozyme Therapeutics, Inc. (referred to as &#8220;we,&#8221; &#8220;us,&#8221; &#8220;Halozyme&#8221; or the
   &#8220;Company&#8221;) is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. Our research targets the extracellular matrix, an area outside the cell that provides structural support
   in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique scientific expertise that allows us to pursue this target-rich environment for the
   development of future therapies. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">Our research focuses primarily on human enzymes that alter the
   extracellular matrix. Our lead enzyme, recombinant human hyaluronidase (&#8220;rHuPH20&#8221;), temporarily degrades hyaluronan, a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. We are also developing
   novel enzymes that may target other matrix structures for therapeutic benefit. Our Enhanze</font><font style="font-family:times new roman" size="1"><sup>TM</sup></font><font style="font-family:times new roman" size="2">
    technology is the platform for the delivery of proprietary small and large molecules. We apply our research products in collaboration with other companies as well as for our own proprietary pipeline in
   therapeutic areas with significant unmet medical need, such as diabetes, oncology and dermatology. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">Our
   operations to date have involved: (i)&#160;organizing and staffing our operating subsidiary, Halozyme, Inc.; (ii)&#160;acquiring, developing and securing our technology; (iii)&#160;undertaking product development for our existing product and a
   limited number of product candidates; (iv)&#160;supporting the development of collaboration product candidates and (v)&#160;selling <i>Hylenex</i><font style="font-family:times new roman" size="1"><sup>
   &reg;</sup></font> recombinant (hyaluronidase human injection). We continue to increase our focus on our proprietary product pipeline and have expanded investments in our proprietary
   product candidates. We currently have multiple proprietary programs in various stages of research and development. In addition, we currently have license and collaborative agreements with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.
   (&#8220;Roche&#8221;), Baxter Healthcare Corporation (&#8220;Baxter&#8221;), ViroPharma Incorporated (&#8220;ViroPharma&#8221;), and Intrexon Corporation (&#8220;Intrexon&#8221;), to apply Enhanze technology to these collaborators&#8217; biological
   therapeutic compounds. Currently, we have received only limited revenue from the sales of <i>Hylenex </i>recombinant, in addition to other revenues from our collaborations. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Income (Loss) Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock', window );">Reconciliation of Basic and Diluted Earnings (Loss) Per Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note8_table1 - us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="50%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Three Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Nine Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net Income (Loss) - Numerator:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income (loss) for basic and diluted EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(20,005,846</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,165,193</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(49,146,146</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,354,237</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Shares - Denominator:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average shares for basic EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">112,305,002</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">103,223,352</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">110,658,757</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102,282,904</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Effect of dilutive stock options, RSAs and RSUs</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,785,837</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average shares for diluted EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">112,305,002</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">105,009,189</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">110,658,757</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102,282,904</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic and diluted net income (loss) per share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.18</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.05</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.44</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.01</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the numerators and the denominators of the basic and diluted per-share (or per-unit) computations for income from continuing operations, including the effect that has been given to preferred dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EW5BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="4">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Stock options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Stock options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Stock options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Stock options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Restricted stock awards and restricted stock units [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Restricted stock awards and restricted stock units [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Cash equivalents [Member]

</div>
          <div>Level 1</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Cash equivalents [Member]

</div>
          <div>Level 1</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds received from stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 39,000<span></span></td>
        <td class="nump">$ 79,000<span></span></td>
        <td class="nump">$ 1,900,000<span></span></td>
        <td class="nump">$ 4,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units (RSUs) vested</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">128,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes', window );">Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,070<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes', window );">Number of RSUs surrendered to pay for minimum withholding taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,930<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod', window );">Amount of withholding taxes associated with RSUs vested during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">347,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,000,000<span></span></td>
        <td class="nump">51,800,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of non-vested stock options and non-vested restricted stock awards and restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 8 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation', window );">Excess tax benefits</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises</a></td>
        <td class="nump">7,055<span></span></td>
        <td class="nump">38,511<span></span></td>
        <td class="nump">426,277<span></span></td>
        <td class="nump">2,713,573<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation cost related to non-vested stock options</a></td>
        <td class="nump">9,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized estimated compensation cost of non-vested restricted stock awards and restricted stock units</a></td>
        <td class="nump">$ 7,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of withholding taxes associated with RSUs vested during period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of RSUs surrendered to pay for minimum withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_SummaryOfSignificantAccountingPoliciesAdditionalTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_SummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate unrecognized cost of share-based awards, other than options, made to employees under an equity-based compensation plan, that have yet to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate unrecognized cost of option awards made to employees under a stock option plan or plans, that have yet to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>2. Summary of Significant Accounting Policies </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Basis of Presentation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States
   generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of
   the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated
   financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2011, filed with the SEC on March&#160;12, 2012. The unaudited financial information for the interim periods presented herein
   reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring
   adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc. All intercompany accounts and transactions have been
   eliminated. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
   estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management
   believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Adoption of Recent Accounting Pronouncements </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Effective January&#160;1, 2012, we adopted Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Update
   (&#8220;ASU&#8221;) No.&#160;2011-05, Comprehensive Income (Topic 220): <i>Presentation of Comprehensive Income</i> and ASU No.&#160;2011-12, <i>Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of
   Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU No.&#160;2011-5</i>. In these updates, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other
   comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each
   component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No.&#160;2011-05 eliminates the option to present the components of other comprehensive income as part of the
   statement of changes in stockholders&#8217; equity. The amendments in ASU No.&#160;2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.
   The amendments in these updates are effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2011. The adoption of ASU Nos. 2011-05 and 2011-12 did not have a material impact on our consolidated financial
   position or results of operations. We have presented comprehensive income (loss) in our condensed consolidated statements of comprehensive income (loss). </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Effective January&#160;1, 2012, we prospectively adopted FASB&#8217;s ASU No.&#160;2011-04, <i>&#8220;Fair Value Measurement (Topic 820) &#8212; Amendments to Achieve Common Fair Value Measurement and
   Disclosure Requirements in U.S. GAAP and IFRS&#8221;. </i>The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;). Consequently, the
   amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This pronouncement is effective for fiscal years, and interim periods within
   those years, beginning after December&#160;15, 2011. The adoption of ASU No.&#160;2011-04 did not have a material effect on our consolidated financial position or results of operations. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Inventories </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
   evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
   compared with historical cost and the remaining shelf life of goods on hand. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Raw materials inventories consist of raw
   materials used in the manufacture of our bulk drug material for <i>Hylenex</i> recombinant product. Work-in-process inventories consist of in-process <i>Hylenex</i> recombinant. Finished goods inventories consist of finished <i>Hylenex</i>
   recombinant product. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We expense costs relating to the purchase and production of pre-approval inventories for which the sole
   use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
   by regulatory bodies such as the U.S. Food and Drug Administration (&#8220;FDA&#8221;), inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or
   comparable regulatory agencies in foreign countries, costs related to purchases of the active pharmaceutical ingredients (&#8220;API&#8221;) and the manufacturing of the product candidate are recorded as research and development expense. All direct
   manufacturing costs incurred after approval are capitalized as inventory. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Revenue Recognition </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
   nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
   resulting from collaborative arrangements. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We recognize revenue in accordance with the authoritative guidance on revenue
   recognition. Revenue is recognized when all of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered; (3)&#160;the seller&#8217;s price to the buyer is
   fixed or determinable; and (4)&#160;collectibility is reasonably assured. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i></i><b><i>Product Sales </i></b><i>&#8211; Hylenex</i> recombinant was approved for marketing by the FDA in
   December 2005. From 2005 through January&#160;7, 2011, Baxter had the worldwide market rights for <i>Hylenex</i> recombinant under the terms of the amended and restated development and supply agreement with Baxter (&#8220;Hylenex
   Collaboration&#8221;). Baxter commercially launched <i>Hylenex</i> recombinant in October 2009. However, <i>Hylenex</i> recombinant was voluntarily recalled in May 2010 because a portion of the product manufactured by Baxter was not in compliance
   with the requirements of the underlying collaboration. Effective January&#160;7, 2011, we and Baxter mutually agreed to terminate the Hylenex Collaboration. During the second quarter of 2011, we submitted the data that the FDA had requested to
   support the reintroduction of <i>Hylenex</i> recombinant to the market. The FDA approved the submitted data and granted the reintroduction of <i>Hylenex</i> recombinant. <i> </i></font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In December 2011, we reintroduced <i>Hylenex</i> recombinant to the market, shipped initial orders to our wholesaler customers and began
   promoting <i>Hylenex</i> recombinant through our sales force. We sell <i>Hylenex</i> recombinant in the United States to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. The wholesale
   distributors take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales; however, we do allow the
   wholesale distributors to return product that is damaged or received in error. In addition, we allow for product to be returned beginning six months prior to and ending twelve months following product expiration. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Given our limited history of selling <i>Hylenex</i> recombinant and the lengthy return period, we currently cannot reliably estimate
   expected returns and chargebacks of <i>Hylenex</i> recombinant at the time the product is received by the wholesale distributors. Therefore, we do not recognize revenue upon delivery of <i>Hylenex</i> recombinant to the wholesale distributor until
   the point at which we can reliably estimate expected product returns and chargebacks from the wholesale distributors. Shipments of <i>Hylenex</i> recombinant are recorded as deferred revenue until evidence exists to confirm that pull-through sales
   to the hospitals or other end-user customers have occurred. We recognize revenue when the product is sold through from the distributors to the distributors&#8217; customers. In addition, the costs of manufacturing <i>Hylenex</i> recombinant
   associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized. We estimate sell-through revenue and certain gross to net sales adjustments based on
   analysis of third-party information including information obtained from certain distributors with respect to their inventory levels and sell-through to the distributors&#8217; customers. At the time we can reliably estimate product returns and
   chargebacks from the wholesale distributors, we will record a one-time increase in net product sales revenue related to the recognition of product sales revenue previously deferred. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales
   allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with wholesale distributors and hospitals and the levels of inventory within the distribution channels
   that may result in future discounts taken. We must make significant judgments in determining these allowances. If actual results differ from our estimates, we will be required to make an adjustment to these allowances in the future, which could have
   an effect on product sales revenue in the period of adjustment. Our product sales allowances include: </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Distribution
   Fees</i>. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesale distributors for distribution services they provide with respect to <i>Hylenex</i> recombinant. At the time
   the sale is made to the respective wholesale distributors, we record an allowance for distribution fees by reducing our accounts receivable and deferred revenue associated with such product sales. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Prompt Payment
   Discounts</i>. We offer cash discounts to certain wholesale distributors as an incentive to meet certain payment terms. We expect our customers will take advantage of this discount; therefore, at the time the sale is made to the respective wholesale
   distributors, we accrue the entire prompt payment discount, based on the gross amount of each invoice, by reducing our accounts receivable and deferred revenue associated with such product sales. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Chargebacks</i>. We provide discounts to end-user members of certain group purchasing organizations (&#8220;GPO&#8221;) under collective
   purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals who are members of the GPOs with which we do not have contracts. The end-user members purchase products from the wholesale distributors at a contracted
   discounted price, and the wholesale distributors then charge back to us the difference between the current retail price and the price the end users paid for the product. Given our lack of historical sales data, we recognize chargebacks in the same
   period the related product sales revenue is recognized and reduce our accounts receivable accordingly. A GPO fee we incur for these transactions is also recorded in the same period the related product sales revenue is recognized and is included in
   accrued expenses. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Product Returns</i>. The product returns reserve is based on management&#8217;s best estimate of the
   product sales recognized as revenue during the period that are anticipated to be returned. The product returns reserve is recorded as a reduction of product sales revenue in the same period the related product sales revenue is recognized and is
   included in accrued expenses. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><b><i>Revenues under Collaborative Agreements </i></b><i>&#8211; </i>We have entered into
   license and collaboration agreements under which the collaborators obtained worldwide exclusive rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of the collaborators&#8217; biologic compounds. The
   collaborative agreements contain multiple elements, including nonrefundable payments at the inception of the arrangements, license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative
   agreements, reimbursements of research and development services, payments for supply of rHuPH20 API for the collaborator and/or royalties on sales of products resulting from collaborative agreements. We analyze each element of the collaborative
   agreements and consider a variety of factors in determining the appropriate method of revenue recognition of each element. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Prior to the adoption of ASU No.&#160;2009-13, <i>Multiple-Deliverable Revenue Arrangements</i>, on January&#160;1, 2011, in order for a
   delivered item to be accounted for separately from other deliverables in a multiple-element arrangement, the following three criteria had to be met: (i)&#160;the delivered item had standalone value to the customer, (ii)&#160;there was objective and
   reliable evidence of fair value of the undelivered items, and (iii)&#160;if the arrangement included a general right of return relative to the delivered item, delivery or performance of the undelivered items was considered probable and substantially
   in the control of the vendor. For the collaborative agreements entered into prior to January&#160;1, 2011, there was no objective and reliable evidence of fair value of the undelivered items. Thus, the delivered licenses did not meet all of the
   required criteria to be accounted for separately from undelivered items. Therefore, we recognized revenue on nonrefundable upfront payments and license fees from these collaborative agreements over the period of significant involvement under the
   related agreements. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">For new collaborative agreements or material modifications of existing collaborative agreements entered
   into after December&#160;31, 2010, we follow the provisions of ASU No.&#160;2009-13. In order to account for the multiple-element arrangements, we identify the deliverables included within the agreement and evaluate which deliverables represent
   units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The
   deliverables under our collaborative agreements include (i)&#160;the license to rHuPH20 technology, (ii)&#160;at the collaborator&#8217;s request, research and development services which are reimbursed at contractually determined rates, and
   (iii)&#160;at the collaborator&#8217;s request, supply of rHuPH20 API which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone
   basis based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the collaborator and the availability of research expertise in this field in
   the general marketplace. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Arrangement
   consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence
   (&#8220;VSOE&#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of
   allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the
   separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Nonrefundable upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the
   license has standalone value from the undelivered items, which generally include research and development services and the manufacture of rHuPH20 API, the relative selling price allocation of the license is equal to or exceeds the upfront license
   fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does
   not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The terms of our collaborative agreements provide for milestone payments upon achievement of certain development and regulatory events
   and/or specified sales volumes of commercialized products by the collaborator. Effective January&#160;1, 2011, we adopted on a prospective basis the Milestone Method. Under the Milestone Method, we recognize consideration that is contingent upon the
   achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
   </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">1.</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The consideration is commensurate with either the entity&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a
   result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone, </font></td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">2.</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The consideration relates solely to past performance, and </font></td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">3.</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </font></td>
   </tr>
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">A milestone is defined as an event (i)&#160;that can only be achieved based in whole or in part on either the entity&#8217;s performance
   or on the occurrence of a specific outcome resulting from the vendor&#8217;s performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&#160;that would
   result in additional payments being due to the vendor. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Reimbursements of research and development services are recognized as
   revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is probable. Revenue from the manufacture of rHuPH20
   API is recognized when the API has met all specifications required for the collaborator&#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and
   development services or supply of rHuPH20 API; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of rHuPH20 API. Royalties to be received based on sales of licensed products
   by our collaborators incorporating rHuPH20 will be recognized as earned. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The collaborative agreements typically provide the
   collaborators the right to terminate such agreements in whole or on a product-by-product or target-by-target basis at any time upon 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any
   of our collaborative agreements that contain material financial consequences to us. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Cost of Product Sales </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal
   costs and manufacturing overhead associated with the production of <i>Hylenex </i>recombinant. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Research and Development Expenses </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses,
   research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no
   alternative future uses. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Advance payments, including nonrefundable amounts, for goods or services that will be used or
   rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the
   goods to be delivered or services to be performed. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Milestone payments that we make in connection with in-licensed technology
   or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product
   candidates to be uncertain until such licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all
   of our licensed technology or product candidates to be uncertain and has expensed these amounts as incurred. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Clinical Trial Expenses </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work
   performed, including actual level of patient enrollment, completion of patient studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts
   are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period
   in which the facts that give rise to the revision become reasonably certain. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Share-Based Compensation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Total share-based compensation expense related to all of our share-based awards was allocated as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Three Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Nine Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">913,946</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">890,276</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,279,940</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,944,552</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Selling, general and administrative</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,008,447</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">867,083</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,082,432</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,971,777</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense per basic and diluted share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.06</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.04</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense from:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,164,973</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">806,078</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,491,220</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,318,728</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Restricted stock awards and restricted stock units</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">757,420</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">951,281</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,871,152</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,597,601</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Since we have a net operating loss carryforward as of September&#160;30, 2012, no excess tax benefits for the tax
   deductions related to share-based awards were recognized in the interim unaudited condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2012. For the three months ended September&#160;30, 2012 and 2011, employees exercised stock options to
   purchase 7,055 and 38,511 shares of common stock, respectively, for aggregate proceeds of approximately $39,000 and $79,000, respectively. For the nine months ended September&#160;30, 2012 and 2011, employees exercised stock options to purchase
   426,277 and 2,713,573 shares of common stock, respectively, for aggregate proceeds of approximately $1.9 million and $4.1 million, respectively. In addition, for the nine months ended September&#160;30, 2012, upon vesting of 128,000 restricted stock
   units (&#8220;RSUs&#8221;), the RSU holders received net settlement of 81,070 shares of common stock and surrendered 46,930 RSUs to pay for the minimum withholding taxes totaling approximately $347,000. There were no RSUs vested for the three months
   ended September&#160;30, 2012 or the three and nine months ended September&#160;30, 2011. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of September&#160;30, 2012,
   total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock awards and restricted stock units granted prior to that date was approximately $9.6 million and $7.0 million, respectively, which is
   expected to be recognized over a weighted-average period of approximately 2.7 years and 3.6 years, respectively. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Fair Value of Financial Instruments </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We follow the authoritative guidance for fair value measurements and disclosures which, among other things, defines fair value,
   establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price that would be
   received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
   pricing an asset or liability. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The framework for measuring fair value provides a hierarchy that prioritizes the inputs to
   valuation techniques used in measuring fair value as follows: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <div align="right">
   <table cellspacing="0" cellpadding="0" width="96%" border="0" style="border-collapse:collapse; text-align: left">
   <!-- Begin Table Head -->
   <tr>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td width="91%">&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level&#160;1</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Quoted prices (unadjusted) in active markets for identical assets or liabilities,</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level 2</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, and</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level 3</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants
   would use in pricing.</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Our financial instruments include cash and cash equivalents, accounts receivable, prepaid expenses,
   accounts payable and accrued expenses. The carrying amounts of financial instruments approximate their fair values due to their short maturities. Cash equivalents of approximately $85.0 million and $51.8 million at September&#160;30, 2012 and
   December&#160;31, 2011, respectively, are carried at fair value and are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices for identical securities. We have no instruments that are classified
   within Level 2 and Level 3. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Segment Information </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We operate our business in one segment, which includes all activities related to the research, development and commercialization of human
   enzymes that either transiently modify tissue to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. This segment also includes revenues and expenses related to (i)&#160;research and development
   activities conducted under our collaborative agreements with third parties and (ii)&#160;product sales of <i>Hylenex</i> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations
   as a single operating segment. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">112,692,527<span></span></td>
        <td class="nump">103,989,272<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">112,692,527<span></span></td>
        <td class="nump">103,989,272<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense related to all of our share-based awards</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note2_table1 - us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-->
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Three Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Nine Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">913,946</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">890,276</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,279,940</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,944,552</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Selling, general and administrative</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,008,447</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">867,083</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,082,432</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,971,777</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense per basic and diluted share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.06</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.04</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense from:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,164,973</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">806,078</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,491,220</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,318,728</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Restricted stock awards and restricted stock units</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">757,420</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">951,281</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,871,152</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,597,601</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">HALOZYME THERAPEUTICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001159036<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">112,705,092<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0001193125-12-460700-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-460700-xbrl.zip
M4$L#!!0````(`$&(:$%^^LI=Q)8``.J1!@`1`!P`:&%L;RTR,#$R,#DS,"YX
M;6Q55`D``]DKG%#9*YQ0=7@+``$$)0X```0Y`0``[#UK<]LXDM^OZOX#UE>W
ME53I[4EF8GMFRZ],LIO$/MN9V?OD@DA(PH0D&("4K/SZ[6Z`)"A+CI/8T2.J
M2=58(MCH]PM-ZN`?-W'$QD(;J9)?=[JMS@X32:!"F0Q_W<E-DYM`RIU__/;?
M_W7PMV;SWT<7;UBH@CP62<8"+7@F0M:?LHL+=J*21$21F+(K/AP*74!EW4X+
M_^O^\O,^.U;I5,OA*&-/CI_6[FHVW1[LB!L`"C?2;KU6E]EK-WT=,4`W,;_N
MC+(LW6NW)Y-)"[]N*3UL]SJ=W;9,3,:30.S8E7N13#[<L1PO]V&_8OG-K?63
M75K=??'B19NN%DM'/%+E2OSP:1J+5J!B@-SM=5[L=HJ5TJB?>MV?[\+:KBAN
M`+X/.4_+&P;<]&FQNT`[-#O=YFZW1!S@R2_@"UX-JQO\Q<_;]F*YU,AY'(&5
MW?:_W[ZY#$8BYLW9#4(Q`]V(H#54XS9<\/$'R3)V@(S=,P3I0@P8,7HOFZ;B
MUQTCXS1"L/3=2(L!P`5V-PLVMVY,N,/:%A`JT+%*,G&3L4L19*B`I#YP+7#?
MR_#7G2L`)-["%R-SFH0BO-[M7(H405Y?*,#C^ISK+`$-'LGT^JV(^T);5`$.
MZ+[,INX3?)8A?C.0H/-$@JBQJZ#[^/6_=G[K`-.ZSUYT=I\?M*O;*E!&#-&T
MRB_@*RN,/7&31C*0F<6%A1+66:-U2K%WK**(]Y7FF1R+0ZUY,A0(S!PFX3L%
M1CW_\A7\93AQRAS>2+/S&W)WC[C@,<'N>]">BTY%0+M.P4&[QJR#5&BI0H_>
M#'8X`2_RFU6)GT$K`$;Y;;E0)*&W[$5SMX.@0V_10=L#?M!VPOXBR?_.XY@/
MN0[G2/^Z]V/)O^3%#Z4#W:WU+\OZN_>3?/?1)'^7]?]8TE^2[7\?#7@GDR\T
M_1_-]2_'^+O+%/W6]I=O^]]!`8YXA#7*H3D;>&G?&P$5X$A%X?7K.-5J;+FW
M)M(_UPIHSZ;G0%D&$C_]F,L4H1U-KZ!^LI(M%I>4^H0^CG1M/9C5DK7BNX<0
MVH4P@NM@=%T2O$D"LW[8D5BN6$])':LXS3,(HT#L]=E@(`.QP4(KJ(5%EM;U
ME%[W1`04&;?.\7&%UFV"W':[#RNTK7-<%TEMG>-Z2.\KNX:K+KH3,1!:B_!"
MC$62U\J#NN0VNAVXJ"Y<]X[P&DCW/D7?]V_V;I!HMYW<C17MMDV[F;%VVW_=
M6NP:2G=1]\=K/U][K-D@J_U<)WZM.C^EY*"L"_,@N[[DD5B7AL^]+=$11[2M
ME7B\SL'6L%:]:S!?<EO#6D7Q5!&+&]LX'0,-5:_[^B67^OH/'N7B^G62YG#A
M#3`CZJZ)!!%]POYH>FB,R(XC;LR,F0'E'N'W$]]7XE#^^0HHQ$;NE+A91ZA<
M9!EN^;VF[GJK53^V5CV"K^H^NG9\$7T/;C6=5:*O\V@'")>9"CY<GZ4TBK,F
M=G\X@2KV=J)&I#A*-N9XX"[1B2B2R?#Z=P'5/(_H%.\PC&4B3>8R\].;%)BW
M-HD>/LX1YI$X&YS&::2F0EP*/9:!N!QQ+>C9'#S%@]LX2ODPBE1`?YT-+D2@
MAHG\),)SXNNQ,IDYFEZ(5.GLC4QF=<7RSK$..%=G7,&W'T&-+@10+8,,OK3.
MX'TB(1.XN+Z\?K\F>K/`(524$6%$U\7E^Q]$J'8(`YW""289RI[J.\U>$\%^
M/X=0,`SXY;'+<6MC-&;Q8?,V#UCM@^0[)+=-`S8C#5BJ%FT#QOH%C.7.KVPC
MQFH/,=PENFW(V("0L70UVE:.FRG4;2*P3HG`LD?BMGG`:H]&W2&Y;1JP&6G`
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M6`4_L/3AKJT?6+(?6/9QWM8-K(8;6.ITQ]8++-\+?.=WHG6>_S-/MJG@DH1?
M+\B?P[^'*,B[G;=\NBWRENC5ZW)]UNQ^=:/ES@?SMN.5:WF&L%BF6WM=@2QL
MV4JP#<3+[\DL\PG:U1M]66J':K6XL>0Z?>68L;17.*_WR[G7=>+BT7]`;TU/
M$-=Q?.JQ9;E-9E>A^'QXN6[STV4WBAY<IDM/*QYY,F65Z'O0M[>?!=GJR:_;
M^0;Z_LD3S"K=&\Q2T(3F2E#XG2K$OS6;V.]BEX*\3;-IO\[Q.V3/>:Y%R8M8
M<`.??T-?(_=2^/.@77QG8>-],Q#>7YZ<GE^6,$(Y!EY4Z..Z=WDLP`>JVINO
M"\#2J)]ZW9_W`$Y]-TO:_/L)[(E(5"R318`M%0:?P#6+(-\&<=#V*)A+,#W3
M:Q8P;=YVB]AV"\1"5O@00*+L-*(P4DB5%6+%:T=B*!-V%*G@`[OBPZ$(V3N5
MB7)-$;K>\0S`GPW.4N0M1B+F-.="#.ZPF[]'V3[L<W)V?/7_YZ=LE,41.W]_
M].;U,=MIMMM_[AZWVR=7)^S?KZ[>OF'=5H=1M).X!8_:[=-W.\PWJ<EN2^EA
M^^JB?8.PNGBS^[.9>7>VPBS<`2K^/LSVB6\.D84$=UF3+29V#B"48`/8L/#2
MS>RE`3",F6P:@9?`OYL#'LMHNI=!IF!8(B9,JY@G.\S(3["DMX-WXXW]XH]V
M]1<"6'7HY=WWVB(MX,=<@XR:F4KWNKWT9M]][JLL4_%>)[TI4?\VFKLM=J:'
M/)&?2,B,)R$[RHU,A#%L`;;T(?TLWL_GH;W/T%Z:,D'OO_?3_WX;&:\@!_PT
MC06[&H&6IB+/9&`:['42M-@3[69*6:88!V)XG.[_SR^]7F=_(AKEI^Z^?R4W
MBZX46_F7E6;92%@F5"OQO04\F7H+GS)I&&=]Z2J0@!#E$;@/6LI"$<+GS.(:
MVK<4R&1(TH`UX,L#R2/Y";^32:+&E!ZSU/ZHB@$L>,9X.,:\A*5P$5U=`'X5
MI)MKIMTK$!C$RJ&@]8*!&#1@$D5YQ#6+>:;E30-V9'`;9RK/#/AT6HF+[!;X
M`]CPK0%!:=@XUT"#R5-\\0)Q`;Q*)HW)806BKF!/0>]=@2]B)%3&N!9R$F1&
MI(;$!4SKQ^"S!(A.)D&4AT@G[1K+H?4^#9#[$'Q:P15P]&/\Z0@@<"RT!3X%
M(@'$1+`1!^XX/@)3(11\S`5D)]*F'`$0#VX-4!6.=5&D)@9\'_(?HCA0`!=`
M:)9A32V!>2(90PV94!@9>*(/J[=*,#5@@QP=)UX%C02:6NQKC&>^T<]:SW[*
M0V26O^3;+*JF+@,5Y`;6IEH"*G`O`P\QRN$F8`8:0Z%Y428J?LQ3+*N'D>"A
MN[,!NX!F]R&3`"PMS-&41SEP6(8<!//$,RG]*C]_U>OX)M4`5J`R6;Q"`7J"
MBEG`X*`QW&U.9J82E`\J*&BT^2#Q.NC1@`<RDAEI*%X)I0'-,(4KY'VC-+UU
M"D4;ZGQH-7L0Y3($T?XIT%R``<:W6V(#6*F(ZGR*^=1I%%.H'P5^A37!.J=8
MA3-C?9&(@<PL_TZ3$4\^B5OZ](62[I8J`K:+?UZ])9#NT[>"]^(>R"@8)6CH
M4W2!R.`TXAD0&1>4`MLB\&5ZB@P&_P*Z)H!'4V9BL$IB=H0L8[&*1)!'PG$]
M35$=?6TMO2$(V6LC@.@F,ALYCEN/*]%!&?`4N(-E.H)2DZ2&0BI30"X1`)'(
M\06#7M)8R.B9T*N@)N?@'T#0Y,\CX(T(P7/E@!TL#B7OBPR]'/4YD"E(7B@@
M)&3T>>U\!>&EJGP8PQ?8DG7`,AFK:"S"/?9$/K6VVWW>V5<VWR@]><8'`_Q`
M$K"@X)/)^Q"`)(BAP8K8:R/[/H#SX?'@8RXUW-.8#9U0>^:Z`%VI(@'P(>3`
M(XA*'W"ITZ*:5R_T0]Q(D_F+R$40#R(92XS?24Z-+ZO+M`;4(I3(%(/[CKUM
M7>1$@-80:G&DKL*WH='F3VKP[(O/2$\DI4?V]2FD1O*AG$65[F@QW%_H.&K^
M_4G=M5MW+Y._;#'VE"P:2RF98.!5F`6@>0GB.D4AC#SXH6:>CB>EF2)'2/,@
MO',\MD,5A`2$^HOH%F8@$"FW.6O1R2%W3#)P,@0QSJ-,II&810#"3DR@QQ"(
M5(Z9$1\"'T&`I6.R1EX*MP5:S-`6;5XSN;57)`-\-Y7+_KQ^*.-#+6RWU'J>
MERWV2@T&P,VD^88S.K5HL#=92/?.N83V0U3[T96NU6/K$;_!D/Y*0&@?82+)
MCB$.%LKHWVQ7UN_&7OLY9;JXH;L1I.'?5ZVIWXN(%UW=A9L6"V82`N7"@HN3
M?O2!:V!C1G@,5=H4]W=_WO<2TEN^GO('<!*@&<>%J*H\$Q1=@'`@W4U@[\(1
M:/LD&QN`-=F<`W_Z$/5BUCQ999^>S6`J7&H)HF_CEP-K+%S4YYJ?N"O;/&@O
MKNV]1@D6@`M;(5_2+KFLPN)A$`#_T-.=*VS&"W,%L<F"V*P62L]KH=R/`3/`
MYP;X7QZQ`]!KL<L\CKG-P#R<684T*[!^G):`^RH2@VRO]XTM@5JKA8SJB!M)
MAG>.'CG)K#NI!\65[G)<@??@@>L5V!8`N%P90[+)H59&;P-&%&+,H+\,""LD
MASM`5X*M`PQ+F8L<Y+3Z0F!2(5*N*4S2!CJD!@*%%NR!PY5+*HV(`T/[0E7P
M<;!6I'B55QH"01%V2M''^9[Z?>NRQ7X_/#ROM4/0R=,NZ!@U)O7T%2044#/:
M3!+DA1?I_DO*XS+IEIW>!",\%X3P$,?2F-GH<'EZ7-M-BZCHK7#V,><:N`=4
M:'IA)"86+[$>Z7::_]<BG=>8)J.'!P2@M%10RF6N,8&E7@2X%2$"OL9BINJ=
M0?T81,I0+:<%)J:P<7_*2CY0,LDII$10#$".:KL&<R35PK:6$=\H;L0*"+#U
MK1;`!#-2>0188>CBH2V7DK_R)*B*)23-VZS<@NB^YS:.8V&1>!TF20[W7-QB
M^[_*6A`[.%`RXTTG$%4QE:[2V]UN@^'I70,0B(2G0"!O!/<6DZUJ>;='RWO$
M18]W%?:^[`H,"E[;\R%L?9#/@/N0*E<':C&`6A2)QOHQ_"LO4LS)2`:C1M%E
MP$+$=0[`IKD]R&Y0PR`!ZHQ!GVO58<"E+O;B1;L!8538HLQEJ6>P%#)2,A.O
M_"JHN(5]PU6J5(EZ"*-L74U#V0N`2Y`G$68UD.H4S0SOGA8[*XNT`@O<=Y9S
M1"883D$JMFG`(6*?$U-91Y^:"XL:3!G8#M!OL)!&Q7C,XOC;'#0A@%KV)799
M.)3,>?<\L>*\JZ=-354PI<E(H1]6DT2$=U3*[#"*K%R*1G.Y$4+*O)F**BK8
M'AZFL0DBO[I<1X;;"%9:S'VXCHO0[F4V=9&N=,W.81O/7#%HQ/R#ZVR"I<1E
M[<V-R>/4]3VH#3H8@%>P`HTMFVV,J7S@_=QU+=B34P6C0[L'(QTJ_+*/.0V5
M(&(,E36V7*A!44/PKSRD"1=<B(Z)3+*/KU:F/B[8O=*V`8][@KU!_.:V=K&F
M:)4$_+%KYU=5KBU&;G&@XAOQJP]J!/4*M85LM#&05/<C=,>A[1BS0.H@CW%.
M(4`RCZ;X+3C#A&J4AD\28`^Z_A?Q6#'J(*!33C)J_PKR*1#%L)4#2D_-M0;V
MW=#K-?"4(2>_9FG#7FPH06+:EE(5ZEY1:*KMO](.YF;NCYWQ'H:J[%E?@/N=
MR>6U2A3RR2K<&B7"IV1@&#V@4(0\;NI%>QOLR20XD@]J_+*T+X]Z2&B3D&M0
MZ2,%_ZL)VT\B7QY>'M6RR+DPWJ=HRK<Z*H>7[VOWOE.M"E4[C_VL@>DK^*\1
M3L@!2=@I`:__Y`K2AH`!E*=[5:O@?"8UF'=K)4BR5L!ASK[(HA+JYQ&P[^7A
M41&N*PG@-`W%ZD-0H]"JDFVRL!EDB3N@AO@3\%1:E@G^:W!ZAIWEE`$#?_,X
MMYGZ&;F7N>B!(YU/V;.*?NJPV79/3@(RC2*ER+#'9ESJ4;167)I$WV8JL^0&
MM=TE[=ZP+JLX3B(B$I&55\EAWEI!SI*X,`\F$Y*HQ1H,M!TJC[(7ZOJ)-C0L
MPHE1[L6R"23V-AB"DP>68JB!'(Z$Y=<4P!JPSQ$+1DH&=<Y(KV;QV"(XQ([J
M#*U&,Z3`$)-<+DZL\_F!=Y:$EW=7)S&W:/&@<0>/FN\+[[`\+];:L$NWS%O<
M6J`ZG6=5PG.7;LP1ZP(R(/7F.G-60QRHRY'J5\I&##Y@">D<Q,-:.Q+ED$UM
M\<(K$UNH_D"#JU1=<4S5#!F8#<V0O]L@[&4DBRE0F&0*RCD0R&?HK8`75FXU
MJ-*%5IDCUXFI62F%>%&Z&!2CE_\;*^O9.@.5A0`I(XIU?>S.)70,-,`^]NUB
MLOO,%I..P5[`M.P%0RG8BILZWPD9`U6Y-ENF\V7``DM)2->"K#BDF)_EV=,&
M95N+R."Y-1P=/A#XJO2<R_,GD3+FJ9=8SJL\O,1RD?NP<%8WS2<$[AGY4ZU,
M:A=BFZK(`[Q03G%^@07]Y(5&/Q/`VOP/R+(%>VLG#,F,79S\!>)D.?W3[>W/
MQ,/#8(0I,+6JL.4Q'Q:H&)%Y4G:/(&"2(RX-I:I2Z(3DY<6EEV&TO"QNOL-P
M%#J=LV40842=AS%A%-<Q\GI915@H05:(H#4FW';+O8S+=GGJR5+M!*=.`.C?
M,<:KC[D[7"G<ID>)Y]<FMD?'<E.,3)E`2W!`-`?D<I59G.LM.$LL`O$X0*,=
M2A>4VUZKU^#K*PBL\SE&W3J)+1<ON\:(^G7^S#48']2GW5;XA?[,(GVW/[N/
M+UN?FNEU,@:!04$LUJHDHOU]W*E*SDA2$/4C-;'3"(&""(UJS_4'D:&U&=+.
M4(#$(?.Q/0$.TM4&D6NXOU#AJ=G0NK6+%F,I)G"CU5SL)$2VGYFJ##-*U*,;
M;/XUF%4=S.3ZH$G4]P8<<X#ZMMXR*-H9-@T+N-;4!+'F!G1(#PE"V)X9Z*(C
MXJ8XP*A4T>RR7<\!Q&>E:>SGCLZ'&]ZS9[74A'&Y\,<<EV5NVQ&U%JC3"G`P
MSZ*)PL#Z?-7'!H3EA#>39/L:8"@N0CE9F#)!IKTH]_4P),$5=06X&H!,XS$C
M$0U8)`?$E:%"S^$06]U0?L$GI8LQ-5&Z/C2-3?`)(5HM)"_O>NH`,T=1HI30
MUX!WZN?1!QK-J]P7LG[Q%$QM-,5)"-(NI3\`H4WX`G5V$7K>BOOMT,*H*$%>
MH1/3`L"#8M5BL.[P80[RJRKQ/VD6AZ994)&-/8NCB2?;*TAS#7'=#;LX<ES0
M@E2UR5,<.::SFHII`RI.L*%)<Q7@3XC.'(_*3/VVTOZX63B/4V+H5,RZ,TR/
M<QH?QZ9/9)T(TFH'!XO>9N$Q_"EMFRS87*!/[4[**^Q"D!X^0%-.=E**0+[#
M.AK;)XWPY^U:>$(V,^1='=Y:&MV17']:')XJ/87Z/D0^%7.'Y3GJ2]`_PN4$
MK<7_6<R9$]27)X?UT1J?_84Y!A'<CBXJLV9*Q9ME)<4>ZJ8@P^RY6CUX0+GT
M@>/41'%D-0.MQ<Y!"AHY8N=K*/$IQ%H.U0"B$%4\#TKL]E@!>R0TN&`=LI!#
MS'Q!I)K&S3VE=#T/IX_E`32WOGIF<!^P`=60E%K6&G_GKV\==-?=%AVU#5SL
MF)D\<V$53Z"1A9]767O"$T*6&V3.:?K[6.I*1;9Y8\E$W"S@J<RLMN%^A92^
M9!"5?`':_%ZW\B>?FUHI$]%[^JK.,E)"]S)RYGYP<MW&1L#WVI&-3,R,C16*
M9].<N\8,P0SYU%90Y9B;/;M9.)B(!RON;-/-P2=:#.`F,LV!P!TSYQ-PC,0[
M[*Z@-,HA2+RAP8!:`2E1@H[#X8..`U,I>IZ#VS+;7H%J$)\5R:JL81&R^!2"
MC/NY-E639*'-&?L#I<2P-I8\:LJC(B,LI_L*=^UB-59%5&0BWV?0\!Y^7^D(
MKHL?7"V'&N?,"]F)$:A8-3Y-@?0-<VFO`WO<C64"X\RIQ0H;H]9S\;NNKO48
ME<<.`X4/Z)!+`_"8XY'WBD6VQYYTO1%H?'8CY]3>$OBD$FT_L$\UE=RV<]PX
MCMWS;BV?0\#S`14XGXE*5LB]BKUX)BK@,H#8]4!0.B*BJ)J'I7:3K1%<PM//
MI]CL_T][;\+<N)$L#/X5;#]_&^T(2,9!$J3]/!%R'[;>YSZFU3W>V8V-#@@L
MBAB#`(U#:OG7?YE954`!!$D0),5#>!'SW)(`5%Z5E5=E)J*2YAM?0[IAN$=X
M^N9E3_DP"@XZ#;=X5T7$Z44N]9&RL/$Q)^J+H%I)>9:5[4>ADVYH(RU3LZ78
MG&G^I*TV[A^`E=).XE$?<KDH@_Z8&Q`BVB(#*IIE&'TPEG#'XC_AN3C*[J:+
MH4='%B2)<NFI.Y;AJ6#\@-?G^'I:[-]-A<IJZ)84"7(4C,(:F?'J*%$"Q/U\
M54GQNW%4!9VK.;Y!!8RJM2)`(.Q?J67$Y<B<>+,P<;',V<U";[6W4L('-,8'
M<,`%>4=8M_X`8,=ZTP\@*^^C`"PW7DH$?P-`N(I_!T<.,,*`S>FYZ`:X&D4?
MBY-%GGB*^TAE>0(U_#@O\N.%>3[J+2)+4:6H1A/%5XE)P2,WM13R7:Z*5^="
M\\#]`@'"+,/R!,DVLD6%2DBY!2VKQ5^55WK-33VN>C`+("L<$<A\H22[G?DI
MV;AXT\1-7>Y.R"V`DHL8@DC1VCQEQ>^G"/1]L)E5]ZPAWX3:DW&GSV+!?%<2
MX#ET!!E2Y0ZTM02W[=J7Q7-5A7*$6O(Z5#60X%N!>O.M5J*XKF%/G#GM$Y]"
M<NA<Q#Q.)2K)&!HOL+\SL+!F^#=DP"V[<T-Y0686I:LO%I4!$/H2O\_M(E!\
M'J/,%AZ/&^@,<EW52F2$.X>YZI6-T9OU;S,,]&'-4\274Q4`O#Z-$G)Z1%$3
M935!JUZ`XE"(P$4U7XK?]%6^CY%&]&_3(#_:Q1H8JG>Y[H[]Y$^45TRQ4;CJ
M030I4JXJR7@`EO%1%93\G.*,O<UB!+.X<Q)&I5N'T6W@WRDUH"+6`-80)2_$
M1W-O8)X%P87D$G'H)Z"*T,>PQ#CB-Z+S+$Q!\3()T#F'E8KK::14,*SLSLB[
MI\R`\!N`G2R.HWCQ_A-?3(F7YH$0_#@;*[F/Q/^FS:@O(YI5/$"`M`0&DAI\
M8`%&5OD3A=DHOPM^LR\UY[$J@E^!6CSO(N\2\7`P);;6W_$K;2$9?X!G[M+I
M8\XN"G%5[IZ!).$9&(,=3':E+'T3E[I%B(I_07B-4[R9>^MZ?]9>;%H&4R4T
M)'GC*SZFL,[JY8ZV)OB4$=8'<G'E@%?=E&P.QX5ZOW@S#5J[.@\'YO7_\\CG
M*/&`)!+4#1=I6-!/8KN,CGEH:QGN-Z`^<BND*<DK<:6Q;(V14XIBG+G+Q!TD
MI`,6R_KQ3+1_6-`;G`Z<7(5>S2MV%M4J5U_2O:(C89%OY/Y51".)@G%^LN1$
MJJJCZN_4BAI%M9<4$`\0))R@Y0!:,_+R1'621&`;I^K%A`4R+^4#K:^6Z:J7
M)_*#0*^+17,+*1">0&7!DEM-U,XE$C5)SLP<0)1&7D`+)AB>6J**1X2*E*L#
MLI"88Q^ZP:.X9I5._7A\@?5/CZ7L>=':0_TM3Y:A>T81$K%VB:]$3Y$W$TSV
MXX(JH-S`_TG$C6\%J>;R<*6HI*5;N&;G\L!S\]U+ZNK!#P(A!>"H1"&[H'7S
M.\^`/E*\'*23#%)"U9SQ16A2N7->?F>.F=HH2ZA/!A>0XSW]2@JA$JC$TYSJ
MQ%'N,?5;RA:IC\H^'^`ORWR.ND^6;(^/ZC>X7"M+JL7SLKX_>N!&#K=7O,`%
MU.@!=37ZG+S,5=2SDP%)B6K*`HY%U439Z4<SH'KK>XDU1B9ER;;E)S]M#B5U
M_EB4S"E?P)6QPB:$I\7I)CJ6%"5#PJS$ZAB./J(0DEJA"D"\*%&R2_,;"/BV
MC'$)=S5A"G5!)4^J%?IJ=7[I<D.QBVYSOWPL+VI0K"]74\6];X63`G6.C52Z
M'MV)P]-)*#2E!J9^6Y73A1AES)?E[5J62J]0[C\>[2;,S[W7BG@05&\92]1"
MZ\]5&>+Q^GRC8"5SS!E+ZB>O-HE%67:,39A$=#Q_M"3RPN4AT9?GPY(M(&JW
M"FCRV&V*5SE%^ZJ%`Z5I.$$Y)G(#D(#P,>TQ9H56SFL\5IP#\@@("]%81(#R
M)93=!5&2K4SR6US<7LY3S(OV1L4H(<.A))8[2?2M:%"WHT3?7H0;U/ULGLH,
M5UZ`2:159?P/S"&@*O+<9*IJOVB=/.(Q188/ED/=DWS,&)SM\C61S.+JGIMG
MY"?PJKO<9B9=1\<%]7C##B/"T$IR<'[B]VZY4U1UL9H*Z4*4@[OGGA=G_$/B
M5N:<4TZ"+V%0]CT^S`U(49,/\-(]`FP*!#M2/Q*A/I1B?548C151DTJJ)&>Y
M(S6C`"&OYB[L]&PN"Q>(FDI#QW)YPJ\?/Y3*$XI4+I<$'N\KOB15,J@@ECY@
MYBLK+`OXF.C%A=W/:L&6(!9F"0;E>.HNQT-^2QHWPH\67CWI_AP.?N`L4".O
M(LJ+9=88XKA#W/RSHHA&@DY>.LFH1'59_`O]5&[^:\A*1#F3?>108Y`S+4E'
M?B:/MJ`/X?J!R`S*542>D".(93:(F>L7-3)YN9<2(L)E@8A*Q2`W-S"2GA\S
MW)I6'17%0.9,7S22EU@]I40MST-A>'KY'BXZ*L`)BIS&0PTAH\(4B1RV8E3O
M(V/'3)2KW%U>8](WA=9/5-^:VWJDW\:RJ.84U(?T5#YQ7[1JD55=5:QIB.^)
M'+F&7G+A]1;,[,+G52XP50E<4+4@][A(1N4L<GGX2:VR+4=WUX*L1DQ6>GT5
MRWQ[41%-38M0S&F)2FTY4R*T?FD0@W95&-R-<^_%@_+*$EY7XOUD1`IQ22LS
M]*"+!3D\145GJ457$2`JLNKL&W"$BCR4Q#HE9).\*ECMTR;:AXIFG%(\JFGS
MQ1).<3BM;1FF-@C[++;+TOHH/'3P3,P[RK%`%B,5$;)RT51>\[2T<$HI):J6
M3DEB8>$(_TW^N2*<491/49*!EU7!W_*ZJ[5555R3;E=9I5>JNW@=`[XI&'CU
M\;HH&%6XTJPD:TTYEE+TAD8-1C3AT"2C5;!H42`6$1>BQ`,ZH*ZP8P)+"0MY
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M"B'^:3D5XN+NTRP:E[MLY%V+U\FPV`Y84;'DAJEHP680D[E*DX[IO9_(!9<I
M>,J[<BVLW,Z3Y_DJ'<KC4&)BT*,JZ%()"RVC9#:*\D>J#Y%MDKB967H[9N*J
M/;]&A,.N*9R?-WP!OY6L@?RT5A0<-KJ3<%6^*II)*8:IS(=P[4GGN/(.95MN
M*8-1%/3PZ\WTC&(GN5*+QOF6H=@#3W\D"19^D5G$3ZR2VLP_71BK)<#Y/JFT
MEBT+C.Q=MG!:*<!(FZUHPEL]E]QTP9`KN:*B(%%O4))?),YSLY/N(*U-/XAC
ML'*0-8:LWD3ET)!#J0+#20KN]3S`,)JXO8)!D<HA[Y?.+[?HZT*SD$JB6=1*
M+!@*2<4Z4.UENCI;V!'\#AGU22U%<,N)R?Q>?<`P"DWVK+!WU29>M*-)MI5]
M`B>IL'X5S&BG*I>0U3H!)H/4G/.>.W>I^MTOKF95/0"^-^]=/W!%H;SJ=!0C
M/^2RX.$$>1"(`M;"0N&ED_/`Q:+%9Y<?4>QKX<FJ0N#S3*8G;YC7^Z.Y[DVI
ME%#+A[V-Z_1K2>CHCK2P"&6U&T5&>9RH_F^%S*GZM'R_/:.0-C?LBIM#A0DF
MK:Z%;E[_NOGPIA0V5^KP^.ITA!55+ZK]5GX0+&3\FC:.&*\XI\.9LM^AZ`-%
M?P\;?Y&7:M'YF(F&^74AO!IR54Y1V6I(9&OR\@>/V\[*D;<@$+).$9DM"B/R
MN%_M%9=+V2U3^4Y1)UJ2L%F45[<K2K`B0$6D'AO`^YZX!;KH/9>N#]&S'&P2
M';5;4VFQ2^U5T;")5N'P*1+/@PV<N#+@7VADA$XUFF7(ARJ-1.^@.G"QC]=B
M5R?>ZZKR_-_YS3SJ\RDWX/$:M>]KO0'%`5`\@[B,9K6L4[4\_,G2<VGL>RF_
M3<'U5BE"B>?E@F.=9Y%J_%]^R!=-L>6QU>C^(+=XR[T,%`M"+^+5BZIN4?AR
MW!-L&X9WJ"/<<=A\@XV%`5JF+[]]QL!;V^3&G"XBJ\IUMM(93&=JS7;/P[^@
M:=W5=]B^K).#/!V\`:/SKZ':%9=216:QRG)1T5(R2"25J88ZOU$D_,W[(G0=
M<>#4C(+2KU3:_MSTY]I9=G-&-<!;\(1**[%4U<=U^YUB3W>4"^3@'.]N_UPM
M:EOJ6\A$,EW76[SV2YN_$J_.JT8K$7VE#P`23US*%;'B(LC-=3=>+ILQV2<M
MSP04^:)$5J6K,K_RJI>I7O42S<C(\E;ZE`FS&[_[+L?V'86`83?DMP"K?ZNF
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MN8HE]DAE:T3R]:DK&\C)<+0:`"Z;(B^3[RDQKC0<X)NZ<'&RE#H]5M)?6T"J
MUVPGSH]BKW')4W[&?=!MN5/9<M9Q;3D>KJ=K0)B&P%R+BY&T0EBY#]C)Y9G+
MI7U<<JFZ,8K')L)>987-P^O4Z$RM^RTE+=2(Z4YE^8GM_8H5!XX1Q>!X0309
MX]7D@4N-L+C12!E(847RV*"LL1;=SGEW[;#YH4L$X8%O?%A<0)3.;J.SDD<.
MERU036Z4FM3%"V9O:4X%=U+'LM-#*7]>R3#G+BVGH;P%(ZE5FY:G=Q[P?HMJ
M(RCC!;%17EX3Q!#I<9$WD)GP8_4L/[7IX%0.*+FR6].R*L:2LU/ZBI``+MK4
MO-Y-"HXW"JZ(`A'&&L5/RHD8<9LM+[95F@X6O95R":X/.!'NF+:JZ<&$;^&?
M,#HV$^4#<J^(#'->0E!7F%7:+7QL'!F6%`*CW@GDIZMM$B@.0J7`(M!3$VFB
M"BT1&.7=[_#^NJC@$'WK'\NQ*7'KDO)V)0D1"=`:*5E6@E:Z:L&OBR(@<^P(
MZ*5\??6>9^ERLQQ!%#)EW%JSF&$M,,#FO.A-UM7*2_0RJY)7PHDX6!'2D,TC
MRQ$97J0F![?2<"ZQ8''K3BW_!=C#8[Y3^GE5`4_Z.!>MBV7D*5THX13%_B+I
M7FK-PYMLJJGQXJ"2L1XD]<7MXX4L/,:-0F/@\9=B(#P/`V'2!"27+NY0R&9D
MP+GP*)M=/,38)@<K:5(1@\UD[8V8MU8^DCS\3\!'*NI:*::)84J,OJNU&S[M
M&WY4KHG2\?-:EK+F?7?5:76\F[O'Y3([J6;@U!T[FN07@E<W)3O"WH\2@7*I
MN^@V3-(TXVVT>,/EHMFR7DH[UK03I>F+O'$V[UB<_QJ;JTY3^://!P,$8B<E
M(E!?:80*5O$49U#6=4\H=P/.>;-R:K)H;+Z`.5TER=$7YR?N)G8QCAYX56VI
M53FU!I*]RI7FM5UC5#*YE./JM7)<O1'7(DYIJWQ:TV.WJ'8"47)C.816M&]&
MP0?G.RBFT_**JURRY5>P$)_OB$JKX^():9US<*1U5]XQ10F8+&TJVPAB]2Q-
M^$4)>4UE/9;4#IANB)')I4P5=94>PM(J3,3'P8$0LVX#<E]X5['E?8LG<#@)
M52`:68E"`S%&I.BHG1WU]9HKO(CK%7FIY9<W1$6$3O:Q:-0?JQ?3W<*-H];:
MHI^U[#&J-O1:2E?J4BUD4$V2\N1BWN,91WWCVZ)(H]Z:0P===$2OM)?AT/,%
M9`A:&/UYKXMZYP@+M%*E;XVTD84-+VX]2\.+K\.MV=)*!=7H;_GWCU=.WBUF
M,#G'&>]64>,,H-Z6=GI1/"D#&`M-PZN-UVLV*W=&U9"#+^MM*,)1WYE>N41;
M`T\]+.28Y;=?R*_=\N/<?BB0Y9S/<5$[(C6&4E;_+.D+N[J3/F\YSVG+M:U:
M<$ZN;#YK!)>YY5-TBSDGO#23CTY93AW<,4&@VN+-T:O2B&O;I!`2KL"E&E!$
MYJ2,='F,?J9C]!1MCQQFI:U3W5@%>>TT]^@7AOW2[3>F3A`7.TRH3.G<QKC6
MG<O'9SU$\9_R]C=7I.HQ)EJQ4`,ALJCALW2&AS%XA3QR)<;8R]NXXHDDS<;2
M'()UP6OD[2\79CSP.9^P)-6'BFDWY7D,"XO2B1,S-Q67!`KJT)94BHJ$^%-U
M97[%AZ[[2]'GM@>V(Z!+$_"'EWR4.:\DTN6-8YE4]<IE@!5##E!-(P_O$(%.
M\,"`PE>0QM7CZGL*&]&:C_+>?)P1LXO+\DLJ12BL5_CK%)"4:Q4=#:K67.V(
M$WG]J0AM\H(J.J#N^/7:1.D7PI?%)LL\0KY(Z--1'C=`&W;Q"^TGG#,+U'%/
M;<##9ZH#30@3KAD\%1/)<V4WB9P4->957G,?:#X?=4LO*F]E_]1D@SY5BL]K
M[3!E6DUR5I.@(NLX`CE1<Z4M,JTB4^A1TN5%"93_Z^)"^P4;T6J?":C?T+V[
MN"B#NS3'VA_\KSIL:U*7,EO)R90C9S=\_XD?ZL!]YN!6L]$K"PXJZ.RJZN!I
M/HO1<-!"\(M!G:)HH<?-\NGTF:Z&OXNH>?4;'/2PZ@PZ&!U.E;SO_?!(J-OM
MF9TQ]8;-T^HM94/O]LWYDO@Y;AZKRMF*;2M,:G/^3:-)S=I_&?1_.Y(`'+#^
M/+?4X0EO=H3O)/Y9$?YP$K^TLA9]?S`95WC^U>C`+]'X<3$ZH-W>`:&C^.<7
M_^5YC$TFU1KM\4*Q\M(H$T7&S$O#8+-R7.F"_W(_:?%%TLTKE#N.G;$ANM^U
MVC3B1RH+VV[]D6GKH]Z@$11A]!"[\Y]?\/^^V"D=CE(YG31GAR-#MYR.L^?'
M61OX.H)=:W2\/3O>FL#7GM[O6R?`VU8.\8'-BQO>TD+/>RZAF>&.L25JDO)R
MXS.U-+:TTW<IXH8QU'L]YP1$O&-R6^MCX.C&T.Y8?+XLMH'!EMZS3^&HZIC<
MWAYQ3-UQ3D%9K[)':B]'+`^"J`!OFBMO_=*B221"7U2N5!_W6E7#<CS+=G3L
MZ'A,RW9TW#,=5ZKBDXE%WZPI<3Q33_$(8B"6I=NCSGLX1]XZ?4>W^Z..MV?'
MVX%N#V#?.IU#>'Z\M?61"?RU3F'?GK4?:(/A-HXR3/4_J<&XHW4[2G:4["CY
M["AYDJG"=1?<YBRFNY$>KU7R@XPZ$>!KG6>X%RO$N#0ZX[)C:\?64V%K5WYV
MEFSMG0!;.R_P!.W$CI(=)3M*GBLEGT=6D/H?_7CD'N"3"7J[ESJL.ZQ/&NL]
M!KSLO2FV-/+^U"*:J)L<N?XZ5>?)U,U!3Q\Y76W#^?%V:`QTPQEVG#T[SMIZ
M;V3JEM7=N#L_WEJZ;0YUQSJ%??ND#M3>[(Q/+$ECG_JA)F1RB#Z0?'1NY6\T
M"/U,C9'MEM[A'L":O%ZGW<Z9Q:,^'&!#LV/Q^;+8TH<.^!<G<7>\8W)K![(_
M<O2!<0H[^:Q3<.=Y<:>C8T?'CH[G1\>MXM%'%==O>UP=.L[0W6H[9]YVM]K.
ME;?=K;;SY6UWJ^U(C*YSK7CJ*-E1LJ/DN5*RJI+SG\MMN^M:<O]``\;**QUJ
M5NR-CQ.%'QB?C.S"8ZD<PQS>:4&4))KGQO'C)(HQ48<3VJ*)5C^=0\,&]CH<
ME6*NN9:ZW\K317&F'_R2L!XS,6F]-'NQ;D0<BTOC@L4\01KV[L^T+'2SL9]2
M02;2A)=FAN1/\_'`*?R'C\'%<8K1;!ZS*3R'PP8)P1PR&H6$F<@0I_;,(IK:
M@R.1QZLPOM3>EC[0]#U:"5O/ZQJ;S8/HD3$<E\IBST_R%*BHR`+2$-'F6>Q-
M@3B:HQO]/GW!'NI]T^2$DQ@""/Q]'9.J8I9C\,CG0;MW=SB.,Z7YG!YC8WJ+
M1M-^H^&>P:/VG3W28<O0`M\Y]._RIPJD-Z+5ACCG^!+R/6N@6X[#OZ$[IJWW
M'7O7B)N7(PVV38!%O81][]*4OZB2X!H>&8/LT9\F;>BA:]D<%KK'N:JPWP`<
MTQH2Y:O)<*(`)<2UE_P[0\LR?OIT\R7)?S1_^EXG&."WVC0*Q.A5G+D,G\&M
MG;`T#?A$8%AK:.J&8RRA(&&?X(1>,1.\-]!'MH'?YJQQ'W.<L87N+)O1+&E<
M%W&!?4YC@7$,.$YVK<A7ST$T+[7/-"J:]C@H#OHX4D/,2*[N*J+">BG;:D.;
MQSO9^VJM]B40B>@@+(K2E(-[*V7K./M65;]A%%X(\I?W(A&Q^.-"J<;:,@[M
M+G9#_-T\]I$]$1_YBBJ:#P$MR\?H<E#>ALZE4;\-=3%+UA?"06/=.3;E,?/1
M/0,=`**&OB,;7\"!%[MW<C#MHBJP+AWMD;DQQ\H&@.BGJA)H)2L'F3_[UO5C
M[5]ND-'@WK=^Z(8>SA"^#H%A&3\A"8'3&$7[!Q/#8FFONUDZC6(_I3;>VET&
MAS]:-JA$)HCW/>$]8RZH-&$-\)O[B0=&0(8*D.1(QSG-J(II3'0Z!=T%+!^#
M#1/"(\6G^$X#40=;SD^F.'F:#Z&'_0'(3&)WQF@.,XUZIV5I[GT!"RX/T@K_
M210PZ'GF@D#/W/_@H96`SJ9G`]^]]0,_?=1P6.X=CHH7Z("IE*I?QOLH/L&/
M@Z1QRCH=+C'NX.)G,=KY;?&>GPA$R<YS\5:+G^*&]1C?K0]1%HQA6Q'N^<&"
M9AL+L)VZ@!8GQ+L^_2&%79],")("?AH/KY&M#ON,'G')%(1/IP^,A;@1_H0/
MS=TX]3T?:)0"I*#]D@PY-"F![(JGA=6HL)@#G4P%U(`<F(PSPB^?:@X09S-I
M<.#C-4L+O#,:9LWM,*`)G6H*RCE^QWM^?,9YV^LE4\QM1]).?5"28(,]<N*0
M\@:#YV\\VLD(GV=I;IWBV_Q<29DW#?V_,G@L2[C-7K\'MAOX/-C)O.>Q?[\8
M5U2<P(W&00^V'0>]X$QN/O^YE2<O,>@UG1DM,397O-#02VX_W&HI5GG^LNU>
M^1WG3Q5(-:NY.8&X^S^S2)AAX*-K+\%]'O\G0Z/N>]++9-<()<A=8Q]5C^_A
MO`Q4=8FJZWR6Z&V"U@L83LDJ^_G%L*'P%<^K4^0:R^%F*?"M1$AKECPZ`<FY
MYLI>6D9P]OU5DB4_]((,?2MT`T&6./HF/SG`Q91&R=@'TR&%DQ^%*RQ^NDU8
M?(][74=[IQ.KU6+5K);@!,3J2UAP7AH4(#W<JP,=D\*OR7:5IAGI*+0CP3Q-
MTH1"'C$#587NWE^9'PO+#-46/`56J)@EJ*$?&CV4C3[W-LI2[D(T,`6)"*HY
M*$W!RZ;RVBI07/P*C)6C,"4_9.!8Y2ZDK[B00@V`EY+P28[T#V0,2`T^`=O;
M\Z(,G^4^!-_S\YB1UR"NTB?<P\H?G;N/1"@:VN1Y<<:*1RF,Q`/5Q/L9?P6\
MW'H0%4<?.>^K/B+X0&"84GP"_P#>0XR2D&8Q'7>7VJL*.C5!Q&&_B%;P\$7?
MO!P6OTG7Q4@)]==`G,HCIBZBI^4(""I7Q-Y?<`6)6OC7`*3;G_B+VAF@1^%7
MWBEL_EOFN2CF\,`C?88>4+PG<0#(C<+/@;+1D*##*4CWA\@SP%Y6V9$?$`64
M?)^ID/+8L=!]IQ1VN6%WY(Q>AT"8&?>/3BO,PA-"\%_8\[=9@I$04M%1R("]
MA%T>A>.;'[88!@2XH@;6JS%&E+983'K5U3&O7%E$LQFF`^"`^9O3"@1TF@%8
M(O;[]^.,"9$1]@0%$'SX`&R]633V)Z#S?=#EM(LGX+(%&!9"9?T?YLE/2BL&
M,)LC@""S7A2C*8+!&$8"+KZ"@NJE%")"T?8"/R3)%JDM5#Y^(@D!B"=10888
MT`M1J8AH#ZDKE1HO_>^+_1TO&8`K-&%.3<QT913ES#`X3XPAEQ+\3!X`<^]B
M)L)<N(LPD!6/^4DF@'GIJRN#^L(O:@GH--)HN?C^!N(2LF^%Q%),=7:+BC45
MBA<TQD1)&XZ9YR=`YXN9^R=`!S3PV0,/&!0/`:Y9@-J3@D%%;H;"4@0A\-R]
M8Z7WX&CFM,#8!`CB7:!^4K!@`^50*IKY::VJ6!%+^.\?LN3BSG7G/]Z`900Z
MS`/R7/'#"V#[&`5@)K#D,^S,7X+(^_,?",Q_2QN`?@66P-T=\/0]Z%0P!8HG
MN!N\_!FY\BM5!*YBV!9W)`.O\^ABOCR*$&J)3VSR\XO_<<,+P[S`P^<K'$P7
MMD'_?O$/8::\_O#J\[\_OM&FZ2S0/G[YY??K5]J+BQ]^^,-^]<,/KS^_UOZ?
MWSZ_^UTSX=#[3'L1&>4&/_SPYOT+[<4T3><__O##P\/#Y8-]&<5W/WS^],,W
M_):)+XM_7J3*FY?C=/QB>4!@D1*V=J&UH$)EA3H-NR*FM/41`<=8"5CMJMBU
M>SD7=GW0D3[X%'FP015$%L^WXSO5:/WK,+>QP*PR!CH60J#FX2C1*'H*7H*>
MQOBU1RV>^"E5JVR%.N9'(?](=)NZ/*(.;D,<C!_`,M*Q0"+(>`6"^*KBI52/
M00K(DG86>I>[**"DX]^RC[]91FXQ9G-^P/IQBE%T#D$*E&3T[AR4T3C17J)"
M57/(BPQ44\H4>%]7],&_,06]S`*>?W-%&I*,<$"T0)D#)).%2!ZIXWGL>!4E
M),;B4*/\KDC!NP%/?O*OZS**/>:V`@<0M9Y/Y['(8+MAF`&0,Q?+24*>,F+\
MSUG2"'-9.Y.G0[[K.[FEC^W`^-*ZL`DH-0Z0?&<5'D(VA^=`>J0L``0('$F4
MS(*#AP%_SBTB20=A3X%%DOJ2`$05(<)5HNNEA7W,`(>AL(J(IO2>9+_I_"08
M*I9-'R*%WDMX*F@JL5F@K42)@NV<W0F<F<(9`T+B&[R$0'PTJ47$M!5$"/7<
M-%.M2GB&)2G:JH*F`DKMNU[^/M@>&9ADE%.K/GZI74\$.9/,P\*F21:`J2G6
MX*;N"A%WT3RZ![S!P;T@53$69E:.R@-*)L84A!"I-*X!'QC!=_IWIC,DQ//,
M>"%D^1.%,$I1X@#)*I#51$OT_$N#=5^JHR*G@?Q$K[_N&T09F<K+/W*\*;4O
MI/&IVH3%LT2ZTS4Z52K)!Q]=(_024`%E:,G&T:,;I(^4N,74KZ+O"]TGC7TB
MFCQQN-CSO+.H('*!;N,+81R/_3M,X<)'!'VI1(DIACZF5.6"E]J7,*#*/<J3
MDH\"#DG@LY@G!\!%XGEUTA483B.L]64X*PH7WF>3"?I7:!$']`8X1'Z<Z[1%
MU1/=!OZ=*T\%)!>G%`43Z''"'X\=.D"6/\X!%E$3_&N)SKZ@.UGK\2-XI3Q3
MB1\5Y2'L+]1I0MT&$=B4X'9-?M1>NHH7A7^#5W.,W/"10J5CC&SX,_([,TR.
MI[2//2Q)(5](:'/8$MPO13!YM$8^*S:G*@6"]RJYN>6A+DEK</(HV!+3!;:X
MZLM;%0LP'7CA"\_-2DI0K8X,%_EQHLHGR5-5G*HK\:)!\4<5I;SF07Q=47^Y
MCN32-0.F\FTC#!Y^<I*[N$I1]@HUB*,;^%=U/%D>J'0A440%GRFYP^O!V]T6
M1*,C_SS&]A2EP6U)&1:E?1J10&%@`3Q['I`69.5!\#$9#H^JD,$[JF&8X*9O
MKL,>1+&>V&NB_,-#[B.I"S&K&"H("CS)XX*31W3?&88QM`00\)"Q839Q*<P2
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MHGI9K60>JLX/G)N@M-3]3$$'N=<5O3'/XB1SPU1^:=U9>;PYJAP`BM#]ZLYF
M[AU>[GGR&-Y/HH).?63;&I5"2#&FYW"=SB-Y!/`&T3P2JE_<;_"R7@KM\=_M
M)K;G%MX>_)'N+&DO/;IW@0FMT)W!`K\]_O/[BHTI#2L>$Y2'NZN)5R6,XN,\
MF?[KU;MW5[]>?7JM_7[]SR_7KUN0V<SY`Z9&G@Z![<,%0_Y2E9B%@.,2B=LX
MZ+@8>C-M-1RB*,LE2RY$Y<QF43D10+*;!Y`$.TH1)`%W(O+G^349\-]R+2Y6
M']=(B1I<$E7).P\PV;VV`9N242.P)XM@!U&/JKLEF-XZZO%YN810A3F/O6+U
M"=XJ`1==^]/G0H`I?60\CW44T?E+B3(5%8E\N!)@TQ6'!V#6\Q-'%[7U4IQT
M`3-/B$HQP7L[21/Q!GT5T/U.EZJCDCD2#A&1W$2'`8OO"H7"4^QD:@,%$4%M
M65ZZY&:D(GJ+5=]$=*DYN<[D`/BS6SA&L83D45*H',\HG:I+T*H7+HP"R>-<
MBE*#Z@+%G<(J=;IT(<M?A;?J%[=.ET*T1>",J^8EXK=)`(T3HGD$32'<FO"9
MOJ_X&>%^P!C:0>-G(H"W80SM6!V>S4,7"V&+:IW+DM"%4%'BLFLE9D&W"4LA
M!]#@S2(.2S?WL9*<`/AC2<#@1`(%7-C%MX0O%P25NYL;!E3V[GLOT];;MA(@
M_-]N]9$%!_QO%D?<];9WX'JOIT'->5<G&\?K'N>>\;_\./HX=>.92_2[!OW+
MO@&&)7P7[LR>AJ/\ADP)9.X[]U&YYJ0*$2*MT*!2#U,^.?D-5>%32W$I><U$
M!>5S==YSC?,LMQ36(2]8J=(L4^T\RK\DV:V7I6[(HBP1A9^N,'MS>QT>+,`I
M64T5#T3ZT-HK/XP?_V:[<)NY3#3PG5^9>,N8Q2YE=Z;^K0]N@?;_44GL___]
M@F^M$'B%<UVRGQ4WL[CZJ7R'MK!DC+A140^5K$,29AYJ85C$I:#:G1^Q,8//
MX94?3[@G+EJ"]<4\8%;-\8Y1\7C;>ARE3H02'05J"^Y_T?N#KDI/0'Q);%;$
M`O12(&"#,A091#"5^"AE4U12PT(4/E#845^$LCI6L$4$H&>NB0"(7$S9T:I-
MO53D+HG($="$^U%X][[B[.C2>:7;/`$/Y.8X5-A43T!$1J$RM_%IB\,!1=<8
MZE0@CVC+V`1\V4='`&59&!Q,:E!.`,6X+S`A.\>=<#<7G38W=U%5BN'9"Z3T
M//"-+U5>8UUY%#"*%2WZ[LOC"95P@7"C\LP[K[U6LJ1^4E;GY/TOHWHN)#+[
MN#0\@->ZZ$H([R53C31<?;S6_(D,&?"@0('\8EYLJ1@4HDQWC7(`YQ$Z?CXF
MTHM.-.48WZ(Q6<>@LDC+&*/,#.3U`7+?\;B;U"I@-;AI?C2%N0`UTGB"#U0O
M5+\%=A9&0[]U7<Q,Q!E%W.Q8_:)MJIB6':"K(S&$,B::,*I1OM11CM&0GG83
M'D/!O^1:0XDZ)`>*<KC5P-GRC^CY85^^2+(66RFNY'A36Z[FB_)(;>D+9.VM
M^L`R?BX):>4A++$W\EAD31R+,_TH:L$.%,<B"K2L!5,8@U5=^6:MZ*B\7Y0B
M620V(1Z*;H+4#0L9N+A]O)!+\JM$I.-'!H#]F(BO/<1^BMB%44J];:C8NT#\
M"YT*\'T"6`)6M94)=]G5"CZAX/,2W1)>_1XOB)F,.@G-E#L7KIIH^)Y'0?+G
M=G*GJ5;SKN^/TOA:S&Z5>.&A_D\6L@+"`4^1E+S4W#7?TD<M/G0,WJD$1O5-
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M]F?D?;@O2E49Y^D\UA^L:Y+XTFT4WM3S<!V7NHUJG>^!7<=Z;N[`<5SE-/)H
MXKD[CDN=1E[COM)QS-ER%&ZCULQ;5#W%'($%/U&&4[?T%>L<!]&E@WUCX'K@
MN1%-)@!:#`([=?T8G0A@#>JSVPB3NGA(46NV*);59U@:1<W">6]Q*HW#N"0X
M\+S@5HCFX@>.5]O#":M4>7$;*4"S#2F;5[7AE(2YJH>7I8;5OBMYV9LB!OI2
M\X<+OFH"H<'#S:#+I44>C3Z][+/DF8$OE[F\&G6.'Z#'YRXU_.&=NU$'Y8U,
M]+PI%&D]A5A41X:W:L:8U1.]HKC:+;J/8Z-@5`=*JRA`0013:I:3-X@6&_>*
MGE-XAXR,.7$"Y_6#V._`Y8!5BAF*EB`<@+P*!IO61D%T]R@=]SEQV&-9FE_\
MN?4C?`Y)ER6IN"Y`9MGCA5"X'C8=HFU#&D&DMW+`2'EC3YQ(7&)<5FNABT=Y
MJ^%YC(51DHGRM]'M?[A#P7]-!AOV*LOU['J9X(W21:DG*_KN%V#1!D8^*J3+
M:X+$N>%2B6ODJ7<M2CLI9YP\X^AB!F)<D@E0)5M4ASQ1#V7>8$X@+,J"%83I
M?/6I*72=2(/:#$#DU$LI]#WAU;KDS(JR*WP!J4VGD;($>4:*'P-?FU$3*[PJ
MZ>?]RQ43@/.7+-=BS_#($#C$RE(<F.^5?ML/(O*%A4?Y5<$"^>524:K+RMTL
MO<;GYH%D>:VPN(N+3:'B,1GDTIR*HUO92)S*R\`+FJ=8S%K(5]%<BF\W%TCT
M"(<Z]PH+,2VG_.O"0'E@J5(YD!MRRK.J+JS-/ZB$DKOUNU'YQH*`87'M_(AI
MO')Q*!7KTDE2=XC455&"XL!G<MDC$T8F"^'GVDLO>5</)+RB4@78JE:1;3NH
MHGYE[FUY^16)J2L87BU]VX3!ZS-&"L\V_60][+*56>/:NSG=-"&!ESRH`>"X
MK:WB0BAID=KH6[(I91ZFC$24=ZD<B\:7LF5H\X`<CSSAHZ*%*'XN[VLLK((F
MFH_'=')!O"TKI]J#3^@E&4LKZ)3#HIZO#6R]YN3C)DIQ*I.A)C\3*\9!$\@0
MQ3Q@A,;FIGPD!N"+:%#.&)VSHK,O`B:,+%%\>?NX:*SD&S6_^XE!,\X3/_D3
MX:+!7T0Z=X9-!D4?$8I5)DF!2,4(^@/[K(9X-L^QM,WCNA-$7FA%]71N;HUS
M\G/9E??8U745-TZ&/H]XC\NB=(J^!OZ=+PRDM='7_)Q18Z6U_,5(9&[9E&+:
ME7N\RRZG+7.GE"X?S<O:*.;>HJ%`DX_778UO=DZH1&Q<DGTMSJ0FW0A67S`@
MHA37"]SJ!0-Y,Z-RO<"M^=*N&Q$LA9T7-TGX-KARD/O$#T6#XTE&;IAJ=Y?:
ME%2NMI2^=^2;>\<7%$H7:6O*9%OV!6C<$T#<.JID))?4[JYJ`K#,<-S;A90Z
M(5IJO=;?3>'>1]/[*4^)R))<RI97;)0^%W_DM0.JO[`\'UQ<I%'R_^UQI+-F
M52RQ<LUD2\0K<^N*B0)U6J;H9KQ!-]U]M#2^#C'-#4?B^?<P[BD]C%>AW:!I
M\:KNU5MW+>ZAF<#!PPC-T3>P5X$5N;D\"2734ZVFCZGG[1;CQS::+^9L/5],
MCCKSJ%1N%^/&<MCDQ;NVH\<&#=]_XH=.`-Q"FV\PB.@I9P+M[+/J7*8:4=[J
M:AYIL?HC=)66.Y*Q2Z=#XMK!-@>C<+=W@+&5@T2<7^;\&U83^F/MOPSZOQT)
M`%IFW8XZ#.'-H]EH);-C%\-`M=L[('0$EM%_>1YCDTEUDNOB$+ZEQBEU$@!O
MP&"SLCEZP7^YG4WZR7W`F6(L]MT@66=Z'LMVV!#'[UKME(5!O*W7'PTLW>DW
MF]L:1@^Q.__Y!?_OBYW2X2@UTDES%K28/K2:S54]+&=;V18'UDU_1/&?\$$L
MA\1K*V>JG;8\T'<GS([9UZU>IZ;.F,76R-`'/><$6+Q*7YV.=?76#_UDRL;:
M712-.P6V9^GN&T/=<#H%=L8L=GJZ,^J=`(=7ZJ^Z^_'+=9@*\*81XM8O+2I,
M$1>@K$Y]4&!5;N%XENWHN&<Z;N5JM./,D:G+@[NENCD<Z,;`/@%%V?%V0R-G
MX.C627#VK(]`&W0HOTW^M+I[1^MVE-P[)1LF&>H2"#]0)898J:B`6E6+LX^2
MIX\Q3K1/'S\&.$$^'+_Y*_/G2TJNSJP$JJ^40&U"AD.71/4O-0DN%>;EL.K:
M>Y9RX5J2<3N*$JD2\*P`/F1I5S+5E4QU)5/G6GW04FMT)5-=R=2SWSM=R=1S
M(7Q7,G4$2;U/\CIM;I^NLS^/94^<6*AKH%N&H_>,+J-W?KSMZQ;8#<[)!S*/
M54F]BF;SC,9^8A]8:K!V]OKJ:++4IMZW>KK=,TY`N#LFMV:R-1CHQDD4S*U,
MQ9R,X?4[<Q/J^*CY,^S]SJ\S=\ILWW)NVHYN#D^A:K!C<FLF&^9(-T^_-/34
M\\KG61+4T;$KK3HSC3G4AX.A/K*&)Z`Q.R:W+3?6^^9`'YW$W;WSL/&O/"^C
MR5/43V\>,VQ4E`\\FD5QZO_-9T1U9O]>1?_E0.\;?=UR#J_@ON\TW/[8W->=
M7E\?&8</Q#9@<V?ZGYS)VM&Q,_W/(V5EZ?;`U@?]+JI_?KPU=<<Q=:-W>&/G
MF1^"YWH;H*/DL=VK6.+>/E7_ZM>KG%MJU8Y#-&@F&W8PGL_CZ!N-K@H>M>\L
MO-YG&+P'L&6/Z(=R6UZU&R\AVZ05<;DU+Q^/6%G:&2E+#_M6:>EV#9`K#8&U
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M#K!):Y=5Z5+B9Y%3.4\ZKA3]7?L9]KZ.[L_8E$`;5^+@W1F^=W?#[MNZ/;1.
M0,=W7&[O=PR'MCX:G4*7J5/T.WYG2:)Y//>LS;'E2M=+=-]"/=)[CJ%;)]%=
MOF-R6\VEFQ8PVC@%)G<NR,F9SAT=.Q=D>1$.GQ`>39[)R7[HZ+C=(RO5M+O4
MQQDR=Z`[_9[>'YY"^?U9G^3G6EC<4?+82K27'.)/U0P57[R5__#Q'Y\B;\HT
MI:(A"D5C4#_7`/3&%X!`]#UE\2POPJUY7Q>_G+L^=DTU-(`KP+8-::1EB>:'
MFBPA(WI8AC'0W$1S0_B3G_INH&7S28SHS=U'ZD\CVYZZ\WG@>[P'!*P?_Y9]
M_`V^#]_EO5CG,;L8LXD?8ITSP7#K@YUUYWM:"H1E:7*I71'H*]JE2O"G`!.A
M`("Y=W<QNW-3AN^J*`$R7A2&V%,5?GKPTRE_FW]V:)G.3XG&`O%WI-E#I&%A
M,*\[)P*P;UZ0)5A*(H#D[6##,`-2`+[4H';F^F'*0C?TF#9AP&%)$SJ(D`1C
MEL"601CIUPS?\,.[XJ/)XDJ7`E=AS06/\%X*[R7TC6B>"K:)9D$$F!?-9BSV
M@$\@6#D/"'7.A0(]N8RNX1A)'_O4IE,WY8L2[G@KP`>[,L%5@-UKT289VJ!U
M[5-W&\ZPE[`69;%$#5G@A_=1P,=H:M$M:#82X41[B4QDWT!6`K"LDVR.UC3A
MX&*37J`B0[XE$?8O9F-.9$EQ%OX-N^-[79KF(!(`$#&NLG]TA?%22I"Q1-`F
MLO;`8E;D(>@-^,4M0]QBYD5W(9!@K$7WBH98H2`NM3^8^IXL\$?X"?M]X)#E
M^JL&(MS'I&!F41;R&P:5=LQ]PR[:,?=&YII.T&V[0'/FEY<V+_NYOMFN`;1R
M#432/&8!4`#51'0`LC^`4OK.-BY-B2#''VELFY=.CK:[3FG3.[65R=MUOGYR
M]1$3+^HX3,"M/+<>:%<QP'&QF_AEZ<RJYA07Q``@RR:@A+*8J2?MU<=K$D'B
M974;5Y:TL68/=TQ2:"@N#=Z2^DFNP);"QE5#(_B*38ERL=%F:;!'5BS>0-P'
MJEP#='^S.&HFX$2`TQ?R12/T5W<V<^_<>+R%(;KD&SJA^XO[#1[FYAR8H"XX
MTV',)L`M,MNK]B8:>6:^84`BMC_5-SK1$1\`H&"QE)<JH"A0I7/93Q:.92)`
M[=&\E.S+C^>Z,T(1^B5?7'^\FE9QHC+7FTH06YZLRXY2>["+.0J;'Z,-2$2Z
MP;FT2KH!?C'8[!#<EXXHQ79^6JLQUGO?C:<+[%OY_`8?"-DW`JS$DCKE<ZE=
MA]I;=AMG;OR(KJM#QR[R2N@8=\8%R6,Q>E*@"/R$)$,]YT#\JNLKN@[WWNS6
M!RLJI2_371/X))A67+KD*V4)PJ_^Z0OW$7Z@\9ZDD50M<ZF]F4RX`&C_`P<9
MX%'PR9%2PG%2=><L2\'0@TU$>(Q)T$&7^+G'60\4PD);O]!Y!2$NM0^A]C]9
MH$!@#LL@R.5+-""/7'Q$>XF?E_ZV9?Q4W`C7KN1#^9_-G[[7$I820X!$0!;)
M)_*CP5,=NZG++=LD0;<9EKOEOBI=&!?[_O91`L:#&F-NN+E:<:M<F[/8C\8E
M>B]'=>IBA%>;9&15P*O(0#*CU:,%%A/+U@0>EC+A4OL\!>+!%YDT$J5N)UT5
MBI$X-`JVHMBB29T>'5W:N5JJJKYYS.B<G?/"\XM;-V%CJ0B37"#6K+IHP`YJ
M5\Q?78@9R=-JB5RNMDHYTN4=N_%Y!`?%VQ8'C5EE4@70%1I@V0E=1\]AZ:21
MKQ+B2UBW^!5%#H20\5A!&"WP-%D0E"6,21N>P<=JWA(`<$K(,)BNS;,XR5"9
M"\1+=FN=NM+E+@<Z!E%X!_]"_5`*]\4,-`4WJQH>)>B?P.:\]Z,L`>:-60""
M'G-5SM>C`3Q1C&T+,!Y1DL):-2#B((!*O=?&/YYD8-!M`"0&7M5;*_DWQX5[
MW,Z[6R4VQ6BJ]0T]]M%#Y8T;8[PV^<CBFZE[OJU3ADKKE*4X'[ICRO!2>\]2
MV,8@F4Q[^7N4)-]K`*5&8&J%0=A&"SU!\Y1?W,3WJ%;#%R@$A,*<#KH9;!<M
M(4S\A%IK9RDW:L;@H^+VKWE5'H'<K,&'\:<'A@I)J@?0)^X=J/\,=Q^5B2AK
M)32+((4]BPLH>YE_42<K!A[AC5[@I"O,6OF9%(6)_97Y]Z`7R(!\[0<$^Q.B
M>K&`IDAE+$.5VI6#Z(>8W$+-BS"C/;CTE4OMXT;/@]G*N#6.EE"2*\F8N:"W
M'@7A9@SH.\9D#*#KS^G;\*\@&S/Y34K/S-Q'L'F!7@FV)>9&!\8^^%=X5BCA
M@15X)XU]#TG*_^H^@&N;:"\5@_S3S552,L"1'I]NO@#W;DI?A*7NX7N8O(-7
MZ#'E-U\2RCI(X>`]X6NE(L]01&&!X5@&(3PW\(1G1`>7$"`F5-&BW#Q,&;WI
M@Q="ICQ*DN3))9'A[78Q1[TD+F4RE_[$J5"FRU7"IU>2I)7.9^?27@PAD7U&
M07T$*K<8EU`%]P;NB46JW#+/S1+&"</SF#EQX"#W+W(*;4D=<T_4,2]'B]3!
MM_LU?ZBF:NJIR/7`5I1<3L4VH9H#]+@:6<?;XZIO=#VN.G#/$-Q5U7F-"L&"
M/9=F[J$9SV`_[:T^TR'UCI]-;_!L6F7L'TGEZ^F0]SV>_$=!W6[/=%WW.A)W
MFZ<Q9P_?_:UKN_?LVNX]<\)W$O_L)+[A58OGT&AR,05QH;W/9A@9C^(?%PEX
M5'<NG^Q"4KN7.JP[K$\:ZU8F^(&OD[^O3;7=4K*2AI*+8/F;CS='KMW:4N#0
MEXY?6H9N&'U]V#M\P]7OC](*.VGV]G5S`/\;G<*5\HZW&V[=WD@W>P/\W\&Y
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M_67APF!]^T_R+,_4D3SX=17CTAP>W`CI[B'MG+'&I=%-&SX_ML)^[1W>:>CV
MZSX8:YBGP-C.'3Q!@[&C9$?)CI+G2LFJ2LY_WG*L>4F-_]1P:$<M4L54EJ6S
M0O8QC(4&$TRC`!B1O/DK\]-'?*QF$LR9#6<9*<-9&M.@P;"6%9WG6[L(@>A6
M-Q)S)`2H>8&5\Y/&P>;R>IN;(RN"`0<:U[)J[F_#4=(/^<".ZKSZGC70+<?A
MS^J.:>M]QQ99=T)<F=."=*S..E@R:HY]PRGP":-)5J5B<9SAY>;C4O*I,/(%
MG#_B$63?]2[[`S[HTKQTC")F4P4!:P,PQ#./(X^Q<>T$T<M1>71FKY@J79UZ
M>2WF3.<3NEK-`U5I/C1U`Q"0DUG*!-6R.?P31U(@D_&/8N8@'X+R&:<%WWS1
MA/QJL+=B7!Q'G/0&^L@V^&2+-,)1;`3KS`_]638C9N!K)#SN-[9TV,5W=L_!
M45V7V@?.(TX`4<Y/G\YB;^H"=\HO#I9-R1A<ULRG+?#GLW(5&M#$C-)4G!W/
M]"Z-7"LX8SM]?60,E[!&1[&2FX"N.'@X=#%@XZ5R?P?ZE0_#H^?'+;?N\0ZP
M^\!WAYQR6H!N]A7!QU%*`4NYOJ$900^QGZ8L!$FZ#7P/"#1AL1Q_))CAZ$/J
M/[9LI^AB6@^^!CNJ_&P"@KXP2V^2!4&A65`MA#3L^,(-@BCEPP])XCG?Q.!2
MFC\I0*:Q=_`1,8]/T8M<9!$-Q!)U6A6U0I.9QN7`5!78'0MI@M7B5AR:EWUU
M&+NJV"ZU3T`N-]#^YU+[WWX,!'&U&9/3M'!3W48X.Y@NZL0@FE&<X+SH.,KN
MIMH4I\9,)GZ`@U83/=_38R"F/5A%>#X<R9?G@>1<RL=@-<6:=)/+=5"=BNY=
M]HIQD4O%OS#Y&EL@^S`!7P%Y?)*@Y"H<OXIP[C<PU?-9<OYVH&DHAN!FE#CT
MZ#Z024V!F-1/">;C-P??TCPI>(*4%?R7-*X<R\;'SM,\L[&?X#R[1-6;`?"<
MSPO62R-7O<#U9SA#S:?Y<#AH#U7*7,S9XUM?S$@+<?AP`#(-VI;EF@<'R[$$
M=-15^"C4)?Q5?!>>!?6<9+?_P8N$&=D47I2DL/$#,$512<]9B.8B,`3PF?H!
MCM03>A)'T=VRP&?WC,^@HY'(\(,[9G]E:,CZ(4@9#42F#^,\>Z`;#L<C!8TG
MPN.<*S90?[<^DH'1@+!8>==SX]A'(PN)";QZ)*SI<VBB1GS0W3P"?0=P^S,<
MIYW3/8<EC>C<>=02(%TR>=0($'>&GQ`#\.!+.&<ZD(.NKR>D7_F9`N]/03>R
M4.?Z59G2"Q^B<:GB,YRJG!(:ZM'8!U*Z8X`72"]FA>&@,3*W0BHUIK&KH..S
M@)LI!8OYI%\<M.K!9PCU><1U!#!5&$_("[T`A+,7&<8`UA@1"Z,4_^:!+``9
M=`&DP!\AB1E(93'_NQ"</X`#9-VB6+@T*)B.53<&+XT&>TMI$0<B.OR<2!)G
MD%M*\P)B($/>E.PTD`186YWT#=X?(#\'.QGW`>Q+G/;(!YA'L1!S;@-+5PE0
MW"VQ89V<U@J=&YQ[FRG<+0\_'/F;T0K:1Y+['X$$040GE@'.QU?@$;.^NOEC
M7_GV^$H!(+-Z;&)N/ODP^0@T`?B)%(##C7\7^A,?C.NT6(^6`YS.\!#=DJC*
MX;L-/1L<Q4M.,[6,P]KR-,M/9OP'#7PFG'"WJ%CQC>'GN^*8#VATV9%WLSEH
M+&2RCU,:_!E.M8=3.*7AI+A4PO]5J(I"(X`CG(KI\J1R;AGZ3J`ZW9@?[B[-
MXJ9CBYS/+R%]^`;?XZ=U<7;"L^AJCK5"HN285QR@K8YC_7)Y<ZG]>G7U,?^=
MG,F:N[AQ%O!S&C3;G9AEF0\LI_=O&.AQ.F'IL3??P,\`%<4-KR1!=JIKWKQY
M55I-&0[N:G"FQD`]P`*0CV)2L6_!``$C].*?E9'D``"<M!&=&W)TK4O.&Q$$
MX?/#"5HO^>DSSC4F#A('+R+F\W]S.@BO13JT>&XCKG6<HF!-PK9D-TU`A?V/
MXW;!',`)Z5,Z>FYQ;+H[%I&'_V1A)?2@+)8O07@W7$8=A8N'V%48PI&H?5H@
M^__.(V*/S(U%,&-5*`9\3J8($/`;/_?.!?]3B1]8,O3QF1QPB4X!O<H["8&D
M-1_&C*/A26?`>XB5SX,5,9L$<#HG)`SN^#]9(JS_PD;`;PF#`-E;F`PZMT08
MVC-N_"C$8>+ZL5PK'^9*$8<<6N2YG\M9O1%0'B6M0,_'70MC3P&8YAN+2"&.
M+X;/"6L\QCV'#K@(7N;O8%!/QAHD%!.R<LJ4DP:71-6GZ<AC.$6HX8?`+ZK]
MEAMJ.(\:?7S83P`-"L;QQK`(`)2R3?:E5"BIT.Z9B//]!B?WWV"BXP=C=\ZR
MU/?`*KT.O4OB/&ZEAVE$MN4#3N`&+RCQQSX(DYZ_+)['2!/Q11P>Q4+X)3(W
M7(^+3GXJ$#(,O9$0@3]>JB/!^0F6[Y@F5,>'<-]CJH:?=+EJ%@H[4;8K'AHS
M]T]NO6-,'2UU,?,[2;*9R$&0%^ERFYT8.N-DYF=,H0.;J>O284]*%39=2,'&
M\"["7V)/OX3\=';O!N0FXN?+`/XG&]_11W6NF&A+WE*$#L@%_F$:Q3[N+EH3
M]AN.:5<]#"XDH(_Y/S&M`/LX`G<[(N]L@0(%W8A>PL<F[YR?-@F8MICCY6/>
M:12X'WO9#./T'J+YRZ.83`W"EV%D4T$)H)<>/WEO0-0I=\;'[`[GJ(($P"G&
MTQWI(W?]W82T'OS#2S/2:QPW<LG)F^<#M9<X=?GRC5RI;<SG%8[5CIRFO7@/
M5M4E>\\>%"SC*(R0)R2'_//\_W=N6)60BANV*0U;1T'W[7M=C44^!!-8#,?+
ME:A4PNR47#+>P0SM&)#82MY*25NYB#Y(QMM<TRO8WV!NDN)NOV"6I:1V5'?F
M[=7-+R5_IO8;7^9XJ!!=U)>O;KZ4WGT?71:@HC5]8?1U=*3@))V"Z8(HR2%P
MG\&`]33XRO<_:CE'/U:,U+I7"T;2N0$PU*R+),J_NAZ`UPQ4=>SFF;."`Z_Q
M]$.K\0K$:,Q%2:3=*L`2=4`,`SBX2"'GKN8U'+^)]H%'J8&^V2SC/N,'.NAJ
MP8/M7X]9O\"?$L4\<IT1@Q)=&K=P0$W=1!C!!"#FQ3G`]-L\L>655N<73WB8
M$O\2A4Q8CL6U%)T?W0M/T+$M@M"+W]283]AB-$##L'U`%BT(6H9G?FZD+(-)
MQCH?P,7D9AF8&T!2-'K`FQ!]_@KO%D@#^W.J>=/(]\J4\17O62$+<S%&+%$J
MXPS.&%A'PBLDTJGTP#=SQ/.WN1E3BXOR-9EC1!E;_@:GN7R6&X#T2MW#ETM$
MQ^@7IO<JV:AAZQ(T$HIWBUU#%"CSD2(I9!<G2\J:&.5"N1OM%EMLJ?@##B)F
M(L(TY%?3!N-&(GB2W!Q4;./E&$3H[C"R?O$C:_`M/BYW.9>@0A8N<V^MC$QI
MEY*QR7(5,Z'H>NZ))IS758\7A84^%"5,/G>+9D)(Z>T)/%T3UA!U#J8@L')@
M<O+"1I%DE?57H#O!=J5XRT("P0?'84GBH#X7@P2NC290`H4^7P1!:FDN[L`5
M+DZ=#ZRX.,O4!__.\3J<!$##DW\>1T6Y4&$'*$<YG?-+=E!/.1I52P"C1/\"
M?X]I[\"7`O^(MK$X)X=P3FKYUZV?*N?AE3>EA.<K7HBQY%L@8H1FD?F!`Y,4
M<;Y1"G\9Y?'Z[:<;Q<*X5*RX>H4A,!0RQQUR@HAB8/<$T:P,D1)5E<="_LD"
M$-R-H<O-=L7BXO'&LK&D6D@5!+['?#Z([U\9Y0WU(G578*+HM0<>+0;+G>N9
M,4N\V+]E/%TL;)4JS.5@,$<6/Z)0@'*GU*.(,.=1?R74?(L9]7J*4=S8Q^"?
M8EWCB=I.GXE0]TYUVJ+`+]5G*Q*AB_G.%;JL@?>^J=>U-X_=VJO';E<]]NOP
M'G",XLXS7T(PQ3-?1JNC]<`EP'DITFDXV+2^"CM%_U+:]V!#!M$#+U+$HA_<
M]0#.GRQ%W9V0KALST!]@1_-8IPNZ(DX0.%W\"]4G!5$O%U:)V;W/'N!%K@<Q
M0AKP/,T<I`3$@\J+,*FA:UP1H5]P"WJ)\GD`8P9??5<.A<HP+3?JL3"(@KM<
M>0,>O@($`<QSH;&,]*;NGR+S&\D@/L_F3%PJRT1#?T5$=Y)A-%5+7$RU4G!9
M>%9_87DK3ZUB3)A"II1!HJI+/Z5"*H];$-$MU9$3)>)HG'FYX>S'2GFTX$62
MNUNT%GE2"H3$..FEPL$%7T8$DRD+L*9J0E2YB_`<$H`=KV'XR7W(#ZRDQ$J1
M7T-<8O>!`"T>))M!Y`KAFQFR,HN5"KC@3VT<9W?%88BDSW?V;P!DR+XIP19P
M>J+9+9Z*J>00&/%1_"<@>D$U3LE2\)0GFJUPB3:6#_P:"S8M^?!$/K7\LR*I
M6@/\L7+\#R8K#$F0DU+M(Z]BEA<<0,0%.L($`L?G@FJ5[RD'71!M0JXN)FJH
M-!ST">&980E`4GXMWW\N+ITP3'US2QE,_"":D\DG(10BQM49.EM8%#?6\*0+
MN!*AZD\7ZP7SNDBA,=`VQW)W-_#_YJ8GMRQO*8U#5BI_$+B'$_0\^$#()CXW
M.$EW<$7#\S_P%4PIOE55"`4%BJ(4CJ,H-;A]E$4A<.1JMZ"-62*RV$E1'_(6
MY(_?W\#=<C7&"RM)*M*"I5#JZRO5U-=+Y)?;T0O@=511*=^F%`K@I!S+(G5>
M+DOU`N7#`YSO/UTT.60JOO*U2^TC<"%&BH#`,_\^+]E'ME(F"M\"0.%4430H
MD5LAA2O+B[E"9OX=^E'`TICJ4!6A%!$T(8]Y88W+=?5\ZH)/X5&6F<3Q#D3#
M)T>E%$;^>+U0P%-66^*R$3\[B+-XN65,IKHX5K&R!DFX7F1YYIK?.1!*4UV'
M8Y<+,O="<B+B8IX[]U,N;;B>Y-)C(S]@F8VW-WO?WJN]WZO:^Y^`X&'&/@%#
M[D*RICO#OYYRBN&_EFAM[Z7NVP$0@&L*Y*?D"/PAB_93LLP1E83K2:EFN%&+
MFL2+@L"]C6)>8>1B38`(B'SD1>^)4+IT^HTIAES_!I4'B`H=HD`8A3&;P$ND
MB">,)?(H@*=8'MX@S9I_10=#UJ,C&%_0\382`P,XS(OP^9F/AC.FHT`G4XB.
M_V7,$E#J;EK8B,N`Q9L7_NP6;T_D`=:E&C9A\3UF6_`//V"X)'IT`VG_<U*2
MC<(/9V&9842%`E1(]PH8<8S!,$'G([;78B[_?^=B5%?URNL>TRD<Z"G'[R[S
M^=^!/.+%W%P5V^E2DWN,TE9BF;%(6Q27_29`N.B!#C"Z">B[=%;-6/JC]M)4
M>MJ`I99D+H7&P1<%`GCRLJ%";3@KP<A)?M)>6LJK8S#?[EG,<XN1)TY(NA\B
M^%Y86O+>+WS"5CY!QB<+`AG0$Z%J[A$*\_8V>\1$82+J0;_Q-:33C7N$IWY?
M]I0/H^"@BTC7942.3U0$/5(M4;RRW*PXH-?JXKV=U+V]GM3]Q5N!2?IA<H.[
MLCNBZTE6NCFXC%I'&YVC<!5=3>!G&0%_2L>S1*!\&`OWGY3&C)?^\@A($?W`
M,),?CR_X;:P:^Y[*O`-YB<Q/IOFO8^KU('_T>=XG$,Y2(NH6*YX)Z,0I%KN#
MFHD\GT[57.&7W?-JF$+A1BGZ48\Y8!85Z`O%3Q>_+\;1`RU0CAU28:4,'BK>
M9,.K6\LD?F\:L+]7#3A8]%6X'7,5CE\75LP;[B;R!3I5*&A7\E;6DNUX_17%
M<E6`U][(*[TGI!X_K0ET%-<`0'VXL;SA)&)HJ.Q<3UPNYIJ"WXJ5VDQ^18=_
M<2U8B3<53TA+GH,C(T-E+2EM1)VV5(QU)*J[(%?/T@2,TOS3:/ZNPY)B,E.@
M-8]&J9>$E4`.&<R\#H?>'/NIN$@5B(O0_+[OLM4FX$T)]4]6;ACQS'T@*@.*
ML&:6K-2P!_96KL;WY')(+U&]<%]V1,4]`]Y32&1+%%N?7V['8_26\?BF""KF
M+7^H$H#39"E=*50H9!">&U,EICBZE$#;I79#@5EQ]4$NJSA$;D(E?B(L+2*X
M4A0Y]'P!\F&X3Z$^4@AC3.%LK(?@3[FI$L@F,7I@L@J-1Z'S.@Z^#H](EU8J
MJ$9_R[]_O'+R;C&>(-L9X)V5NIY"J+=Y3`(V(O.F811$=[PO01&3+R*WU>AW
MS6:-R>U5[UWXH1+;7I(>2(I8=PT\];#P&_UH6\G+(]M^G-N,!;*<\SDN:HJD
M,91$,9G$X`4^E`^E:SOKTAD\[L]IR[5M4EP>T6(_^;-(^.(RM_R*5I%L)K]?
MY*^74P=W3!#(3E2H5)NC5Z41U[9)(21<@4LUH(A,0]]^K>6R-]MVL%?;UI%?
MQW=^+`KL/DPJMX(>WT;Q*W&,?\937%H^70R@GK!@^.Z*IL<;*9!V'4%_DL9P
M#K.2EZQ+M@*;8^S?EE]57+C:2(%KIMZ7%BI?G.&HMS!P&N-:=RXOT7R(XC]Y
MY;,\V56[2EP/#%#GD%L/GR6C,HRC(.`WM\6E?9G'%T\D:3:6]CFL>Q=C#066
M)E4SOQ_$[0H/0[JIJ($I9VD7%B43*&8N;RZG4H?.""6`*O2Q:/[#<A,>CVVN
MB[DQC!%G.'BH,/XEO[C-;U_274E7UN66[P8L9K(1U33RHH!,)P\L>FJ2`S2N
MVD_?\WY2N.8CL9(P(&87S19XT9-2-2VKLSZQ>S\A!@LP\K7<PDNIN!>UA0^R
MXU1188$GJ;"8[G#%&)OZB0!W+)8%3*@VO8[0*TZS7:FCO1UUSEZ/NN%"AV-L
MV/<+[F>\2@68TJ;EW4'AI+\.\6H@\.!C``=(%]8IT5)MDKPY&8_V0"-<+@@9
M3<7FE$ZTSW37B[I17O#3RE,QD7I(;4##TX&H!M771`.V!Y=ZBD0>#PTG(F68
M_-C<!56:H2L>Z)JNV*LZO),0@M(+@F3N>B"=/[\P7M#/<^R`*WY^\,?I].<7
M(Y`3C;>4IU^7F\Q3YGB>L!_E/P0WJ$_]CQH*6CZK!"69Q2^6["_>*?XWC(%5
M!+QF%+6`K3_X7^T:]LL/V`W??^*'.G"?.;CY,YO,97_*&4<[^RS6GH`6@E\,
MZA1%"SUNED^GSU/L(_*.=]5^@XVH5IU!1S)"ZG3(^QY[EA\%=;L]LS.FUK>=
M[_;-^9+X.6X>J\K9BFTK3&IS_DVC&ZKE$4I;2P#ZBL]S2QV>\&9'^$[BGQ7A
M#R?QU:.EY/L7,^+J//]J=*!NCMPIS1U?5E6S2+INQ/@.)MN.3%L?]0:-H.B&
M49\29X<C0[><CK/GQUD;^#J"76MTO#T[WIK`UY[>[ULGP-M6#O&!S8L;%N#H
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MI0[K#NN3QGJ/`2][;XHMQ?9=?&IQ<N3ZZU2=)U,W!SU]Y'2U#>?'VZ$QT`UG
MV''V[#AKZ[V1J5M6=^/N_'AKZ;8YU!WK%/;MDSI0>[,S/K$DC7WJT9N0R2'Z
M0&(6+:[^+0O]]%R-D>V6WN$>P)J\7J?=SIG%HSX<8$.S8_'YLMC2AP[X%R=Q
M=[QC<FL'LC]R](%Q"COYK%-PYWEQIZ-C1\>.CN='QZWBT4<5UV][7!TZSM#=
M:CMGWG:WVLZ5M]VMMO/E;7>K[4B,KG.M>.HHV5&RH^2Y4K*JDO.?RVV[ZUIR
M_T`#QLHK'6J@]HV/8]<?&!\?[\)CJ9Q5']YI090DFN?&\>,DBC%1AQ/:HHE6
M/YU#PP;V.AR5&OOFX4C0U/U6'L&,<R;AEX3UF.&<99ISJ4R+JQL1Q^+23'4Q
MX]+'1O'^3,M"-QO[*15D(DUX:69(_C2?H9["?_BL<!SQ&<WF,9O"<S@`DQ#,
M(:-12)B)#'%JSRRBJ3TX-WZ\"N-+[6WI`TW?HY6P];RNL=D\B!X9PYG2+/;\
M)$^!BHHL(`T1;9[%WA2(HSFZT>_3%^RAWC=-3CB)(8#`W]<QJ2KFBP:/.I^#
M?7>'(V)3FAGK,3:FMVA^]S<:.!L\:M_9(QVV#"WPG4/_+G^J0'HC6FV(<XXO
M(=^S!KKE./P;NF/:>M^Q=XVX>3G28-L$6-1+V/<N3?F+*@FNX9'QF.9CZKD4
M;40/7<OFL-`]SOJ%_0;@F-:0*%]-AA,%*"&NO>3?&5J6\=.GFR])_J/YT_<Z
MP0"_U:91(,8!XV!Z^`QN[82E:<#'IL-:0U,W'&,)!0G[!,>8`Q(QO-\;Z"/;
MP&]SUKB/.<[80G>6S;0'/YWBNH@+['.:G9ZZ`4T;KLA7ST$T+[7/4]S>M,=!
M<=#'D1IBD'QU5Q$5UDO95AO:7#'G]L#:^FJM]B40B>@@+(K2E,.D*V7K.(]9
M5;]A%%X(\I?W(A&Q^.-"J<;:,@[M+G9#_-T\]I$]$1]#C"J:#P$MR\?H<E#>
MALZE4;\-=3'?V!?"\0W_PK&Y+9T;T3T#'0"BAKXC&U_`@1>[=W)8\J(JL"X=
M[9&Y,<?*!H#HIZH26"HK__W#%D-L]S8&>;C7,<BCZACDMZX?_\L-,O9A\M8/
MW=#SW>`Z!`')Z$3N!A^7J*<,/FY$N*,==8S0:P0^[JL<`4W!@&^<TYAZ_`<3
M<XGI6'&S=!K%?DH=X[6[#.Q,-*+QO)H@WO>$]XRY.`B=X\J;1,CAZ`E763J.
MJ<=3'SZ*!Q:(`VB7,9C+(3Q2?(HK=="J("-^,F4)'P2?^*"*`9E)[,X8C:%'
M"/BR*(`*++@\*$;X3Z*`0<\S%W3GS/T/VD<)F`?T;."[MW[@I[`S01?>1?&C
M1`>L\E3],EY]\@E^%W4MF`MDQ\1X6!0_B\GV;XOW_$0@2BZ%BQ>H_!3/!H_Q
M@^$ARH(Q:'#"/;=AT$-@`7;N%]#"2G/7IS_0GIT0)`7\/AX?&KF%H-+I$9>\
M#OAT^L!8B!OA3_C0W(U3W_.!1BE`"@=MDB&')B607?&T<%`4%G.@DZF`&I`#
M[V1&^/%G(X(XFTG;%A^O65K@G27HX'"3'VA"!I2"<H[?\9HJ8-<UD4PX<._]
M,8GTU(?S&,S]1TX<LA-`!?^-5B3Y>_,LS1TA?)N;,"GSIJ'_5P:/90EW#^OW
MP':SQ0<[&2T^]N\70]A*O&&CR>.#;2>/+SG1-ADUWBIH)#'H-1U/+C$V5[S0
M,"#3?H[:4JSR5'G;O?([CCHKD&I6WG4"*9Y_9I&P^#UXZ&46NN/_9.@_?$]Z
MF4QHH01Y%,9'U>-[.)H%55VBZCJ?)7J;_,@"AE-R`'Y^,6PH?,7SZL#"QG*X
M6;7%5B*D-<M3GH#D7'-E+RTC./O^*LF2'WI!AFX\1AQ`ECCZ)C\YP-F21LG8
M!],AA9,?A2LL?KI-6'R/>UU'>Z<3J]5BU:QLY03$ZDM8<%X:%"`]/(``.B:%
M7Y/M*DTSTE%H1X)YFJ0)1==B!JH*(PM_97XL+#-46_`46*%B;*6&(8_HH6ST
MN;=1EG(7HH$I2$10S4%I"EXVE==6.8GB5V"L'(4I^2$#QRIW(7W%A11J`+R4
MA`\-I7\@8T!J\`G8WMS5EG%0ON?G,2.O071M2+B'E3\Z=Q^)4#0?S//BC!6/
M4L22YT2(]S/^"GBY]2`J,27DO*_ZB.`#@6%*H3#\`W@/,4I"FL5TW%UJKRKH
MU,2KA_TB,,8C97WS<EC\)ET7CB?47P-Q*H^8N@C4EX-MJ%P1>W_!%21JX5\#
MD&Y_XB]J9X`>A5]YI[#Y;YGGHIC#`X_T&7I`\9[$`2`W"C\'RD9#@@ZG(-T?
M(J4%>UEE1WY`%%#R?:9"RM,40O<UBO`UBM;L+:8WVFM,SS2J0;T;=H=H?6)S
M$%AXG'^4___/L/'YXEU03Y!/B>HUHMS11O4$]-IU"/MNQMWOTXKB\=0V_!>.
ME-LLP4`;60!1R$![$'9Y/H&?+:#!,=[$[0#0+&JV!)59+&96Z^K`:GX61;,9
M)C;!?OF;TPKTWS0#L$06Z^_'&1,:29BK7$+A`Z#99]'8GX!)X8.I0(?$Q/70
M#T+P_?`_S).?E$8R8#9'`$$E>E&,EB[&^ACI3_$55$A>2A%(U)Q>X(>D.$62
M'L\V/Y&$`,23J"!##.B%>&:)8"*=ABHU7OK?%\='O&24MSAH<VIBSCZC?$V&
M:49B#$4L;B,^D5-S[V(FHJBHI#%.&H^YH22`>>FK*\/IB%_4$C@RZ<#,Q?<W
M$)>0?2LDEK)#LUM4V*DXU^%`FB@%$&/F^0G0^6+F_@G0`0U\]L#C4<5#@&L6
MX.%,L<8BRTQ13X(0>.[>L=)[8/EQ6F#H"P3Q+E`_*5C0++O41*?L[>PI3H<E
MVO,]O,T-S_KO\J\L'#'>E(VS`,[3-Z).X`;L=CCSZW-I5P$LR;-JDT]YRN\C
M9?9>16"YG^&QU(RPZN&S+YI60V4;13&M;:.8,J"*2506[R*H*6'K#YH&*)<$
M..V&[S_Q0QVXSQS<5L&DIXSK[.RS16QM4*<H6MB29MDX_DPU1N]X:=$;+"U:
M90<?2=CL=,C['@NWCH*ZW9[9&5/K(U+=OCE?$C_'S6-5.5NQ;4688\GE[ZTE
M`+V!Y[FE#D]XLR-\)_'/BO"'D_B]U_V<3G?Z3TN"KHND.XL6BH>^03XR;7W4
MZ\8<G1]GAR-#MYR.L^?'61OX.H)=V_4[/3_>FL#7GMX_B1Z86Y7S'<B\N&$!
M7N74M3L6LAB+=+'B9XR7/Y.49VO/U-+8TD[?I8@;QE#O]9P3$/&.R6VMCX&C
M&\.N5]P9L]@&!EMZSSZ%HZIC<GM[Q#%UQSD%9;W*'CGY#F/GV=:UHV-'QXZ.
MYT?'E:KX9&+1ZR:EGJFG>`0QD*[3]-GRMNLT?:Z\[3I-GR]ONT[31V(OGFLO
MVHZ2'24[2IXK)4\R5;C&^\.FFW0_TA.M\8*,^H7B:YUGN!<KQ+@T.N.R8VO'
MUE-A:U=^=I9L[9T`6SLO\`3MQ(Z2'24[2IXK)9]'5E";P$L_'KD'^&2"WNZE
M#NL.ZY/&>H\!+WMOBDV=EG/D^NM4G2=3-P<]?>1TM0WGQ]NA,=`-9]AQ]NPX
M:^N]D:E;5G?C[OQX:^FV.=0=ZQ3V[9,Z4'NS,SYM/'CO3(V1[9;>X1[`FKQ>
MI]W.F<6C/AQ@PV9C>3H6GR2++7WH@']Q$G?'.R:W=B#[(T<?&*>PD\\Z!7>>
M%W<Z.G9T[.AX?G3<*AY]5'']ML?5H>,,W:VV<^9M=ZOM7'G;W6H[7]YVM]J.
MQ.@ZUXJGCI(=)3M*GBLEJRHY_WF36<5::0[>OL:;K9B=M]EPNU:#W'IK)^1=
MA_<L3*/X\546Q_`O^M2S&WC76S7P;C6)MIE?YPR.=WZ=8VTYOZ[I_+LG?N@$
MP&T5,WI*;V-GGUTQA:*E57_<HXS.D<2UX]\/1N%N[W2C<YX1X;O1.4=P,>F3
M^Z#-7."_[P;G6C)WZ(CA:&#I3O\4BB\ZSFY8/668^M`ZA2C_5KG<`^FF/Z+X
M3_C@Q3R./):<JW8ZFBHQQ^SK5J]34V?,8FMDZ(.3&**R,G-U,M;56QP1-&5C
M[2Z*QIT"V[-T]XVA;CB=`CMC%CL]W1EUG82Z<L>SR'&>)QVW<C6ZLM&=7.HQ
MAP/=&'1EH^?'V_[`T:V3X.Q9'X'G6I[24?(4"GU6EW6TKMNIEMRTJD?I+ZG;
M^1A'<Q:GCQ\#-TROPO&;OS)_/D/@GUO%3G^Q8F<]<;I:G>,O?CDQ<+MZ@ZY6
MYW1(W-7J'!UCNUJ=YT+XKE;G"+))GUC"W-B;:DQ:AXM$.XN,TJ%C+`/=,AR]
M=Q+]4CK>;A@_TRVP&YR3CZ`=JY+"JT89G%'4F2^:3'R/G;V^.IKTJ*GWK9YN
M][JN?&?-9&LPT(V3J-0ZCS*>WYF;L&D4C#5_-H^C>X:ZK"OGV;N<F[:CF\-3
M*%?KF-R:R88YTLW3KTD\]83F>=:B='3L:GK.3&,.]>%@J(].HO=\Q^2V=:YZ
MWQSHHY.X-'8>-OZ5YV6S+'!QBL"8S6/F^7Q"&\8QW%D4I_[?](O.[-^OZ+\<
MZ'VCKUM',!3G^T[#[8_-?=WI]?61<?A`;`,V=Z;_R9FL'1T[T_\\4E:6;@]L
M?=#OHOKGQUM3=QQ3-WJ'-W:>^2%XKF7H'26/MZ!_?=5WZU+^:A5^JT+UP=H6
MG.`UQQD;_^Z[MW[@ISY+GF<3SL&J)ISKB-25]B^IE>\?3ZW\B8';RF@_MRK9
MEN905]K?E?8_^[W3E?8_%\)WI?W'D7U"$U&+LC2)LMAC--6:5_MC`FK,[ED0
MD6^@L6_8RY^=:_W9H2,RMN[8?=T>#1K!T47;3HFWICXR#=UR#I]S.L_B?ZG&
M/&7>".FON?L8@PNJI>ZWLU5<1Y-:M77;'NG.Z!2*1SHFMV:R9=GZR#Z%8^H\
M*H0^I%.\UB14W)E;84<CYZ/!0.\-3T'*.Q:W!*0W-'5[T#\!%I]U!O0\RU<Z
M.G9E0.?AO`[QSJ<^.`GGM>/MIET)!F9?[SM=:^NN>.5,CL%SI>3NRX":5XJT
M+@>J5O*T*G)QEI0#O683%L=L_(G=LS!COSQ>Q;$;WM$M^==^X@51DL7/KR;(
M6:P)VI!276'0DDJ;WO%4VIP8N%UQ0U<8=#HD[@J#CHZQ76'0<R%\5QAT!$FG
M5VB?`<O=U+]GFGL7L[-N/G7H.$ROIQLV_,\\A6Q$Q]P-F6OHCCG0A\8I9!-/
ML?SG8QR-,P_><X,N,;YO:;;-D6X/3J%O6L?BMN6*`^Q_V.4$NH3N660$SI..
M*T5_UWZ&O:^C^W.4NH$V%O%I+>8!ZNX,W[N[8?=MW1Y:)Z#C.RZW]SN&0UL?
MC4ZA@<LI^AV_LR31/#X*49MCJ[ZN3=^^A7JD]QQ#MTZB<7/'Y+::2S<M8+1Q
M"DSN7)"3,YT[.G8N2+'%7U><#QT>3+5H\DQ.]D-'Q^T>6:FFW:4^SI"Y`]WI
M]_3^\!2*Q\_Z)#_7LMB.DL=;8+QAV6GK*N-J@7"KLMGAVJ:#K]S`PT[]8`M\
MF+S/9BQVTRB^"L>O61C-_!!_N@[?N''HAW?)1Q;?3%U`[UDV)ARN:DRX"T)N
M4Z,\LHZW1KEO=#7*';AG"&ZK`.^)%U,.]E.>_'D:,Z:]@_>F"9Z5;$R0W>8P
M'@<=3I6\[_WP2*C;[9GNUD1'XF[S-.;LX:OWNVL3S^[:Q#,G?"?QST[B&X;*
MGL-%H?<LU:Y#+YHQ[>7O49)\KUUH>4CGQT4"'E7.[,D"RNU>ZK#NL#YIK%N9
MX`<N!T"%Y@N%%I!"FT2@C]W$]WA+=#_(<%COFX\W1Z[=VE+@T$GCEY:A&T9?
M'_8.?V'N#$?Q'IJ]?=T<P/]&IU`2T/%VPZW;&^EF;X#_.SAWNZV[>_::NMWO
MZ99]^,+<YSX\^URK4#I*=I3L*'FNE%RIDD\FYD7E2(EVH2GU2EVHJPM_=%@_
M7ZQ/,=3U!T.7@(TOW'L6NW=,2[AB*P)>YQODVC(-MCN?RC0MW3;ZNF%TE_'/
MF<T&GYQE]SLVGS.;34,?](>ZTS]\B*1C\QYWLZ5;0TL?&2??)>MD[NF^F4R8
M1Q=S*06'?4F3%"^D1'.\29+HVJ>;JX1R=)]NOG1]`/>\!3@@0\NT5)@V@Z[3
M?B?)>E-WAGU]>`19@([)W?[N6-^Q_EFE_LZSF4Q'QXZ.'1W/CX[G%A@___K/
MH[%#NM#X\V`SL7BDF\-1Q^8S9G,7&G\6;#Z?T/BI.XKG6D764;*C9$?)<Z7D
MDV8K]U8C^LO"A<%PX6+AG,7<LSQ31_+@UU6,2W-X<".DNX>T<\8:ET;7+?K\
MV`K[M7=XIZ';K_M@K&&>`F,[=_`$#<:.DATE.TJ>*R6K*CG_N75;^MTV(F_=
MM;[:<'[,_!^O9BP<8WO\MX%[UZQ7_,0-$O;?/RR\77ST%9]C\]9//#?X-W-C
M`/2U"Z`U^O[%A6E=V"9?8=FGBL5>1UXVRQ\!DOG1^"W\+FFVVC]MOM#2SRQ;
M"8'98!W\_W4KY9]97(<#L1'M\/]?&"/X17FMTJ<65_K\.&^X@&E<_+/\:7RW
M^.*;,/73QU?P^]@-KL,Q^_:_V6.S3\-&-LW^R+`'?(':3RVL%,UF47B#9=G\
MDNR'+$U2-\0._*5E?W$#-_385?)A\M4V/W@I+:IEH<__SM]^H8V9Y\]`PG]^
M<?W^+>!K6H[1-T96":85BU8!?.L'+'X%5+^+XH:$N/(\%J!F@!U-KZMKE[Y7
M7>P3N_,3G*^0OG=G#3GZV]7O'_[??[][HWW^[<VGJX]OOGR^?G6C7;]_I:Y:
M_C!?%A7,CP!KG+$Q$B#*8@]';R0@T=Z4=-H]"Z(Y"LF;;W,6)BP1VWD%9UXS
M#SLM*ISY<O-:98L!3!F9AN7`QMT"A#WB8`!]*]*UB(/MV'U[--@=#E,?GL.'
M/DR4-^!]X!T>.2`N[T!VDC0*6;(>^*_7L._8MRC\^M&-TY#%R=2?)U_?4;_E
MY9A=#%[\H]?CQW*.VT:@[16I?_EQ-(<M.W-;H&7N"JWQ6(P_.2:N">QR]-H"
M68OH._>;/\MF']U'?#/Y,H_"#3_[-HK?N-[T8QR-,R_][,9W+`5U^SEF;LJ_
M<14^?IC0I((/,?`XA"/#]\C4:D"XEK0Y,%ZG2>NM=N%)LB*./,;&R2?F,?\>
M;?"W<303J%]/Q#]N,CCWDV22!<&C`#;YW?=0X8\%3*_0QAC#X0\8".22CS&[
MN@.(QC<N(,*AWJNBZ/?6<."IL6U-^@\3L2(L\`IG+X&7Z>(]/UH"6;X@1:\"
M/P26!XHT;:2?/T7@"ZHT;R;TSA8DWS663TGNEJ=@2RH/GI;*&Y^>.UZ?MM`O
M+FRXC8C[JSN;N7=N/*XA\-<U!ZF]C>[8$8HG0.(]6'$=@7>@('K]YT5=?K[N
M\UP;/BU!!4(J#8,@\C#40I$<HO6K:(9N-MEUPN.6D5@JLD&?7)38J(3!*5Y\
MB!?-\,J)4XEEO/EXHY(!`U^71D\28!MH]H(56;MMT;*.%JUEX;#U.`V.%J>E
MK&J"UIY818D.L4W?,L;W,1M_CHK?O6:!C[>>8'-_`;#C?/<VVEW;'):CLO+9
M'N*#X+^--[U7"LRB#'7N'WXZG48!!L<_N]]8<I4DD>>CB.%?L'/*O^!H8^/7
M60R/\$Q%0]0_P8NQ[\'+7RD:__4+X)I\_?3UYNN7M?AC$+;G*-AO`>\"VI)H
M;Z.X.-3>?/."+(%?BV,(_=HPS-Q`$/:=ZP/6(1ZO0..$*%M_L.WM1+8J]N-3
M(*,2C[X@/XWI#GA5+M^&'J;QSGW<5=!)$J4ED/O$TQC\3Q;NQG<X8BQWZ"&=
M!)9'+[,KWDR:&<=;<'(5;JL`VS].V_#MT%@M-_A/F%4KD#IE7NW#*%ZO-PZ+
MV7YUXD&%<1NV'3%2!]YAJY(9,ENXF^.Z91#,+DGECL`]"`&VX?2^J?":35@<
M8V7-/0LS\&JQ#!-<O.@3\V>W69R@,UM?=K.^7*DEZR6V6\"V;PS7"O?*E$__
MQ3\&CLK7/6/Z93Z)`1,A(0WXMBJ9M1HO9]`(KS)$N\2A44)N#0[6D^!0Q(V*
M*$$E/+"?+08HVF8S^=L8XB<FP];[T#;,IR;$Y^@7C!Y&=Z'_-QM_N&?Q9Q;/
M]B?1B_G/1@"I"&2QB']^BA[=``M?9>*IH7FZ$O1_?#2-?TO0EB^U4X!6FI2'
M`&B%`!\"G#4VR^8@78=>S-R$@=ZB_UZ'A10V#.JO+G\>CGI]6?R\>K%V4#7*
MC55@&ECVL+\Y3'[JN\%FA[8QV$UHNW9Q!;A=9:#I\_#W!?/U(VB?IM5Z[3#N
ME<O&G@XCA8SOHS!FDRP<4ZZ(OUL<*N+-W7@?VQ0F5<Z-74%]&$+L*B-ZVE38
MB98X;1+L+C7\1'38N]/3;*LOG@;O,_PP'/PW7Y(;NGT#*&).'!Y]&\7O_!!5
M:S5UO)<T]I*;:KW!R,YQ:@5M#;KB>MM$N?%VG209GN0!9L3!;X<EWK-T8:VK
M1!`1UCLD68:FX53)LA^L%/+!00A;(W7O6&XJOL%[=`%]F^^2#Q-8@`K\=AWX
M_IC%;*'`QY1$V`RV,E)T)Y9\)KRJ#);P;GR0D?&Z`&YAC=V`L-;,;PZ$L)\V
MLIKV;;Z4HZ>M0'P"%'=6UWRL"+:S.?K.22"W5>9MQP*:W0:^]V$";B768,$I
MD9<DEA#Y(-0!UP;6Z"V[;5(/:1J7`U."NGRI$D"Q-P5?MW2H_/)X-9GX`=:.
M+8_LF?U%H)9=1K<'*@W7+;D)>+S0:R,@:V*,IKCZVQ1"OJH"9Q&<VU4R8_,X
MU)J0>4F.=P+OKO'?09)]<]J0@-ITOV>7M&F8XWU:NJW(=;>)SA\+Z81IBQ?3
M:+&FON<^:[M:0?=$V.TNVWUX+/=:]774Z)T3%_=1#W8*V.VBPNCP^.VU+NRH
MT3LN_HG7DCP:)/H1T&6HN@CE\B/BM\>`A>Q;;2YX=&DO@-YDZ68PKPBHM@)W
MM5$\K->#:Z`J8;)P%WZWI6E;W5JOJ/EM0'U*G%MF#?>#K1)F56].<5?W/7N@
M/R4@(OBUA]A/6;RA*[_,:S8L!9\68"A(?`G=612G*RUS^8<5.W"%.=)Z"Y;*
MT=K#N2&R'V,V=_UQC9IJ7(#?%N.1O2G&*X#E:,N&G5>>AX$)#/:C?[6;KG5.
MOS\8]D=%6]#Z5;:#I%GON;XU&-HM(2G*!MZS=#>4L:R!U1OT%^&I6VL74#6B
M4J\WZ%&7P59083N_WWWWU@_\U-]5X\/^P.SWG5X)I/J%MH:G$8F&1L\<5$C4
M$)YLEI%-\)K-8X;7:_THA'\'#/^!I89\-]/O8</.69P^?@3XL/#DS5^9W[`P
M>S4YG1[V&RV!OQ.XGAK;1LP:](V^Y0SWCFU^0_@CZ-KK\)4[]U,W4"+`VVJ+
M?G]H.HYC*9BL77-W,#;3L+V^U>L-G<$6,#9JQ+"#<D)[9`YL2ST-&JV\/VB_
MRGCF5Y"RKTI$\ZOX3).K_>:HU^OWK>/":JMF!69_!$:>>408W;`@`,/JZZ]@
MO\5N0.RZ&L_\D'H%HR,@.;;>E2>6.;BOCPE!XM.'.75X;(*"99M#QQH^.0I-
MN_14*>[T';O_]%M_A3>PB[T_'!E62?4>`U9;[?U1W[2&3[_U5V"TX[T_'#C&
MT#XJ!#?=^T-C8#A/O_5;5>O;`\MVCN=PM':R[6W+&8UZQG%AM=6VMX:.:1Z1
M$6/M>MO;QM#JV4>%X*;;WNZ-3,MZ>JEKVNUMP<BR+'MT1)IV-WM_9-JCWA$=
M^=OO?3#->D<E5CLW]PUCV.L]O;F_"L---[]I#GHC9]O=%*8^S>P%"MXP+XLI
M<$:]+@`\+)'$3V2IN'M8G0Y54[K7)!"PF"W!H'I_)(+J.P5NW_@V<G_J$39/
M$N'U1E\]MHY]BM@V.NH.B'"2K&R2W"BJ.>@[_6&_IR9!Z+.;+=7,!#"<T="R
MS%&3M7:3N!C8HZ$#FK*Z8GUVH-G"#7'M#\QA?["`:^W*(B9+6GKLIQD(U'7H
MX9/C7[+T?93^FZ48O=U!U'4PZBMYG*8+[P#<-OYBWQB.1L;VX"98HHK_P=S!
MO1M@YO4J?>7&\2-LLG^Y0<;6"IJQV@FW,3W0&ZJP-EAUIX`VXS_&W.W^00%M
MEB2SAD!2RSD"BJY)1CH#LS<<F7L`]*WKQ_3P:S_Q@BC)X@94_8H?^:I\158;
MX=>^TN>^7H=PU"1??T>GQVQ4]=`WAY43K3'(.\<TMYOW@NDP'[:P%TQYW4^U
M5\4.-/N%.1A9X!:L!;P>@AW!WD;-VSUG.+('O9T`'LUF/HW-2NA"5X@E."ST
MP-C2OB7^CZ$?_/PBC3/V8G/]],/NEUJF86J6$MG:CV[\(;Y)T=<CZ:N]?]8`
MG<KM,RI9,RX--='78-4=@MEH:,"NP>36^U663J,8:[@VHN*RPK^^L:!!EJ^X
M`]`:>26[!XU7,^Z$8@;8Z2-+S0PL66U+D#:@E&F!.BW;'ZU`:C88>*>D6A@+
MO!UPNR5:$^!V83\BH4;U<EYG?S5>O)G[AX2P-UA\'K,I"W&L`1QOT8Q1$XC/
M[K>=V`5VOV?999XL6Z\=8"W+`/KFH&]6R+1;P-I8(Q>]D=D#DWYP"(*M`0TK
MRL'-;`=:`K_^-8K&R4T4["*4``\,G+X*2FF%YLNWK2(Q'<O>P?)MA*37,T!Z
M]XG[ZO4M"QSY36B/)JK,DNR`]_V^,1S0>/IEBVP`0NLJ(G`;^J/^3F!H5<XP
M<L">,HW]$F&-(/3!<3('C6%06R*^@O_ZZ?N(A]"V#K8.\<*+LB=6+;4+H!I&
M9XR^&I9K`Q1=Y]B2.#UC."P;))7O;[GX5W&[Y"NU3VJ40QPXYK"W-WA*%[.^
M7L6Q"\XQI=<;P-8S'',PK!>F;:!K>`'#[MOVT-K7XINSR@8K:>#L#9[M6-4S
M[)YA]MM!MYLT3\^T1B`R2T&H3;IL"DDCV1GU',/J;0?)SA0RR$R_UU?+&Y>N
MM#5`#:\G@!(T[>6RTA"@_#_RPF_#NNJVEW&)EE8I;+(.HKW`W^;*(@KER#P\
M[.W:'HF`U9/`OJ(H=PO!,:TG(_Z.+[L^K>2LJF)OT=P(3X7#BWW[^__'H7+:
M=BL[BFW;MEGOD6S:=DV]J&K"W@KXXDIFY2;F#N(&PWY5II>NU@ZLEK$$RQ[M
M%ZXV\05G-#@0L=;$'(8[@&O9==^=")DY,.UZ^)8MNR6@+=EK#K8"LUHEN&I*
M>T-2+C8EO3`NU6SKFC7;`]ATY]:.D>\_`8"->%Q+OU[OD/1K`J$Y;`OA;!Y$
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MKJN.,1JH]E*3=;>$M`V1+7AB:`QW"^>JU%?;XBG'`=$VS56`KDQX;09EN_+I
MP<A6==S6$%Z#G@_3*-Z1<AB.P$1>!9ZR7EO0VA#.')C#H7H*;@69Z/(H22W*
M+T`SD+U0<X.N9>6-,QB9*_=-$T!VCDPKP34LTUQ-_Y:XX-&8]SCC5<TI>#2W
M68IJY'-4V#>B$:>2]%Y9O+_)#><?=@[8#NX>\SI=9]@?JA6AV\/VE$QH?@MY
M]RQ8`=9&UX47(.-ZYO$MMC68LC&5\FW;^;7GC$I63-T:V\'1*$;2-X:&8[8$
MY/VJ0;4-NY<ZEAIG53_=9M%F,7)S.#`V7/63^_#.3<%GAX]LVZP2K"O+JEE=
M76,K,)J5PPPLIU_'^09@_!'%?^(!$'DLV9H<(V/0<VK@*"VR'2"-".*8?:M7
M1Y`5@"@N!1Q\Y%#C_$<6)^@&IH\[[P"P;L%=@=>V:T!K^'83DC8=&W:7VO!K
M79!WYU%G\%#MH=.OI\D2$.20NW>N#TN'N.(F?M+V@XV;@+(,:!&72G;GV?5!
M0SNE/D!+5VL#5-L\-)IF?:N_)ZA:>4DCO$KEU#)PGX1:4]P#OMMH,-H8*&R=
M[B934+3W/JSVR^,7,/2N0[!$0`K]\.[*2_W[787%>F8/?$R%F<U7WPG4;=@]
MM`W'[MG[`_J:@LB[)O6%A4>KN1;JFM5W`G6K0./0L<W!>DJWA?G#G,7N'B@-
M)_*@KUX=:+[^3N!N=ZO/Z9G&2+U2L`74_*(=AN?W<D&SM$+3Q7=U";/5XCNZ
M:+E;Q#>^3+EB^5PJ=LQZ$,JA>HNQ9IW-`&DM!GUK:.\2D)8B@9FDG<*QA7A8
MHU*4;#TH%)3<TQ"6WM"TU<-B]6*[`:RADS_H#0=;`/8^"J,R:7<W9:(/)U45
MMJ7KM8:M[0U6RU9O;NX)N%:UB>@='8YL:[Q?>Z167&T"G)R[]3FZ\O[*_)@U
MFWK3\H)\Q21MOOA.@&YE_5<LTM8@QR)C\]0]BYHMO%M@6W<NVA[8??0O6HS8
MK%YS-_`U[S*S>_AVU\EH#5!U'8/:`-2<6#L":,==C-9`M;1'4&O0=D:PAJ#Q
M)D([;CBWS1(-&\V)?'MMGGTW9BQ8]Y;5LTI47K?D#F%LV+X).P!L"63D,3;F
MC3@PI_/9_?8+"]G$3['9,PG3;;7`<NOCNR2\+0"HQP&?1T6!5/PP>;5D6ETK
M<\/L.8.AFGM:N^8V(*Z?Y5O7#W3A,N-.8.3JA,;]@KT*\H/SB\,E_?O1VL)6
MQT&&BF=I)?".HM1[!?A0M&F5^NB/!OW16L[OG3+J4V^^L=CSD\;W[C>;+8$"
MWS-7R'LM*-M`OLM16,[HZ>#>U2B?VF$0AZ%XFRE$VU*\WIG\-:Y&\=K,O38'
MHW[)VUJUVFXA^\JG.;"8IM5\F$Q\CWW-/]+L"OI@8/0.!7X^&VDCF/N6;3IJ
MT=.3POP[EHQB(<C7Z]D\CNYYQ5ZSD4#FR%1+`9X"[F;MRX:#X4@=[/F4D.U`
MB/M6S^X9!P*_G1`/+,/I&4^\\7*8MQ!BTW9*0=N=P+U]^27>H#!Z341XH3*R
M'50-8\@#>]!O(ID+4$FQPBO1Q=2XW:4L>M:@YUAJ%';EBFV!:YNSL/MFSU:'
M0^X%NE;C8M";+(T4?UK"K:NCZALXM+$E=*D+PC26=_.O/"^;973#_#6X])Z_
M[2Z]L'I]PS(':CI\_:*[`[)A3G8$KJKCC*QM@%3;WZ!U^LX/6))&L%59.HW&
M[3HEK>X1MKI$TJ[&LS>'\8EPO`[3F'V+0A7%!B[.H!29.EKLVO1;0MP6!L8<
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MMI)`9VB72Y(/3=LU*FQ@XT"4+<&MK1S927<PLQP@KU]I8VA:M;NS![!MK%W`
MHG1H^>5QL7\+=BODG0&N0Z![1BFU:A?'?U%GP^N0]\QL&C%LT"AUDXK3IT+O
M"(BZ3?^BYTFQ[?KUKF\*90U+SOPSHNQ&G9O.1A;%MY6*]O<9BLJ6!?Y8T#:H
M1H9V#N3!:-!(,H@&U:*^0],@6?-]6:272#G[@_EW4VSW>P^FRQV3?_\(JJ:5
MV5RY$66#SKET-B'03C$X&NJUF2L`M.M=]@='0KM=MZ3"1@WPC(K>FB9/.V\[
MU3?-X<A1PQ^-0.#WJ5YG,6Q23D:N'-ZS!_I3.4RR_C["DD/'&5H5W=)H\0T`
M+DP*>HPDA09+OXWB"?/3+-XXQK0$%]OIC]1&P%N#M0&66Q36-[BGZ)AVW[$;
M8M:@7'I+5+:QN.UA7^V!?&!,6LM:SQI8"WOZ"#G21`48_?[N$*DH>VY??)B(
MD2^K+UJVVR*DYBUK:(T,)5JR(1R[0Z+EYB`L^H8Q@M/B"+!HLS$HW&P,^D.G
M[QP!"BWW!&%AV<@+:[]8++Q%\Y&>>D?40[$K!+;9#3BQJ50??!`,]KX3#L2`
M'>Z"I1C\]P_?;N,`_O%_`%!+`P04````"`!!B&A!(UGN>"@,``#4D```%0`<
M`&AA;&\M,C`Q,C`Y,S!?8V%L+GAM;%54"0`#V2N<4-DKG%!U>`L``00E#@``
M!#D!``#M76UOVS@2_G[`_@>=]\.UP#F.D[ZEU]["==HB0+8.G'9W@</AP$BT
M350B?:24Q/OKCY1%VZ)(B;*LB"X._5#'YE#/S#-\&Y*C=[\\1J%W#RE#!+_O
M#4].>Q[$/@D0GK_O):P/F(]0[Y=__O27=W_M]__X,+WV`N(G$<2QYU,(8AAX
M=RMO.O4N"<8P#.'*^PKF<TAEK=[P]$3\&[YY_0]O3)8KBN:+V'LV?IZ3ZO>S
M9WP`C-?)Y=*'G9T,U[^$"'^_XS]Y'#!F[WN+.%Z^'0P>'AY.'N]H>$+H?'!V
M>GH^D`5[ZY)O'QG*E7XXEV6'@S]^O;[U%S`"?819#+"_E1+5Z.2&%Q<7@_17
M7I2AMRR5OR8^B%,35N+RC"7$7WU9K"^^Z@_/^N?#DT<6]+@-/.\=)2&<PIF7
M`G@;KY;P?8^A:!D*X.EW"PIG'`4(":]A>'9Z<7XJY'^^S%@;X>`CCE&\NL(S
M0J,4=<\3]7Z;7FW@"_D_5Q$\\4DT$#\.RN4'3>'=)E$$Z&HRNT5SC&;(!_Q1
MOD\2_BP\OR$A\A%D\G\;P'5K?"(5+F$,4'A`#385/JT"7^%CG(#PX'ILZGTB
M=;Z"N_"0#B7K:PQ_3,(0W!'*6]@]',TIA*+YU?&?JAH:0[S"][Q"0NNYM4[J
MD%#L&=4(-09R0\D2TG@E^LG_)F@I3/X%QO:@*BIH"V`-`JMJ:!EBC9['LJ+&
M@'DW0!,8?'Q<0LSJ>*!!\-"`:I!KDFP,Z1+.(*4PF$+>Z!)H;R.#X*$!U;"1
M2;(E2#4<OJ*"Q@!YX[GBRX,(7A/&;B"]70!:@\I2\7;`U:"U7+Y5>#4HMJJF
M^>0I)O[W!0D#OH@376>\JC-Q-0MGP'P0^DF8+AZN.8P<0*X#Q`$,)$11Y=X+
MDZQB%(LZ3D^]OB?+[WX$./#6PE[9LJ9:\P\@%*O(VP6$,:NRL;9PGJ1F`&ZX
M9^!X`6,^5PUKH=%*-H1V&X-X/0.=S,8D6E*XX$,,GYJNW;G:(ZW$#PD2L,6G
MD#Q4$EDJI`6D]_\*3]?[2^;:PZ%P[@T2_GE,>"O"(IC"/S&^/`G2:$U6BZ=S
MNTW32U%RG"'Q<P5"$><@5#'(&G`:S)@!=I=&-!+6GP.P'`A##6`8,_E-:KK^
MZ3`+;/R<??V?$6,<SSBAPO/D`_CZ!8;I8]7?!QU`%-SR;D;\)[JU>Q`*SD?Q
M&%"ZXFO`WT"80`UT2[F-2CO>,:)Y[0#UY0/XQYS#%`-*68D!$RM745L?<>^0
M\C-*(JUIL^>16N`)Y;W]^]ZPYR6,8R)+\3S1=SQ`$>]+?^F"LVR%SJ;0AQP\
MGVKP`;3$RTJ+N\E0.>:,F#/7B)&+[Q4'JR$B_[.;AL]CS`Q][IJA;RA<`B17
M=+PI3_C`3JNZ6RLI-VFQ@IZQ]<(UMM8PC>-?YS8O=#Y:L[YTS:PR$G03@O52
M82<<I/7^LN*.45`.-F/DE6N,7"-PAT(4(UC2"^D*=3F+N`$K,;Y6SQ_4@IVY
MC-G,ZO1!A9PYSFO7'">+4%KY3TE9MQDQH<Y(>>,:*4K@T<R(J:##=)@@9UQ<
MN,;%CD9\-"@&X\K[68.("_R4:B/9*FDUPU/7J%)<ZPO!OFW+V2U[-.24Z"`Y
M<BZ"L,6,XS'_'\66-.F*'R%3.C4D6<Y%%:QZN]+^[6E7YFLCIX!,T4-MJ<[\
MJ-ISM'BEPS@7'1F3*"*XE(!B$8>M7P0K3>]>J"/@O4H*Y0:@X`J/P1+%(-S1
M0#>CMQ!RF!X;^)(PYX(H4[&+BV'P$5",\)SQ=4H2"?O"@`\7R$>Z\=!&R&'"
M;.!+PNQB+*Z/_+H24D.+8,"[@;*YV6#'TW;/5^Z!GEGN@6[K]<C,R]7LK:OV
MGHGC%<^]9]\P2'B3A<%S=[9*L]FS+DJ\_:F3V1<((<L@?"8D8/KHJKY89PU$
M->>F(6AARJ;@7`CF&OG9?L<MI/?\#XE=N]XWEG6.AA*LD@OG0C"3)13'KO%\
M>U1+PX*V5&?V+\&\'0PE17)7V;F(RIBP6(QS\@"K=CZO%ND*Z&26]BNW?+`U
MX,R5Z,PU3$;=+CH4I-(]G`OF3"&#7&MQHN62.W-(THVR3"_M>%I:WEE&*G!+
M?MR+W\"0USG_##'OC$*.?A1$"",6KV^QF(FR%726,5L%)'5VD10'!Y&B(:1*
MY@A%OR-WS!VVUGB=\GMG9M?BE`;7<B)M[ER0(3VL\X5@DD>M;_FV0NX18XM\
MP]-)*5-+B@CE2_6G6(@73CC+Y??Y?LMO7I^75NCF:EL<IN00;RBY1QS"A]4W
MKM`5WK2JD<_[YS2\HN\@K(7_W\&5MJ.:),C>3]%`MB?GCK6D]WC2Y`<B'L5;
M3>X&R^Y,QU#P"+DQJ2))<B[&<@F7%/HHA<D_AS`U,I^K183&Z$\3979B1TB@
MG6*23N?"-)\!PJ);F&`1ZYO,<B<I-\<H-83:"AXAI;:JR>/NY@A05Y-VWMU3
MR#N52[C^_PH7;TAH.+43.T)&[123?)I#-N[PN9.XP8K(7/D?@L&<1I(Z<S3'
M'>JRRQGR>)'VDH85IW85_1!DVZDJO<`<&'+'"Y0SYV+&4#CS7*N++J_HA_`"
M.U6E%QSRM$_APK/X1H-P]\R@PIZ5Q)'19*63Y,.Y.%L9<-.VL87,D7%HJ95D
MT;E;5/K;V3>0(A*H>NFV&&N)=[=WLH>6._$?:[^0-#L7'#(H(6:!;-\8I%:X
MDV/08)4&@[^2D<_9I=!XH5&C7!UAU_JF$OHVAZEKJ">]UQQFZ7>Y-=A"(]8:
M4-[L=NYHBD&)3P@#[._9B+7"/Q+%6@4EQ<[=)N#H?0@#]HF;Y(JQ1&3:28^N
MEIQHMY!QK>,J<=F=2^E56ED=$M)L;+I`:;ISP;YAK@%W;.[E(L4J#O0;&J*O
M9KQ8F(B\VJGVDU17M:$_T3./S)V>R"KR:G7IF2C[??;]<^]-Z!S@;/.$:_(A
M80A#9I5YSRAZ^+Q[QD?E#P5PS42F/<3\D+"$0O['KF2:>J\`LT'>0JLDS8=+
M]]R&96V?K!KZ3#5T5I$X9+%3E;>MRSM@^G-#MND&B:K;L*WQ4:HQSU5CYB0]
M#<K]39<+YE>;2[.;<4@3:397MF9YH9I%!V9_2Q@2-C?(]=R&A8R/4JWU4K66
ME%QG')6R?_=V@>YO/25W\Q[IGMNP5N$1JI5>J5;*)+P"JOU-4XCH59O&$-H\
M:.Y:?<1U:YK7JFFDA*>BVM\TVH3">V<B;L-,A@>IQGJC&HO+*=?YN+"7A]E@
MJJ&Y)VDQK3#F'CCH%,)\RW-CKHO"=&%'Z&^>`J[)Q""*4)R.E2(V0-*9!\2V
M\[!2\38F""6/4TR8IMQ5)@D;Z;2+;QUNW;?<Y#5XT63.Z/U+?OIW=YIM$HOG
M%7O52+%G6:W/.]=KD]"]H%YA5;6'?EY6?8=ZRN3_>?U>-J-O76DK6E6]4T?E
MR7H9T:[3Z=ZYHT(MF]KOH#N:5,%=`/PD;FPM8)!>A2R#JA3L+"*G,VTAO;$"
MUNKN;^=QVPWZWPG]+LY0$1]JKSB8"KK-B0+6*L.=.YQ,P<.O((84@;"4DGPY
MMQG)8[5)A-STTE;3H<`T^):/!"V.KA7O/E-QU@FO=(';.-36`][ET-M.WNPG
M5""7KZGZLDJ=HR>'J[JSCLV&WIVLQ`=2MWH"T7=AM#)J\)D6+TO:"CE/M:TB
M,CUXN_>26^B.C6OJEX4UM4VWW.HBVO!^2'4@K(R@MSKZF5X9J=K7`F670]VA
M\\H_=<Z$.OBK!+I[PT65$IND%A4:M+Y(U5^*R!!-DIB1A/IB:Z<D$8^!H48U
MN4U=(]7V7%,];5O\&"U#LH)P"M.IDE5SM)!QFU9+)1R>,QC>,JR.M)4;LJV.
MM*87#ZLCK07*+D?:ZHM&YFM%W<$\HG>:F,X5V+W0Q/'`[K&_,Z,>.9JW+I3?
M;'"A]ZQ::;TNK+2,'52KRZO2]Y&K77^=XR6MC@+E[RE7;5T/=I?#PN^I$\-@
M=`\IF,,O270'Z61VB<*$?[L^YRWFC#%?C2,\US3WVC5T=O%6S&\W:?]37*,X
MIN@NB87??"7;X^O9#;`1I0#/\Z=5U9NY#2OMK$?<D_C<_=V&NA_'T&<P5,%"
M7$_DV[</D_RQ.D1--??=.VU_6"WKZ8V#ZYO"X&K3X[=[%JAP'-$X7%F=2E0/
MR[P;B%KN>.OF?_P/4$L#!!0````(`$&(:$&3!DOY01(``-M*`0`5`!P`:&%L
M;RTR,#$R,#DS,%]D968N>&UL550)``/9*YQ0V2N<4'5X"P`!!"4.```$.0$`
M`.T=:V_;./+[`?<?=-D/MPN<ZZ2][EYSVULXC^X&2.+`2;I[GPZ,1-M")=%+
M4JG=7W]#6O)3#\JF)%H6"A2.30YGAC/#&<Z0_/F7J>]9KY@REP0?3\[>G)Y8
M.+")XP:CCR<AZR!FN^[)+__YZU]^_ENG\\?%X-9RB!WZ.."633'BV+%>9M9@
M8%V1(,">AV?6$QJ-,(VA6F>G;\2_LP\?_FU=DLF,NJ,QM[Z__&&M5Z<3C7&!
M&,"$?G*PMV_.YK]X;O#E7/SW`K];@'7`SJ?B[X\G8\XGY]WNUZ]?WWQ]]X;0
M41?&^M"5OY[$39F;U/#MZ>E9]X^[VT=[C'W4<0/&46#CJ-=:C^D+]>(^[[HQ
M)@OX\*O#%QU6&[_OSG^,FVXAG0J9N>=,(G9+;,3E#.5VLU);B+\Z<;..^*IS
M]K;S[NS-E#DGP&++FC.9$@\/\-"2_#OGLPG^>,)<?^()E.1W8XJ'@`KR"(`Y
M>WOZX=VI`/+=8^C[B,[ZPT=W%+A#UT8![]DV"0,.\O1`/-=V,;O"'+D>.['$
M0,^#FP51`N"WF8_?V,3OBA^[!0%VJZ?B"4]YB#SMQ"S@ZJ'IDG@>>B$4I.@5
M]T848Z'!1:8B#X(>/!\HF6#*9[W`N?XS="=BC'O,"^"9!T$/GE=XB"G%S@"_
MXB#$!?!+ZUDF7@6$-`>`)@WCQ/XR)IX#*X28)#XK8A/2.Z]BAZBMC&"RQ8SM
MMC"5[R7>8P!![?`%=QP7Y$JL;B=6--`JT@LH;L"[T+0;M>DF`B@;Z\50'8?X
MR"V(\G;O"O'%0Q1Z?&>$X^ZE8RPYT_&Q_X)I06S7NY:-*?*\8OC)#A%6X)Q9
MO\42;(&E<`-7>"76][=N@*T;CGUF<;)L\X-TW6)ZG$4':/YEC28P+SAPL!-3
M)8;6YQ9$([E<`#W]\?2MU;&N7&9[A(44PQ\1/(L,K16(UA*D%<.TOH^@_C#W
MF&+:/&*O$>0)AXW0Q%F2O!XB]B(9#C[V"*%)5QC(+O8XB[^1)K-S>A9Y:-]%
M7_]/N*I.Z.'^\!H$@<PP?L3TU;7QXQA1++WG2^)/0`>DR]CSO,AY[`\'V"9`
MWC?L/&#J$FC'.'M"+TMQ@B4>>]+Q+W.L;E-X=S$;X`FA7,A_;^JRBMBX/>PZ
M1Y>:UJ/KO`6UCG&,-'S'16L.8TB)7[JT1/B3*OE)*+@7$`\O;%\WP80MK>*5
MM.+6G;3BS&K-7JNZ.ZINA1S50]"2G*O(/TSD8UF#U<:]`688+.08XLPKB)4\
M(B/-ZZD@!M]%[EPB*Y1ZUK=$8@]@CG[%`:;(`QQ[C@_VB_%YY!^AR3(I+`BC
MS,5K.WRI8N5*,RZKBUA9&K&Y=)7$U_6X)8FIY=J7558J:=01\J6@'D8<>JOH
M]+2A8--\HF,*!7M?$76>8)0,YV^CS7$%61O$%S0.;41DO@17::F2A9-2%(SF
MB:2+V;+-`YJ)[R3R2PH"Y\%#P3WRLR.-<H:JCW,BW=&?"!IRG.Z$AG5&1YRZ
M-L>.1.L9U)T-'I_SXJ*L/O5'"8D*M^9OE2)ZQCBN92KQ&AL3)/GHF)"C#5I\
M=7`.6K^\]<N-\LOU4"&B4!F$EKH=N3)*F59)YF#+VTG8XE69J99(O"+S]0Z&
ME!GJ<Z'IV/EXPFF(EU^2@(/=N?:D8?UXPO!(?%"T>3?!&,:5]7S6D%!KN3-Q
M;ED1?>>:6=A:T]8B)%J$"OFUG.G^<!7Y`?9$N:[$4Y+WLN*AL-Z+V!:T>0I[
M]@5:WS[/?,K`C4J<T6@/-"U\5NR\"W5;57'B&\410>+BWUU;['J[7LB7UB2B
M0@?`1NR59ZYPJG.\Z7$WD2<Z)&:YM*MM%,:AMXA,1+E>NUEX""%)6S[1P/*)
MTC;5XD+<8\N]M[;/!-O7)DIJ2Y348E'JW:=O;OG$XA30EGDXTV`?K`A\?7;B
M$W+I9^2%N,<8AN`U<&Y=].)ZP&E1)(,$;4X?0EX[I!1H@`;W)*#QG\(3SMRJ
MU0B_-ONTH.%B)JFX]!!C&78UH[T1Y13:YWS5SF00?_@%YD=C#71+>GT6+4&>
MI0`_!^2%@2LLY/@FF(1<N+N!#5H@%\95@C(]BO*&JXV#EXB-Q2G35^0)OR"S
M@"&E;?V%"[FBG&BTM$^B,3G\LM5BE9TI0E'0_K?.HK'+0^LLJBRABX^_N9B*
M6OW9K:C45UM/,SL?E1N9R8G#+]$]&J-1G4+405TD\'(G91M5-1=2#4;]M$K'
M@$GVGV5ZAYD]C/(1%40ST3RI39EY7F`1<4TD/&E&6P>O*;:Z=?`:=XBJ5'<M
M^>"4<CU$ZY4=G!2W^<'V(%5[D*H]2&7:&:+V(-61':1J^DK=^N35\.@VY["$
MYC%J.3Q5"I\R$FG["%-DI/Y9^W$IK4QK+69K#7*MP3Z':=0D(9JCE`-0^P"J
M;0UXH,3&V&&?P.*M.H'74W!>7+9U4JA`/W,CWS1W<7Y)^$T`LR+?K6!]#I;N
M:8R"B+K/X"%BYR:8EW;O&@UK&UZ?_-^'PL<%J16(,7EPSR>!G-@;QD)QR[L\
MO?=$P"%F]YCWA^+#(^BE,+B@M3T6D?*)T-]=/A;WKH/$/Z$IWK0&E8RHGS<;
MPS\1&!Z&OH/%R`_](C07A:3QT*`O+%%_N#D&V&-BNX+?XA>!WUS6KD)A=Q/%
M70.\6FNU8&W9J+A9K$[+Q3RC?DNQO]FGCF!U?943(PT0>R(<>:N_B],K]X3_
M%_/-<RT@K]%7HMW9/J>1-")A2J*PK$A!8=DUYO1IZ<RH;J'=S,PTCZ>5K,G+
MX/0HV%ATF8_8\[[A[-G/9XB8]&-SF;2#DQ$QY:?F,Z5JAR+B[+\.^YSNT>Q=
MM2=P3#N!4\NY7D./L;3&PW#CT99:9Q.Y2ZEUW0:@DAIEY9,4K8JW=7M'5;=W
MA/=ZJ!;P&E')G_=:\Z9%>+=I$-8`6$L(!ESGL[PP:IW*E6F>!Z!VRL]/\(DA
M6^X)JEVMK&^@^I(C^Y.086:U03?B>$!Y$K:V$Z2+9T;>)=)D"W20NG18_,F^
M:$,??'U)^`$!J_&`*`]`J\;N))&"S);Z</D5@3L_`I=&"9^LUOIP^NQ2,@'G
MRT<KPR3/LT)[?7C=!)SB*0G4L,IJ7?_!"LV&2?-J9=P1!.UV:I$-2U/Q(R`]
MRYH84\50'OG99LN8DH/R&)!E(3=+!4P[;--DI[4-FVMR96]SRN?U#E'+69HR
MN)3\"I$^D5JN136?J=')O-8N'IN&[Q/ZI$RKPH$8U9[Z<%VMD8U<B_[PUK7%
M6R2BGBH1H234=P2D\>2!*(T:AH$C[-#S!"QIP*/Q/V$<924&V,:`@/,LJ@S5
MB=,'6_?IA'C03X3V'$=:)>1=3VTO9/#U$Z*C>659+PA`@B*<[\"-!4,E[">@
MSPHRHZ*!->HC-'%MY%V)5#:9"/!WKH<9)T$\=VQ'P=`&6N.&&1Z%GF@]TT7D
MOA#UT785TOCE$#)#'I_-QT_PFO.;:[2A$$T!H6B$%P-=!W+5%L7?<P[UA_>8
M/R(O^:Q340@:K<A"=^_05%1:QW9\R:I"%OUY`CZQ/79!'\2?_6%D"1(-265C
MU\6OFV'TX3&T;<S8,/2\660K6$2.`Q"<T.:7*'!<!W%!7T0%>Z!SZAPY[W-R
M]N=D.5@=D$QF6>UZ)#4'HP/B;<)B40]+DQ$IDY/1FKB%R<JD`OI)>($3=8WL
M<:1S<XT2)STH1GP.HQ?,P)X!0KA/)V,4W(!:SE_14N1N;<@=D.Q*>R:+F&J6
MW61$]'%2%]HR$(+?M_Q"<&C25ZLJ1Z_QAKE7'(1XY8#,`LT[S,?$66_P+?7R
MB%T`:?2X\1!3BN-!GLC%RD#]5V`TIGZB[ZW64:-UD(%F'(&Z?"8BS!TCGMUA
M::2GF)5.)*,H"*TQT?R$F)AF-Y"+04KDD]!.^\//,@A<[MC$4_E$EM]=80^^
MHG*'1\QPMH#H`%O&RJA#:G8'IG,78W'6<&[4A4,G+4GAS8N=`)5KES*&3IZ2
MPC`./P^>F+G:9ZNY2542Z<S1MU7=I***='Y5M)MMS&T.I3)3VW:X,;<[E,JN
M?3?6C;G>H50N9>[B&W.90[DK7L'\P.9%#,WD2G7Y@XB?'UI^EIU%B"MY3UM6
MEYE0B-G<B(KI&MF<'`;'W&UXJ&%0DB'F>-.#E7H2#S%W&QZ]5)F7B%G:W`AG
MG_Q%S)VF1S9J.9*8&PT/<G9/NL0,:GJ\4W0[/N9+P^.6Y!Q2O-W;]$A"1R8J
MYM71A`.[JM+;AKOT.V;+8NXTW?TNG(:+&:-Z-+.Z*\_:LT?*Y_7U'SMJ+Q)1
MA6_`_6B:I:FBVQ\.X3HUB+1A!#X#:L6EW7(%OL<\U0:]W[1!,0`+!8ZU`/$/
M"X`88(:6QVMC/,4=>'R56K4#WWG=ZWP0*QFQBUG.!9)*/0V[M4QM%C=>(,FG
MTLA[QAJNFI4*K@ET"=PRKS=5ZJFSOH]A4,7Q8IB,>[W2FNH\L>U/0@XA<>#T
MAT.(F!70RN]3FQ3<8L2P>"WDQI]0,@]SLSVVS![U7\!50%V5S.^J3!MS=U0!
MW5V)UU-TXZ"IRE<M8VHY"Y*GI&]:;D8N\3JGAOL&1^RV;VU]J3H)MS7?E*1.
M4?+]1WE39<RM1OF$MDION$J80!4P/7*=DF\CV@6`>53^2@DK/&]1I]JHZ=EV
MZ(?RZ<@K/*'8GC^9!)\]+.UHX/1\0KG[37Z?2D<*W?K`FS??]UOGC=6ZF.I#
M9BY>>0)LOHN<29X^.37F')/F>;['">>*C,DO'JN_T&X@JF\@UI+.JW(OZ1"2
M<!M%B*D*^M.F@L8=K:BG`5JY0<O:Z^9BGK+B=L6^M6EF.GXY!D>EHQ&9MD*S
MMZJ;*A0:F64[#MW3+I_&4)6Y(*IU-:X(:*?*'OTIN>@DD#R0DIZ$2VI5?[I*
M7174K9AQZ:HBFJ%2\V1<YJHH@:D"6?#9V\KS.<>Q"C79`]S:0%"F[+;FQ$T!
MFM1LY=I4&9.V42"S56ZS%*!&NK)S,JFM3<%?#6]S\+T,X8_4A$E:8U.P%W7B
M10A8;6^LAU7$^!N4ZM!#T$+$C,E<Z*%K5?*,S5L<QWK9;LDH;\G4DJ2H<@?A
M<),4T;M8"<IYIJR=5@3$1"UM<LC:)BV:E;1HNBZV*Z;F)$;*N:"4%[ZWM_[3
M6NK#)>O)[6U\LEKKP^FWF8<#/%7"*+UMFR(Q-X-@_!OW.U%U$,_7[T19NI:9
M?H[G.!?R)CO56[LQ;1ZHS0,=L[*7H!`Z7]/*?Q$\KX<^W&Z$G"$ONKXTNOXK
M":64AO6==E]<R+KR($=V*BJ[BRF&7?6%N/QNI4GP`'M(WM-,UL5A>>L@6[R:
MLO%<BH*T[P6]W)?E,_0CL_DQOLRG.*M["$0EV`ZPZ[^$E(EIC>]=`/%;N3VR
M$`4JX,IX3TTS?9H`&T9IT0?:*AA4'X>>`S0_.9>![0/%$^3&[W?(&^'C6\R3
MZ-\;9+74Q3_D&Z!]H)4AT]'@3(XN[O?-)Z%`YTHP3A"`@F@G0C!V[R@Q@,WR
MI`]@/RPS*,_VKAM6U)+^>D']KV7L(I,Z77!C7O';A1&9;KPQ+^]IF.*<9R?J
M?W6B1#$VZ*D\K52JN-S&/&JW"^6:P@YSGINKC0E*%]@;\%#<+@S:.RPQYR6W
MLLA/"U[,>5%M/\W(C7G,>=Q,,Z&)4=+6NV.&%UXW/4'5EI6UA=B'5(C]R(G]
M15Q<BRD35^#P6>H)B0^;"KK:]^_6O+<!IR26MX`^CA'%TEZ*&XA!/-!<VI;O
M<ES,EFTBF]K[BJBC=B'LWO#KNY10(I%MJS;:&%&=K7UNUZZH6R?8R&+M!NKK
MWK)8I6W96>J6%`2.N'/L'OG92VHY0]7'.2%\_4G^8U-)#6O#&D)L3ET;_&^)
MUC,H,1L\/F<2D-.G_EKM1(5;NT>[%-$SIN"Y3"5>8V.")!\=$W*TP?2[=!JX
MWK;^L89U/@WQK9V=HJNZ`N!:"KKU<23YQ8:]9<68FO#].=7:L@;JZ3[5-]LS
MIU!JKM"ISFNI;8P=]@ELS*J;=#V%Y=UEJ:71"OTTU@F'PD>)3!/K#T$2?!+(
M86\8"\5V8+0U#PX-N\?B<6WX\"CO1`&N8Z?'(M'X1.CO+A^+V1!9&C1-KI<N
M>T3]O-D8_HG`\##T'9@L/_2+T%P4DCY:>CX)Q<OHFV/T&"/BF0+LB%\$?I_!
MF<7.54BAR0.L!&133C7`,STNV&F=5]!;8ZKD]'*@$KTVI@:O1-X5M0_&5.V5
MP)/]+,QF&9\Q*>,&.JCMYG9MF]NUY)<-V5M-4^GH>_'?"\"';_X/4$L#!!0`
M```(`$&(:$%:QEV9H4(``-B0`P`5`!P`:&%L;RTR,#$R,#DS,%]L86(N>&UL
M550)``/9*YQ0V2N<4'5X"P`!!"4.```$.0$``.U]_V_=.)+G[P?<_\#K6V#2
MP',GZ<;N;,^WA>,X/<8ZL<]V9G;0.`QDB>]9UWK2&WUQ\OJO/WZ31#V1%"51
M*B:S6.RT8[-*]2E5%8L46?6'__B\3]`SSHLX2__XS>OO7GV#<!IF49SN_OA-
M59P%11C'W_S'G_[G__C#_SH[^Z\W=]<HRL)JC],2A3D.2ARAQR.ZNT-OLS3%
M28*/Z"'8[7!><T6O7WU'_^_UO__V]^@B.QSS>/=4HA<7WW:HSL[$,]X$!>%)
MZ-C#OO_N-?]+$J>_/)(_(2)P6OSQFZ>R//SNY<M/GSY]]_DQ3[[+\MW+[U^]
M^N%E/?`;/O)WGXNX,_K3#_78UR__Z_WU??B$]\%9G!9ED(8M%66CHGO]XX\_
MOF1_)4.+^'<%H[_.PJ!D*AR4"VE'T'^=U</.Z*_.7G]_]L/K[SX7T3=$!PC]
M(<\2?(>WB`GPN_)XP'_\IHCWAX0*SG[WE..M6HHDSU]2^I<IWM'W1I_P(WW"
MZW^C3_C?XM?7P2-.OD%TY,>[*RV@'SN\!-'+U:1\R,H@F22J3+F0O/]^1EX=
M?V^UO'TI&8>J>$F<;!<$!\XDH7*];&B$?.RWUT2.CH3X<XG3B`[COZ4,#/;'
M^5.[94PIVRSL,$RH$6=YS8\]E3`,DNSO;X7/GZ?195K&Y?$JW6;YGMG\^6-1
MYD%8GNB*D!%=O/[^U8\_O&*:&,'H92,BE>$\[\H9Y&']+/+C`&PQXF68$>\^
ME&<)?_.<?)MG^PD(RVP$T=^3Q^0440=.CHNLRD,\5>_\`21L$4H:M7%Z]O%^
ME%$PE?RI?A8*T@CQIR'I<>CG^H'_]P^<Q-*..K[#'K\-BD<F0VW[U$Y>XJ1L
MO(%9SMFKU[47B5___;PH<%F<O@^A,=V@=:W)+"HU'?6(T79B\VK)'/R8%?A:
M%M.H+;4Q_>G\_O[RX?[TO3L1,9DM&QODD7E>5'E.?=;&2GMC(8U5(WC?9D\&
MPIJN4IB>E8A1*&`TOP,R93M9^=@-JF7VP;0O@N*)S$+T/Y?_J.+G("&2%>?E
M19#G1[):^$N05*=3V$A:&-,?!4QV!2O"15S#9&<CI.K[""%BLS_[02+?H*!$
M-0?$6"SB0`><QQG)="*3USM!&-(?<$M.`9)L&F5;Q(58$-]]&>0E",)'O(O3
ME+[#97%:Q.Y%,`+._&&8542".QQB(LUC@C_@4L1OW8Q@)`'*`RQ@=-(!P_C3
MT+?>R[A*G\GSL_Q(A-$HOSL$1MDJ,67ERG^'4^9MC@]!'%U^/N"TP,1E;\HG
MG'?2&8V.K2AA5#\"E/Q&+,B@<F%KT7K15%`BS$D+%EDS2BV2Y=5SY?E8!"F#
MPHC124[MR1K19K'@Q9IP<"VX>J)K8PXG+WV#V.;O(O9<2MO*D^5EXJ&PLU2%
ML]3;/",Y8GF\)3*R'4B2:!WH#J%^6C630,7Z81C=(*\?O[J5#PNCB(&<9(,8
M$=_.K<DVB!#".,`,*`P#;C&D"V&PFF>71+'V-&2,5;`3CW[&`9IJ!N88\*G%
M.*><`\\EUW'P&"=Q&>.".,U]F86_/&5)A/.".E!Y'-@LMR>',=FQ\&2CMJ6%
M6EF,DZ]G?]=7YV^NKJ\>KB[OT?F'M^C^X>;B/_]\<_WV\N[^-^CR_WR\>OC;
MZBN,N9A:\F9Z)?'=AWUZ232[[U`F`G!GLO@BI1_M@<.,^S:5M(3K?Z`:+;5$
MX->GJGI3\C8XTAU)NUW8T\&P^Z]JT54[K]V18%]B#=+T,R8Q&!WXZ/6_Q4Z2
M5HSV80LI#/,*1WV/U>/5C0<S<S.`$TM7#X;;$W^+MYB($-WA9YQ6`Q%&-QA&
M]6;19;VK1\(IW=K<_;%S.P,?MFR`R7_$I`^Z]K66O+NW*J5:<''\Q,,^$(,:
M$TGD\5X$DSX`0SQI!Z]N[0.2]$RG'H\$P0:U)%#[D),QY#6&%)?T&$CM$8<L
MI\=\??"&M+P@_XW+$0ZA(H'V"3T,M5OTQT.E\\,RF>Q+[&U;&->*GCX>"*5!
MG,CD\"L>P<SV^[C<LW-2:721I66<[G`:DCE,`]](`73<<AA$YY"E?CA<)CIZ
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M$_CC(UT(0_[!1_OD&[)$UGX1*_,:$)^PE+_K#W[E95RHFS;3'0&_0^6/5RC`
M#+F&1.*3?_3$LG82?Y8NXY%TW>5&CV3=7<DL'5SN]X?![3^JQ#W==)3'P.TT
M2I*,7"5:48*_@C'K0PLRJ`!E+5K_Z!^CA%\6SD;@]X)0@F>Y&C12@/N-S3K0
M,-P#/[%<.77]`W[Y-QF!?PN_'A3CJD\[VA-?T*_W-$.]\0'C2DEI_T#+O$F2
M=^P>?N>]AV%X>6<F\<3\!Q9VIO%PV>UY%,7T6$B0W`9Q=)5>!(>X#!))6,TK
ML2$$.MEL#:ESQ'F0"NQ@OZ5D_6/S#2&B%1G.XA2%G';]X_X.,%!*1#`(V@V2
MPQM<.+O#91"G.+H,<EK6J3@/PVI?)33Y?HNW<1CK3J38$,)XD#TDV8.&J:`\
MR%8RU<63>B"*^,C576>R\#4AJBG1"QF/(/X6SG/Z)W&LC^SX<V9+Y0G]4:N?
MK]:),.=T$^@E`VM`_))!H3AKYL6-8.5=9PWF83+P.S5&.&.NV$/>MS$(9'GO
MW)?[-V.0<$<YQ:.*!Y#)%;LI,51NO#\,*G%2B]M-D[ICX)(BE1R*+((/6_^@
M[D@!O3A[>Q\DN!`2_91E4:&OTZ4>"I36&,3N)#:*<9"W44-1G/`>Y\_D'[5H
MVCBI'0\UCPX`Z$Z@FL%P-3:,`ND=M4K)Y(+"+"$,LSPHXV>,@EV.\5Y50'B%
M1&`<#C&>SY:"HKZ6"#]3#@13Z)G1-".NG@)V'ZPU6-#D;D!&GL2)"Z6`]Z@O
MLH)=#Q-57X<2-OUPJ,U\L_C=C7SU6+BO629Y>A9S<\`TYJ:[IMKP^JG=2)'9
M<+[:J@LD^Y#L4;%NMBP/NB<+)@/6SB@X"U<(>VK8TA!(>^Z)H;0)UD(ASZ(J
M+%%!4U,00[:7E8U#="!DGE!@8C:T\<-;,FLD&:N$*OQ*.P<9::`R"@L@W33#
M0`"W"A\42I&7<!H6$:.6"F"%/E-XB:H.[8!K=YP0GKN?<$HFR(1@.H_V<1K3
M:88N4<PN8DL,M+X?!:VSXK>B!+N"/D*Z_I</3KQ!.T[.+#+H,%C_<KH30#])
M@+H,X+WL-/6SS!!]61C8+`C6;SBF%,`BC09=V5I*S5>X66_5`F?"S0KJ*@VS
M/;[."IT5*T?"&+)!:-F6%<,6,>=!Z]`*8EC0QFPH>I&0P;US#8M[X12)KX3$
MURJ)U[/H#[@<M.63,3!6K!14MM_.`-!+0X<</Y%`129=+A"1[&;[$'S61D,#
M!=@)UR$0)P=<=<,!9L0!651GI5N*KE^RABUT_4ZH-YJS,6`]'&<"-8;,50,0
M[2AYFV?/<82C-\>/!8ZNTB90GH<D>^4G',P;RU,8@86RB9!/XMU(+E!KM:F2
M&F;/H"%9?PO;&1P:6U@WU9H5>CRB%Y0;<<YO48NVY>C%[O=Y]/^J@I<%?,CN
M,+7XF/4>;>??A\R-4R_S**C;"<NIK7N?P?USX&Y`+(5%<=^@>12=W//Z8:R:
M*ITDZ6_ISZSO<<6]5%J=0H8D.#4U#V.94B=YHG_^$L,;NZ/U)B!RTH2)9$L!
MO8:BV[;3#`;:[36*WMG=58X$V\TU2-/?[*2#SQ[I:!1*P]??LITJ]85!ZC5+
M?I/50!@S*<C/":8_T(WG/:T7_:O)ZNU(H4J`V\/JE@(?I@,HEF\KE**4=DNZ
M00TQ_S0@D</5T'<"C7^[,>!9SZ%^"N*4SGPW*3TM>[/M="MM6I5JU&%+#.-4
MXZ#);F5'.<^Q&*RJ>3^26[U,\8[>>9NE=(T54F)$##"*BT-6!$E!-XJ:#K-P
M9DB2L!R3>>8MYO^5LCQQ@79@T36&`8PYCH<HFZ0]-50^-%;"_E;?$_D7+5;1
M6:&P-K0L8((V.YR-KF:`7M0LOJ5(VQ6%8./%<J*/MFYJ1]9..'ZFN\G6BE*1
M^N*">EAFY^O3`<T&]J+I^Q3FS4C@%N-],%?I,YF7LES?L62`QA=#4P`Q6YA$
MX(UI]6121+EFA$]F=)MC6E.D[M0CSG"0Q/VF?,*YL;/]5&:^&-X8Z&:+M.&T
M^F)SCIBV<[3@6)]#8LD(8X8XMWG)B$/_G`&]QEB?5^(].QC(0`G2AV1$--BE
M"_!>R]?1\Z69F2_N/`:Z70ICXN3/6L)>VL'NT7SWA5-KS^<!!*X9$#6!Z[03
M-=]'$\BO9S8T#9*,>>RK'W]XQ?R5_D8!2^ZH=Z(+*XIU/6\$".I>%L-7FQ*M
M9=&;3TU%C:?3UG#M#=?I6#IM)1<1.\K"BNZ6J3XV3)?[X8D=;Q)N'#5N'%4Y
MW1T@,S%!Q+IBDG\=<!YG[%MN),/]SJ=)^J3?K'48[-'Y,O5J`)EGV1,B?R94
MI6"#38`]F";M!-?,B*>-F;^$,X2SCW3Y?V9PWEG!U1>=8T5S<8H.YM:+$Z2#
MAX^\\T*ZC56X.,EK9.255UI`MO!.`Q?/3O(.2JK<VRS`C\TY@S,0@UJTGAUU
M(VM9<6CP//Q'%>>X\P&<WM`;.+4PA@%0(Z[1$#L]N:RI5Y\XQXK6WZ84#.@Y
M3<$"U3PVB''9-(4N'909F+PY.Q\ID>DIH#NQO&P((V;0/#BN81^$9D<Q_Z?)
M>=,CS'W5L?(-YW6Q8G;T>')T-REZYX7OXC1(0P?)JY&15UYI`=G".PU</$M>
M!R7M&79#X6/R.A[.@)^V:'U+7O,LQ#@JWA&KIIV-B)3X9CO<O\:"#JIGK"6@
M;M?8`2*XJ_"R:$R4FP/=YB\N/^,\C`M#C^M!.O@79`2D>T%*(K@79!]"9L<@
M_R>Y>9.;+_NF6M%<A'VO]DW'(67Y]4%"NE5,XH"UL8AX9"%+_T,7L\]!0A>\
MM^S3Y.EG&XV:QK$`JBLR`6:GT,@(>KBP>E\=#@DK:1XD5-1W2?;I*MUF^9Y]
MYAY80%A3`UTQ'0>N<^?4CA3L$NH8\?KW.R5J>B4H3+*BRC'=<4JS](S%'VE=
MGT;*"+3^,L(A:C:;4'HD,?!BJ2#N@[!#G%%<5K1]:AI6].OUFZK\D)5_PR5M
M,J@-K;;D4&%U'+QN2+6C!:L)/4J^X0.+Q##18?Q^\.)^.!-G?>-)ID<U`_18
ME8BP0$>2"5$F@/ML`17M9BN^>I-UD"[K4PP$6D)H1>XL%7JCP/:Y-)+TRRGE
MNR`5MZ:9];^IBCC%!<!>LZW(?"!UVW8H^OD!?R[1&V*UOP#.,;(V+XA861)'
M@;C3?DL45I]RO-F*E4N0W)/?\-8W`SFA(]Y`]4==*J93L=0%X]47[@ZEMO=H
M]H^+3M^E\Z;ODA<IVGV\2^-M'-(ONGS.)IGQ+5%.2-)BZN#,OW5)K"4QT))I
M%+3.BLF*$FS!-$(ZQ<IAOP_R(PWE$A_4,D(UI_671+-PF<%X,EGU<0T5XC,0
M`)73&X30*8JG'0U9*EB*Q^=Y3DLVT(#\MMD]&(I[HSA`E1(>#;);6MB:'*YK
MT4@1%85YU1,S0%,CQU!:%JCEX4D,K._7'^W]S4P"=;EF&$;W7HU^/-R5FB&9
MQE1'6-Q-9HA[_"+\8+!`E('"&R\PEX#2#@<HNS`@B\GVO5B[:<_CVD?6<2S`
MCG^,AGER$L2:'BH2CY=14?Y"VE!OZ%DKA=4CM4,XXDA\%Y5_T5R+>""F6]!Y
MYG6F^#Y(M/YU#3N)QGC3W-BOKCHA:EK4O;DNZ!>DM-3%;SL2@+H3EC":PA,#
MX]>M/&$EC.I;)ZM&TK1*%G3&R+3TQ.(0#TP%BFFR\YI6]0N86Q_&U64_^@6\
MJ(OA!,G0II^1`NPZWQ"(D_M[NN$0%_;,L@P[M`_)_DG-"/L4WX80JF2\+:1N
MP?@A*J@DWE8R?8D234F/Q7W$F>3^)>9::`-!V(+.,Z\Q!>1!(H`6"U82#5N<
M#\'Y,LC3.-W1(]&LX<A03#:,AS&J00"R,6D'0P7>`8&4-Q.Z/9,()6*DJX?>
ML;+7XUN1/0FTIT`&XJM^N!\>8(JFNK&K!U&S(&/LWHLPRN[I/65)A/."[KF4
MQP]9.2+5'4$/="1I+,#.J21;8K"#2>,$[)_AD>A_@SB']4\A+0""'@+W,#7F
MP@W%Z9-!0-%9*6HG)G=&K!^)%8^WLPT?`B^]MQ[S[I+TGE_&3FSAE)[7&G,J
M:AP3L![K$Z">M%T?P0'N>-1X*56MRVLFXBBSQ`;@F-32D/R+T5:8!T+X2!X>
M^Z5I`AC%8/7Y88)T(TUWZCPB!(UP_/=SPCNB_-\EP4YOS04.O]MESR\)"3=D
M\L.I_2K8K6M76CS49GI_'&T/.JVI7]UH(_I3PQ11KI/?J/@2]HZ86)#\#0?Y
M91J]#4H\_^7J.:__GH=0UJ]<-V[.VS?SG&\(];=,_@!$GX#((Q!]QF2S>"N^
MOO(2#LYL0L-V?8,PXJNM03EHCBD8&,ZW@YHYXMS=V<`#&>?NU7-N<&]<1G/Z
MHNG?7+S?EH_#UTJ93GZ7ER01*(\7A$\>)%=IA#__)S[.?ZD:MNN_72.^^C4K
M!\UYWP:&\U\\9XX$=\38(\)_K@VT%>C8OFYQ4Y5%2;)%DB@Z,PCC,\"LPP+Y
MB:D8*!S8S2!W=T;$'H78LS9\/[]`TN-FVM2[.,'Y!9EK=EGN+*J<,(6R&B6V
MKIETALRW"P4[9X;`>*.:^<S7?H=W,5U1IN6'8.\@15!SA7KQ:G3=-]\=,__5
MJ_@Y>_<M<T2YS\X+^8*#9YOOR.^*^19@8`V7,6IQGJ:/O8$N<DD-4X>)I5@X
MBF4#>X8CVZ!KT44L0V(,;1<]C&JK:(:YLXD3ENXM@FTE3+`'MU_\18D5J>S*
M;5;$-@4;K4BAOO/;P^I^XA^F6WWKVEXHQ8XU6=:DM+9M6W*'_.--D-!ZV213
MQ=B7.C@M2'Y"ANW2[P\Y?B(`XF<L?FMMDW9<P,US#%B-I=JP@#1:>_EL[;<M
M#$7KZ'38(GJNRC>+K@N,#ET\,9.`VZH6AL8P>^,AK5`CS$23JTN^SC8U]65$
MOH7`"WY3\Z[H=\8W01&'Q(W>QDE%1/J`2VKK`\<]Y[,#N,3H`'YSP7$&KW4O
M/\X6M'_<B6]$B=KVJ&&*&%?V"5OP9==J6>2T.9"Z]!&:9=51=YL*&W6D!'PL
MCN4F[%CN@6BAH,.7*4P]>/ER1?"/C2U$PA:H.J@:6BT`-@6GH(N;K5PADJA@
M5M7$>2QA9F$7:J`AD3S"*?Y%PN%\(7OFS]C1F5MFR*Q^3N'"I0/A6HKPH`@3
MD_UH78BL-QRX_))&_-KE;.5>S)T,@FI+=FVX$QS1S^*_P)XP`0-HX0%Q0?(.
MAQEQ5NIG=D9N00=C[=:`:K,?C60Q^[<1_=2(Z@NN$I%O+N$(%N`F"4TOR9R$
MV>8067?S&N`',<U=$9M,:4E-6CZHX-AT2_TIG("V5*:#KCW+`=K%?&T:/.6"
MY>PQX#LQ+9\-XIQ8\M;P8D7*"L^\TZ4BWO04`>>T[X(X_TN05%CZ('&5DN4G
M6]2:W=22%L8Q1P&K77$2HL6<SQ9"K[DOH4.,D"X.&E(DT?HV^2T(%;!"?<*8
MXT@=/$1))(USV1(#5:X?!:UVKVF8%O,O:Q"]HE8U(=+-;'6]*PA?F@Q+!A/*
M8+`:S)K+KP(3ZZ2-,]^2E#?)6`5)@>0]WC_BTQ,VHRBAEF#6H-I%V"@T*^;^
M."$\=S_A%.=!0LO#1?LX96?H:%945W\SOJJ1/(#R_2E`FTQ_*L(52WPU%RA9
M!_8F!MSAA(:4BZPH"Q8G6)BX#8XVO;_F,@4J#N9$%?6[=ZN#Q>;$V:![-<8Z
M?60[<Z3@B1C336<NK1D#?KE<1!M#4RS*A4[*#`5)0E5&,/$O=X(L^!3D$>@Q
M0[)(X`O?@7BN&`A8*D@I<A.9C;*NFNB4>1S2Y(U*]#&-R^+N_N-0BF.B`4MN
MAH%(:8T=@CG'<'BSMIOMX.>VBDS-I@,XTQA!'+V9`[D]=#.%R\K';::+.*.I
M'WHA.'X+?K[F*\<_?,9F&044D@*"5@$'P0_P*`V+DU=%4>'H;953C.Q*"C\9
M)$]FEY]Q'L8D;S!-TB,9`4[BDR!W)OG)6%>L);<_)-D1XWN</\<A5F_C?,C2
M9S)MXNB<Y8,/61DD\M]I;LI;KHN/@[^*V55@U-C#2L\&JGRWIF)KJP/1Z&+K
MP[54V"O5*YZ+Q(.U.Z\;U#P=\<=O$!.@N_:D(M!2DNB(2]1*L>$7O\5WR67*
ML@VL.:$TS)54I7E#@,@3XCU;CG;6JB'5G;103;/T3&B\8-K+U-K["B)H?;DT
METY<O%X[E&J$^,IBJE'5BP=7*QU_>5%6IU2P<"NN4F^SW'2(Z8N.N[8Z_RN.
M=T^$]5E`)`UVF)[9I[HA"Q%=A&4'9Z0_YLU&BAC'-PO9L-[?*KK-`KB$"9]P
M5"7X9FNE>?%5DQZZV9[JENW##A8T7^YY0`NBI178K)O6TMQB\71)5?7V#\2S
MJ-^."*/M,REA^]0Z0K+GHI\?:/\MZ-,ZJZH3](N)>B^YVV.^Z75OL7EL2PFP
M6SP.5+,];$>V[G[P&)D4EX8E8M12>[3=Z1!?T%#W=C-7V;J&>U4S_/^G8+\/
M=B2HW`9YF>*\>(H/RD]T@Z,!_'Q8^,:W]4/7]><A.7J&T1`@B0+]S&E@OM',
MP""9.9GW%D4Q&'IFP#BT%-.^G*B=\2XCV8B5(^I&`CBA6>C&`=7#UG4^DPS]
M"TET\'I.=ZBK0VO=;I3T'4<#B1(3E.U3=)@@_D)1H=ET><#Y/DZU$JO'`40$
MD\!-/%`-6C<:Z"7HO5]I:T\:#.)6(Z1^B/?-SAM94A[R[#F.R&_(+W*49B5=
MQ9/?EX(1)HM2=3X-XX'3WD_9#G;IA'^)\^Q`%N+[0(H)ZD.#%N,!G-(&0..<
MIL'K.NFP)#UC:$GDV;N`S9DGXKCE.'R:&.>]$6F.G'CH2.V?5VF9X\]9:N>=
MIM$`OCDL?..9^J'K^N60'(K:%YS`(Y^<CL$G?YR.8KXO.OEZ=IMG(<91\8XX
MQ#7)2=("O\.XN,,A)FF([K3?()63H];GX5.,GT6M1NF>VGD:W>%=E5!&Q_=Q
M@HLR2_'I2;1I+``"T$28350:2;]NJ)HD7/^B;,N%?IB1^+!/TBTGU+("B6J.
MX$81^[H?)&@??([WU9Z$"W&1J3K0.A==?40G^LA;?>SK9Z$JC7"N6V7`1,]%
MC,-&&:!'KEU_]*1?<M<ZJ\"?]96<4Y`5M]@9!97&%@FW"TH/<38!LDJW8RV^
M.=[A0Y:7UW&*SS_'NB/SRS_VZ_!;G3J7<N$A/7XQWJQ0W)J.O4&/M",2E0!1
M$=#/5`A`/W>CU5:G;[-]$)\F.DL_S./3VI-5-^I4]FR=+>:_BREIQBEK2T_M
MN"E_+J"CLD/2#^0IAMGS9`Q0.2N5H$W5*I.$BQGAJ4B]U1/].^MT"QZ/-0Z2
MYT1>_BWLS;$=(ZID,/E;D&E$*R?29GO&:+S,HWPJ'>I&;>;:HF[UM5P>M8R"
M3)X$'C+=S#TT_E^5>#_KEN^8IWS)V4Q/66[3&*V6/,]?9+4LG;B@GUG&PA[G
MQ09"]UBR%'%(0/E`#%/SYP?R4Q&$[&Z6W?Z>NP=!;Q*X5EE_6V`I7:VP$>!0
M.::E_\F!>.DY;$N=/.DLU`U!\L/@-_,<:,RPZG#&'<;K'"NG=K6%M+*8?[E3
MP\#-DE&.5(`OR!SHQ5AQSB'_+]9_U)7L%M.,SS[4J,*E%YU,1^`+,P=Z&EJ5
MN7W$%^M9VO78DOKQV;],*S&'+N;9$JQI$791Y3G5"$U([8L\#)%#+Y?LX/47
M0>-PK;"T&01B6K!(#>H$N7<E#L;C:PM(>M&[K@%P%WQZ'Y0XCX-$-P5IQ@)W
M9%0)WFO':))X,3?0B6AHQ$A&HF;H!OV49P5(G3E;T:F\^_KO'ECQ7[/\EZN4
MG60N!LWX9#"P'2M%[QFR4>;E+?E42(,ITZ&T`[48[(,Q#TE/_WX6IV<'/L(#
M>WY'.X"0R>:G+(L&[?ED,+`]*T7OV;-1YN7M^51(@SW70Q$;ZX,Y#PG?2+RC
M`T"OHQQP7A[IQU9Z#/SR'U7,CG(/)>PVA#!6;@^IMOCQ6!:S?BOA>Q>"!=&&
M=>#DI_`;0D_R\DG`I(S\(.@9.%P3;U"*>W<I`.:"#[@<:*6D'@H\#RC$[LT"
M!GF7GP.Z`AIF`#(0N.60I<P.%YF:LCJBU5SC8(:Z.KJA$(5US&*WE774XU8N
MK6,20M'LFX^68S)LM9=IXC=1%Z;BW%RIM4J?55!R?ZC($IM,:#?;;1QB"Z\;
MI@$I(FD'1"H?:298NW"DC32*37A.QI(*3KB6DP[75YR/*..(ACU@G;"S!"3`
M>Z7G(<%;L1JV;_$AQV',D).?$\P.ZJ71^3[+R_A7]GMM`JQ)&-VQ!SJ:[U@]
MS:G^A?2R6#+K4!']F]@-:R3SWJ"&._,:F?\&G2P7-]WUXKS8P/12-;XC:>9E
MBG=44#@-11)OACF0F'JX!4,6$F^.[#"\>6DYAH%G6S):B(-;,T9L<^H/B@>>
M/,NB1+@M)42-PE&@VJJ%5F0KUS$<(9-VH^QDAXQN'GC3$W(!@)MU$0[7.G0&
ML;L1Z$61$3+CY!6.KN/@,4[BDK:O''<`9I@!]!$86XC]0S!CL,TJ9,4><U.5
MW'JC>C>`6)Q4]N:2=Z(HQ`$1E:E.Y012UFH.:*FZU10V:Q>YFBZC*D6DS%#+
M#36;1S3&R,6O:H[UH2>@FE<+H,]:]+F,7J[N)#JW`%7(!8>-0LX2<)JY*9]P
MW@^BZ@!F2P0SG=A!J:<0>PSS<O^H"LO[(,&&<JJJ43`YO498.7\_&;)ZKJY\
MOBJGHP,1&PF[[SI:YF)YF6T2Z@E"`\:QMWB+B>>2$/Z,TTIWV[8W"B92:82M
M0].`E(OM*_;%.GW;]0@DABQBG"5MI:G[*#XL(^\Y&M62Y@M*.O`!?X0^A90%
M[V$7ISO:6>#/QP2G^'.W7++#;XTG\EGL2`U1`,Q:=B":&<P\?-W9S$:601?T
M9Y_I"X,S.`?.PR,\VFV1?I*B!LG'`S'_M!15;E22:P:"E.8WB"Q5Y5>,6KL@
MOU8$Q2DQ-A:)P4B,AJI?/U[P2@@N2E+#G+YQ(/AR<^&=F(8?LF%OLR:%GQV'
M8.FF21T=Z'QI%FIXIKF34JTU7'GD_#D5GIAX.IED^82'?`=D3ET8(^!Z5/34
M.$^C]T&<EC@-B*.:%Z=F$IB5J@V,>MDZ1O[%UK`#`I]:E!C.=F@E@D77MP.K
MQAD(@C2M6,>)%L@60UXX[KF[^$]=^LUNFT9!YL6^C1:.9B-G$,=:.SLJP8>F
MRXTT;]9DRVS_X-QZ2V44D,ZD@2-YAR4G#/:/<4KO.IW?7J&@H->#I-U8?W:1
M["`7\8XW<60!@`6'1`0*)]%!G41_R%+RYRJ-Z"?XX<39.!P@6;80OTF0#6/7
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M&NCU]^EPSMJ@\;M%)%>]`:6AZ/(^RS>P[OIZ+()8($@8@BV)R(]-"(KJ$'1[
MO^X9D5D@UC;SL<(FBB)$*S8D.9FCV(1#)S+^KC78!JF`&H;8@6D:@(Q#L5B,
M'Q:[UZ"CER)M^JD"1'P?#^5-+[RDO3!T("@+V!SGKSC>/1'ISHD"@ATF<]$C
MSF^V#&1!#YN7!`)!SN!HO&8D#Q@?F@2T]JA9"!?SK[&0>D4%!3T2#!#G0/-S
MS@-)3(0CKK^+/A?E<F(/Q`Q7K^<L$*^GX"^E35X4"<N:U;_"G.T<!<E%MM]G
M*0<F)X</6;_/F53J6Q-.7#"&JBSF2B5M'3+7NE@L&CD!WS]+U3!%G&L=FDX7
M(7(K+\&[4U<>IBC:`BJYW&YQ6-(@S1(+6AP_.[!:^!MT=W_.OY_=W7\$3+XU
MD4\D2[T`."ZMT'/Q*K$8`CN06MBB7#NY,,":F5XLF=U/23!&(%U4=-,%$W<O
M295D&/9%P&.).HL:V*2=R,NKN&('?-+"9?5-X*D072QD@#>,74$7^,[DCTV]
M?>0YIV3DW;[F@\_PY2L[.HAS,R,`M0=H+(A6/DEC+9'%AG[[0=*?"TTS`6HV
MVH`.V\"]K!4+0J9E7*]([G%8Y:Q$P>7G,*DB'+TC'LA+68JORZ<[JN?[K-)7
M@W3#&Z@4I$O%-'4@E]#(8A.]*Q7TZIA(?%'+&-6<$7T32.)-4P+51P;^!(A$
M8"G52#D$*LHL_*7=)<BD/]&-`K9C4*7/N*`Y%-M#8*L.\G>'F<0]%>(I2R*R
M%J-US\JC11IA00200UA#:1*(08IULP=+<?K9ID2'.*$_5[I=@/K-ZJ@&$R$W
ML#"C='G!^Y8@?0H*UB6>[6W2Y[TYGF^W[*`7/MW>MR6"*"9D"Z6M+31$L7*I
M(3MQ^@5Q!!T[RBBVU]E<\7A$+3%051\'F$*.J:@Q!0TQS$)@64QK.K<R71]'
MZJ.C]Y/M,72>.;TLU$377S(QGA\!K`'J?8960:^@+N&L"'#UHZ42HMZFIK[5
M16.&&[%SNY&W;J&./$['4G`LXJ-*IH<"<;]&WY2.?IG6Z,*>'/I.C!V\_FV7
M<;@6VS,9`<1T0\6F.R+@KJ$6FVAO\#G6'1.RHO2LX4,?U&"G!SV:Q2S/3OQ1
M;3@WB%*2M32A]=':J'1O,WK;?*RUR92>65L?U'#+5RV:]:VM(_XD:^/4@/9V
MC4E^1O=@KO:'/'OF9[J4M96M*(#*Z@R#:*KJV$GO@<-?QRF^*O%^].PB$7KF
M[CU(@]ZNQ;*^L\O"CVSP3$D1HP7T]).K]=(93CYIFE)J2UHO2@Z8@6D*#=@A
M6LSH;"$,%N&3*#=TE<UG&>@46@]O((.V(?3-Z'3Y\W@L`.9FR)Y-MN9'[FR&
M94R>[4A]-#5U^CP%#Y"Y:1-H"X,#3Y_UT(;2-RM*WPQ.F\!-0`-@;J84SFAM
M?F9PYJ/DVM%^&)7F.+BEU*L9C_Y<<\]@?D:@Y[7M);^O]OL@/]*]U]-JC@X_
MT)XG;+2XY,&NC]%S8C@MV.<TT0;,KOJ!"X80'?]<J*!M_#>'V\K]_^:+VC])
M6?,49XL95R2SK;O_20>0P4LS+*8.^39I*"M!=,-C)\K[%624Q1S6^5B^K%$P
M8&A`'\V@KE9<'CH3P?5F>Q_OTG@;AW0;*0SI%^XXW=UF21S&N#B/HIA*%R0V
M1TSGLH0X@.I&#>WQU'G\5CZ\ZD)8T[0M\44M8U1S1B]:WLB;PZ__C$H9/CN[
MM%8*22M!JY6#X`S8T^$B*&AK6/H?NE?^'"3T6\R[(,[_$B05;LN]ZLZ\V-/#
M+'E&`ZP709.1+;8L&@.E=]"($+'9EOT@D6\098`8!]2R@%@\S<:'6RHXCVKD
MO4H/55E<TQ[)KXT?<XT4,%YC`:+VDQ'2+^899G%/;:4U^`WB!!O$2-!KL+:Z
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MN)5@2F1'5!(DB4+IA#`P'R^\T?1>:/IDUF@U?9>%3QC%6]:\M(ZA116&N"BV
M59(<4417+MFA0$&2H"U5/*9U+`KZ4\GEX*T?N8"T;QT^8X$V$JWKR@5?Q?`G
ME/]^%XIW\47-?Q=$AC@,DK<</?WE^YB`*;-479``6J*O<:ZT>@GKS:!&<;ZR
M>=4"*_1L6XN()!E1*^37.0O/?"_-?,`K1!>HHHH-NHH-:\5&DF+WS5/$>L^K
M-=X7HW?=/#QN*3GEM7U1T^\=WM'V<5E^!)YUU8)\C9.M2>7KS;$J*;ZRJ54/
M$7I&;27[ZN?1:2_!:OK,6RW^DT^:,Y6\X%RI?$=?U`QY3Y?6['0F\`RI%N1K
MG"%-*E]OAE1)\97-D'J(T#,DDTR<:?_:I\@1;^&]S;S(-@/%4?A_\HEQFH&O
M,3'R'=O3E^1R9G2E4H*857YH-"BZ7M&*UGQ_7/5JUWPZP!RXOG*;B6^]1Z\[
MVZV-2QM<W<UK3!0VIA&F;G7'B]ES>4"F-7!UWV8E&1:3>!NTH;>2=-:$Q7:Z
MHTVN,(FD,DFYG`X')S!P);YW/E49]4\OC7%]NYRI3J[J/F1O,-%DMDOC7W%T
M0PSY`>=[E?HM"0'FAU&0FM!N1;5N5!XATO"5\#)#CQBU](@R0)0#2`AT@JWV
M&.$C,''("9*\\Y;R]BUE]"V5A`/@[:BW^$`DBID&2*`\WV=Y&?^J4H@5!531
MAT$0;>$':^D7._IN%K=O1^WH#2+_2C"[<$RG$IET@SYD*9FOHBJD_X2I#3$5
M&#^!(XUO[E.S!CS]"_4KMO,*P[S"T74</,8)ZTET41&_)GF%N3"*!1U0&RY;
M0$V+K;%(%O,<&]%[&Q"<!DE$&R3(@'M?3H$CW;FMD0E7`;P1>+D_)-D1D\DQ
MH542^H`T/F)!!^,CUH!J'QF-9#$?L1&]UTI=T)SEG$CI+!`>,@5,[1:=\AQT
M?B&I)'DF7=E^AG26YA+D>5'@LB`3I03K/0[H_=_H)KVC/?#R.-V1`61FS^M_
MTHHEA:F*JD/^P%=S72FH=Y'7M686<V:7JM!?$D:"$]N,V*"&&_,:F1]\C==&
M(6^.3"4725`4AM*NAO'`QJT#T#/6(<F7-SZ%J+V@2P<@-@*\0.N)TRC<A/G%
MQS1[+'#.-O78?72ZM$]#UBZ(3!DR:&-1U^4>YT7X=:X^331>3&]K!6>7BC+$
M:MJ63'8V\.*T4IAH?OQSC'-B<D]'5L/!+CX;B<&#M04T1>0>@6F-,&X&8:HB
MTA#X$]WEI*4/S"YDV_$`-KXQ0'LV.`7A\J9H"<EDD=V<50J0DJGZ$QMGY._7
M`R6^'3_#BZ3#C:)<KONT&O)Z[7=M*$4N.Q-_!%OO20^I?2Q"66I:%;)'>5*]
MO'L4H"VN;B[>-$`$5,7)"DI3SFD4AL6L=E#H?H/0SC$?N1P^9*6G>3":DQ^+
ME'ZZ")*0'O\GJX>;[660I\0)"TU%X],_FRH`N^$+<"S$I4*:4R,NF*Y[J,2=
MQ(J*9@UK^NFIIC;50%<-`BX.O*""NHMZJB.#0EY<9T7Q;:L7F-,MZYD+KH$;
MJJ,K!@&>BU$7CY<F@N+-L1TCCA6>?PKRZ.9`1Q:7GW$>Q@4NKE*BLSB+_HKC
MW1/!>4Z,--CA^N^W>1SJON2L+010HVH053?MKD%UO%@:MKI238TC.MTS9!GH
M9J8\4,B!F"`;)$39H$88%*>(B[-!M4!(2-2,0DPFB*P17NME%OZ",LX,?:HU
M%`@-X5I#!Y6&/(JN`VJZJ<JB)','F2X^5(9UW0+/\31&3E68=1B<HZD5#8O:
M_U515#AZ6]&]">Y%3/3B`_[$_J3;2+,E!C*!4=":]SH)TW+3DBT(=6#CE(B3
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MFBVGVGTKH#KQKF$`;K_5Y[[O<?Y,9%*O3CYDZ3,NZ.*8+D0*5NM?_OM%5I0?
MLO)ON&PO[;6<.-$-"<;YPU.0BG6,9FD`*`_L!0BP%W!ZL0)<\XNMB2!5K;L(
M@H0PG=TY^7GLMB&7B._6D?47;[;1V>RC8I&1)3KB4KJ@O.GPY?2(B4>2(Y)"
M"0$A;YSX\#:X0JM4NC-,GAKOV16=SO66D.J9I)]IEIZ)MT)T4Y)XSIK6L@PM
MX&JF*\K>WZHTANPH1_4EJ@JQ7I1'VG_R#7G@+]H#&WH"J,,:0Q#:@QJVLB]X
M2,,@;/]D0]'6#MOP1J=']+/X+Z5$C!3HG,8$)+?\EC1'!&?U=[C`]*`B_<K:
MECRN&U0S-!KSMZ*$\8,1H&J'F(!F,<^P$[__\9]3\:_]4OEJ0>B;URR#TN7>
M)#M?N*W2B-Z:$(5\1+V?=[@NXW,GVGFQ/0K[AG?N>`/L$[A63+.IX(KQNCL0
M;J7NF7R'?5-YK*Y21I[0?+*NG\'W0;UJJ+>JCNJZ/755K"W&L#5\?$'?-A\T
M5@QU6L1Y3_NPU]C>97E;C/.R[H$D6C'1<BUI6@6)4,W[($Y+G`8D&!$M%2,C
M[$H/ABC2O*9*VZ+,:SQUY2+,ZT'J7U9FSVY#-GDZDNK4-L^O&^*A<UIKB8G0
MQ'Y)"#H/%![&?0]4W&VXRINUT6*34IU)33<VKNTZCNXE;9.8"M47[^M5J,MI
MQ]1KJ"[`.3%U=\8:XI*"6[6T]Q3<\%WYJH)+H?L;/8FIM5I;*Q@P:1\^G;^.
MAI3-MMK*M!.3UE7FMR])0P[#JZ(KS<RH.I<C0#!UHX0FALYCMV[H="&K8F^O
MWSKKRXB32ZOC"PN*WJH#\CL+*\`L/L52.VI4\QZ73UG4'?`KCK2?7<8S@OH*
M,Q5R^U%F#M8YFU9LH5*OI^+R2-=+$R>VZ;P@MI9F`F]WBR8R6GD#:):4_?4Q
M7]]*_/BVC,]3US(JP)(*Z-+>Z^G**Q4LUWN#U:^-T]U#)KY`B#FY_1#1[AB=
M;!6IM.:2.WP7#P?*T;7ZF,$:M!_(;+F'FX;4CT`/6?-AL_Z8*7W@[&Q^GVYZ
M^]!>9$%5U9T[\EI5]>6-;F^2#8IP$>]2=BR/A1MO=[`]U)WTJ;2CN,$=ZL4<
MLDZBZ_93M.D4O0Y#1;G97F3[?9:R2R^Z8_5UTRBV1U]3TH-GG!8QXD7@E#A7
M>\Y<3!]PV3;#8KA"CJ60;O^L'0[<OJA8>E$RN`U*^WW0G+16[O34E'8QB<^9
MNMEW\J?IS$!;'$^$KFA3/)(35*OA26*:NJF>=/:5OW30**K:T(-N].M<!W5'
MV3`HGD[WH\1YG'Z+V.A$4^I^]TU+1-%2B?VBHI<\J[*((Q8EVH,"[V*<+!/^
M1C3[_<K5NV!KQ#8/NL/Q_K'*"PI/?4IV5%IEP\ZG!9@]_.$5US`O3Y98MH*.
M6%.19%?FBG1'I_U:0,U7A"KKSV5%Y+(BHH45,7TY!*@)GXO>Z8H`7?ZCBLOC
M55J4.5-X[W+;7]B=M+JHE2:-7^_Q7U@1IXGJG5W;::9>%PGEZP*:5-9NH*H=
M%P))4BBNOFX0%Z4M>+?N?@&PFN^4%U31B[O[C\6WB-]P76T_*!FZ,:4M"CUT
M8PJTQ+4#2'*NOR@4;23`"?G5[B><XIPL@-+H/-K':4QKT])/._7%-"T:0;]!
M@@/OJMOAT=QN`WU9SH#N)*!!%RC,&Z3N+<*"7GH6`\0HV/=@+VXV(.YZ>5V]
MSTG,AJRI<5$\!)_?$#O8QB7=,F5!_/$TS@_LM8[D!9-QS0)>IT].$"_F/U,A
M:O?":6#@G!!AA00OOD6NRWX@/-$5<(&U)%@?.?DRVZ2&S$*D.BQL?*2)#DES
M3!-PG1KQ./-13HV`$XJI2"PKE"S13(/)^I0E$4F%>>+:[H#2:_H5F6X-/3-&
MD4-5O1P'KUOMTHX6H,KE&,'44[3@\)MZ2?9"VOL6;+Y=NF6%7:%&9U@19BP@
M-YG")QQ5";[93J^6;FI_[9`_T#:1:P4U^T!+:6:YQ8%#5?2\0O!FI8UF-RN`
M[XP]>;?F>J"_H`O&7]B&:T\EL[=2M;KP;Y/TVM`S</;VI[%+X.(GNNB1H)B5
M9:;+AHLLI5]F<!K&VJ_A$@7+2SLT4.>=YL,(91KTXD-68O3Z];>KOY#S,*37
MVFF]6EIUB@@SE,M4^WV0'UG0CG=IO(U#6HZ[Y8-J1DLG;H8%^0'GY?&6R$V/
M7M"<C>V0?L#$Y1[(\Z1\6[$*9\0;Q,CY8KQF0#L<D/\A[D6Y`/92FPU3>HLU
M'P85MU`59^X6?6W7F`0KFB1?[0]YQH^SZ'?XFM%('@ZZ^IX*(+8!L%X:PSX5
M?<A2:A7LP_E5&F;[>H-;$T:&B&#2#SLH=6HQ#L-B?C`H]*DE\6^7,@7B).B%
M(%IF6BEI<5R=,RR!0A0XAO#MT7"NTA+3+30653.&+68DTP\S._T2T3VIS9M.
ML-M>!!@)1/2F5QJI,U@ZX11D6%+19E/R]YB!+Q8+/1/VR\:BBCS]`K**!A?_
M4K*4RNRO@8@&,_PN8O-4YJO:!19[]`8U#T>=;Z*0'V!@]*FZK2&KE>]STJ@G
MM'O@"G1[EX/WNJM1=^Z<\-XZ[$@ACAXR^GF&I,8W6_K#?97GF(J)H_-"K(_?
M9?E?X_*)YF3T"&+P67WA8^DG0I2T746);:';11^W<OG;%;#T[X*QATJ![.1F
M6]TT3#R;'89&]^@C[1C&K@B(?TE2H*!H]HGH30!)$L1$@2F<"ZO=HM&NXJX=
M/U@LM$L>RB(;4R[Y!RJZJCU(JOTDJ;9<3+7#97G_*73K\LY*K;$3-3QD1`U$
M!>_CE%[6&3.'C.4$.#=,`]V+^>/8P,3R*3(:+%T1;(E9$Y[,8@57SP*N:Q6<
MNBU1P$$H8"\4X%E8]$$#[DN1WVQ/)3\OBBR,:;"E?Z%B\K/A<D]*E9[F\0,K
M'#Y/`2?UP*<Q@RCS/4=2725D8M6]H(5:MNR/=?`3=RDZ76P!2W(OI(Z>`Y/T
MI%'')Z8.&@9$?S#1J976Y#@LIQ#+FMH^:81K8[UR(\E0\W!Y7^12]!I>Z&Y2
M<_NH?DX!>@')A58N%/E]3#OFI2D.F7J8(5`_P`UHND*0#_%[UU#>%KWMBH<L
M9`)ZZ+9*RE/PK5H6*8+RGA<9J'?W[IKJ`G1?\3;(RQ3G5UOQPWT5TM/:M.WV
M45Q:*D2QHDAT=;L(TBB.B(?32S*\-$%QF_/*<1'K^,9+]"N#D0=2@99E@7X9
MBOHN4")!%8J!Q6LJ!R(D0\U&?"L;WY,70J%XR\)I_4]9R/H69,%&U*(V'1D;
M8?E%/"$N^;.HU1GQGHVB,0MTP15_7U5=N:4IV96?O*JKM,SQ9Q+<Q;LZB'=5
MR.\JDM]54K^KNF)+V'E70?VN#B2W"/B[*MB[XEU(@,J+_O>[FO"N%IWG11FA
MCX<L'5FPZ%V67Q+1Q0O@ZJ7+A1P')>=QGAYOM@]$('R3'YZ"](J@#@/5X0#?
MA/-BU@=^-8;)'T@RZ!P`%+95*E`7!:,B3BI)Q[8@J:A-#M`(RT)9(S'E&*3L
MS"C[/94<<=&1)+LO.8&WKZZ9;NI7Y["(6]EY=:7FU97LU67\U<6M[+ZD"/_]
MZD:_NG4WRZ;>;!'[)3=5690T(4IW?'MDX;TTZ7D;Q)\(LI^T@MJD,=T--,.E
M;L`K<Z8=MI/;[$P3[!@"<?(MCLLJ[WU<=\@7Z,*<*X4T]^5<:F).O<^X").L
M(!Q)".[>.:*?5>M>;P]Y3)M1\%HZ_*_TBO4;\JA?5'.'$[80]3_=J:.M`SJ?
MY\KU0%T)W"\"V7"F\^;IW33^U;UI+\CXMT6FQ!#Z",2>`5,B=#'=:'`#U?]<
MR02"U@0.K0F$M2I*I@HL'@!9FP'OJ+[N\"'+6TV8`^%(6J");0RP9O*:@FBY
MK-<20K_R&Z-##>&FCC$_]V(-4&F[><"N4N),>V4=JO4\YP/^)`60/$O)CR&_
M5#G&B<:S@?&GJ7!KUYJ+<S$OFP"LWRKE4V?.[S#QS?D<X#V/Q#D!>LX0A_CD
M.GZ')V@/'^69":O6,-WZDPTM?`N?,9`Z+7R:AG@,7W>ICA?%-[*?SV2$JP.;
M=+;+<E&MKC`J[METCC5NQ*6<#>H5"A3[4N(2CO2`]>]G^Z\3P-O>BRB'G_[J
MWV_I[<GQ(HS-E1>Z^2N.CFWY$_KNL^K]<775D9_RK#!<`#<2@=W@MH`B7<$>
M@6&Q6#8H],B"-HS,J_(U0T"Z=6K0;C$`IJR&G2\134M^RK*(WH_3%4QBYSK$
M6*)P.IK%.ZC)?83L]1=A=C9EW9)`M;0_!7%Z35[Q34KEOMEV[*8Q&HW\E!B]
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M*,&L^%&,0.>%"9`5L7X$%ZCX/5I$DWW7!V-OMDU4-L98X!#K%'M='BK;MH'3
M[S"X,'PS>J<U9]*THN>V>!?YN#R^PR8PZBMBHWE`W.2:"+2]<#62P<KWHB9)
MUS^GP-@@B0\BC$0D>GC"?F5\;D%C"?06USY(;W3X%86@4;L,/W\^)CC%G\65
MXN(I/C35^'NX]6,!PLF0X$W8T`U<-SR8I>C9AAB.I/&($ZQ[G&>.[)(W9"E8
MUPE7VE]4_L&0,Q'`H1WO,FA\3(,]/09K6H[>YO@0Q'4A`OFZEC*%F<T2(`0Y
M4D,3J6;R6S>@.1&V9[@25\,F&2T-REDW]['?R)<;89*AY35BW((Y"(V(N[+B
MNN=A28T,ABV_5(*Z*ED[(M9_^'@@,20M!<BI:M-Q\S0.FL&/"H%J5OY%/Y.<
MTP-?\T?!MHYYWH:\R6HPNG;SQTJHX;"@&IS$N77UL,QFN@!5-&7OAV/9"&+0
M37-+:(J-\@%*J,UQ*[%,NZ(U`[E%A@]!QR'$[E="#M&+@+(NQI6"A2+%&XE=
MR<&OL&$`:1,[%.3>!!"M;&.CB'+1YELLF816Y6S*!9EW8<4UW.YB:[U"Y?6Q
MXY,\[(*UE1@\+-=<01#C82Y/CI+]&A<%"OD0Q&ZG]Z^8+^U+\Y2>UTI?`X7)
M9L2-8*GNZ@=<FD'4)%*98=$!>TD+LG@5<[#D$A:(^RQ7*3$(6@Q.?^NF&;+<
M-:'!FPTCQ(S7[U7DD92F=RVU5/M+D%3:"R]2Z[X-8B,WXAHME&+'2<[OK9ZA
M?WGUW:M7K^F7&?1,J7Z/7O_KJ\VK5^S_ZTNL054^D==!IECRY]??;_[MQ^\W
M__K];]F!NM>O?MC\^.\_;K[_[??U\+H]`FVC+-6V"TIT3[)8]J$(_?!J@VBV
MSD:])0[.?_N:_9;\+^%SH*TFGG%R!'#X[CV@J[0?OK2VV[OG1.\%*>(RU,VU
M&>`\BLBG&*28,>[-+!9LYKP1&S1:L>>4_*OXY_&;[5UV#)+RV)J$*G\W#H<H
MT3<L?EMZ3S]VY9)Z0X+T,U5!P8K'<)K%XHIU5;A9*'*!HHTK,'6-QZ.XZTF^
M0347AXYYBW-:)"C8X4:TR[2,RX0U>^5U:6ZV)*5B-\55T,9R`'#?:2`;CQY'
MOJZ33Y&M?[6_82)[?LV'W]5AG.BA<7I)F3&#B0<+`*Z#!*X!LXL>'##Y,ZV]
MPHH>P(0.0,`NCW\G;#0+@:)YRSN,A?@$2/N[MS@AO\IIQ&.'38W75IRPA3@D
M[DX=[;GQ^3Q7/DKN2N#^>J+A3.U9\&$'S&ONU.3EWTM/$">3E[T`,WSX>B7E
MB.Y$[$AV+BE'_GW44X[^BL@J,?$+4<ZZE>W")QQ5"2^>G%=D91@'CW$2ES'M
M?D6D,Y9O%<2B1#8E1Q(]^IEQ@*Z/.0]BM=\'^5%4@&8(\9+UK@<VX$_$']RQ
M/GTE"W^Z&=H3'HN`U>];1_%V'PTFZ7]U@Z%6?U,^D;BEDU@A+2-0N3'8QYH9
M,,!\E<K<'&YC7X+IK-"T%WJ/RZ<LZ@[X5=GUMSW=V'#9M#VW$&>T02?#?EU_
MP]\9XA9<TQPI;S^F!T7S/7W5EWGRT?;-4>JVTW8(,$TA_<_GCT>Y!]$&29T&
M_)@RYX.6YLW3+]DR(/'S-7D^^3?Y%_F!'HT@__C_4$L#!!0````(`$&(:$'_
M$SEGSB4``%=R`@`5`!P`:&%L;RTR,#$R,#DS,%]P<F4N>&UL550)``/9*YQ0
MV2N<4'5X"P`!!"4.```$.0$``.U=6W/C-I9^WZK]#]J>ATFJIFW+;M^RR4[)
M=COC6K?ELMW)3&UM3=$D)&%#D1Y>W%9^_0(@05(D`((B)5SBRD/<-@Z([UQP
M.3@XY\>_OBW]T2N(8A@&/WT8[QU\&('`#3T8S'_ZD,8?G=B%\,-?_^O?_^W'
M__CX\>\7#[<C+W33)0B2D1L!)P'>Z'DU>G@8785!`'P?K$9/SGP.(MKK:'RP
MA_\;GYW^Y^@R?%E%<+Y(1M]=?K]&]?%C_HT+)T9](CKRL<.]<?87'P:_/:,_
MC="`@_B'MQC^]&&1)"\_[.]_^_9M[]O17AC-]P\/#L;[?_]R^^@NP-+Y"(,X
M<0(7?!BA]C_$Y)>WH>LD!&V%_.TY\FD'1_O%M[@M\+\^TF8?\:\^C@\_'HWW
MWF+O0S9$B?X_4##X%RPXX_/S\WWRUP^(!Z/1CU'H@P<P&^'_?WVX*6@6CA_^
MOEJ"/3=<[N,_[E_E4IH$WN<@@<GJ)IB%T9)`1]_%??Z0K%[`3Q]BN'SQ`?W=
M(@(SU"WJ#\$:'QZ<'QU@4'\2][>_/KSNW4^CN1/`WTEWZ!,7:0P#$,<?))!R
M27L/ZC%=+IUH-9T]PGD`9]!U$'[7#5/$@&!^'_K0A4!JC+(]]1[R9>C[SG,8
M(6Z\@LD\`@`+36J,7-+>@[H)7E%/823)K+7FO3]^'X4O($I66''_E<(7#.H.
M)#(#X9+V'A22?90"[_/;"PAB.:XT2'H/X@K,0!0![P$@?J=`9A`-DMZ#0/R\
M00O.$MR&<7P/HL>%$TD-A4/8W^B3T/UM$?H>6KZPU).5E($SJ`8PYN42)L0*
MD0I>AF2R0,NSI!T)R7<T.0X_20XX6<I]\`HD#O0'1%!TN%L`3^`M21U_<!Q%
MOSN"\^0\^T,J%.UO6VMO!_UIZV'(E;C#L%A40PY%7J(,HFUM$.0'U=+!M@;8
M08!M/6QYB!UF'LF.AMZ`R0N;0SCT@#H(ET<Y]/Y0GD<<PJ$'U(%'/,HM#:F#
MPK=TL)W]M;PHA>3;&5P'L8KIMSJ\#B*6ZF8+YY8N&U<^<3ZPEPC$:"XF7I9;
M-(Y\-)BZKQ<*)KB/@X/1QQ%M7_W1";Q11CSB^K`0%T'@`2]SDZ'A^J&[UL#'
M7K\P:F,B_LT_18.>/,=)Y+@)[0AMUX"?]21)M]]MB!EGB?\P!N[>/'S=]P#<
MQZ/&/Y#A?SP8Y[['/Z%?%>-X0MW6QMG\<S&<JH`GT?K0G,BE':$?UV3>]&[F
M+?9?D)8'R4=W`7V/4L^B<-F)6_DH0M;0PPBIZT\?CO<.CCZ,TAB-*7S!U*4Y
M;9/+$S00#P_FVG?F##;7_FX4GVMC+QE]K(#1%`":.6&(,'A73B+2ZUH[HQC/
MP5`*X),"`62C?P!SB`>-]N/.DL5_=C.CV,^&4')_K(S[EPA)Y/@W:)%[^V^P
MXK*_T<Y`_C<PE`(X5""`RS3"0*]A[#K^/X`3\:<@?E.CQ,"'44KB3)DI7$,?
M1)=H./,PXAM"K951_&<B*%@_5F$$N66&RV48D,,".<3$TS3!-^PX7(`_)0F)
M#!2,&%`I)Q5K-465V6ZVC;A&OXL%&R9&6Z.D(L!1SE>GRH6!)U(Y451:&BR(
M"HI2#"<<,?RX7W<P]/6'7#@^#OUY7``@%_]0(^CMD%GK[YYP>P$2Z,HYC434
M`_B*T+)"KI:F,S2;(=8O0!##5Y#YJ>0\1BU=##M()UY<^^$W26<6DU#LR*KY
MD>3<6S656?=GC<?8HU4,!OU\&:*^`QS>AGZ*0Q]Z)'XN[V64=[/QM#1SXF=B
MYVG\<>XX+]G<!/PDIK^I3U+YK_]9#'(ZNX8!&@Q$\V@80X''"XU&DFSS>79S
M0),X1JP4#+W>0,4\*\_"<IIEC3V?7<=[C;D5@<EN%VYS-R5OL&2DKR!Z#F-`
MVF):&$9HWD<=JY1A?A9I%66CG2J)LE5O77:-P>8B/-QK>AB,EB&>?G'L$?H?
MOE9X=7P2C91<.E&T0MOE7QP_K1^D,9LDZ=3*F*.:5-22&'+1'^'0ZX;H*^+K
MHP=*S#<+M(D?@`L0^&<?W($D9QG+BH7-M1:T>.BY?#_9)E\:BK,B$;$->:[_
M66OYK0^U/*O8):_["+PXD(:)H(EIB@X4T1J#&&*4HM):NE((<J&?V";T-O&:
M)$BVR$Z'%5D2)HZOU$JS^+=[W\E\+VOO#ACF*6JNYQ98/.9<K&=V6B+7!'45
M%AU=+I9SNZSM%CK/T$>';8!?2#2#H`2G3GE2DUP+\JBHT^'`MB-KA07MO@=1
M8U5R[ZK4#-GS_!/C\5[S\M%H:=.SV[VSP@>W]O-IO:$&4I8\GM9'3F5Z:-U2
MFP7$-SG$%BNOK1&2Y0V>"M<ZMU(M7IXO65Y#_<7*&SF5J76N)"E+-=-$1;8Y
ML(M)]6:ZIK9W8>#*&F>UK08R[;1M$D"A@FX&/1AMKB7B(+E$_X>)I*Q9S<T5
M-PL-E?C`7BGU,A?F$FA>W[5G'C!'XD(P5.!GS&.PP0+OY`S1T?VQJ;AEG!YL
M-YC!Q^![.GB"GG<KSVRESKTE*U'FL&G$Q8&-,W4>G<R-KF@TT5^(S3%3"8YM
MD^#$\V`&Y-Z!WDUPZ;Q`M+6O<(#ER)`@TE_*,BBHW*WS6SW@)]<!\#X[48"V
M&/'$==-EZN,84;3KA"YD+;TR1/K+708%E;MU+BU6[C")+98)<F6-FLIQ8#>6
M:O='VWYS@SM$\S;/[8BH]+?N_.*]*-E:_'_MD4;>;?$88+S)8X#1=VN]?O_^
M.&#PPPYB\#0B@_7(QK),)=ER_N$3FG3C+XNI/"]9YNA89T#VH'.2)@N$Z/=R
M(N!J09/`7.DWL9129]W[6R;UFSA.I25.&YLN;8JCE'0SF8YUDN8_6^>Q2?F;
M]2%ESGJOC@3??*]NM.`K3H,.:[P4E4D*(`6H]*59MKHW<C4(EW9A:T.%SE_4
MV<%\-@F;NZ)S6QHMY/I:/K9M+>^0?X;)(&-7<:F4,TC>6U_"=^%5:4TM47.M
M'$KF62C['86ST5K/HZSKT7<X1>OWH^^^!D[J042DVN.2C8O$'308(>=\D>M!
MS7T'B9@2I6EH-M'`:KO(I+S@J`,ILC98]G[BT?%!G,/].0R]F/URC=U,E71Y
MJEC<8S!'6V1ML.Q"ZA:Z^5O91Q"]HG_$1;T?QAT&MZVNPA0,V=9D#)0E@BE6
M7WF5(]Q.+@75-X>784Q""VD%!\%ZR&]JZ+K(!U3F4;1K?<2(IS.RB#R&/OMP
M6FNA2K9MBED5XMJ`;4VG\(#8CUB'T_I<H4G)#\F[]9P]S+E5V%YWN;8,?SL9
M&-1+^1'XJ,_YSR``D>,C\!-O"0.2$AS7Y>*+6Y90=[G+XK`U5T.=3Q(+L?Y"
M;8[8SIP.TQ>`U328ES5W&/)CMC)T#\7$4N9GL$JZ:[64&'*M_=U0B=90;.FE
M?@]9L@LG9:[IKS'`D=L(;8J5\L*)H8MW$-!/$^`A:-4R6*)Z2KVZ,U#R_4&7
MBG+:K-1C^*FIP4+$A>GLR7EC7_SP6QNH&:V82L&?V2;Y7P&<+Y#23]"XG#FX
M2Y?/()K.&M=@Q$88NM"17EG"_0$F3ZHJ'2$76X6>BI.`2'NUR1DI<WO<N0>+
M58</NDAF89/RD!2A=V$0KN^LV2=_62(#UQU9:.5AP[+%A[Y'HV93,RJ.)K12
M&:P*K=C*K<CX<.O:L/-PE+*<2"T(Y6BS(!34WXATJ%',20%2+L"$T5R19P"/
MY#X*7R$2[L4J6P\+Y\C$3>!K]C*-#VN33C0P9J[$*@Z%SKAL#5`QQ(6TN3Z+
MO4B6Q?Q.O/]+XRP[SU/X`-PP<"$IP%!"?PK[3PS;^8RYNK4=?A3A-Y9-.72G
M!,AN"^T*UDK85Y=53D-ER<&W:%W%;2,'LZV%4ZX`&K$+"4KTLP^(+`-OL@RC
M!/[.4PTY,IL518X#MM9O^=F!`6;C-,#!J-/96AF%HH8"0W%D"6U6'5D>T,"E
M053G/%.=`,SQR4^AZB!&1@!-L%<@^W^%=7F")<'.IPNQS2K4A0]%9)1E^Y@F
M#YJUSZ14B$6F2GFZ6P=?)5BX:)24[7,*+:/&3@G;TMX&X:\!HL%5MDO]/BNO
M1M,B,\NL2:F#7$<VZ(D<4M&M;+L&$8QI(<],?PC_J1;IHD"U\B1X/]\H:]%I
M31%W9(,"R2$M:_;H<Q)BQXTU$5:SK+-"P]HHS)*R%"1KR_6(@/->'4K0F*4"
MDJ"L+>LC[Y'N=6MGLLN]"\HME0K2(/J;Q0*\\8[[WO$*.S'XCE>(JRQ%9)FG
M`FV-<G?0Q/U7"B/`K3K+T)`NQ)K-)Q*F4&2&ZX"RJ&MCU6%$GH>]IA&3E:0+
MRK(6SA]AT<ES-_5;=(2=&+SH"'&5570L6W3DF=%+0[2;3R1,H;N^;*W0A^KY
M!./'<;?H?WB%?75\O`K?`X3(JQ\!66^;.I&;,(=T0U24`;%?)R;(5J)HA<R"
M6\E)CLY<+6A`V5+UD!>B;6B\46*K&OQS;)$B8#!;*B62J<+G0.4]VV/Z\N(3
MACD^9=A-,`NCI=-6=D.6T@15D`9#5>'$MBUE[C(F=X0>3%*<Y3<K-^M=I,E=
MF/P#)+A4&G-2D"55I@K=M+R<(&2!4;6P+D41VC^[`'CQ->(ESOJ,2P;1![Y?
M`P0:,02Q%;Z2+(?,`%OLY<%\\U/\D).D%IX2YM0/)SOZIIEGFATQIP@HL^YY
M/YMQXEJ7$C1F:I,DN.*9Q/G1]M5A%T\LI]'<"?((;F0?%VD,`Q`W'EDB%1I]
M'%W!V/7#&$W[Z!]5RI$3>*."5L6S\<I@RD>?&:;["KLJB=_+YZ""/=U`_2IQ
MB3EX?9[.\EO*YNI"C(;12)4!#RK#PNO%`%@\K]SZUF0GCZ33Y=*)5FC)@_,`
MSJ"+KY"R,"4TZ]TC+KH5MV=IT(=U@\X[PH^C*UV-RKY&16<J7ALV((G>#`H:
M*SE4BD3SA`1^X;/76UE"9>'_K5(I#I222.PRSLO01](,L^R=DWD$LMFJ:8U'
M=6M<HQQ52-]75QU6UW7!1I$3S,FP2AF*S+H3M57K<2?D=LT%C%<:I?U_JMM_
MM;62T-#L\ZMR4,*7:H+6:B);&P,2V:.XN;IXUE89E`&L(@!VV1$-EJK&254J
MW90V=5RW*4I)CJL%[5]&F%J-`X8=]26P-`D:1;XD]K#D[*\;N2I[E)97Q:'4
M`99=5IJ_BZDG<B^M\Z1NG3G%J"!1$[R*W_7$]&&/XXOVK\+6@[S/J7'Q$E^U
M!`G/E.1(E)E/.V^+)SFM(.PR%LZSF])83NO&0BE&E$1).I6U44OM%"5HU&2&
MX0Q+M&K)$*DR-FG9E"E>VL'8971K22KJ=<E+TSNKFQZBJQ4M1<2CC%J#1*D"
MX^,WU2'#J\C4!&U565@;WZEA"89NESV1*])%Z"-,,=[I)JNF,9TW+ATJ1'\>
MY60JE)%\660[M09*KA$:'+X+$\G%J@.M,HMBRJ"X0)`'8)==X0`$F*58(DFC
MR<T)")BW>N.#YCU"04W<'NOT:NJ)\.!([2`[TBLJF=(^1/']0+<.U%5`VT"6
ME;(JG4#:9=5RU_:\Z_M/?:[O1_]#?_K?]YO\CH/'2?=CG,6P8F>!M_']?K_N
M]+_U[X>/!A'W+8^C6>!E<5E#(*^D+J8:3?67/7_L-->G97+-72<X"R;2;Q)8
MW"I@"1K])2T!@J9BM$SD['CR+'@<371%Z#F),,^8PCJ;;=*+_FJQ$:PB^9YE
MFG+MP(B\GZN$R]P$B'$IV0%S=4.23G]MD`12)%NS3/ZX"#3:[#M^OJGGK@HR
M!'I+6P8!70]8CR@,?AWV@,2!6(E?T5ZA1=$/R75_?HW)M/%.E&;(70H*S=)[
MLL>L5:93DLSRF#V=U3BQN@ZC2]0#.LOX3Q',GT;&;38^7+=Z:\1P.*FZG%E7
M7_D1S+%Y/(`77$N#,D9NC9"DU5M).H(I-@CZ3!L#I3#Z5N%7%`;H1Q=4]D9R
M*M&]&S.THSLN^E9SZWJBC[OX"B0.]!O>XI->WN+O\EZ5%,<TVEG\Z"Z`E^*J
M-Y^7+WZX`N`11*_0!>R3\<0G8R%/*G)?RN_`R[(QX;UT_,2I\K&E[^@],6P1
M.-_O;(,67:RR)19-26#R!EG/@K?_266)3[9IDMM2RR;[]-+085"6&*_"I0-9
ME?BV]2%;M)%GVD4LVI;XIY<Z"OT/7\#R&40,W9*B4A8:M54+*^]Q)%A@Z:7L
M(_!1G_.?00`BQ\=O%+PE#"#>=^`["NJ8X*I/1WJ[%:DC,VB]6<M4:AA>8R[?
M)&#)VJ<-_@5;%D+FMFQP;O'U5LD;EHJ?M8KH`?@XT3\9/,'\C#'3&@2BMSH]
M.S1[CFO87?%2IB=;1`NHP?[+G*&`DV,OG_-97AM)0F5/J0:Q*ZH]LF@MW69-
MOCF1]X2^PO$\U/YN]7I4PTK]U7JL)AR@9<86=-@LV^1:3Q"5L`(/A_;<.4O^
MB7X[GU'FN61IMS@<JB]4O8[>U=RI_*,2HY$R0]^BFJ^]7*KAM71Z?P!HU8,N
M7MXPZ*\!1(?%QZ\BIXNHO<U:T0)=OS,Q)T.%U'Z&/G[%[P%<[%Z"?IJ4EY]K
M^2OZ=6C^+G$(+O#W$@;F*.YT]XT#`%(,M'$%WLA@O,$=^"CO_OTN?./XYZS*
M.E+62LGL+\#!,O&FR%QP.0&<KCOP[L(@HO\D#XEX]]\#]JW_G?>`8/F%[I5J
MR,6*0+OTG3CF'!,%;55)<'`%;PB\B56OS7^-`PS,!.37('R.T6D:8[T)7M($
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M+]`M4Y.M&5D6_70=1I6T4.-=3HJ<`9BML+OF%MT!,.Z(C%9[0^(0MW9H9,<>
M'NOA.'J//7R//7R//7R//7R//7R//31AJUOVE!%-DP6(GA9.H,(5T#H6S3?`
M&K@'6EF8&\BI909")H.;.$Z!=Y7B_6-V*"#\B*LKR><W$+DP;@3P%BM.QTYL
M4<E-L/.WWD;KTGT4N@!X\35BMJSJ2-!HKBDM^B$!D'HC3_?Z.MT3$.FC#JV[
M&MZF)BOU4TD47)^-?R'3^TV0F=HFQ[S!/FVV<NZ.3S3Y[^'>X<GQ"3.1H[&*
M3DT<E_M]<T$</SEO%R``,Y@0JR^>@%29+)@+._:CN0I*KZ0;PJ>+J39K*?L^
M^R[%!RW$*[(Q(`^&EF%0V3WDKX:>0G0JB^]`,IWA'QY)&5R$$.U,X]P"K\/H
M5Y@L<&$TQ&?$)5`_;NSDBYKKG4#;=L(>.N,=[7TZ/SDX-T4_:QB?0H01X?L"
M`[A,EUWTKFM/ENA35]BEGIP>GY^>Z*XGDR7FRW16!S*)X]"%V&#P7S`3LBU`
M]5#$TI9^_1FN,_W`4\WYM'=P<GK$K*M@Z<-/<K_5R'E\W"_G<=;I^S-/U<EJ
MA25MM_<MO8/[M@Q^9_=#NZF>ZR.5";/$@Y-Y!+([%&ZF]*-F`=U*!Z.R![5Y
MT:?1W$$BS'W808RTQ<L$'7C5:HN58DN/Z#>@+>?;0/VJG7K695ZY.<O"(US.
MGY_03S$:/G99M*=:'^XCJB:;076H.2\-QR"]WJD/@(L3=#18S^K3I@UM@F71
MZ(%8I%?LR@"P^`^DA^M;79WQ04UN0&5JCZD9Y*#]LX..+G,G\NZ=*`E`%"_@
M"U/@K:T-%N$ZX.+<+$*K7Z@36[X/(9HYI63+:VF?7'E(^;L!HR_,!V#DK>`5
M[;#=OV\PY/@T6*H%]K3!.=Q*/'^4I31X6FE80S&SR((W9?7X!4;AR\*)EDYE
MNF1O""7:&RQRSDHBQJO?^S^VE&^")`)O82`G8U%K^R0L0DMO1G27;S4X+,<Q
MG=U"%R?ZQ&\4F9,62_0;=J3L^JS;*E;(?$.8^FT?.7>K1:C,%^<-WQ93O`_`
M!9`D#NN$_.L+DB82`7@E_YS.GIQH#A+FK?WNOFV:TNV.,U1/S_>.-"IYK4A7
M:9'P2EFR+]`'<1(&[+@3U2-ZU^MN_"JU_>3L7=T?P#SU\7!6BK6</9!WY99B
M4ZG39Y_>Y_#9HX-80P(3%"LU>R#O2BW%IE*ISP_'^D_50_$&R2M(T-\+5M`*
M#O<@RK9L+%7>Y==-T]]=\J:BM"=(/[37VJM\,`_(&(,4/(47H`S:FJ*O/X%H
MR5(X24+3=$425D7,YP>'1R8LNM4)M[(U1OHLO0?LVH5IPN\,L*H&I\?'9\<&
M6'R1?@EK,@Q8K\($[4P3*1M%56YGIZ?GA^<&G`5)NJ59&GAXZ<I7HWS1N@9T
M+<H6-^!]Q<]`Y!VYP_5MFH(,AYPJU<E>[W>FNWE-0U$AZRBW^)_?7#^-T:]S
M]R`NJ1X$B(,Y4[XX,$@`#M+$_(D[ZMF./FR:$NZ(+51#S_;&VJNHR(M']]T;
M3G:#=6V:F@T&O%2D\X/^K^JW'O+6W+OUU*"^/9JF.'WQEOLMO3PY`V6#(T?%
M2C;3@DE?0+((O?4&OS<2TO3IR"!-Z@.SLF$_.SYB*5!%"798UH2SO2(+-%VY
MT;#PRKSA5+-Y7P:I1D^DU>/<R=$G;::7MNN/(7PRFW=FG'YL#I46*<[.^V>Z
M3Q^=[EMN9OD/CZF+T]?,4M]?Y4R)\T."AWKP4C>Y=`(/O[S#7NZ<B?%]E,G`
M([<P_!L&'49EKLJJXUDY.1X?Z7_L:W(LWV<V+@W;[1Z=HS\[[B+G6,8/G.HB
M`DZ2]3$)5M/9$QH0F$8O"R>X04S-WJY+WA<K&YSYEJ",=97=`KZZT=TB*CD4
M,I;A(!"R0>Y\:-VH(],T;4.8-)^;(5L$QEY9`(\]FW7NPS15Z(Z0IEOF:X%.
M4\-5&CEYHI5PY?C)JMQ6,*_L1<U-DZT03,7?9,+-WCV(7,SR.2C0?`Y(HAB<
M!C`[`4]G=R`A&SO.96VG'DR3=E=\E9#V(Q,NY:M)D\K;1^K\>`K+WUT!'_TJ
M(K>5>"H3.X^&Z-8T71D$-'V0N:.%8!?YJ6X"M`M""@D!/R?5IWI.J@J1VC14
M=""K<GB"Y%+"UBHN"8H!H3E*9MQKS52]HI3@.7W,SAZX?L^:!Q=FBQ`U$!Y#
MXUA2&Z[62()+GV@GJVL8P'@!O)_#T&.EK>`U-$)^M3'3A^;Z;'N&E>6O8?3;
M34"<J;%0EK6&1LBR-F8JR\/>93ITE>:#\^V+DX`(.KY0F.OMC)#E^I"I*,<[
MB!#<\8Z2EQI9O*%4F/O8\/UDF9ZH&-HER?Z>$)[*)3-N(U5N8NW[3GDP5N4:
M1JO#"XB2%2Y:\J\4DML2-!_QK/"X;H64?N0$WJCHX2\CU(=2JZ3CPD4EDRHX
M@6U*T"@JS\,>EL@V98A46:6T;"J5=5K!_!&LDNMMZ6:6*KTO%MEEN6+P];,U
M)7<;J3$V*@])KS3&W-%>K.J5R654LDJE/N.DG&*V3K-54(9(#P]XO9"TU.)8
MH=+.\IH*V;X^5O#H);A;X,0`EPRZ6;Y$81:RP\\'+FRMG:":ND<%)<2QG1W,
M0*%#,4!,6100!<F>>4T-$9,8A"F9^'`=G30!$<([G<V@"R0DUTYCD@C;T5!9
M6N8-Y3+K5I!J6X;(FNW,[1:276]7=.C8EJ_^&YR2&,3:&7)#-UN%R$!EZ26Q
MB`4=]4!#R7-56T8#RFA;JZZ:)ZZ;+E-2O?<*(!RXE"9"A7[V`9%7X$V6893D
MA;"X'&)HQW!=FZ=)PV&GRX;TUH$`30O!9SI'Q+(?@#D>D09JQP7\<Q0V;L=E
MB<Q2$UE45`$^[2+3L7J/<QXIR7`\CS?Q/(_R_O[`'FAN/GWF;5Q[<1192NW,
M490K7PJ1I;N^Z@I56Y@8"BILK2SNNILZTV5:B&5G#IA=3+IH0Q*EP/O\AFL>
M\T-?3NIS;$XWHH1J;]J=%?DX>3^,QN7XHF*]PM9J;_%RKMY"YQGZ,*&Q2'(1
M,.W$RF;>=ODT[_#:X5AUWUXS1.X]NX0E*KU<-]L4FTJ71V`)0$C0&&!X$BBH
MHV//A-P+&9QIFL1A&KDX"7)VGX)847F53XTFQ\K:UF[:DRJ92ZMP)57P9@@M
MW?9.DP6(N%QD3`!M!$9H@@P0_6K^;7?2[S+9&R3F=@GWKOJGE2_[\_+%#U?X
MV2QQO$K)68+&&'E+8*%3^;#+^NYVS_52!YQC[&E]\TSI1CFATF-L#8348PX)
M&C6NH[5A7:PJA4G+,8K.M9U[4&6.TE(KG4L=D5EUSJVSBW?.E3!5E>=<>VVU
MHHW9)14O@ER2SE2[Y.&AIV`MPG7X8Q9$CLL0:2(UL3*V2T[7H''QB+E1XW)D
M^LF.%S4NA\<4T=T*HANEJ/03W$9&=ZMK<&-]R-)+M7I/;@>MXPEHR]?50T4?
MX#RH)/,9/TR<U4H_P0@BPUD`^*9BM'-M/?%9R1WN0YLV`E,$+8-E.Z$$&DRM
M[5.J/H*4.PY4A+77OTQ0U3^J@;CX?E!>0[.$5_=SCL=[QP,($40ZV=Q=&+BR
M<JRV-4N4U9%3:1[N'0Q^):W:(\:-=SUMQ+MR/6-*@US?/61_<`_9^WG]#WQ>
MEZO0WAY4WD:AGPB8YW$I+/K%T["E>(,KW3E^7F`XKTS!$AZGH;)@<#GU*^3%
M&;Y^8AHF'4:62GP2>)4RO/SCG+BY`2)N!V&I1Z;&HK:*GHS93J?:G=T$W@Y$
MOQ@W]B3,JO4NF(J%S0T07CN(7'#G^@CN_897Q0TOPYFJG]S>;WBW<\/+R1T5
MN@N0UZ.,%_!%D#J*TU)/AO-21W%`Z+=Q98OK9V>Y=.9.Y$F)3-3:*+&)@.BW
M%94[X(<7E<W5%'W]"41+F7,^A]"4G8HD'+IGT?TU56/;[#ND2FFXO@DKJU&1
M%V>D8F'E8(5_+R'[7KT;JB"],`]5ZT83+>JA(M;)OW)C:>P<\0#@\CF-8KRO
M9[\L["1QF>Z,UP(9D%0SCEB:H5.!WW+E&UA'!NK8%&T9"&Z1=%3W&640O%TK
M2>_@HW\H?9.J43W6OJCMWU8^",";U(F4W]:H\R@?QE`^\AX!5&PI?0V<+%63
M0&7O(_#B0"\/P;UP8N#EFRWF?-"[2U.LO3?0HDZU[K8L@Y3^H?UHTJ<WFW2#
MAY%Z';4_P)3+78XMSA_,RQQ0.Q";(O0.D*B,#3J*-#`Q)K6.@F;V8(&TF;B*
MC!'ZF+6*Z`AY,@,401X,E3YSK=_8X)O[P5W$7]^!Y"9`_P*W81S?@^AQ@?C)
MRR!R5@^^QDF%,_+1=[B#[T>HBQ'I0VDRD<].%*!UN0`DB+KF-U6;#?/2\5V<
M*QW)>#J[2Y<@PM\DQ\L@7,(`_^LFJ(^^0\;,83Z@ZE#7)N%F2LUA\%J5CH1I
M_-RD)-VL7V5^$A7FSZD#556Z^K?0G@*Z6`&AGZ*]AN2H!^Q79^,=$*9^1<,&
MT?(UZQ6H.*>=LBW9D#9!IWD.1OV"?H:7?)O$U9FY4$&9DAM.8M7=M')Y_0K@
M?(&T>8+TR)D#M/EX!M%T1C0ZQIEG$R?PD)IGRL^WY`W[L<K2-^2!?C%D6]GI
MU)@JL>%I4%BE+:UH]7OQL,T9)X?=,!;YN8;?@ZI5IM?DVC*K\-$.=@NH4ZY@
MM!!'Y&+4\2_#Y3(,,N"3)(G@<YJ0HW!([:APAU8N5%F;D2$Z-5JWAF!`YX)W
M1D]3;/[VW1`9KD8=L>8:<V2]HXJ;*^2LD2M$QF&E-&V(/HXK]KU`>\H".3KM
M'4]R,"QU+TR"!'IXYP-?P2-PTXBDR__\YOHI,MEKQ,VLN#MGJSY9ABF[?,0P
M_2H[H'2QB:+<Q#"8K;IV>$Q"][=%Z"-(,:Y+F*RX=P[G]2F\2OOG44:M^+*!
MC$$T4]<:J+U7+#>:6/%`$.?F4^XV+U;-S>@W)_)XB9X&[%O9NL"48?,.L3=`
MO9YIM\+AH;D5)(\:HE-5>C"XF10J-`!3],HLEF'E9V&H_=TZB=;P&6;87*PE
MK,##M:+OG"4_7\-V/J.LM!1+HZ4->".H>IDTV5M-R1#8^<<)(QB-E!GW%M6\
M$#P#KZ7GO@>`]C_0Q0YO#/IK`)/XX?$K5Q5:VMNL%2W0];MM9'MYFB<Q"1>/
M!)&VHI?>T!:>(`FTEDX']U'H`N#%V$E1G04_OX'(A3'S=EF"1IG[1EK9J9%+
M@#'7T">>![.Q;F3R`G+]#O'=,8AN3Q2;)<%Q$\<I\*[2"`;S>X"&E-]1R]KI
M)IUH9+BMRKNV>^N(T]+I?/-M48U%\4V0<;%V(TG_?H\V1DP_X8X'8*2^[IA'
M^JU?:AV;.1<KU^G9/?N0?D[^-ZS4V.YLL#0F3[@6W8%OY$],C[HDH9'J(XFM
M\*_JHQ2"G78KH*>0I(;YAK[-3J.R43>F*<#F2(OB1[JKPWWZ[$-W.D-#PM#P
MJDOO]EEB%S8W4KQ"1%2,MNT_JIX#K+\X7>5TED=_)NR7N1(TIBF`)"RJ!8.F
M5-J&*4?N`NUBUD9_L9K,9M"'3L).[RI!9)I497%1L9[I8]P;"I89T=:-U$XA
M-\+3=!=U-N#I[%>8+#!3</(FYPT!B>/0Q9`\_)>'QZ_Q+R!.UG<D+/GWZT\C
MI6A3A7Y`J9OA;._\[-.1]OD.:['U5>W/-JI%=B`,^`X@ON`?'DEI3H04>),X
M/^I>AU&=9<RPZ2U_T2!-VS8KJ"Z>[)T='9]_,D05:Q"?0@01P?L"`[A,EUU4
MK&M/!JI.5XA4)4[WSL<'XQ-M5&+[;J=:'`-QS!&30NR:`9BD44.9!NQ7(]62
MVA0-"'UG90N8`?T_[F-,SVAKA_[Q_U!+`P04````"`!!B&A!$`YCUJ<,```@
MA```$0`<`&AA;&\M,C`Q,C`Y,S`N>'-D550)``/9*YQ0V2N<4'5X"P`!!"4.
M```$.0$``.U=;6_C-A+^?L#]!]5?;A>HXSCIMLU>TL))=ML`21PD3J_`X5#0
M$F43E4B7I))X?_T-*=%ZL5YM)U:QP@*[LC@<SLS#EYDAJ3W]^<7WK"?,!6'T
MK#<\..Q9F-K,(71VU@M$'PF;D-[//_WS'Z??]/N_G]]?6PZS`Q]3:=D<(XD=
M:[JT[N^M2T8I]CR\M"9H-L/<<+6&AP?JS_#''_YM7;#%DI/97%KO+MZG:O7[
M41OG2`!/J*<;.SH8AB7"GF,?62`N%6>]N92+CX/!\_/SP?/Q`>.SP='AX7#P
M^\WU@Z;KA80?7Z;<(RER]<94.!X0*B2B-C;T'J%_EI"KXBG(MV*_1A]),SPY
M.1GHTIXE$9]A>8M\+!;(QBOR.?+8EZ6/#VSF`_OAT>')\:'AK`JK*+&'%0Z?
M&?<OL8L"3Y[U_@J01UR"G9Z%I.1D&DB<(@AH@B0VDB-7K255_C`("PTI]`BY
M7&"1)A;8/IBQIX$I53(.^X?#_O'05*2`<^#GF]:1?*#J#8"H#U28$WM5K[I2
M5`$ZB66=(DJ91!+ZG?ZMWBP6A+HL^@DO%"H?.?/P!*I;ZN'Q_BK?UJIP\""9
M_>><>0[TYT]_!40N+[%$Q!,]BSAGO>+B59.F40>[A!(MW.'WAR=6W[HDPO:8
M"#B&'TE._[)"7M:[B-O[TT&61Y9]``-G3'_2SPN.!?0-;8EK>!'5CDC*:MK(
MLP-O@XJQ9,7UHK?&^IN#<HOE%<Q3/KYF0MQA_C!''$>FFN`7"7T\A*<.8050
M/PZS2`%3*^1JO5-\WUO`V=*L5X!9$?<.N-K`52-6"=4F2'4(52,T05,/EP$4
M$93B\Z$A/B'/#IX4/+"28\ZQ<X^?,`URY[QRDHHA],/:;&?861&_;HK;!*$R
M:"HQJ0U)!T49%,E9++^H8OZJ`40W:>7@,+)M'F#GT\L"4X%%:D@4E%4,B>^S
M2$1L+,.G&Q*UH$@.B?RBBB%1`XAN2.3@<,?9`G.Y'%%'A7H+%<J#-Y2WGM<C
MK1@P'];6=</60M2Q5HR_U3Y9M\1O`5X=U"KAV@2M#J4Z*"6GO'*2BJFO&4;=
M+)@#T14%MTDR3M(KT?KK"BB^RT*1X-"9OLKTJ7DKYWW%7%5N_&YNRK/^!?,\
M-&4<Y'S"HQG'.I>?1J*"I@*5XRPJ*796S*^#J"#Q'_@^XLNQ^T!FE+C$1E2"
M<\L"*@F=W3&/V)EIJU&-BAGM:&U[(&1N,==*L+=B_I9IH)OPML`SSP'?J&;%
M\#Q:\\>;`-RYYSM#>@.(*['=`;0=I!M`:OYM@NFJ3BFHWVT%ZG_-T_\Z5%/Y
MV>@LB0J_P&1R>45=QGTM=I2F+:,H1>Q0X67.JB0>=6RF65D)7F^%2QWS;HSG
MSG`Y1YXZ%O,PQUA&@RG]JM3RP^&A/LZ`)(Z,?\&HHY*!CGH2,!8<?7(HXFF%
M3#L("B&X0QQTG6,)4XR7@T>ZO`*<X2;@6.]2;;S9ZO3W`&ME3C%V+Y@/ZL[!
MHA!FA7O;YJ10.5$Y;$<UQU3<BEJ84NUD=MK?/5(4.`0J=6@6HXG$_+/'GD4.
MAJNB<N2.-T,.N%N:?0=4$5!C/D.4?-'-@8-P'@A"L8B@*BHL!>OH<"TL2_+1
MSH/AU&'1W$%OXIA7(;6%0]Y!5R,769J$K`*G=O:Q@Z(@*;^6C:\R>5D:OK-R
MC8W!TBW!*NLWV0SLT"@YD9)[%J7*^I6G4#J3EYR+RST15V7RRK-PG<DKCU67
M'*BN,G^3H]0=$N47>HIN\E1A4.L*3V?\M*_I^T1JSP\66(A_E5^.:1P;E!&4
MPZ&SCAF?<\5+K\(I;E\!+NHO=5_Q'KN6OHWX45V9.^L)XB\\=8M1OYMS[`)B
M`%7?7"[\`]0]>/$]0Z+XE]R+U,AF+10U;%@@;J]Q6;LM"4RTTP3P#(SPAH$D
M4E6_2S1CJ7;$MQ;R0-+!SI2'.*6I\E`%>Z^H];7B_TKJ0D=KJFZF;[Z2TA=Q
M*Z^D.HS-IJJGA_,K:7ZY:B17\=-!\E8K_$K?>CT%O1F7%EV[<UQV`SJ\87W-
M;,VHI(KZU3?U^NI5?WC4/QX>O`C'R-A$A-@&S40P];838>TB<2TILK64#"=*
MAN'W6\F0O`'=3`Y&;S<4Q45BJID%HC]#:*&OF)OKVP5":`%R*PZP)X5YTX]9
MU9,E=9_<P:2V+-DZZF&[UO&+/6_<_*J2?MI.`)VUY,O&,B3KF1_;24+H$Q:R
ML2"):M%SD1C?]/OF<P;"TA]\@)?1"RU<^4&`T51(CNPH@:.F^#_JD8?KA/Y*
MQ$=X![[AE<2^\J1`PP#(B`Q4C5\X"Q:&D``)S-?Z&>9QPIR)9N,$/#JX@*(&
MSGJ2J^B:$I7[5!-[^'N0IR#$;AS#=':)PW^O:!R0TZ1J581)I7Q&L41\65NM
MK*AE:H9ETW"?&`KPE,@"Y3+IG(N`J\UD=7KMW(.0*:%=)66H7OA!B8_2O'\5
M!3.JK&340;5X!%?\BJH=UD!%%>=($!NZVR7Q`HD=",>3X7S<YT*#;,4BV[^V
MZ,8[,4>]8Z_A4<4U0VQ6N64F*-@E*="Y+G7+E/P%`50SQ)T[Q"7%7,S)X@;[
M4\R-8F44J7'K,!\1^J;2WS-8L@HE+RK=M]1WFOHSXQ/,?4(CZE#F_+)D)S'\
MWU3DWPC$-S!A^2AA3Y$V=SG-OHU^!2X3?F&T6/XRBGU+/[+G!#_IEV/W$IX\
MMHA<H7L\4P$UX\L;XH$_!MZ!Z*V6Z(;57MG/""-,6=/-B(<Y%AC"\/EJQRTS
MSHN*]XU:Z`1@#N8>N[`,X@(%JNGVK4G1G<K\M;`N=<O6PLA-'0=2L(#;RO<.
M.Y9RW^+!DW%C>VEWN''M/0TYB#.<LC$'&#J!+1\03`[IWII7LN_^F?WR1WZ_
MK*)J67^\4NE"Y#TN7,ZHO$-+/]'="@K;.8%G#'^/50:8SB8L7[?:Y"T=.[>,
M<NP&U%'L\U4L)6DGB/G?",L?:?5H6S;>UC>+B^+;:L*6J78'*](<":Q/J4.7
MTAJ<+T?@;7@$R=ACK$&84D6G/%ZC;VZLR<A7>8;:^ACR=HZYD>>I="QV]`#2
MW]%5SB)X$!KPR)DP`RR3:UIY)MLQB=9V6-@7$4D+,U$CQ]%[:\C;*B=5PJ9M
M(YHS&V-'?.;,CR+6L7L-L0-`J0]9Y*6C$B[<)I5;.D96F-V@%^('OM'N'MN8
M/*DV&^GYN&`T%3A/]->>XZ#ZS=K[2NU]X1&J+J0EHJ:<U,:>I?A*L2G--NVG
M\:\4"1U_Z\5\#TCD-]Y.)'9E`AVC0?E*XRA>4_%-.&4;\[]EB^VT>3;3PLXA
MBK<9>%Y?L#-^PGI[HR@M4T#<TF`_<:)M['Y"G((G*`J<Z6SQVB;B3GBUS%/5
M(=>5$`%V+@/5>KC'%>Z6W^)G720F[)%"//W,H6&>"K2;5GW5^+1.J#V%6&+L
M0I]6`G,8Y?'5`!.4EI#L.=S*2TQ%,]5G;":@<$;#CK9[>:BQ.W[MG.G"_(%1
MX#/C\=K[Z<7V`G5)/W+H8>R.*(6@,M+_!A$J,57-@"E$#6.^46/MM'290VX6
MQ@8=<V?LVFFM'%]Y`R-MRZ6=M@D'AADQ1"[5B&A@E<WKM],>-?=;XFD[GETR
MTTK#'9Q:'%OJ]\53[Z:',S9G\#?K1O>8^-.`"]5J_JYX9;^IPZ*E'65]MZ@Z
M6=VD2LO<_=M`'0D8NZ&3GMIW"3UY#2IV`-.'1W#B55X''A[T>0A0&#LC$4T/
MX.#\A\BY,H3J!.@E'CROW<J>@PBC7D;F"0.90=X;<%W\P*\R3M/:>U8Z]&['
M;E:PD1#,5IMUCBI12OT&,V$Z)$Q[R)OR>.49I/"8??VUIDYJZ<J-'AX"V\9"
MN('G+:.94D1+KA.=XKE`U-'?JE+K;[@,B3L>NBR.SO*E4UMMD*2=J]^Z92)'
M>2UY6KW"PR#]A.QY9)E0;]63U?_.&O(8T>78G<S!-F.^F"-Z!<8+[^V4)('W
M)E`[$8OOE8/XZ:U@-4V:`''"B7+VPV-[86GBZDKDM^R"5>H0W7YNP<1YUQTX
M<SMBMJ])N3+`WH%V)<&BV*D9RQMJO8FCJ4MM`6K5:Z4N-JK\9J9HDIRHTTV:
MU]N[JK\N/4SQ2^$%GN+R?9\W?@0!&9>E@Q*<EP4BQKW1FZ5F!38*;LVFK0YK
M'<5,0?X!V6TXM-4J\904J2)646J^$1I4:/T4OJ9!3H^NH7=NK3VG/"XC"EAA
MV!)Y<AD'0RL'L8PD*?Y>KO=!_`NQF$0SO)+O$]7?+5$)E#"Q/79O<7CI(W%7
ML5&MU,ZFJOFVZVIX"E9C$.>=3=9^PN)WE]B#5UQO6*H%=#W_OPM6;[KZG@["
MCSO`X_\!4$L!`AX#%`````@`08AH07[ZREW$E@``ZI$&`!$`&````````0``
M`*2!`````&AA;&\M,C`Q,C`Y,S`N>&UL550%``/9*YQ0=7@+``$$)0X```0Y
M`0``4$L!`AX#%`````@`08AH02-9[G@H#```U)```!4`&````````0```*2!
M#Y<``&AA;&\M,C`Q,C`Y,S!?8V%L+GAM;%54!0`#V2N<4'5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`$&(:$&3!DOY01(``-M*`0`5`!@```````$```"D
M@8:C``!H86QO+3(P,3(P.3,P7V1E9BYX;6Q55`4``]DKG%!U>`L``00E#@``
M!#D!``!02P$"'@,4````"`!!B&A!6L9=F:%"``#8D`,`%0`8```````!````
MI($6M@``:&%L;RTR,#$R,#DS,%]L86(N>&UL550%``/9*YQ0=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`08AH0?\3.6?.)0``5W("`!4`&````````0``
M`*2!!OD``&AA;&\M,C`Q,C`Y,S!?<')E+GAM;%54!0`#V2N<4'5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`$&(:$$0#F/6IPP``""$```1`!@```````$`
M``"D@2,?`0!H86QO+3(P,3(P.3,P+GAS9%54!0`#V2N<4'5X"P`!!"4.```$
:.0$``%!+!08`````!@`&`!H"```5+`$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note4_table1 - us-gaap:ScheduleOfInventoryCurrentTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Raw materials</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">962,751</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">201,822</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Work-in-process</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">715,241</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">290,647</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Finished goods</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">508,071</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">74,794</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,186,063</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">567,263</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMFAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
        <td class="nump">$ 715,354<span></span></td>
        <td class="nump">$ 1,156,903<span></span></td>
        <td class="nump">$ 1,427,707<span></span></td>
        <td class="nump">$ 1,487,822<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenues under collaborative agreements</a></td>
        <td class="nump">4,618,969<span></span></td>
        <td class="nump">21,785,525<span></span></td>
        <td class="nump">19,103,970<span></span></td>
        <td class="nump">52,187,447<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">5,334,323<span></span></td>
        <td class="nump">22,942,428<span></span></td>
        <td class="nump">20,531,677<span></span></td>
        <td class="nump">53,675,269<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of product sales</a></td>
        <td class="nump">226,635<span></span></td>
        <td class="nump">11,723<span></span></td>
        <td class="nump">440,516<span></span></td>
        <td class="nump">201,675<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">19,503,491<span></span></td>
        <td class="nump">13,514,352<span></span></td>
        <td class="nump">51,476,329<span></span></td>
        <td class="nump">42,647,265<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">5,634,034<span></span></td>
        <td class="nump">4,263,520<span></span></td>
        <td class="nump">17,833,165<span></span></td>
        <td class="nump">12,237,152<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
        <td class="nump">25,364,160<span></span></td>
        <td class="nump">17,789,595<span></span></td>
        <td class="nump">69,750,010<span></span></td>
        <td class="nump">55,086,092<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
        <td class="num">(20,029,837)<span></span></td>
        <td class="nump">5,152,833<span></span></td>
        <td class="num">(49,218,333)<span></span></td>
        <td class="num">(1,410,823)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
        <td class="nump">23,991<span></span></td>
        <td class="nump">12,360<span></span></td>
        <td class="nump">72,187<span></span></td>
        <td class="nump">56,586<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">(20,005,846)<span></span></td>
        <td class="nump">5,165,193<span></span></td>
        <td class="num">(49,146,146)<span></span></td>
        <td class="num">(1,354,237)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net income (loss) per share</a></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="num">$ (0.44)<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract', window );"><strong>Shares used in computing net income (loss) per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
        <td class="nump">112,305,002<span></span></td>
        <td class="nump">103,223,352<span></span></td>
        <td class="nump">110,658,757<span></span></td>
        <td class="nump">102,282,904<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
        <td class="nump">112,305,002<span></span></td>
        <td class="nump">105,009,189<span></span></td>
        <td class="nump">110,658,757<span></span></td>
        <td class="nump">102,282,904<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
        <td class="num">$ (20,005,846)<span></span></td>
        <td class="nump">$ 5,165,193<span></span></td>
        <td class="num">$ (49,146,146)<span></span></td>
        <td class="num">$ (1,354,237)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_SharesUsedInComputingBasicAndDilutedNetLossPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e557-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Paragraph 5A<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Deferred Revenue<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">Deferred Revenue</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:DeferredRevenueDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>7. Deferred Revenue </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Deferred revenue consists of the following: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Collaborative agreements</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">44,034,015</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,716,806</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Product sales</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">319,367</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">167,184</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total deferred revenue</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">44,353,382</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,883,990</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less current portion</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,470,247</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,129,407</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred revenue, net of current portion</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">34,883,135</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">36,754,583</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><b><i>Roche Collaboration. </i></b>Under the terms of the Roche Collaboration, Roche paid $20 million to us in December
   2006 as an initial upfront payment for the application of rHuPH20 to three pre-defined Roche biologic targets. As of September&#160;30, 2012, Roche has paid an aggregate of $20 million in connection with Roche&#8217;s election of two additional
   exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets. Roche currently retains the option to develop and commercialize rHuPH20 with three additional targets, provided that Roche
   continues to pay annual license maintenance fees to us. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Due to our continuing involvement obligations (for example, support
   activities associated with rHuPH20 enzyme), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Collaboration. We recognized revenue from
   the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration in the amounts of approximately $503,000 and $491,000 for the three months ended September&#160;30, 2012 and 2011, respectively, and
   approximately $1.5 million for the nine months ended September&#160;30, 2012 and 2011. Deferred revenue relating to the upfront payment, exclusive designation fees and annual license maintenance fees under the Roche Collaboration was $30.1 million
   and $31.7 million as of September&#160;30, 2012 and December&#160;31, 2011, respectively. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the nine months ended
   September&#160;30, 2012, we received approximately $7.0 million in deferred revenue relating to the manufacture of rHuPH20 API for Roche. We recognized approximately $334,000 as revenues under collaborative agreements from deferred revenue relating
   to the manufacture of rHuPH20 API for the three and nine months ended September&#160;30, 2012. Deferred revenue relating to the manufacture of rHuPH20 API under the Roche Collaboration was $6.7 million and zero as of September&#160;30, 2012 and
   December&#160;31, 2011, respectively. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><b><i>Gammagard Collaboration. </i></b>Under the terms of the Gammagard Collaboration,
   Baxter paid us a nonrefundable upfront payment of $10 million. Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the $10&#160;million upfront payment was deferred and is being recognized
   over the term of the Gammagard Collaboration. We recognized revenue from the upfront payment under the Gammagard Collaboration in the amounts of approximately $121,000 for each of the three months ended September&#160;30, 2012 and 2011 and
   approximately $362,000 for the nine months ended September&#160;30, 2012 and 2011. Deferred revenue relating to the upfront payment under the Gammagard Collaboration was $7.2 million and $7.6 million as of September&#160;30, 2012 and
   December&#160;31, 2011, respectively. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><b><i>Hylenex
   Collaboration</i></b>. In February 2007, we and Baxter amended certain existing agreements for <i>Hylenex </i>recombinant and entered into the Hylenex Collaboration for kits and formulations with rHuPH20. Effective January&#160;7, 2011, we and
   Baxter mutually agreed to terminate the Hylenex Collaboration and the associated agreements. On July&#160;18, 2011, we and Baxter entered into an agreement (the &#8220;Transition Agreement&#8221;) setting forth certain rights, data and assets to be
   transferred by Baxter to us during a transition period. Effective July&#160;18, 2011, we had no future performance obligations to Baxter in connection with the Hylenex Collaboration. Therefore, we recognized the unamortized deferred revenue of
   approximately $9.3 million relating to the prepaid product-based payments and the unamortized deferred revenue of approximately $7.6 million relating to deferred upfront payment from the Hylenex Collaboration as revenues under collaborative
   agreements for the three months ended September&#160;30, 2011. For the nine months ended September&#160;30, 2011, we recognized revenues under the Hylenex Collaboration from the upfront payment of approximately $7.8 million and from the
   product-based payments of approximately $9.3 million. There were no deferred revenues relating to the Hylenex Collaboration at September&#160;30, 2012 and 2011. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In addition, pursuant to the terms of the Transition Agreement, Baxter no longer had the right to return the <i>Hylenex </i>recombinant API previously delivered to Baxter. Accordingly, we recognized
   approximately $991,000 of deferred revenue related to such <i>Hylenex </i>recombinant API as product sales revenue during the three and nine months ended September&#160;30, 2011. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 5<br><br> -Paragraph 83, 84<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccruedExpensesCurrentTextBlock', window );">Accrued Expenses</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - halo:AccruedExpensesCurrentTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>6. Accrued Expenses </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Accrued expenses consist of the following: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued outsourced research and development expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,735,396</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,910,273</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued compensation and payroll taxes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,339,791</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,223,936</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other accrued expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">966,486</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">481,365</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,041,673</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,615,574</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedExpensesCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other Current Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AccruedExpensesCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation expense related to all of our share-based awards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">$ 1,922,393<span></span></td>
        <td class="nump">$ 1,757,359<span></span></td>
        <td class="nump">$ 6,362,372<span></span></td>
        <td class="nump">$ 3,916,329<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted', window );">Share-based compensation expense per basic and diluted share</a></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="nump">$ 0.06<span></span></td>
        <td class="nump">$ 0.04<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation expense related to all of our share-based awards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">1,164,973<span></span></td>
        <td class="nump">806,078<span></span></td>
        <td class="nump">3,491,220<span></span></td>
        <td class="nump">2,318,728<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted stock awards and restricted stock units [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation expense related to all of our share-based awards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">757,420<span></span></td>
        <td class="nump">951,281<span></span></td>
        <td class="nump">2,871,152<span></span></td>
        <td class="nump">1,597,601<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation expense related to all of our share-based awards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">913,946<span></span></td>
        <td class="nump">890,276<span></span></td>
        <td class="nump">3,279,940<span></span></td>
        <td class="nump">1,944,552<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling, general and administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation expense related to all of our share-based awards</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">$ 1,008,447<span></span></td>
        <td class="nump">$ 867,083<span></span></td>
        <td class="nump">$ 3,082,432<span></span></td>
        <td class="nump">$ 1,971,777<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocated share based compensation expense per share basic and diluted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment, net</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note5_table1 - us-gaap:PropertyPlantAndEquipmentTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research equipment</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,207,401</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,231,763</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Computer and office equipment</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,524,340</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,266,041</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Leasehold improvements</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,137,187</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,019,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,868,928</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,516,951</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accumulated depreciation and amortization</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(6,505,278</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,745,903</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,363,650</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,771,048</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 10 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>10. Commitments and Contingencies </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations
   in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny
   coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial
   position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the
   aggregate, would have a material adverse effect on our consolidated results of operations or financial position. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Income (Loss) Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:EarningsPerShareTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>8. Net Income (Loss) Per Share </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Basic net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted
   average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted-average number of
   common shares outstanding and potentially dilutive common shares outstanding. Potentially dilutive common shares outstanding, determined using the treasury stock method, principally include shares that may be issued under our stock options,
   restricted stock awards (&#8220;RSAs&#8221;) and RSUs. Stock options, unvested RSAs and unvested RSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when their effect is dilutive.
   For the three and nine months ended September&#160;30, 2012, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 7.3&#160;million were excluded from the calculation of diluted net loss per common share because their
   effect is anti-dilutive. For the three and nine months ended September&#160;30, 2011, outstanding stock options, outstanding RSUs and unvested RSAs totaling approximately 1.9&#160;million and 5.9&#160;million, respectively, were excluded from the
   calculation of diluted net loss per common share because their effect is anti-dilutive. </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="50%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Three Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Nine Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net Income (Loss) - Numerator:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income (loss) for basic and diluted EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(20,005,846</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,165,193</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(49,146,146</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,354,237</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Shares - Denominator:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average shares for basic EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">112,305,002</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">103,223,352</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">110,658,757</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102,282,904</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Effect of dilutive stock options, RSAs and RSUs</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,785,837</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average shares for diluted EPS</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">112,305,002</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">105,009,189</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">110,658,757</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102,282,904</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic and diluted net income (loss) per share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.18</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.05</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.44</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.01</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16381557&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>9. Stockholders&#8217; Equity </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the nine months ended September&#160;30, 2012 and 2011, we issued an aggregate of 426,277 and 2,713,573 shares
   of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $4.56 and $1.70 per share, respectively, for net proceeds of approximately $1.9 million and $4.1 million, respectively. In
   addition, for the nine months ended September&#160;30, 2012, we issued 81,070 shares of common stock upon vesting of certain RSUs. The RSU holders surrendered 46,930 RSUs to pay for minimum withholding taxes totaling approximately $347,000. Options
   and RSUs to purchase approximately 6.9&#160;million and 6.0&#160;million shares of our common stock were outstanding as of September&#160;30, 2012 and December&#160;31, 2011, respectively. In addition, we issued 375,908 shares of common stock, net
   of RSAs canceled, in connection with the grants of RSAs during the nine months ended September&#160;30, 2012. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On
   February&#160;15, 2012, we completed an underwritten public offering and issued 7,820,000 shares of common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriter. All of the shares
   were offered at a public offering price of $10.61 per share, generating approximately $81.5 million in net proceeds. Randal J. Kirk, a member of our board of directors, through his affiliates, purchased 1,360,000 shares of common stock in this
   offering at the public offering price of $10.61 per share for a total of approximately $14.4 million. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies [Policies]<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table1 - us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-->
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Basis of Presentation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States
   generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of
   the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated
   financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2011, filed with the SEC on March&#160;12, 2012. The unaudited financial information for the interim periods presented herein
   reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring
   adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc. All intercompany accounts and transactions have been
   eliminated. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
   estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management
   believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates. </font></p>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Recent Accounting Pronouncements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table2 - us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Adoption of Recent Accounting Pronouncements </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Effective January&#160;1, 2012, we adopted Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Update
   (&#8220;ASU&#8221;) No.&#160;2011-05, Comprehensive Income (Topic 220): <i>Presentation of Comprehensive Income</i> and ASU No.&#160;2011-12, <i>Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of
   Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU No.&#160;2011-5</i>. In these updates, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other
   comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each
   component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No.&#160;2011-05 eliminates the option to present the components of other comprehensive income as part of the
   statement of changes in stockholders&#8217; equity. The amendments in ASU No.&#160;2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.
   The amendments in these updates are effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2011. The adoption of ASU Nos. 2011-05 and 2011-12 did not have a material impact on our consolidated financial
   position or results of operations. We have presented comprehensive income (loss) in our condensed consolidated statements of comprehensive income (loss). </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Effective January&#160;1, 2012, we prospectively adopted FASB&#8217;s ASU No.&#160;2011-04, <i>&#8220;Fair Value Measurement (Topic 820) &#8212; Amendments to Achieve Common Fair Value Measurement and
   Disclosure Requirements in U.S. GAAP and IFRS&#8221;. </i>The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;). Consequently, the
   amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This pronouncement is effective for fiscal years, and interim periods within
   those years, beginning after December&#160;15, 2011. The adoption of ASU No.&#160;2011-04 did not have a material effect on our consolidated financial position or results of operations. </font></p>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table3 - us-gaap:InventoryPolicyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Inventories </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. Management
   evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price it expects to obtain for products in their respective markets
   compared with historical cost and the remaining shelf life of goods on hand. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Raw materials inventories consist of raw
   materials used in the manufacture of our bulk drug material for <i>Hylenex</i> recombinant product. Work-in-process inventories consist of in-process <i>Hylenex</i> recombinant. Finished goods inventories consist of finished <i>Hylenex</i>
   recombinant product. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We expense costs relating to the purchase and production of pre-approval inventories for which the sole
   use is pre-approval products as research and development expense in the period incurred until such time as we believe future commercialization is probable and future economic benefit is expected to be realized. For products that have been approved
   by regulatory bodies such as the U.S. Food and Drug Administration (&#8220;FDA&#8221;), inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. Prior to receiving approval from the FDA or
   comparable regulatory agencies in foreign countries, costs related to purchases of the active pharmaceutical ingredients (&#8220;API&#8221;) and the manufacturing of the product candidate are recorded as research and development expense. All direct
   manufacturing costs incurred after approval are capitalized as inventory. </font></p>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table4 - us-gaap:RevenueRecognitionPolicyTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Revenue Recognition </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We generate revenues from product sales and collaborative agreements. Payments received under collaborative agreements may include
   nonrefundable fees at the inception of the agreements, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and/or royalties on sales of products
   resulting from collaborative arrangements. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We recognize revenue in accordance with the authoritative guidance on revenue
   recognition. Revenue is recognized when all of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered; (3)&#160;the seller&#8217;s price to the buyer is
   fixed or determinable; and (4)&#160;collectibility is reasonably assured. </font></p>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table5 - us-gaap:CostOfSalesPolicyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Cost of Product Sales </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal
   costs and manufacturing overhead associated with the production of <i>Hylenex </i>recombinant. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories. </font></p>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table6 - us-gaap:ResearchAndDevelopmentExpensePolicy-->
   <p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Research and Development Expenses </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses,
   research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no
   alternative future uses. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Advance payments, including nonrefundable amounts, for goods or services that will be used or
   rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or at such time when we do not expect the
   goods to be delivered or services to be performed. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Milestone payments that we make in connection with in-licensed technology
   or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product
   candidates to be uncertain until such licensed technology or product candidates are approved for marketing by regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all
   of our licensed technology or product candidates to be uncertain and has expensed these amounts as incurred. </font></p>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table7 - halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Clinical Trial Expenses </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work
   performed, including actual level of patient enrollment, completion of patient studies and progress of clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts
   are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period
   in which the facts that give rise to the revision become reasonably certain. </font></p>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table8 - us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Share-Based Compensation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Total share-based compensation expense related to all of our share-based awards was allocated as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Three Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>Nine Months Ended</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">913,946</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">890,276</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,279,940</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,944,552</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Selling, general and administrative</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,008,447</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">867,083</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,082,432</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,971,777</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense per basic and diluted share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.02</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.06</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.04</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Share-based compensation expense from:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,164,973</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">806,078</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,491,220</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,318,728</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Restricted stock awards and restricted stock units</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">757,420</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">951,281</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,871,152</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,597,601</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,922,393</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,757,359</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,362,372</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,916,329</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Since we have a net operating loss carryforward as of September&#160;30, 2012, no excess tax benefits for the tax
   deductions related to share-based awards were recognized in the interim unaudited condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2012. For the three months ended September&#160;30, 2012 and 2011, employees exercised stock options to
   purchase 7,055 and 38,511 shares of common stock, respectively, for aggregate proceeds of approximately $39,000 and $79,000, respectively. For the nine months ended September&#160;30, 2012 and 2011, employees exercised stock options to purchase
   426,277 and 2,713,573 shares of common stock, respectively, for aggregate proceeds of approximately $1.9 million and $4.1 million, respectively. In addition, for the nine months ended September&#160;30, 2012, upon vesting of 128,000 restricted stock
   units (&#8220;RSUs&#8221;), the RSU holders received net settlement of 81,070 shares of common stock and surrendered 46,930 RSUs to pay for the minimum withholding taxes totaling approximately $347,000. There were no RSUs vested for the three months
   ended September&#160;30, 2012 or the three and nine months ended September&#160;30, 2011. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of September&#160;30, 2012,
   total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock awards and restricted stock units granted prior to that date was approximately $9.6 million and $7.0 million, respectively, which is
   expected to be recognized over a weighted-average period of approximately 2.7 years and 3.6 years, respectively. </font></p>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table9 - us-gaap:FairValueOfFinancialInstrumentsPolicy-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Fair Value of Financial Instruments </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We follow the authoritative guidance for fair value measurements and disclosures which, among other things, defines fair value,
   establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price that would be
   received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
   pricing an asset or liability. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The framework for measuring fair value provides a hierarchy that prioritizes the inputs to
   valuation techniques used in measuring fair value as follows: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <div align="right">
   <table cellspacing="0" cellpadding="0" width="96%" border="0" style="border-collapse:collapse; text-align: left">
   <!-- Begin Table Head -->
   <tr>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td width="91%">&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level&#160;1</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Quoted prices (unadjusted) in active markets for identical assets or liabilities,</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level 2</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, and</font></td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="2">&#160;</td>
   </tr>
   <tr>
   <td valign="top"><font style="font-family:times new roman" size="2">Level 3</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants
   would use in pricing.</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Our financial instruments include cash and cash equivalents, accounts receivable, prepaid expenses,
   accounts payable and accrued expenses. The carrying amounts of financial instruments approximate their fair values due to their short maturities. Cash equivalents of approximately $85.0 million and $51.8 million at September&#160;30, 2012 and
   December&#160;31, 2011, respectively, are carried at fair value and are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices for identical securities. We have no instruments that are classified
   within Level 2 and Level 3. </font></p>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Accounting Policy: halo-20120930_note2_accounting_policy_table10 - us-gaap:SegmentReportingPolicyPolicyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Segment Information </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We operate our business in one segment, which includes all activities related to the research, development and commercialization of human
   enzymes that either transiently modify tissue to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. This segment also includes revenues and expenses related to (i)&#160;research and development
   activities conducted under our collaborative agreements with third parties and (ii)&#160;product sales of <i>Hylenex</i> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations
   as a single operating segment. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for clinical trial expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197414<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408645&amp;loc=d3e63676-111659<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfSalesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 8, 10, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Paragraph 3, 5-10, 15, 16, 17<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 69-75<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4556-108314<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4492-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 06-11<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E13BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 15, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_StockholdersEquityAdditionalTextualAbstract', window );"><strong>Stockholders' Equity (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,055<span></span></td>
        <td class="nump">38,511<span></span></td>
        <td class="nump">426,277<span></span></td>
        <td class="nump">2,713,573<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.56<span></span></td>
        <td class="nump">$ 1.70<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options and restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued related to restricted stock awards, net of any shares forfeited</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">375,908<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering and issued shares</a></td>
        <td class="nump">7,820,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter', window );">Shares sold to underwriter pursuant to the full exercise of an over-allotment option granted to the underwriter</a></td>
        <td class="nump">1,020,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PublicOfferingPricePerShare', window );">Public offering price per share</a></td>
        <td class="nump">$ 10.61<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock issued</a></td>
        <td class="nump">$ 81,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 81,476,845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PurchaseOfCommonStockByAffiliates', window );">Purchase of common stock by affiliates</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,360,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PurchaseOfCommonStockByAffiliatesAmount', window );">Purchase of common stock by affiliates amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,000<span></span></td>
        <td class="nump">79,000<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="nump">4,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted stock awards and restricted stock units [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes', window );">Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,070<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes', window );">Number of RSUs surrendered to pay for minimum withholding taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,930<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod', window );">Amount of withholding taxes associated with RSUs vested during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 347,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of withholding taxes associated with RSUs vested during period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_AmountOfWithholdingTaxesAssociatedWithRSUsVestedDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of RSUs surrendered to pay for minimum withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NumberOfRSUsSurrenderedToPayForMinimumWithholdingTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock issued related to RSUs, net of RSUs surrendered as payment for withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_NumberOfSharesOfCommonStockIssuedRelatedToRSUsNetOfRSUsSurrenderedAsPaymentForWithholdingTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PublicOfferingPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Public offering price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PublicOfferingPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PurchaseOfCommonStockByAffiliates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of common stock by affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PurchaseOfCommonStockByAffiliates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PurchaseOfCommonStockByAffiliatesAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of common stock by affiliates amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_PurchaseOfCommonStockByAffiliatesAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_StockholdersEquityAdditionalTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_StockholdersEquityAdditionalTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_StockholdersEquityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_StockholdersEquityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares new issues to underwriter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Summary of Deferred revenue</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note7_table1 - us-gaap:DeferredRevenueByArrangementDisclosureTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Collaborative agreements</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">44,034,015</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,716,806</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Product sales</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">319,367</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">167,184</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total deferred revenue</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">44,353,382</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,883,990</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less current portion</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,470,247</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,129,407</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred revenue, net of current portion</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">34,883,135</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">36,754,583</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventories (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of Inventories</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
        <td class="nump">$ 962,751<span></span></td>
        <td class="nump">$ 201,822<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
        <td class="nump">715,241<span></span></td>
        <td class="nump">290,647<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
        <td class="nump">508,071<span></span></td>
        <td class="nump">74,794<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">$ 2,186,063<span></span></td>
        <td class="nump">$ 567,263<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before last-in first-out (LIFO) and valuation reserves of merchandise or goods held by the entity that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of unprocessed items to be consumed in the manufacturing or production process. Also includes purchased parts that will be used as components of a finished product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of merchandise or goods which are partially completed, are generally comprised of raw materials, labor and factory overhead costs, and which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E65AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (49,146,146)<span></span></td>
        <td class="num">$ (1,354,237)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">6,362,372<span></span></td>
        <td class="nump">3,916,329<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">796,163<span></span></td>
        <td class="nump">851,613<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td>
        <td class="num">(6,610)<span></span></td>
        <td class="num">(992)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="num">(2,201,808)<span></span></td>
        <td class="num">(3,909,636)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
        <td class="num">(1,618,800)<span></span></td>
        <td class="nump">89,979<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(3,021,100)<span></span></td>
        <td class="num">(576,918)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="num">(2,106,754)<span></span></td>
        <td class="num">(2,183,864)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
        <td class="nump">62,385<span></span></td>
        <td class="nump">89,453<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">3,469,392<span></span></td>
        <td class="num">(17,718,311)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(47,410,906)<span></span></td>
        <td class="num">(20,796,584)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(873,165)<span></span></td>
        <td class="num">(271,521)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(873,165)<span></span></td>
        <td class="num">(271,521)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
        <td class="nump">81,476,845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common shares under equity incentive plans, net</a></td>
        <td class="nump">1,596,590<span></span></td>
        <td class="nump">4,141,615<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">83,073,435<span></span></td>
        <td class="nump">4,141,615<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="nump">34,789,364<span></span></td>
        <td class="num">(16,926,490)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">52,825,527<span></span></td>
        <td class="nump">83,255,848<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">87,614,891<span></span></td>
        <td class="nump">66,329,358<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable for purchases of property and equipment</a></td>
        <td class="nump">$ 508,990<span></span></td>
        <td class="nump">$ 6,954<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_IncreaseDecreaseInDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>halo_IncreaseDecreaseInDeferredRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>halo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalExpendituresIncurredButNotYetPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>5. Property and Equipment, Net </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Property and equipment, net consist of the following: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research equipment</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,207,401</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,231,763</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Computer and office equipment</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,524,340</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,266,041</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Leasehold improvements</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,137,187</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,019,147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,868,928</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,516,951</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accumulated depreciation and amortization</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(6,505,278</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,745,903</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,363,650</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,771,048</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Depreciation and amortization expense totaled approximately $286,000 and $239,000 for the three months ended
   September&#160;30, 2012 and 2011, respectively, and approximately $796,000 and $852,000 for the nine months ended September&#160;30, 2012 and 2011, respectively. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment, Net (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of Property and equipment, net</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
        <td class="nump">$ 8,868,928<span></span></td>
        <td class="nump">$ 7,516,951<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
        <td class="num">(6,505,278)<span></span></td>
        <td class="num">(5,745,903)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">2,363,650<span></span></td>
        <td class="nump">1,771,048<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of Property and equipment, net</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
        <td class="nump">6,207,401<span></span></td>
        <td class="nump">5,231,763<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer and office equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of Property and equipment, net</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
        <td class="nump">1,524,340<span></span></td>
        <td class="nump">1,266,041<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of Property and equipment, net</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
        <td class="nump">$ 1,137,187<span></span></td>
        <td class="nump">$ 1,019,147<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>76</ContextCount>
  <ElementCount>164</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/StatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0205 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0206 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0207 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/DeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0208 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0209 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0210 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0402 - Disclosure - Summary of Significant Accounting Policies [Policies]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies [Policies]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0502 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0504 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0505 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0506 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0507 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/DeferredRevenueTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0508 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0602 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>06021 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0603 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0604 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0605 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>06051 - Disclosure - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/PropertyAndEquipmentNetDetailsTextual</Role>
      <ShortName>Property and Equipment, Net (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0606 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0607 - Disclosure - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/DeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>06071 - Disclosure - Deferred Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/DeferredRevenueDetailsTextual</Role>
      <ShortName>Deferred Revenue (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0608 - Disclosure - Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/NetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>06081 - Disclosure - Net Income (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/NetIncomeLossPerShareDetailsTextual</Role>
      <ShortName>Net Income (Loss) Per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0609 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://halozyme.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element halo_DeferredRevenueRelatingToReimbursableResearchAndDevelopment had a mix of decimals attribute values: -6 -5.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '06071 - Disclosure - Deferred Revenue (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>halo-20120930.xml</File>
    <File>halo-20120930.xsd</File>
    <File>halo-20120930_cal.xml</File>
    <File>halo-20120930_def.xml</File>
    <File>halo-20120930_lab.xml</File>
    <File>halo-20120930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued expenses</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note Table: halo-20120930_note6_table1 - us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock-->
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="72%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>September&#160;30,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued outsourced research and development expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,735,396</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,910,273</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued compensation and payroll taxes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,339,791</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,223,936</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other accrued expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">966,486</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">481,365</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,041,673</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,615,574</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
